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ADDENDUM
After completion of the research outlined in this thesis, it emerged that there was an
error in the community pharmacy cost estimate. Based on information included in the
1998 Drug Tariff, an 'on-cost allowance' (calculated at 17.5% of the Net Ingredient
Cost of prescription medicines) was included as an element in the community
pharmacy cost estimate. However, this allowance was abolished in 1992.
Consequently, the community pharmacy cost estimate was overestimated (by 11 -
13%) where prescription medicines were obtained. Anyone citing this research or
using these estimates should account for this. It is important to note, however, that
this overestimation serves only to enhance the relative cost effectiveness of accessing
P class medicines from community pharmacists as opposed to general practitioners
(as community pharmacy costs are lower) and does not alter the key conclusions of
the research.
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ABSTRACT
Background - Self-medication using P class medicines has been promoted in recent
years. Policy makers believe that this will help to contain NHS costs, as users
substitute the purchase of these medicines, over-the-counter from community
pharmacies, in place of prescriptions obtained from general practitioners. It is assumed
that this will simultaneously secure savings on the NHS medicines bill, dampen
demand for general practice consultations and promote more efficient use of scarce
primary care resources. These assumptions were, however, unfounded in evidence.
Aim: To assess the extent to which increased availability of P class medicines
facilitates substitution between general practice and community pharmacy and the
costs accruing to stakeholders as a result.
Objectives: profile users accessing P medicines, investigating patterns of use among
different demographic and socio-economic groups; map the access routes adopted by
users; assess the extent of substitution between general practice and community
pharmacy services; develop a model to predict users choice of access route; and
investigate the changing distribution of costs.
Study design: Cross-sectional descriptive study, with prospective follow-up of
users. Semi-structured interviews elicited users' routes to access P medicines and the
time and resource costs incurred by stakeholders. Costing analyses estimated total,
mean and ranges of costs associated with different access routes. Consumers' surplus
analysis calculated the net consumption benefits accruing to users facing different time
and money costs. Cost minimisation analysis examined the relative costs and
efficiency of the alternate access routes.
Participants: 1185 users recruited in 15 community pharmacies in Lothian while
obtaining a P medicine, either on prescription or over-the-counter.
XVlll
Results: Substitution: the majority of users buying P medicines from a community
pharmacy successfully substituted this in place of obtaining them on prescription from
a general practitioner. However, a fifth of these users subsequently visited a general
practitioner also. User Profiles: Healthy, more affluent users were significantly more
and less affluent, iller users significantly less likely to attempt to substitute. Costs:
Substitution generated savings for society overall, with all stakeholders benefiting, on
average. Resource savings swing heavily towards the health sector. Users were only
marginally better off, on average. Time and resource costs were significantly higher
among those in less favourable economic circumstances, who perceived themselves
not to be in good health, or who were frequent users of primary care. Cost
minimisation analysis indicates promoting increased self-medication using P
medicines accessed from community pharmacies, as opposed to from general
practitioners, enhances technical and allocative efficiency within the primary care
sector.
Conclusion: Policies increasing availability of P medicines have improved access for
many users and are consonant with encouraging enhanced, graduated access to first-
contact services. However, they promote differential access that is systematically
related to the socio-economic status of users. Already disadvantaged people are
further disadvantaged. Consequently, inverse care is emergent. The challenge facing
policy makers is to improve the efficiency of the policy, simultaneously maximising
the substitution potential while avoiding the emergence of inequities in access. Making
P medicines available free, over-the-counter at community pharmacies to prescription
exempt users could potentially realise both objectives. Longitudinal, whole-systems
analysis, developing broader socio-economic theories of consumption, are required to




The best thing for being sad ... is to learn something.
That is the only thing that never fails.
You may grow old and trembling in your anatomies,
you may lie awake at night listening to the disorder of your veins,
you may miss your only love,
you may see the world about you devastated by evil lunatics,
or know your honour trampled in the sewers of baser minds.
There is only one thing for it then - to learn.
Learn why the world wags and what wags it.
That is the only thing which the mind can never exhaust,
never alienate, never be tortured by, never fear or distrust,
and never dream of regretting.
T.H. White
The Once and Future King, 1958
ACKNOWLEDGEMENTS
There are many people whom I must thank for supporting me during my PhD studies
and the preparation of this thesis.
The Medical Research Council
The study upon which this thesis is based was funded through a Medical Research
Council Training Fellowship in Health Services Research. I was enormously
privileged by the opportunities afforded to me during this fellowship. It provided me
with unrivalled opportunities for professional development, enabling me to undertake a
thorough training in health services research and explore the potential contribution that
health economists can offer in this area.
The Dept. ofCommunity Sciences, University ofEdinburgh
During my fellowship tenure, my academic home was the Primary Care Research
Group, General Practice Section, of the Department of Public Health and Community
Sciences, at the University of Edinburgh. I am indebted to friends and colleagues there
for their support, many of who gave generously of their time to discuss ideas and help
me to enhance my theoretical and methodological knowledge. Their lasting gift to me
is ongoing collaborations and friendships with a community of researchers of the
highest calibre, from a variety of research traditions. Particular thanks are due to
Professors John Howie and David Weller for their support during the writing up stage.
My academic supervision was provided by Dr Sally Wyke (Director of the Scottish
School of Primary Care) and Dr John Forbes (Senior Lecturer in Health Economics). I
thank them both for their input and patience. I extend particular thanks to Sally for her
personal as well as professional support.
I am also grateful to a number of external colleagues: Dr Rob Elton, who provided
expert statistical advice, reviewing my results chapters with a keen eye; Dawn Sykes,
xxi
former Pharmacy Facilitator at Lothian Health, for her assistance in the design and
recruitment stages; staff within the Public Health Section at Lothian Health who
assisted me in collating local statistics; and staff at the Royal Pharmaceutical Society
of Great Britain (Scottish Department) who assisted me in sourcing community
pharmacy costs.
I would also like to thank my examiners: Professor Nick Mays (London School of
Hygiene and Tropical Medicine); Professor Christine Bond (University of Aberdeen);
and Mr Mike Porter (University of Edinburgh). They made my viva stimulating and
unexpectedly enjoyable. Their consideration of the research was careful and
constructive. My thesis has, undoubtedly, been strengthened as a result of our
discussions and debate.
Thepeople who participated in my study
Particular thanks are due to the P medicine users who generously gave up their time to
take part. Without them, this study would not have been possible.
Myfamily
My love and thanks to Mum, Dad, Lynn, Leigh and Sophie for their love and support,
as always. Heartfelt love and thanks to Kevin. Without you, this would not have been
possible.
I dedicate this thesis to the memory of my grandmothers - Edna Myles and Margaret
Cochrane - strong women who led the way.
To everyone else who helped. Thank you very much.
wi 1
Introduction
Rapidly escalating health care costs have required health policy makers to reappraise
provision of health services, maximising health gain within finite resources. A
multiplicity of policy initiatives have been applied within UK primary care to
achieve this end including, cost containment, demand management, skill mix and
graduated access strategies. Key objectives of these policy initiatives were to better
target and meet demand and reconfigure first contact services, enhancing patient
access and convenience.
Efforts to optimise skill mix within primary care teams have been particularly
pronounced. Recognition of community pharmacy as a valuable and underused
primary care resource resulted in early efforts to better utilise their skills.
Reclassification of certain medicines, from prescription only medicines (POMs) to
pharmacy available (Ps) under the supervised sale of a community pharmacist, was a
key policy lever applied to engage community pharmacy within the broader primary
care demand management vision. Indeed, this strategy was one of the pioneer
primary care demand management initiatives.
Implicit in these efforts was a substitution hypothesis. Policy makers recognised the
potentially double substitution opportunity this presented - to move from more
(general practitioners) to less (community pharmacists) skilled and costly care
professionals and from public (via NHS prescription medicines) to private (over-the-
counter) payment for medicines - thereby alleviating pressure on NHS resources by
transferring an increasing share of direct health care costs onto consumers.
There was a widely held assumption within the policy and practice literature that
promotion of self medication for minor illness would help contain NHS costs, as
users substituted the purchase of pharmacy available (P) drugs in place of
prescription (POM) medicines obtained during general practice consultations, thus
securing savings on the NHS drugs bill and promoting more efficient usage of scarce
general practitioner time (Bramstad et al., 1994; Griffin, 1994; Anderson & Schou,
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1994; Ferner, 1994; Thomas & Noyce, 1996). However, this substitution hypothesis
was unfounded in evidence.
Early research efforts investigating the economic implications of the deregulation of
POM to P drugs identified the potential for substantial savings to both users and the
health sector (Temin, 1983; Temin, 1992; Ryan & Yule 1988; Ryan & Yule 1990).
However, these studies, assumed that substitution did occur, an assumption for which
there was little evidence.
While there is evidence that utilisation of both prescription and over-the-counter
drugs are price sensitive (O'Brien, 1989; Leibowitz et al., 1985; Leibowitz, 1989;
Ryan & Birch, 1991; Huttin, 1994) evidence regarding the extent of substitution or
complementary usage between prescription and over-the-counter drugs was scarce,
contradictory and inconclusive (Blaxter & Britten, 1996). Further, much of the
research is quite dated. It is based on either very few drugs or particular groups of
users; and many of the studies are American, the results of which may not be
generalisable to the UK. However, the key failings of the studies undertaken thus
far, are that they are based mainly on retrospective investigations into changes in
aggregate prescription data, pre and post deregulation. This approach failed to
investigate the complex choice processes and the associated costs and benefits
accruing from users' actual consumption behaviour.
In addition, studies investigating substitution between prescription and P medicines
typically have failed to identify the mechanics of it and, in particular, whether it was
patient or doctor initiated. Yet, these factors are crucial to understanding the extent
to which substitution or complementary usage of prescription and P medicines
actually exists and in accurately estimating the economic consequences of this.
There are multiple potential outcomes associated with encouraging increased self-
medication for minor ailments. P medicines may be used to directly substitute
another service (i.e. a community pharmacist in place of a general practitioner); they
may be used as an adjunct or complement (i.e. used as well as other services) with
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general practice and community pharmacy services used in tandem by users; they
may generate additional or new demand, with people presenting with problems they
would otherwise have ignored or dealt with themselves (i.e. lay as opposed to
professional management); or they may result in duplication between services, with
users attending for problems they have already sought advice on from other health
professional and/or services (i.e. presenting in multiple treatment settings, rather than
just one).
Available evidence suggests that there is no simple relationship between availability
of over-the-counter medicines and demand for NHS prescriptions. The assumption
that pharmacy available drugs, directly and only, substitute for consultations with
general practice and prescription drugs in the management of minor illness is overly
simplistic. The interface between self-medication and the NHS is likely to be far
more complex (Thomas & Noyce, 1996). Complementary usage of some P drugs and
general practice consultations undoubtedly exists. Thus, potential savings arising
from reductions in general practice consultations may be less than assumed.
In addition, the limited economic analyses that have been undertaken to date have
tended to focus on a particular perspective (for example, the net benefit to
consumers, or savings for the health sector) rather than investigating the changing
distribution of costs and benefits across all relevant stakeholders and the welfare
implications associated with this. To date, no cost benefit analysis of policies
encouraging use of P medicines accessed from community pharmacies as a substitute
for prescription medicines obtained from general practitioners in the management of
minor ailments has been conducted.
Thus, despite current extensive use of both prescription and over-the-counter drugs,
we still do not have a clear picture of the kinds of people who use them (Leibowitz,
1989) the factors influencing users' consultation patterns; the extent of substitution
or complementary usage between POM and P drugs; the welfare implications
associated with changing distributions of costs and benefits as a result; and their
impact upon the changing structures of primary care (Blaxter & Britten, 1996).
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This information is urgently required to allow general practitioners, community
pharmacists, users and health policy makers to assess the potential contribution of
increased availability of P class medicines from community pharmacies as one
option amid broader efforts to channel users with minor ailments to the most
appropriate primary care service provider and inform how best to reconfigure
primary care services to deliver policy aims.
Research involving detailed description and analysis of users' consultation patterns
in accessing P medicines and on the economic implications associated with this is,
therefore, timely and highly relevant (O'Brien, 1989; Kennedy, 1996; Mays, 1994).
The research outlined in this thesis addresses these issues.
Organisation of the thesis
Chapter 1 critically reviews literature related to the theoretical and methodological
underpinnings of the research. In addition, it synthesises a range of literature
relevant for assessing the impact of policy encouraging increased self-medication,
substituting pharmacy (P) available in place of prescription (POM) medicines and
consequently between general practitioners and community pharmacists. The chapter
ends by outlining the aim and objectives of the research.
Chapter 2 outlines the philosophical stance of the research. It then presents the
rationales and detail on the methodologies adopted concerning: the choice of the
study design; sample(s) selection procedures; the development and processes of data
collection; and data analyses strategies.
Chapter 3 addresses the central question regarding the extent of substitution and
complementary usage between general practitioners and community pharmacists
among users of P medicines. It presents data analyses: profiling the sample;
identifying patterns of P medicine use among different socio-demographic and socio¬
economic groups; maps the routes adopted by users to access P medicines; assessing
the extent of substitution or complementary usage between general practitioners and
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community pharmacists in the process; and outlines users' views on use of
community pharmacies and increasing availability of P medicines.
Chapter 4 presents a model identifying variables predictive of users' choice between
the two routes available to access P medicines, and summarises analyses
investigating whether there were any significant differences between users opting to
visit either the general practitioner or community pharmacist first to obtain their P
medicines.
Chapter 5 investigates the welfare implications associated with policy encouraging
increased self-medication using P medicines, outlining the changing distribution of
time and resource costs accruing to key stakeholders. In addition, it presents the
results of modelling exercises exploring the impact on net benefits to stakeholders
resulting from numerous policy scenarios. Finally, it addresses the relative
efficiency to both users and the health sector associated with accessing P medicines
through prescription and over-the-counter routes.
Chapter 6 presents an overview of the research and discusses the findings. It outlines
limitations of the theory and methods applied. It then synthesises the results,
contextualising them to current policy debates, discussing the 'success' of the policy
aiming to encourage substitution between prescription and P medicines and general
practitioner and community pharmacist. Finally, it identifies the winners and losers





The main aim of this research was to assess the impact of policy initiatives encouraging
increased self-medication, substituting pharmacy available medicines in place of
prescription medicines (and consequently between community pharmacists and general
practitioners) in the management of minor ailments within primary care, investigating
the changing distribution of costs accruing to key stakeholders as a result.
In exploring the issues around this research, a diverse range of literature was potentially
relevant, covering a number of disciplinary areas, including, economics, sociology,
pharmacy, health services research and health policy. The initial literature search is
outlined in Appendix l.
After initial immersion in the literature, a number of more focused areas (listed below)
were identified as relevant for informing the research. Subsequent electronic searching
targeted these areas, alongside hand searching of key journals, scrutiny of a relevant
literature index and cross-referencing from sourced papers in a bid to encapsulate
relevant literature sources.
The literature chapter comprises two separate sections. The first briefly considers the
theoretical foundations and outlines the two main economic methodologies applied in
the research: consumer surplus analysis and economic evaluation. The second
summarises and critically appraises a range of topics of relevance to the study,
including: incidence and response to minor ailments; self-care and self-medication; use
of general practice and community pharmacy services; and use of prescription and non-
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prescription medicines. Policy relating to concerns to 'manage' and ensure appropriate
access to and use of primary care services, and general practice and community
pharmacy within this, is then outlined, considering: the extension of community
pharmacists' roles; medicine deregulation; and primary care skill mix substitutions. The
evidence relating to the efficiency and effectiveness of skill mix substitutions within
primary care generally and between general practitioners and community pharmacists
specifically is then outlined. The literature chapter concludes by identifying gaps in the
current evidence base that underpinned the rationale for this research.
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1.2 Relevant theoretical andmethodological literature
1.2.1 Consumers' surplus analysis
Consumer surplus is a demand related concept within economics that measures
consumer benefit (Call & Holahan, 1983; Tresch, 1994). Demand theory assumes that
consumer preferences can be represented schematically using a demand function. In the
1830s, Cournot was the first person to define and draw a demand function. It depicted
the simple empirical relationship observed between sales and prices, noting, as a matter
of widely held experience, their inverse relationship and thus the negative slope of the
demand function (Blaug, 1996). Indeed, the inverse relationship between product price
and amount consumers purchased was observed so regularly that this became known as
the 'law of demand' (Call & Holahan, 1983).
Just over a decade later (1844) Jules Dupuit, a French engineer, extended the simple
demand function introduced by Cournot. His primary theoretical contribution was to
recognise the distinction between total and marginal utility (satisfaction) derived by
consumers in relation to demand prices (Dupuit, 1844; Blaug, 1996). In considering the
value to society of publicly provided goods or utilities, Dupuit recognised that the
benefits consumers derived from consumption of such goods could sometimes outweigh
the price they paid for them (Dupuit, 1844).
Dupuit was also the first theorist to interpret demand as a function of marginal utilities.
He explained that the negative slope of the demand function resulted from the fact that
the extra utility or satisfaction gained from additional consumption of a particular good
or service typically declines (Blaug, 1996). His distinction between total and marginal
utility became known as the 'law of diminishing marginal utility' (the decline in extra
satisfaction as more is consumed). The existence of income and substitution effects
typically observed within consumer behaviour also help to explain the downward slope
of the demand function. The income effect refers to the fact that when prices rise (fall),
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consumers' real income decreases (increases) and demand decreases (increases) due to
the fact that existing buyers increase their demand and new buyers enter the market.
The substitution effects means that if the price of a good rises (falls), it becomes
relatively expensive (cheap) compared to competing goods, therefore, you are likely to
get some switching or substitution in purchases and associated decreases (increases) in
quantity demanded. The combination of these theoretical developments paved the way
for the introduction of the 'consumers' surplus' concept (Marshall, 1920; Call &
Holahan, 1983; Ryan & Yule, 1988; Ryan & Yule, 1990; Wonnacott & Wonnacott,
1986; Stanlake, 1976; Blaug, 1996; Lipsey, 1987).
1.2.1.1 Applying consumers' surplus methodology
The application of consumers' surplus analysis can be demonstrated through an
example. Figure l.l is a simple demand function that illustrates the quantity (Q) of a
good that buyers would be willing and able to purchase (demand) at various market
prices (P). In analysing demand functions the 'ceteris paribus' assumption is made i.e.
that 'other things being equal', everything that affects the quantity demanded, with the
sole exception of price, is held constant. The purpose of the demand curve is to show
that quantity demanded is affected by price and price alone. Each point on the demand
curve measures the maximum price that a consumer would pay for successive units of a
good when purchased one at a time. The consumer will pay no more than the marginal
benefit of each unit. Total benefit (derived from all units of consumption) is measured
by the area under the demand curve (Stanlake, 1976; Call & Holahan, 1983; Tresch,
1994; Pearce, 1983).
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Figure 1.1 illustrates that: at price pi, quantity demanded is qi; and when the price of the
good falls to p2, quantity demanded increases to c\i-
FIGURE 1.1: SIMPLE DEMAND FUNCTION
qi qi Q
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Building on these basic principles, Figure 1.2 highlights the consumers' surplus concept.
It indicates that the consumer is prepared to pay £5 to consume their first unit of a good,
£4 for the second, £3 for the third, £2 for the fourth, £1 for the fifth and zero for the
sixth. Thus, if the market price of the good is £3 per unit, they would buy only 3 units
and no more as they are only prepared to pay £2 or less for any additional units.








2 3 4 5 6
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Consumer surplus measures the difference between the buyer's marginal willingness to
pay for successive units of a good and the price they actually pay (Call & Hollahan,
1983; Tresch, 1994; Blaug, 1996). The 'surplus' arises from the fact that the market
places the same value (price) on each unit of a good that the consumer purchases,
whereas, the consumer places a different value on each unit (as a result of their
diminishing marginal utility from consumption) (Lipsey, 1987).
Consumer surplus is particularly useful in evaluating the merits of proposed public
projects. Governments typically provide goods and services to consumers who do not
pay directly or fully their costs (e.g. health services or subsidised prescription
medicines). This can result in a gap emerging between what consumers would be willing
to pay, rather than do without the good or service, and what they actually end up paying
(Call & Holahan, 1983).
Generally we find that when consumers can buy all the units of a commodity they
require, at a single market price, they pay much less for the quantity consumed than they
would be willing to pay, faced with the choice between that amount or nothing (Lipsey,
1987). For example, in figure 1.2, the total cost to the consumer of buying 4 units of the
good is £8 (4 units at £2 each). However, the demand schedule indicates that, they were
willing to pay a maximum of £14 for these 4 units (£5 for the first unit, £4 for the
second, £3 for the third and £2 for the fourth). Thus the consumers' surplus is £6 (£14 -
£8). This is equivalent to the triangle ABC.
Consumers' surplus can also be used to measure the benefit to the consumer from a fall
in prices or costs (Blaug, 1996; Ryan & Yule, 1988; Ryan & Yule, 1990). For example,
a reduction in cost from £2 to £1 in figure 1.2 would increase the consumer surplus by
the area BCDE.
Indeed, this is the main application of consumers' surplus within this research -
examining the net benefits or costs incurred by consumers facing different prices to
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access P medicines via alternative routes, either on prescription from general
practitioners or over-the-counter from community pharmacists.
At first glance, consumers' surplus appears to be a relatively straightforward concept.
However, its application was made slightly more complex when Hicks (1943)
highlighted that ordinary demand functions do not account for impacts on income as a
result of policy changes and thus may yield only approximate measures of consumers'
surplus. He thus refined the theory, advocating that it is necessary to hold real income
constant, and proposed two different measures of consumers' surplus - compensating
variation and equivalent variation. They differ depending on whether the reference
utility for the consumer is before or after the introduction of the policy. Compensating
variation adopts the utility before as its reference point and measures the minimum
amount of money compensation that would need to be given to the individual after the
policy is introduced to restore them to their original utility level. Equivalent variation
adopts the utility after the introduction of the policy as its reference point and measures
the amount of money that would need to be taken away from the individual prior to the
introduction of the policy change to restore their utility to its original level.
In practice, estimation of compensated demand functions is notoriously difficult. If the
income effects associated with policy change are believed to be small then there are
likely to be only small differences between the two measures of consumers' surplus.
This was assumed to be the case in this study. Differential income impacts potentially
emergent from encouraging consumers to self-medicate using P medicines are, however,
considered within the discussion chapter.
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1.2.2 Economic evaluation
Methods of economic evaluation present frameworks for the comprehensive
identification of the economic factors involved in decision-making. The basic task of
economic evaluation is to identify, measure and compare the costs and consequences of
alternatives being considered (Drummond et ah, 1987; Drummond et ah, 1997; Gold et
ah, 1996).
The philosophical and theoretical underpinnings of the methods of economic evaluation
are firmly rooted within welfare economics. Welfare economics is concerned with the
principles for maximising social welfare and economic output. It aims to inform social
decision-making by studying the effects of policies on the welfare of society, assessing
their relative desirability and making explicit prescriptions, with a view to optimising
social welfare. While positive economics seeks to describe how the world works,
welfare economics is essentially normative and makes value judgements about how the
world ought to work (Gold et ah, 1996).
Gold et al (1996) define welfare economics as being 'concerned with the means by
which we can assess the desirability - from a societal point of view - of alternative
allocations of resources'.
Welfare economics is based on assumptions that individuals maximise a well-defined
preference function. A social utility function is defined as some aggregate of individual
utilities. Maximisation of the social utility function is the ultimate goal of any resource
allocation scheme (Nath, 1973; Gold et ah, 1996). Welfare economics investigates the
changing distribution of costs and benefits and their potential impact on social utility,
resultant from policy changes (Begg, Fischer & Dornbusch, 1991; Coast, 1999).
Early developments in welfare economics can be traced back to the eighteenth century
and economists such as Hume (1740s) and Smith (1780s) who began commenting on the
appropriate role of government. In the late eighteenth century, Jeremy Bentham began
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to consider group or societal welfare, rooted in utilitarian moral philosophy, embracing a
theory of social justice that advocated policies that produced 'the greatest happiness for
the greatest number' (Brown & Jackson, 1986; Gold et al., 1996). However, it was not
until almost a century later in the late nineteenth century (1880s) that continental
economists (particularly Italian contributors) began to explicitly analyse the public
economy within an exchange framework, exploring issues relating to public expenditure
and taxation (Brown & Jackson, 1986).
The founding father of modern welfare economics is commonly regarded to be Pigou
(Nath, 1973). Pigou believed that the welfare of society was a summation of the welfare
of the individuals comprising that society. He outlined certain 'self-evident truths'
including, the assumption that it was desirable to promote social welfare or utility; and
his 'equal capacity' principle, which asserted that 'all individuals should be treated as if
they had equal capacity to enjoy a given share of income, leisure and welfare' (Nath,
1973).
However, in the 1930s, Lionel Robbins critiqued Pigou's work, particularly his
assumptions concerning cardinal measurement of and ultimately direct inter-personal
comparisons of utility, which he believed to be incomparable in an objective, scientific
way. He rejected the normative approach, believing there to be no place for ethical
value judgements within economics. Robbin's work initiated considerable effort on the
part of economists to frame ethics-free welfare propositions upon which to base policy
evaluation. The result was the re-emergence of concepts such as efficiency and
optimality, which were believed to be more neutral, value-free concepts (Nath, 1973).
The next key developments in welfare economics came when economists shifted their
attention away from partial to general equilibrium analysis. The partial equilibrium
analysis, founded upon the ceteris paribus assumption and techniques of comparative
static analysis were useful conceptual and analytical frameworks. Their key limitation,
however, was their lack of consideration of the economy as a whole (Call & Holahan,
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1983). In contrast, general equilibrium analysis specifically embraced interrelationships
within the economy and sought to identify conditions conducive to promoting
simultaneously determined equilibria in all markets i.e. general equilibrium (Call &
Holahan, 1983).
The Italian economist Vilfredo Pareto was instrumental in developing the theory and
application of general equilibrium analysis in welfare economics. Pareto, like Robbins,
rejected the strong assumption of cardinal utility and direct interpersonal comparisons;
instead embracing the less restrictive concept of ordinal utility, using it to develop a
framework outlining the conditions necessary to achieve optimal allocation of a
country's economic resources (Math, 1973).
In a distinct attempt to make economics more objective and scientific, Pareto's model
invoked only two 'minimal ethical judgements': (l)that individuals are the best judge of
their own welfare; and (2) the Pareto Improvement Criterion which stipulated that social
welfare would be enhanced by some policy or change, provided at least one person feels
better off because of the change and no one else any worse off (Gold et al., 1996).
Applying these assumptions, Pareto demonstrated that optimal conditions of production
and exchange could be satisfied. Pareto efficiency is defined to occur when consumer
and producer surpluses are maximised and the distribution of resources is such that it is
not possible to make anyone better-off without making someone else worse-off.
Economic thought pre Pareto is characterised by a muddy dichotomy between efficiency
and equity. Pareto's key contribution was to explicitly distinguish efficiency and equity
considerations. He neatly sidesteps interpersonal comparisons and related distributional
and equity issues, by restricting his model to consider only welfare enhancing policies
(Blaug, 1996). Pareto's definition of welfare maximum was ingenious in that it defined
the optimum as one that engenders unanimous approval because it does not involve
conflicting welfare changes (Blaug, 1996). By definition, the optimum is achieved only
if at least one person is made better off and no one else worse off by the policy change.
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As such, it obviates the need for interpersonal comparisons of utility and abandons the
notion of a unique social optimum, highlighting the possibility of an infinite number of
incomparable social optima (Blaug, 1996). Pareto optimality subsequently became, and
remains today, the dominant benchmark within mainstream microeconomics for
assessing whether specific policies improve social welfare or not (Gold et al., 1996).
Two primary objections are, however, routinely levelled at the Paretian model: (1) its
inability to consider policies that make some better off and others worse off (i.e. the
most common policy scenario); and (2) the fact it ignores distributional considerations
(by accepting that social welfare can be enhanced by policy provided at least one person
feels better off and no one else is any worse off) tacitly accepting the status quo, thereby
introducing bias in economic analyses in favour of existing economic conditions and
institutions.
Refinement of the Paretian model was, therefore, required if it was to be productively
applied to the vast majority of policy changes that generate both winners and losers.
This was provided Kaldor and Hicks (Kaldor, 1939; Hicks, 1939). They proposed a
modification to the theory to redress the limitation of the Pareto criterion. This was to
become known as the Kaldor-Hicks 'Compensation Criteria' (subsequently refined by
Skitovsky in 1941). In short, they proposed that a policy change may be regarded as
socially desirable if it is possible for the gainers to compensate the losers until they are
in a position where they are ultimately both better off.
Kaldor and Hicks argued that such a change constitutes an improvement because it is
'possible' to redistribute welfare gains in such a way that no one loses as a result of the
policy change (Gold et al., 1996). It is important to note, however, that the Kaldor-
Hicks Compensation Test is a hypothetical criterion. It does not require that the winners
actually be required to compensate the losers, merely that they are potentially able to do
so (Blaug, 1996).
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The Kaldor-Hicks criterion underpins the primary decision rule upon which cost benefit
analysis and economic evaluation rests. However, it suffers from the same critique as
Pareto's i.e. that it ignores the possible importance of distributional issues that could
lead to policies being implemented that favour the rich at the expense of the poor.
Efficiency purists argue that policies should be judged primarily on the basis of the
Kaldor-Hicks-Skitovsky criteria, addressing issues of distributional justice thereafter.
They contend that the role of economic analysis is only to inform policy makers whether
particular policies are efficient tools to achieve desired changes, and not to pronounce on
the merits of such change (Coate, 2000). Others argue that the function of welfare
economics is to explicitly consider applied ethics, rather than avoid it and that it is the
duty of the economist to draw attention to efficiency-equity trade-offs (Blaug, 1996).
Changes in welfare and their distribution are inextricably linked. For a policy change to
be considered to have generated a real improvement in societal welfare, it seems
necessary to prefer the second (post-policy) distribution to the first (pre-policy) one.
This and other concerns regarding the Paretian model and its usefulness for policy
analysis are explored further within the discussion chapter.
1.2.2.1 Applying economic evaluation methodology
The existence of scarcity and thus opportunity cost considerations underpins the need to
undertake economic evaluations. Priorities need to be established and choices made
regarding efficient ways to provide health care in order to meet needs (Gold et al., 1996;
Drummond et ah, 1987).
Drummond et al (1997) note that economic evaluations address two main issues -
clinical and economic effectiveness. Thus, two key questions underpinning any
economic evaluation are: (l) is a health procedure, service or programme worth doing?;
and (2) is it worth doing compared with alternate uses to which scarce resources may be
employed (Drummond & Jefferson, 1996)? Drummond et al (1997) expand upon these
noting that other pertinent questions relevant to most economic evaluations regularly
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recur, including: who should do what to whom?; with what health care resources?; and
in what relation to other health services?
Economic evaluations evaluate the relative efficiency of different methods of providing
health care services, assessing the relationship between resource use, processes and
outcomes (Earl-Slater, 1999). Simultaneous assessment, of two particular types of
efficiency - technological and allocative — are inherent within economic evaluations.
Technological efficiency is achieved by securing the maximum output from the
available resources and technology at our disposal. Allocative efficiency addresses the
distribution of resources and is achieved when the best combination of goods are
produced, that match the priorities of a society, using the lowest combination of
resources (Call & Holahan, 1983; Wonnacott & Wonnacott, 1986; Earl-Slater, 1999;
Kielhorn, 2000).
Economic evaluations can be classed as either 'partial' of 'full'. Partial economic
evaluations tend to investigate either costs or consequences, but not both (Drummond et
al., 1997). For example, cost analysis focuses exclusively on cost. 'Full' economic
evaluations address both costs (inputs) and consequences (outputs) (Drummond et ah,
1997). Four main categories of full economic evaluation exists - cost minimisation
analysis (CMA), cost effectiveness analysis (CEA), cost utility analysis (CUA) and cost
benefit analysis (CBA).
All four economic evaluation methodologies adopt a common approach in that they all
seek to compare the costs and consequences of health care interventions. Further, they
all deal with costs in very similar ways. The primary difference between them is the
differing, although sometimes subtle, ways in which they measure and value
consequences. Table 1.1 below presents the four forms of full economic evaluation and
summarises the key differences in their approach to identifying, measuring and valuing
consequences (Drummond et ah, 1997).
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TABLE 1.1: MEASUREMENT OF COSTS AND CONSEQUENCES IN ECONOMIC EVALUATION*
Type of study Measurement/valuation Identification of Measurement/valuation
of costs in both consequences of consequences
alternatives
























Adapted from Drummond et al., 1997
The economic evaluation method adopted within this research is cost minimisation
analysis (CMA). It is the most limited form of full economic evaluation (Drummond et
al., 1997). However, it is the method of choice when the outcomes (either health or
other intermediate outcomes) of the intervention and comparator programmes are
assumed to be equal (Briggs & O'Brien, 2001). As such, the decision, and thus the
evaluation technique, focuses only on costs and the principal efficiency comparison is
made on the basis of cost per identical outcome (Drummond et al., 1997; Gold et al.,
1996; Drummond & Jefferson, 1996). Cost minimisation analysis is, however, distinct
from the simpler cost analysis method in that it should in fact consider consequences,
even if they are ultimately presumed identical (Drummond et al., 1997). Cost
20
minimisation analyses are particularly useful for considering the distribution of costs and
the extent to which they shift between key groups (Gold et al., 1996).
There has been considerable debate among health economists in recent years regarding
encouraging 'good' practice in the conduct of economic evaluations within health care
settings. This debate has culminated in the production of guidelines or common
standards that have been adopted by key academic journals, providing both editors and
referees with benchmark standards to inform their critique and encourage systematic
appraisal of such research (Drummond et al., 1987; Drummond & Jefferson, 1996; Gold
et al., 1996; Drummond et al., 1997).
In the UK, Drummond and colleagues have identified benchmark standards for health
economic evaluations. They devised a comprehensive checklist for critiquing economic
evaluations. It address three key areas: study design, data collection and analysis, and
interpretation of results; which are broken down into ten detailed areas of consideration,
which implicitly identify the key stages involved in economic evaluation (Drummond et
al., 1987; Drummond & Jefferson, 1996; Drummond et al., 1997) (See Table A 1.1 in
Appendix 1).
It is unlikely that every study will satisfy all the criteria outlined by Drummond and
colleagues. Nonetheless, they offer a useful guide on how to design an evaluation, the
critical questions to address and the pitfalls to avoid and are a useful tool to identify the
strengths and weaknesses of studies (Drummond et al., 1987; Drummond et al., 1997).
As such, the cost minimisation conducted within this study is presented in the
Drummond format (within the Methods Chapter) outlining the key methodological and
practical issues that merited consideration in the design and conduct of the economic
evaluation undertaken in this research.
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1.3 Relevant policy, practice and research literature
This section of the literature review summarises a number of factors influencing the use
of P class medicines to self-medicate minor ailments within primary care and the
resultant substitutions between general practitioners and community pharmacists
occurring as a result. It begins by outlining the incidence and management of minor
ailments. It then summarises trends in self-care and self-medication; use of general
practice and community pharmacy services; and use of prescription and non-prescription
medications in the UK. Simultaneous developments in policy, relating to these issues
generally, and the promotion of substitution between general practitioners and
community pharmacists and prescription and P medicines in the management of minor
ailments specifically, are then outlined.
1.3.1 Incidence andmanagement ofminor ailments
Minor ailments are variously defined. A variety of synonyms are used including,
common, self-limiting and trivial ailments. However, they are generally taken to include
conditions that require little or no medical intervention (RPSGB, 2003a). Definitive
figures on the incidence of minor ailments within the UK population are hard to find.
Sources suggest, however, that 90% of adults suffer from a minor ailment within a two-
week period (Whittington et al, 2001) and 94% within the last year (Reader's Digest,
1995).
Sociologists have long studied 'illness behaviour', including responses to minor
ailments. Much of the research evidence presented in this section is drawn from
contributions from the literature of this discipline. The most common response to minor
ailment symptoms is to do nothing and leave them untreated (PAGB, 1997). If people
do act to manage a minor ailment, the most common reaction is some form of self-care
action. Indeed, most people express a preference to self-manage rather than consult with
health professionals, which usually only occurs after self-care efforts (Hassell et al..
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1998; Whittington et al., 2001; Hassell et al., 1997). Survey evidence suggest that one
third of minor ailment sufferers treat with either an over-the-counter or prescription
medicine they already possess; 9% purchase over-the-counter medicines; and
approximately one in seven consult a health professional, most frequently a general
practitioner (PAGB, 1997). The likelihood of seeking professional care is related to a
number of factors including, users' perception of the seriousness of symptoms, whether
they have any experience of a similar situation and whether they believe that
professional assistance will be effective (Whittington et al., 2001). A number of
research efforts suggest, however, that a 'natural hierarchy' appears to implicitly exist
within users' care seeking strategies. They range from watchful waiting with no action
taken at one end of the spectrum, to advice from pharmacy assistants and pharmacists
sought somewhere prior to seeking a doctor's advice at the other end.
Community pharmacies have been variously described as a 'first port of call', a
'stepping stone' or 'filter' into seeking professional advice and care in response to
illness. Users appear to value the reassurance and 'safety net' of the community
pharmacist's opinion, acknowledging that they will be referred to a doctor, if need be
(with approximately 6% of cases actually referred on to doctors by community
pharmacists) (Hassell et al., 1996; Hassell et al, 1997; Hassell et al., 1998).
Care seeking behaviour among community pharmacy users also differs considerably.
For example, observational research highlighted that customer typologies exist among
community pharmacy users. Customers were found to fall into one of two types: the
'determined purchaser' and the 'worried well'. Almost a third (29%) of community
pharmacy users were described as 'determined purchasers', whereby their interaction
with community pharmacy staff took the form of: either demand only for very specific,
named, products; or slightly more personalised or inquiring demand (Hassell et al.,
1996). These users appeared to purchase medicines in the same way as any other
commodity (Rogers, Hassell & Nicolaas, 1999). The 'determined purchasers' contrasted
with another customer group, the 'worried well' who typically presented and described
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symptoms or problems to pharmacy staff, receiving either reassurance or a product
recommendation. This group, however, comprised a very small proportion (5%) of
community pharmacy customers overall (Hassell et al., 1996).
1.3.2 Trends in self-care and self-medication
Self-care is frequently regarded as the most obvious and immediate response to
maintaining, promoting and restoring health (Fryklof, 1984; Dean, 1989a). Self-care is
variously defined. However, a commonly cited definition of self-care is that provided
by Lunde (1990) as follows:
"Self-care is what people do for themselves to maintain and cope with illness, which
includes health promotion, disease prevention, treatment of minor illness, the
management of chronic disease and rehabilitation."
Dean suggests that the bulk of all care in illness may be regarded as self-care (Dean,
1989a). Others concur, variously describing it as an important adjunct to conventional,
formal care (Defries et al., 1989) right up to the dominant care response, with
professional care regarded as supplemental (Segall, 1989). Indeed, self-care responses
are central in three of the four types of illness behaviour described by Dean as follows:
(l) decision to do nothing (e.g. watchful waiting as a strategy); (2) non-medication
forms of self-care (e.g. home nursing); (3) self-medication strategies; and (4) decision to
consult formal care providers (Dean 1989a; Dean, 1989b).
Self-care is a broad and complex concept, incorporating notions of autonomy and
influence, relating to consumers' engagement with and informed choice between the
matrix of formal and informal health care systems (Dean, 1989; Gross, 1990; Luval et
al., 1989). The concept has engendered much debate among sociologists. Polar
opposite views on its merits have emerged: ranging from very positive perceptions of it
as empowering, promoting consumer sovereignty and choice; to very negative
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perceptions of it as overly individualistic, victim blaming, and concerns that it could
result in the negation of the broader structural and environmental factors that cause
disease (Chappie and Rogers, 1999). Whatever the perspective, it is often described on a
continuum of care: ranging from no care at one end; through to self-care managed alone;
and ultimately self-care shared with professionals at the other end (Chappie & Rogers,
1999; Bentzen, 1989).
Self-medication is regarded as a form of self-care and may be regarded as referring
broadly to the use of non-prescription medicines at three different levels: for health
promotion and maintenance or in treatment of self-limiting conditions; or in the early
stages of more serious illness; and supplemental care beyond that provided by formal
care services in more serious and chronic illness situations (Payne et al., 1996).
Despite the considerable extent of self-care activities, and self-medication strategies
within this, self-care and self-medication strategies have, for a long time, been relegated
to the periphery of formal health care delivery and their role generally under-
acknowledged (RPSGB, 1998). Self-care has, however, been recently 're-discovered'.
A number of broader political and policy developments have encouraged this, including:
UK health policies encouraging a 'primary care led' NHS; the slow, but steady,
deregulation to over-the-counter availability of medicines previously only obtainable on
prescription; broader cultural and social developments that have championed increased
consumer choice and sovereignty, seeking to empower individuals in health care
decision making, to take more responsibility for their health and more actively engage as
partners in the national contract for health; alongside the desire of governments to
transfer a share of escalating health care costs to consumers (RPSGB, 1998; Fryklof,
1984).
Self-care is now increasingly acknowledged by health policy makers as a 'hidden health
care resource' to be tapped into (Fryklof, 1984; Chappie & Rogers, 1999).
Consequently, encouraging DIY ('do it yourself) health care is in political vogue
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(Reese, 1990). Self-care strategies are increasingly prevalent. This trend seems set to
continue. Indeed, Smith asserts that the information age may result in the traditional
pyramid of medicine being inverted, with industrial age, professionally led care being
increasingly relegated to a more subsidiary support role within a system that
increasingly emphasises self-care (Smith, 1997).
Yet, despite their commonness, self-care practices are reported to be relatively under-
researched (Haug, Wykle & Namazi, 1989; Segall & Goldstein, 1989). Segall and
Goldstein (1989) reviewed research evidence investigating potential correlates with self-
care activities in the late 1980s. However, despite the expanding interest in the field,
they noted that the literature was "characterised more by debate than data". Their review
highlighted the often contradictory and inconclusive findings in the area. Some studies
indicated that adoption of self-care strategies were independent of age and sex, while
others noted that results relating to these factors were contradictory, allowing no firm
conclusions to be drawn. They did, however, outline a few emergent trends that
suggested that self-care tendencies appear to increase among the unmarried, better
educated, younger, or those sceptical about doctors. Overall, though, they concluded
that no one or group of socio-demographic characteristics were systematically correlated
with self-care behaviours.
Chappie and Rogers (1999) in a more recent review of qualitative studies investigating
what encourages the adoption of self-care strategies identified a number of potentially
important explanatory factors, including: sense of autonomy and control; social
networks and the influence of others; the timing and stage of the individual's illness; and
the meaning of disease to them. Evidence on the effects of self-care efforts in terms of
its success and impact on health service utilisation were, however, found to be mixed
and inconclusive (Chappie & Rogers, 1999).
Having outlined the incidence of minor ailments and trends in self-care and self-
medication practices often adopted to manage them, it is also useful to consider who and
26
what influences use of general practice and community pharmacy services generally and
their use to deal with minor ailments specifically.
Large bodies of research document the influence of a multiplicity of socio-demographic
and other characteristics (e.g. cultural values, family and other social network
influences) that determine the social situations that may either enable or constrain health
related behaviours (Calnan, 1989; Dean, 1989). For example, research investigating why
people use primary health care services commonly finds that people who consult most
are also most ill (Neal et al., 1998; Campbell and Roland, 1996) and that social
disadvantage increases need and consequently utilisation (Campbell and Roland, 1996).
Trends in health care utilisation are undoubtedly mediated by multiple contingencies,
ranging from psychological to external environment and social factors (Campbell and
Roland, 1996, Carr-Hill, Rice and Roland, 1996; Neal et al., 1998; Rogers, Hassell &
Nicolass, 1999). Specific trends in the use of general practice and community pharmacy
services are outlined below.
1.3.3 Use of general practice services
General practitioners deal with approximately 90% of all episodes of care within the UK
NHS (Payne et al., 1996; Bjoke et al., 2002). Approximately one in eighteen symptom
episodes are believed to result in consultation with a doctor (Campbell and Roland,
1996). In an average week, the average UK general practitioner will consult with 140
patients (Payne, Ryan-Woolley and Noyce, 1996). 70% of people who consult a general
practitioner receive a prescription for a medicine (Yuen, 1999).
Research indicates that around four-fifths (78%) of people registered with a general
practitioner consult at least once a year and that the average number of consultations per
person per year is five (Tully and Temple, 1999; Hassell, Noyce and Nicolaas, 1998;
Hassell et al., 1998). Studies highlight that certain demographic, socio-economic and
organisational features of care influence user consultation rates with general
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practitioners. These are summarised below. Demographic factors: in general, women
consult more than men, twice as often in the 16-44 years age group (Campbell and
Roland, 1996). There is little difference in use by marital status, however, the widowed
and divorced are more likely to consult a general practitioner than those who are single
or married (Roger, Hassell and Nicolass, 1999). Socio-economic factors: users from
social classes 4 and 5 consult more frequently for most conditions (Campbell and
Roland, 1996). Employment status and type of housing are also strongly associated with
utilisation rates. Unemployed people are more likely to consult a general practitioner,
especially if they became unemployed within the last year (Hopton, Porter and Howie,
1992; Campbell and Roland, 1996; Carr-Hill, Rice and Roland, 1996). People living in
rented accommodation are more likely to consult for a range of conditions than owner-
occupiers (Campbell and Roland, 1996; Carr-Hill, Rice and Roland, 1996). Indeed,
housing tenure is a stronger independent predictor of consulting behaviour than social
class (Campbell and Roland, 1996; Hopton et al., 1992). Consultation rates with general
practitioners are also higher for women living with a partner (Carr-Hill, Rice and
Roland, 1996).
The organisational feature, distance from services, is also predictive of utilisation rate,
with an inverse relationship between distance to facilities and utilisation. Elderly and
disabled patients and those with transport difficulties are particularly affected by
distance (Campbell and Roland, 1996; Hopton, Porter and Howie, 1992).
1.3.3.1 Minor ailments and use of general practice
Having considered statistics concerning the utilisation of general practice services
generally, it is also useful, in the context of this study, to consider the utilisation of
general practitioner services by users seeking advice and/or treatment for minor ailments
specifically.
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The absence of agreement regarding what exactly constitutes, or how one might define,
a minor ailment makes measurement of the impact of it on general practice workload
hard to disentangle. Literature estimates range widely, suggesting that anywhere
between 30 to 70% of general practice workload is taken up dealing with minor ailments
(Whittington et al, 2001; Payne, Ryan-Woolley and Noyce, 1996). It has been estimated
that between 100 and 150 million general practice consultations a year are taken up
dealing with potentially self-treatable conditions (Editorial, 1994; Hoog 1992). Further,
it has been suggested that a significant reduction in general practice workload could be
achieved (in the order of 16 consultations per general practitioner a day) if users could
be encouraged to more actively self-medicate minor ailments (Hoog, 1992). One study
indicated that 39% of general practitioner time overall is taken up dealing with minor
ailments (Bradley, 1998; NPA, 2002a) and another that over a quarter of general
practitioners believe that they spend over 70% of their time consulting about minor
ailments (Walker, 1996). These estimates suggest that the resource implications
associated with dealing with minor ailments within general practice are likely to be
considerable. Cost estimates are rare, although one Audit Commission report estimated
that the NHS could potentially save £263M a year by encouraging people to self-
medicate minor ailments using non-prescription medicines (Audit Commission, 1996).
Such trends may help to explain a British Medical Association discussion paper
considering whether general practitioners should continue to prescribe medicines that
are available without a prescription, over-the-counter at community pharmacies
(Whittington et al., 2001). They also raise the related issue of what the scope of the
NHS should be? For example, the place for privately financed care and self-care in the
treatment ofminor ailments. This is an issue explored further in the Discussion Chapter.
29
1.3.4 Use of community pharmacy services
There are approximately 12,000 community pharmacists in the UK (Kennedy, 1996;
Yeun, 1999; NPA, 2003): 10,460 in England and Wales (NHS Confederation, 2003) and
1150 in Scotland (Scottish Executive, 2003); dispensing 665M and 60M prescriptions
per year respectively (NHS Confederation and Scottish Executive 2003). Most
community pharmacies open between 31-40 hours a week (NHS Confederation, 2003).
The number of community pharmacists in any area is regulated by a licensing system
(NHS Confederation, 2003). Community pharmacists, like general practitioners, are
independent practitioners contracted by the NHS to provide pharmaceutical services,
with NHS dispensing fees accounting for around 80% of a typical community
pharmacy's turnover (NHS Confederation, 2003). Approximately 2% of the NHS budget
is taken up by community pharmacy (Kennedy, 1996). Remuneration of community
pharmacists is funded direct by the Department of Health, is subjected to a negotiated
global sum and is, therefore, limited. 12% of total NHS spending (£6,726 in 1999) was
expended on general pharmaceutical services, comprising: the cost of medicines;
pharmacists' remuneration in the form of dispensing fees; container costs and on-cost
allowances (Yuen, 1999; OHE, 2001). UK outlay on pharmacy services is, however,
modest by OECD standards (Yuen, 1999).
Six million people visit community pharmacies in the UK every day (600,000 in
Scotland); more than to any other health outlet (NHS Confederation, 2003; Scottish
Executive 2003; Payne, Ryan-Wooley & Noyce, 1996). A broad range of conditions and
symptoms are presented within community pharmacy, with respiratory tract,
gastrointestinal tract and skin problems most common (Hassell et ah, 1998; Smith and
Salkind, 1990; Whittington et ah, 2001). Survey research suggests that between 80% and
94% of the UK population report having visited a community pharmacy within the last
year (94% in Scotland); approximately 70% within the last month; and that, on average,
people make one visit per month to community pharmacies (Tully and Temple 1999;
Scottish Executive, 2003; Hassell et al, 1998). Thus, utilisation of community pharmacy
is high and, in general, people visit community pharmacies more frequently than general
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practices (Hassell et al., 1998). It should be noted, however, that these high utilisation
rates are largely due to patients accessing prescription medications via community
pharmacies. Estimates suggest that four-fifths of community pharmacy users per month
visit for this purpose.
Research indicates that community pharmacy, like general practice, utilisation is
associated with particular demographic and socio-economic characteristics. Key trends
are summarised as follows: Demographic factors: women are significantly more likely
to be users of community pharmacies (with the exception of women over 75 years who
are actually three times less likely to visit); whereas men are less frequent visitors,
especially if they are in full-time employment. Age is strongly associated with
utilisation with the most frequent visitors to community pharmacies aged between 25-44
years and the least frequent between 16-24 years. Those who are either married or co¬
habiting are more frequent and single or widowed people less frequent visitors to
community pharmacies (Tully and Temple 1999; Hassell et al., 1998; Rogers Hassell
and Nicolaas, 1999). The chronically ill are also more frequent visitors to community
pharmacies. Socio-economic factors: employed people, those within higher socio¬
economic groups (professionals, managers and non-manual workers) and those who
remain in full-time education for longer are more frequent users of community
pharmacies compared to those in lower socio-economic groups, with lower incomes, or
who left full-time education at a younger age (Tully and Temple, 1999; Hassell et al.,
1998; Rogers, Hassell and Nicolaas, 1999).
1.3.4.1 Minor ailments and use of community pharmacy
Utilisation of community pharmacies for health related advice is, in fact, relatively low,
with research indicating that only between 5-10% of users actually seek such advice
(Hassell et al., 1998; Tully and Temple, 1999). Nonetheless, the average community
pharmacy advises approximately 10 clients per day on minor ailments, representing
approximately 100,000 minor ailment consultations each day in the UK (Whittington et
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al, 2001). In addition, survey data indicates that more than half (57%) of community
pharmacy users report purchasing an over-the-counter medicine within the last year
(Tully & Temple, 1999). Thus, the community pharmacy represents an important
community based, health care resource, widely used to manage minor ailments.
1.3.5 Other factors influencing choices to use general practice
and community pharmacy services
Available literature does, however, suggest that there are a multiplicity of factors
(alongside the demographic and socio-economic characteristics of the individuals users
themselves) that potentially influence decisions regarding if and when to use general
practice or community pharmacy services. Key factors relevant to users' choices to visit
community pharmacies are summarised below. (Related advantages and disadvantages
associated with users' choices to visit general practices can be deduced from their
opposites).
There are a number of recurrent advantages identified by users associated with using
community pharmacies. Convenience factors are amongst the most commonly cited
benefits. The open access nature of community pharmacy, the immediacy of advice
with no need to make an appointment or wait, alongside the proximity to users' home or
work (usually within walking distance) facilitates easy, quick access (Hassell et al.,
1997; Hassell et al., 1998; Varnish, Jesson and Wilson, 1998; Rogers, Hassell and
Nicolaas, 1999; Whittington et al., 2001).
The possibility of a proxy consultation on behalf of another person is another commonly
identified advantage of using community pharmacies, with over a quarter (27-30%) of
all consultations of this nature (Hassell et al., 1996; Hassell et al., 1997; Hassell et al.,
1998; Rogers, Hassell and Nicolaas, 1999; Whittington et al., 2001).
Drawing on previous experience and the ability to care for oneself is another important
advantage identified by users. This is particularly the case for conditions about which
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users have received advice on management through informal, lay networks, or which
they have successfully self-managed and/or treated before. In addition, many people
welcome the opportunity to manage conditions they consider to be trivial or minor, often
citing alleviating pressure on doctors and the NHS as a result (Hassell et al., 1996;
Hassell et ah, 1998; Rogers, Hassell and Nicolaas, 1999; Whittington et ah, 1999).
Finally, specific features of community pharmacy service are also seen as advantageous.
The pharmacist's specialist knowledge of medicines is appreciated, as is the fact that
many users perceive that pharmacists have more time to consult with and advise them
than doctors. This is especially valued if the user has a negative perception of his/her
doctor e.g. finding them to be unsympathetic. Friendliness and approachability of
community pharmacy staff is also frequently reported as advantageous, with users
comfortable with relationships developed with pharmacy staff over time, and expressing
loyalty to particular outlets as a consequence (74% in one large survey) (Hassell et ah,
1996; Hassell et ah, 1998; Tully and Temple, 1999)
A number of disadvantages associated with using community pharmacies are also
identified in the literature. Lay beliefs concerning professional boundaries are
important, with many users noting that it is not the role, or indeed that it is inappropriate,
for pharmacists to diagnose (Hassell et ah, 1998). Related to this, the inability of
community pharmacists to consult users' medical records is perceived to be problematic
(Hassell et ah, 1998)
Disadvantages regarding the organisation of community pharmacies are also identified,
particularly privacy concerns, often relating to the lack of dedicated consulting areas,
alongside availability of the pharmacist to provide advice (Whittington et ah, 2001;
Hassell et ah, 1998).
The affordability and willingness of users to buy medicines from community
pharmacies, is also frequently raised as potentially problematic, especially for lower
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income groups who qualify for free prescriptions on the NHS. Faced with a choice
between either paying for a medicine at the community pharmacy or receiving it free on
prescription, it is suggested that many users have no choice but to visit a doctor (Rogers,
Hassell and Nicolaas, 1999; Whittington et al, 2001).
Finally, there are also a number of perceived disadvantages to accessing medicines from
community pharmacies in that some users are cynical about the efficacy of non¬
prescription medicines, with many believing that medicines from the doctor are
'stronger', alongside user concerns over inappropriate and/or over-utilisation of
medicines, often related to concerns over developing 'immunity' to medicines (Hassell
et al., 1998).
Survey evidence investigating user attitudes to choice between consulting either general
practitioners or community pharmacists in response to a minor illness seems, however,
to contradict their actual behaviour. A number of studies suggest that when people do
seek care, generally they prefer to consult a doctor rather than any other health
professional (Jepson et al., 1991; Whittington et al., 2001; Caldow et al., 2000). Yet,
other research indicates people frequently identify the pharmacist as a good source of
advice (Hassell et al., 1998); eighty-six percent in one large survey, with two-thirds
noting that they believe that pharmacists should be consulted more frequently to avoid
consulting a doctor (PAGB, 1998). Interestingly though, the same survey highlighted
that user views were not borne out in their actions, with over half reporting that they
obtained most of their health advice from a doctor. Indeed, evidence suggests that
people are ten times more likely to consult with a doctor or dentist to deal with a minor
ailment than a pharmacist, whose advice was only sought in 1% of cases (PAGB, 1998).
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1.3.6 Trends in the use ofmedicines
Medicines are often central in self-care efforts. Their increasing availability has
enhanced user opportunities to substitute between both care professionals (e.g. general
practitioners and community pharmacists) and types of medicines (prescription and non¬
prescription) in the management of minor ailments. Thus, it is useful to consider general
trends in the use of medicines within the UK.
1.3.6.1 Classes of medicines available in the UK
Three classes of medicine exist within the UK under the Medicines Act 1968, namely:
general sale list medicines (GSL); pharmacy medicines (P); and prescription-only
medicines (POM).
General Sale List medicine (GSL)
General sale list medicines are licensed products which can be sold or supplied direct to
the general public in an unopened manufacturer's pack from any lockable business
premise (RPSGB, 2003c; Whittington et al, 200la).
Pharmacymedicines (P)
Pharmacy medicines are products, licensed as GSL medicines, but restricted to sale
through pharmacies (RPSGB, 2003c). They are any medicinal products other than those
designated as GSL or POM products (Whittington et al., 2001a). They need not be sold
under the supervision of a pharmacist, however, the premises must be under the personal
control of a pharmacist (RPSGB, 2003c). Written point of sale protocols must be in
place to direct the safe sale of P medicines (Payne, Ryan-Woolley & Noyce, 1996).
Control is exerted over aspects of these medicines, including: maximum dose and
maximum daily dose, dosage form, period of treatment, quantity and maximum strength
(Delatraz-Delporte & Stanford, 1998).
35
Prescription-OnlyMedicines (POM)
Prescription-only medicines are those medicinal products described as such in the
Prescription-Only Medicines (Human Use) Order (RPSGB, 2003c). They may only be
sold or supplied against the signed prescription of an appropriate practitioner i.e.
doctors, dentists and certain nurses (Whittington et al., 2001a).
Over-The-Counter medicines (OTC)
Over-the-counter medicines comprise
(Pharmacy) or GSL (General Sales List).
medicines legally classified as either P
1.3.6.2 Use of prescription medicines
There are 1500 prescribable preparations in the UK; 10% of which are frequently
prescribed (OHE, 2001). These are categorised into 16 broad therapeutic groups, relating
to either a bodily function or aspect of care. In 1985, a 'Selected List' was introduced
(and revised in 1993) identifying items either included or excluded from NHS
prescribing. Excluded items are typically products for which cheaper generic substitutes
are available, or those considered not medicines. These products excluded from the
NHS have become known as the 'Black List' (Scottish Pharmaceutical General Council,
1998). These products do, however, remain available via a private prescription (OHE,
2001).
In 2000, total cost of NHS prescribing was £6726 M (£560M in Scotland) consuming
12% of total NHS expenditure and representing an annual per capita spend of
approximately £113 (with an average net ingredient cost of around £90 per capita, per
annum and an average cost per prescription of £8.98) (Yuen, 1999; OHE, 2001).
General practitioner prescribing accounted for 10% of the UK NHS budget with 75% of
this spent on repeat prescribing (Bond et al., 2000).
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93% of prescriptions written are dispensed (OHE, 2001). Approximately half of the UK
population are entitled to free prescription medicines (OHE, 2001). 85% of dispensed
prescriptions are exempt from prescription charges (of these 55% are exempt on the
grounds of old age; 15% because of low income; 10% to children and young people; and
10% to those who have a prepayment certificate) (Eversley and Sheppard, 1998; OHE,
2001; Rogers, Hassell and Nicolaas, 1999). 15% of prescriptions are charged for
(Walley, 1998). About 60% of prescriptions cost less than the charge (Walley, 1998;
Griffin. 1996). For every chargeable prescription item dispensed, patients contribute
approximately 6% of the cost (this figure has fluctuated between 5-10% during the
1980s and 1990s) (OHE, 2001; Eversley and Sheppard, 1998). In the 1990s, NHS
dispensing grew by an average of 3.6% per annum (Yuen, 1999) and spending on
pharmaceutical costs and chemists remuneration by 63% in real terms (OHE, 2001).
That said, UK prescribing costs and pharmaceutical expenditure remain moderate
compared to other developed countries (OHE, 2001). Nonetheless, pharmaceutical costs
represent a sizeable and growing share of NHS expenditure, which is not subject to a
cash limit. Consequently, health policy makers have been keen to stem the seemingly
inexorable increases in this area of NHS expenditure, implementing a number of
measures to manage and contain costs wherever possible.
1.3.6.3 Use of non-prescription medicines
Reliable figures on the utilisation of non-prescription medicines in the UK are relatively
scarce and dated. Sales of non-prescribed, over-the-counter medicines (P & GSL
classes) were, in 1994, estimated to be approximately one third of the NHS drugs bill
and used to treat one in four symptoms (Blenkinsopp and Bradley, 1996; Payne, Ryan-
Woolley & Noyce, 1996).
In 1972, Dunnell and Cartwright undertook a landmark study, across a stratified sample
of British households (N=686), investigating self-medication practices of adults
(N=14l2). They reported that wide ranges of prescription and non-prescription
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medicines were routinely kept in British households, with over-the-counter medicines
outnumbering prescription ones. They found that the average number of medicines kept
per household to be 10.3; 7.3 over-the-counter and 3 prescription medicines (Dunnell
and Cartwright, 1972). Over a decade later, the Proprietary Association of Great Britain
commissioned a UK wide survey investigating adults' (N=1217) use of over-the-counter
medicines over a 12-month period. This study identified that over-the-counter medicines
were used in one out of four adult ailments (PAGB, 1987). In a Canadian study of
medicine use among a random sample ofWinnipeg adults (N=524) respondents reported
high levels of effectiveness of over-the-counter medicines (94%) with almost two-thirds
(63%) reporting having used an over-the-counter medicine within the previous two
weeks (Segall, 1990). All three of these studies reported that respondents typically saw
themselves as healthy and able to discriminate effectively between conditions that they
could self-treat and those that required medical advice and/or a consultation (Dunnell
and Cartwright, 1972; PAGB, 1987; Segall, 1990).
Common findings across other studies indicate that non-prescription medicines are used
more often by women than men and more frequently by the better educated, although
this may be confounded by associations with higher income (PPRRC, 1996). Evidence
from the RAND Health Insurance Experiment also indicated that better educated and
more knowledgeable consumers used more over-the-counter drugs and, further, that
such consumers spent higher proportions of their drug expenditure on over-the-counter
products (Leibowitz, 1989).
More recent research gives further indications of utilisation patters for non-prescription
medicines. In 1996, Payne et ah, conducted a postal survey (N=679) investigating
factors influencing consumers' decision making processes and willingness to pay for
over-the-counter medicines. They identified that the variables most likely to correctly
predict the purchase of over-the-counter medicines were: a stated preference for an over-
the-counter purchase; prior knowledge of over-the-counter availability; if the user was
liable to pay prescription charges; and if they were not taking any prescription
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medicines. In addition, they identified a number of other significant predictor variables
that were associated with increased likelihood of buying over-the-counter medicines,
including: users within younger age groups (<60 years); less frequent attenders at
general practice (4 or less in the last year); and among users expressing no loyalty to a
particular pharmacy. In contrast, they found that: users exempt from prescription
charges; on regular prescription medications; over 60 years old; or on low incomes were
significantly more likely to obtain deregulated products via an NHS prescription route
(Payne, Ryan-Wooley & Noyce, 1996).
A diary study (N=549 people within 215 households) investigating household medicine
usage over a month, found that 52% of people took at least one over-the-counter
medicine per day (Hassel et ah, 1998). Another more recent survey of a population of
pharmacy users (representative of the UK population) found that, among the high
proportion of adults who reported having used a community pharmacy in the last year
(80-94%), over half (57%) reported buying an over-the-counter medicine in that period
(Tully and Temple, 1999). Purchasers of over-the-counter medicines were found in this
study to be more likely to have a car, to be married or co-habiting, have left full-time
education at over 14 years and to be in professional or non-manual occupations (Tully
and Temple, 1999).
Use of over-the-counter medicine by those also in receipt of prescription medicines is
also estimated to be very common, at between 71 -85% (Carlisle and Green, 1994).
39
1.3.7 The broader policy context
It is useful to contextualise trends in minor ailments and user responses to them within
broader health policy initiatives that influenced these developments generally and the
promotion of substitution between general practice and community pharmacy in the
management of minor ailments specifically. Related, and often simultaneous, policy
developments are thus considered. First, a chronology of efforts to 're-badge'
community pharmacy is presented. The profession's efforts to re-emphasise their
expertise in medicines, as well as their broader skill base; championing their suitability
to adopt an extended role within primary care service provision, and successive
governments' policy initiatives to embrace this, are outlined. Next, simultaneous policy
initiatives facilitating the deregulation of medicines, thus increasing the availability of P
class medicines, is detailed. Then, concurrent metamorphoses in general policy
direction, regarding government concerns to manage demand within primary care, are
outlined; highlighting the shift from concerns to contain demand, to facilitating more
graduated access, while optimising skill-mix. Efforts to effect skill-mix substitutions
between primary care professionals generally and between general practitioners and
community pharmacists in the management of minor ailments specifically are outlined.
Finally, the evidence on the effectiveness of these initiatives is reviewed and critically
examined.
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1.3.7.1 Extending the role of community pharmacy within primary
care
A detailed chronology of events associated with proposals to extend the role of
community pharmacists within the primary care sector is outlined in table Al.2 in
Appendix l and briefly summarised below.
Community pharmacy was, for many years, not seen as an integral part of the NHS.
Rather, community pharmacies were viewed predominantly as sources of medicines,
rather than advice. First official recognition of the under-utilisation of the pharmacy
profession came in a 1979 Royal Commission on the NHS (Merrison, 1979). This
represented the first in a long succession of reports, spanning the last 25 years, authored
by both the profession and governments, recommending extension of community
pharmacists' role. Health policy makers recognised that genuine improvements in
primary care services could be realised if the expertise of community pharmacists was
more fully utilised. They appreciated not only the unique position that community
pharmacy occupied at the interface between lay and professional care but also their
accessibility and skills and recognised that these advantages could be harnessed without
requiring large scale structural change and, perhaps even more importantly, cost.
Consequently, health policy strategies of successive governments sought to capitalise on
the benefits associated with making better use of community pharmacy and thus
supported efforts by the profession to extend their role.
Initial policy documents, while supporting an extended role for community pharmacists,
seemed to focus primarily on the profession's potential to assist in cost containment
efforts. In particular, policy makers were keen to secure community pharmacy's
assistance in managing the increasing NHS drugs bill; enlisting their support to secure
improvements in the management and use of medicines and in reducing medicines
waste. Curtailment of drug expenditure was perhaps an easier political strategy to adopt
to contain costs, with its effects less visible than many others (Grund, 1996). Only in the
late 1980s, when policy initiatives began to envision an NHS 'led by primary care,' did
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more serious effort and attention begin to be devoted to integrating community
pharmacy into the NHS mainstream. In this period, community pharmacists were
increasingly recognised to be essential contributors to multidisciplinary primary health
care teams; with identified responsibilities including more active engagement in, the
management of medicines, chronic conditions, minor ailments and health promoting
activities.
From the mid to late 1990s to date, policy initiatives have progressed further still,
outlining that community pharmacists' extended contribution need not be constrained to
extending access to services specifically but also to provide broader support of user self-
care efforts and facilitate more active user engagement in health care decision making
generally. Alongside enhanced therapeutic roles, community pharmacy involvement is
now acknowledged to be instrumental in improving both the quality and range of
primary care services available, with new contractual and remuneration systems
currently being devised to incentivise these developments and encourage more active
engagement in the planning and delivery of innovative services with partner
organisations (Bond, 2003). The challenge for policy makers is to design incentive
mechanisms reorienting pharmaceutical services towards more safe and effective
therapy instead ofjust safe and effective drugs (Huttin, 1996).
1.3.7.2 Medicines deregulation
Around the same time that it was being acknowledged that pharmacists were being
under-utilised in the UK, efforts began to deregulate or reclassify certain medicines.
There are many rationales underpinning medicine deregulation, including: lowering
health care costs; making better use of pharmacists' training and knowledge;
encouraging increased self-care efforts; improving user access and convenience; and
increasing sales of pharmaceuticals (Andersson & Hatziandreu, 1992). Deregulation of
medicines was enthusiastically embraced in the UK because it complemented broader
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policy goals. Cost containment concerns seemed, however, to be the dominant
imperative underpinning medicine deregulation. There was a widely held belief that
deregulation, by increasing the availability of medicines, would encourage self-
medication for minor ailments. It was assumed that this would help to contain NHS
costs as users substituted purchases of pharmacy available (P) medicines in place of
prescription medicines (POMs) obtained during consultations with general practitioners;
simultaneously securing savings on the NHS drugs bill and promoting more efficient use
of scarce primary care resources.
A drug may be considered for deregulation, from prescription only (POM) to pharmacy
available (P) status, if: it is used to treat minor ailments; if patients can understand the
drug, appreciating its effect or otherwise; and be familiar with the condition for which it
is used. Drug safety is, however the main consideration concerning potential
deregulations (Andersson & Hatziandreu, 1992).
A small number of medicines were reclassified in the UK during the 1980s. In 1992,
however, a European Commission directive sought to standardise both the availability
and classification of medicines across member states. This directive required regular
review of medicines classification, stipulating that the prescription only (POM)
classification be retained only where absolutely necessary. This resulted in the UK
Medicines Control Agency revising their procedures to expedite medicine deregulations,
where appropriate. Thus, from 1992 onwards, many more medicines were 'depommed'
i.e. reclassified, or switched, from prescription only (POM) to pharmacy available (P)
over-the-counter at the chemist (Hassell et al., 1996; Hassell et al, 1998; Bond, 2001).
These developments were significant amid the broader, ongoing professional and
governmental efforts to make better use of community pharmacists.
Increased availability of P medicines made self-medication of minor ailments, and the
associated substitution between general practice and community pharmacists,
increasingly possible. This engendered vigorous debate within the literature and a
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multiplicity of potential advantages and disadvantages related to deregulation and the
increasing availability of medicines were pondered. Unfortunately, space will not
permit their enumeration here. They are, however, outlined in table A1.3 in Appendix 1.
1.3.7.3 Demand management policies in primary care - graduating
access and optimising skill mix
Rapidly increasing health care costs is a common trend across western industrialised
nations. The combination of ever-increasing demand for health services in the face of
finite resources has resulted in an inevitable, and politically uncomfortable, disconnect
between the demand and supply sides of the health care sector. This has forced all
western, industrialised nations to devise cost containment measures. In many countries,
the UK included, primary care professionals have been strategically placed at the
vanguard of efforts to manage demand and contain costs, by virtue of the first-contact
and gate-keeping responsibilities traditionally associated with their roles. The two
demand 'problems' commonly identified are, increasing volume, compounded by
inefficient responses to meet it. This results in the worst possible situation of inefficient
utilisation of scarce resources.
Labour costs are typically the most expensive resource input to health care production
processes, typically consuming around 80% of total expenditure (Office of Health
Economics, 2001). Basic economic theory posits that technical efficiency is attained
when output is maximised from available resources (Begg, Fischer & Dornbusch, 1991).
Thus, in considering cost containment and enhanced, graduated access strategies within
the UK NHS, it is no surprise that health policy makers have turned their attentions to
skill mix considerations. The concept of skill mix aims to match clinical presentation to
an intervention based on skills and training (Kernick, Reinhold & Mitchell, 1999).
Ensuring that appropriate skill mix combinations are deployed in the provision of quality
health services has become a key health policy priority.
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In the UK, academic and policy literature has, for many years, suggested that general
practitioners' skills are being used inefficiently, dealing with trivial conditions that could
be delegated to other, less skilled and less costly, care professionals (Whittington et al.,
2001; Payne, Ryan-Woolley and Noyce, 1996; Editorial, 1994; Hoog 1992; Bradley,
1998; NPA, 2002; Walker, 1996; Audit Commission, 1996). In recent years, however,
academic and policy debates have shifted perceptibly, moving away from narrow
demand management goals, simply aiming to deter consultations, to broader concerns to
effect more expeditious, appropriate and graduated access to primary care services.
Central also to these policy efforts have been the objectives to develop a more
responsive immediate care system that enhances patient access, choice and convenience.
This has been evidenced by developments like NHS walk-in centres and NHS Direct.
Maximising response to need, in efficient, appropriate and acceptable ways, to as many
people as possible, in a timely fashion, within available resource, is the new end game.
Increasing demand for under utilised, cost effective services is, for example, an
acceptable strategy in this more enlightened approach (Rogers, Entwistle & Pencheon,
1998; Gillam & Pencheon, 1998).
Skill mix substitutions within UK primary care
A number of initiatives have been introduced within the UK primary care sector in
recent years, involving the realignment of professional skill mix in efforts to support
more graduated access to improved immediate care services that simultaneously ensure
that the right patients are seen in the right place at the right time while enhancing user
access and convenience. Both lay-professional and inter-professional skill mix have
been experimented with. Specific service developments introduced within the primary
care sector to try to realise these policy ambitions include: walk-in centres; expansion of
out-of-hours and minor injuries services; the introduction of nurse-led telephone
consultation services such as NHS Direct and NHS 24; general practitioner telephone
consultations; virtual consultation services and referral of people with self-limiting
conditions direct to community pharmacies. (Rogers, Hasell & Nicolaas, 1999; Rogers,
Entwistle & Pencheon, 1998; Gillam & Pencheon, 1998; Whittington et al., 2001).
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These service developments have been backed up by the introduction of targets within
primary care to ensure that patients are seen either within 48 hours by a general
practitioner or other health care professional within 24 hours (Department of Health,
2000).
1.3.7.4 Evidence on UK primary care skill mix substitutions generally
Evidence on the success of these skill-mix substitutions within primary care, in terms of
clinical, health service utilisation and cost outcomes, is however mixed.
Lay-professional skill mix substitutions
For example, randomised controlled trials investigating the impact of lay-professional
substitutions, encouraged through the distribution of information booklets aiming to
promote self-care in the management of minor ailments, found either no (Heaney et al.,
2001) or a very modest impact (Little et al., 2001) on subsequent utilisation of health
services.
Practice nurse-general practitioner substitutions
However, three randomised controlled trials investigating the substitution of nurses in
place of general practitioners to manage minor ailments in general practice settings
generally yielded positive findings. Practice nurses' patients were significantly more
satisfied with their consultations; nurses did not write significantly more prescriptions
than doctors; although nurse consultations were, typically, significantly longer (between
2-5 minutes per consultation) compared to general practitioners (Schum et al., 2000;
Kinnersley et al., 2000; Venning et al., 2000). Two of these trials found that there was
no difference in symptom resolution or health status outcomes between groups, but did
identify differences (increases) in referrals or re-attendance rates (Kinnersley et al.,
2000; Venning et al., 2000).
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The national evaluation of the nurse-led telephone consultation service provided by NHS
Direct, investigated the impact on demand for immediate care services following its
introduction. It concluded that while it had not reduced demand for out-of-hours general
practice care, it appeared to have restrained its increase (Munro et al., 2000). The
national evaluation of primary care walk-in-centres, led by nurses, demonstrated
encouraging patient satisfaction and safety results; although again nurse consultations
were found to be considerably longer (Salisbury et ah, 2002a; Salisbury et ah, 2002b;
Salisbury et ah, 2003c; Grant et ah, 2002).
Only one of the trials investigating nurse management of minor ailments in general
practice examined cost effectiveness and identified no difference between groups
(Venning et ah, 2000). Yet, another study investigating substitution of nurses in place of
general practitioners to conduct telephone consultations within general practice out-of-
hours type settings demonstrated cost effective use of resources (Lattimer et ah, 2000).
Evidence from the literature leads one to conclude that substitution of nurse practitioners
in place of general practitioners is generally effective. Further, research investigating
user views on wider nursing roles (undertaken in Scotland) found that doctor-nurse
substitution appeared to be broadly acceptable. It indicated that while people's first
preference is generally to consult a doctor, they would consult with a nurse if confident
in their abilities and as long as they could still consult a doctor if they felt they needed to
(Caldow et ah, 2000). These results are encouraging as research investigating doctor-
nurse skill mix generally, suggests that between 30% to 70% of all tasks performed by
doctors could be carried out satisfactorily by nurses (Richarson & Maynard, 1995).
Clearly this could have profound implications for medical manpower, health
professionals' roles and costs.
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Community pharmacist-general practitioner substitutions generally
Community pharmacists, like other primary health care professionals, have come under
close scrutiny by health policy makers concerned to ensure that their expertise is
optimally deployed within primary health care teams.
The pharmacy profession's desire to extend its role complemented successive
governments' cost containment, demand management and graduated access policy
agendas. An opportunity to 'kill two birds with one stone' presented itself;
simultaneously meeting the ambitions of both the pharmacy profession and policy
makers. Policy makers believe community pharmacists to be perfectly positioned to
mediate demand for primary health care services and reinforce patients' own self-care
behaviours (Rogers, Hassell & Nicolaas, 1999). Consequently, they have been keen to
include community pharmacy more fully within the primary care loop, maximising their
skills and encouraging the development of their role from reactive, paternalistic
dispensers and controllers of medicines into proactive advisers and collaborators with
both patients and other care professionals (Kennedy et al., 1996).
Extension of community pharmacists' roles have resulted in various skill mix
substitutions being tested within UK primary care to see if community pharmacists can
improve patient journeys through care systems, facilitating closer integration between
professionals and improving patient access to and benefit from medicines. These
substitutions have been mainly with general practitioners and have included involvement
in: repeat prescribing schemes; medication reviews; health promotion interventions;
management of common and minor ailments; and various other initiatives.
A multiplicity of studies exists investigating the success of community pharmacists'
extended professional role within the UK. Examples of successful community pharmacy
involvement in new roles were identified in the course of the literature review e.g. good
therapeutic control achieved by a pharmacist led primary care anticoagulant clinic
(MacGregor et al., 1996) and successful pharmacy management of medication review
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and repeat prescribing systems within general practice (Jones, Matheson & Bond, 2000;
Bond, et al., 2000).
A Cochrane collaboration review investigating the impact of outpatient pharmacists'
roles on health services utilisation, costs and patient outcomes was also identified (Bero
et al., 1997). It included 14 studies, involving 1991 patients over the period 1973-1996.
The review concluded that pharmacists can successfully substitute for doctors in drug
management and that the delivery of services by pharmacists decreases use and/or costs
of health services and improves patient outcomes relative to no comparable service.
Based on these findings, Bero et al., (1994) recommended that pharmacists should
continue to provide patient counselling concerning drug therapy and also to continue to
educate physicians on this matter. However, a number of qualifications were flagged in
the Bero review. These concerned the generalisability of the studies; the poorly defined
nature of the interventions being studied and the general absence of either patient
outcome or cost data. These are important qualifications in terms of potential UK policy
learning, particularly as the studies were almost exclusively American, raising several
doubts regarding whether this evidence, rooted within a health care system characterised
by a fundamentally different philosophy and incentive systems is useful in the UK.
Further, UK based research is urgently required to redress this evidence deficiency
regarding the impact of extended roles for pharmacists.
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1.3.7.5 Evidence on substitutions between prescription and
pharmacy available medicines and general practitioners and
community pharmacists in the management of minor illness
specifically
Another key area within UK primary care where community pharmacist-general
practitioner substitution has been promoted is in the management of minor ailments.
Suggestions that community pharmacists could become more actively involved in this
area can be traced back to the initial landmark reports that proposed extending
community pharmacists' roles (Merrison, 1979; RPSGB, 1986). Health policy
documents embraced these suggestions, albeit only implicitly at first. Perceptions that
high levels of minor, self-limiting conditions are being inappropriately managed within
the formal primary care sector have, however, resulted in more explicit policy support
recently for community pharmacist-general practitioner substitution in this area. Indeed,
this particular skill mix substitution now represents a key plank in policy initiatives
aiming to foster more graduated access to primary care (Hassell et al., 1998; Whittington
et al., 2001).
Policy interest in this particular community pharmacist-general practitioner substitution
opportunity has been intense. This is due to the double substitution opportunity it
presents - from more (general practitioners) to less (community pharmacists) skilled and
costly care professionals and from public (via NHS prescription medicines) to private
(over-the-counter) payment for medicines - thereby alleviating pressure on NHS
resources by transferring an increasing share of direct health care costs over to
consumers. The widely held assumption within both the professional and policy
literature is that promotion of self-medication for minor ailments will help contain NHS
costs, as users substitute the purchase of pharmacy available (P) medicines in place of
prescription (POM) medicines obtained during general practitioner consultations, thus
securing savings on the NHS drugs bill and promoting more efficient usage of scarce
general practitioner time.
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At the genesis of this policy idea, however, specific supporting evidence did not exist.
Even to date, there is a relative paucity of evidence on the consequences of deregulation
on the demand for prescription and over-the-counter medicines and the extent to which
they may be regarded as substitutes in either the medical or economics literature. There
has been no overall cost benefit analysis of policies to encourage use of the community
pharmacists as a substitute for general practitioners in the management of minor
ailments using over-the-counter medicines.
There are, however, a number of related research efforts that offer clues regarding the
potential impact that deregulation of medicines facilitating substitution between care
professionals may have, including: consumer surplus analyses and medical gain
approaches, modelling the benefits associated with the deregulation of particular
medicines; retrospective utilisation reviews of prescription and non-prescription
medicines; and prospective reviews examining use of and demand for certain types of
medicines and related services. These more general research efforts are relevant for
considering the likely success of these policy initiatives, in terms of the extent of
substitution actually achieved and the associated economic implications, and are
summarised below.
Consumer surplus analyses and medical gain approaches
Early research studies investigating the economic implications of the reclassification of
prescription to pharmacy available medicines, conducted not long after deregulation
efforts began in the USA and UK, indicated that substantial savings to both users and the
health sector could potentially be realised.
Temin (1983) was first to investigate the net benefits associated with medicine
deregulation, applying consumers' surplus and medical gain methods (with the choice of
method dependent on the drug examined and availability of relevant data). He applied
consumers' surplus analysis to estimate the net benefits associated with deregulating
topical hydrocortisone in the USA. In applying this method he made a number of
51
assumptions concerning: the demand curve for the drug, the change in its full price due
to deregulation and the rate at which consumers would respond; which he then combined
with estimates on the number of individuals currently using the drug on prescription, the
number of individuals who would switch to buying the drug over-the-counter after
deregulation, and number of individuals who were not using the drug who would begin
using it when it was available over-the-counter. Based on these assumptions, Temin
estimated the benefits associated with the deregulation of topical hydrocortisone in the
USA to be in the order of $433M in 1981.
Next, Temin used the medical gain method to estimate the benefits associated with the
hypothetical deregulation of penicillin within the USA. He noted that this method is
more suitable for conditions that are more difficult to value from the patient's point of
view as it can be used to value the expected outcomes of deregulation without reference
to the demand curve. The medical gain approach utilises epidemiological, population
level data (as opposed to individual consumer level data) such as prevalence of the
disease, treatment patterns, productivity changes and changes in rates of medical care
utilisation, and relates them to expected increases in the use of the drug attributable to
the switch. Using this method Temin estimated the benefits associated with deregulation
of penicillin in the USA to be in excess of $ 1B, in 1981.
Oster et al., (1990) also applied consumers' surplus analysis in a hypothetical
deregulation modelling exercise of two histamine H2-receptor antagonists in the USA,
concluding that the switch was a relatively safe means of self-care for acid-peptic
disorders that could substantially reduce the patient use of health care services, and
consequently costs, related to minor gastrointestinal complaints.
Finally, Ryan and Yule undertook the only application of consumers' surplus analysis to
investigating the impact of medicine deregulation in the UK. They applied the method
to estimate the net benefits associated with the UK deregulation of loperamide and
topical hydrocortisone, calculating them to be £4.2M and £2.0M respectively (in 1987
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prices) (Ryan & Yule, 1988; Ryan & Yule, 1990). This is a well-conducted and
methodologically rigorous study. However, the study suffers from a number of
limitations, some inherent to the consumers' surplus analysis method; and others due to
their specific application of the method.
Ryan and Yule adopted a number of simplifying assumptions (as did all of the studies
identified from the literature that applied consumers' surplus analysis to investigate drug
deregulation) which if altered might have changed their findings. These limitations are
outlined below.
The modelling design adopted meant that the results were not based on actual, revealed
preference data, which would have been better. Perhaps more importantly, the study
assumed direct, successful and complete substitution between the two methods of
accessing the medicines. It assumed that everyone who previously accessed the
medicine from the general practitioner on prescription would switch to buying it over-
the-counter from community pharmacies. Yet, if a user is exempt from paying the
prescription fee, it is unlikely to cost them less to buy the medicine direct over-the-
counter and thus they might not switch their consultation route, thus violating their
complete substitution assumption.
In addition, the P medicines Ryan and Yule consider were among the first to be
deregulated and ones for which there were very obvious symptoms (e.g. diarrhoea and
skin irritations). Consumer awareness about them was reasonably good. Hence, they
were obvious candidates for deregulation. However, fifteen years on, a large number of
medicines have been deregulated for use across a broad range of conditions. Thus,
symptom recognition and user decisions or confidence to self-medicate and switch
consultation routes to access these other medicines may be less clear-cut.
Further, the study did not consider whether, after purchasing a medicine over-the-
counter, users made subsequent follow-up visits to care professionals. Thus, the study
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implicitly assumed that user's substitution efforts were successful; i.e. that their
condition was successfully resolved without requiring further professional advice or
treatment. This may not always have been the case. It is very likely that some users
would have required a follow-up consultation with either a general practitioner or
community pharmacists, to obtain further advice and/or treatment. This is important as
such complementary utilisation of services would reduce the estimated resource savings.
A number of crucial costing assumptions were also made that influence the results of the
Ryan and Yule study. They assumed that all users faced the same costs, meaning that if
one user found it beneficial to switch they all would. For example, they assumed that all
users were currently paying the prescription charge. Clearly, this is unlikely to be the
case. They did, however, acknowledge this as a limitation, noting that only if cost to
users of obtaining the medicine over-the-counter was less than the cost to them of
obtaining it on prescription would they in fact switch (Ryan & Yule, 1990).
Important assumptions were also made regarding the cost of the drugs concerned. For
example, they assumed that the drugs concerned were being subsidised by the
government, with the prescription charge paid by users less than the true cost to the
government of providing it. Similarly, they assumed that the over-the-counter price was
less than the prescription fee. For the two drugs concerned, these were, in fact,
appropriate assumptions. However, these assumptions do not necessarily hold for other
P class medicines available on prescription. In many cases, the prescription charge is
more than the true cost to the government of providing it and/or the over-the-counter
price of comparable P medicines are often more expensive than the prescription fee.
Building in these alternate cost scenarios may make the benefits of switching less
apparent.
In applying the consumers' surplus analysis method, Ryan and Yule did not address key
theoretical assumptions that must be met to ensure robustness and appropriate
interpretation of their findings. In particular, there is no consideration of the
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distributional issues implicit within their findings to highlight that within the overall
(macro level) benefit identified, there are likely to be winners and losers. Identifying to
whom these might occur is crucial in appraising the impact of medicine deregulation and
self-medication policy. Considering the distributional considerations in moving from
individual consumer's surplus to groups of consumers' surplus is the essence of the
policy debate and my research question.
Finally, the consumers' surplus analysis method is in itself somewhat limited, in that it
focuses mainly on the net benefits to consumers. It is, therefore, only a partial analysis.
It does not clearly elucidate the associated changing distribution of costs and benefits
impacting in the health sector as a result of changing consumer behaviour. Ultimately,
decisions to visit either the general practitioner or community pharmacist to access a
medicine depend on the individual's own cost-benefit calculus and trade-offs. Rarely do
individuals consider how their decisions may affect others. However, individual versus
aggregate effects are key. Policy makers and analysts should address interpersonal
comparisons, even if individuals do not. Broader economic evaluation techniques are
required to investigate these issues more thoroughly, particularly as one of the key
drivers of deregulation of medicines and self-medication was a desire to encourage more
appropriate utilisation and relieve pressure on primary care resources within the NHS.
Overall, the Ryan and Yule study presented an important first step in investigating the
potential benefits to consumers and society associated with increasing availability of
medicines deregulated from POM to P status. However, it also raised numerous issues
that require further investigation and research.
55
The study presented in this thesis aimed to address many of these issues and extend the
Ryan and Yule research in several key ways:
• by adopting a prospective design investigating actual usage or revealed
preferences in P medicines' usage;
• building in follow-up of users to assess the extent of actual substitution and/or
complementary usage between the general practitioner and community
pharmacist in use of P medicines;
• including all P medicines available, both existing or recently deregulated, which
varied both in price relative to the prescription fee (with some costing more and
some costing less to obtain over-the-counter) and whether they were being
subsidised by the government or not;
• applying both average and actual user cost data to derive benefit estimates (e.g.
accounting for prescription exemption or not);
• considering a broader range of potentially relevant costs and benefits;
• elucidating methodological issues with respect to the application of consumers'
surplus analysis and the implication for interpreting and generalising the results;
• and extending the analysis, applying broader economic evaluation techniques to
investigate costs and benefits and the changing distribution to all the key parties
involved (users, general practitioners, community pharmacists, the health
sector/government and society overall).
Overall, these early studies, applying consumer surplus analysis, suggested that
potentially significant benefits could be realised through medicine deregulations that
made substitutions between accessing a medicine on prescription from a doctor to
buying it over-the-counter from a community pharmacist possible. However, although
largely methodologically sound, their findings do need to be interpreted with a degree of
caution. They were based largely on modelling exercises, attempting to predict (by
comparing prescribing levels before and after deregulation) changes in demand and user
consulting behaviour associated with the deregulation of medicines. Further, they were
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premised on a number of uncertain assumptions, the most important of which was that
direct and perfect substitution would occur, an assumption for which there was little
actual evidence.
Retrospective and prospective utilisation reviews of prescription and over-the-
countermedicines
Evidence that utilisation of both prescription and over-the-counter drugs are price
sensitive is, however, well established (Leibowitz, Manning & Newhouse, 1985; Birch,
1986; O'Brien, 1989; Ryan & Birch, 1991; Huttin, 1994; Hughes & McGuire, 1995;
Gerdtham & Johannesson, 1996; Lundberg et al., 1998; Eversley & Sheppard, 1998;
Joyce, Escarce & Solomon, 2002). Research results consistently find that price elasticity
(defined as the percentage decrease in demand divided by the percentage increase in
price) is negative (i.e. as price increases, quantity demanded decreases) and inelastic (i.e.
quantity demanded falls proportionately less than the price increase). These negative
price elasticities are generally in the range -0.1 to -0.6 (-0.1 to -0.3 in the UK); that is a
10% increase in price gives rise to a reduction in demand of between 1-6% (Ryan &
Birch, 1991; Gerdtham & Johannesson, 1996). Changes in the prices consumers are
required to pay, clearly affect demand for both prescription and over-the-counter drugs.
Whatever the scheme (fixed fee, co-insurance or prepayment), increases in charges lead
to decreases in consumption (Huttin, 1994).
Investigating the policy assumption that prescription and over-the-counter drugs are
substitutes is, however, slightly more complex. Standard microeconomic theory posits
that demand for a good is inversely related to its own price (i.e. as its price increases,
quantity demanded decreases and vice versa) and positively related to the (cross) prices
of its substitutes (i.e. as the price of a good increases, demand for its substitutes increase
and vice versa). To test whether two goods are substitutes, it is usual to regress the price
of one on the quantity demanded of the other (i.e. to investigate the impact on the
demand for the substitute goods as their relative prices change). A positive regression
co-efficient indicates that the two goods are substitutes - that is - individuals shift from
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one (e.g. obtaining a P class medicine on prescription from a general practitioner) to the
other (e.g. buying a P medicines direct, over-the-counter, under the supervised sale of a
pharmacist) in response to changes in relative costliness (Stuart & Grana, 1995).
Specific evidence regarding the extent of substitution or complementary usage between
prescription and over-the-counter drugs is scarce, contradictory and inconclusive
(Blaxter & Britten, 1996). For example, O'Brien (1989) investigated NHS prescription
drug utilisation, identifying positive cross-price elasticities of demand (+0.22) between
over-the-counter products and prescriptions that indicated that substitutions occur among
individuals eligible to pay for their prescriptions (i.e. that a 10% increase in prescription
charges results in demand for substitute, over-the-counter drugs increasing by 2.2%).
However, the existence of such substitution was less clear among users exempt from
prescription charges. Stuart and Grana (1995) also identified economic substitution
between prescription and over-the-counter drugs among an elderly sample in the USA,
which was associated with level of insurance coverage and among individuals with 'less
serious' conditions.
In contrast, however, Leibowittz (1989) found no evidence of substitutions between
prescription and over-the-counter drugs within the RAND Health Insurance Experiment.
On the contrary, use of over-the-counter and prescription drugs was correlated,
indicating their use as an adjunct, as opposed to as a substitute, for formal medical care.
People with complete insurance coverage purchased more of both types of drugs. The
policy expectation that people assigned less generous insurance for prescription drugs
would substitute over-the-counter drugs in place of prescription drugs obtained from
physicians, was not supported by the data.
Other studies concur, reinforcing the suggestion of complementary usage of over-the-
counter and prescription drugs, often finding that those who consult the most, also use
over-the-counter medicines the most (Blaxter & Britten, 1996; Carlisle & Greene, 1994).
Blaxter and Britten (1996) in an article reviewing the lay use of medicines literature,
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also note the contradictory evidence base from qualitative studies investigating
substitution, citing numerous studies which suggest that substitution behaviour, where it
exists, differs depending on the types of symptoms experienced, the drugs concerned
and the age of users.
There are other problems with the available evidence base concerning the existence and
extent of substitution between prescription and pharmacy available drugs and the
economic implications of this. Much of the research is now quite dated; it is based on
either very few drugs or particular groups of users; and many of the studies are
American, the results of which may not be generalisable to the UK, given the very
different health care systems and incentive structures that operate in the two countries.
In addition, the economic analyses undertaken to date have tended to focus on a
particular perspective (for example, the net benefits to consumers or the savings for the
health sector) rather than investigating the changing distribution of costs and benefits
across all relevant stakeholders and the overall welfare implications.
However, the key failings of the studies undertaken to date, are that they are based
mainly on retrospective investigations into changes in aggregate prescription data, pre
and post deregulation. This approach has failed to investigate the complex choice
processes and the associated costs and benefits accruing from users' actual, revealed
consumption behaviour. Even in studies where substitution between prescriptions and
over-the-counter medicines was found to exist, they failed to identify the mechanics of it
and, in particular, whether it was doctor- or patient-initiated. This is crucial to determine
the extent to which substitution or complementary usage of prescription and over-the-
counter medicines exists and in accurately estimating the economic consequences of
changes to prescription and over-the-counter medicines.
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Recent UK evidence
Two recent research efforts have partially improved upon this situation, as they
investigated users' actual consumption choices and the extent of substitution achieved in
the use of prescription and over-the-counter medicines in the management of minor
ailments within the UK. It should be noted, however, that these studies differ to the
current study in that they investigated the impact on demand for general practice
services of paying community pharmacists fees to provide access to and advice on the
use of certain medicines (used in the treatment of a specified range of minor ailments)
free to eligible groups.
The first, the 'Care at the Chemist Scheme' (Whittington et al., 2001a; Whittington et
ah, 2001b; Hassell et ah, 2001; Bojke et ah, 2002) comprised a before and after study
investigating community pharmacist substitution for general practitioners in the
management of 12 minor ailments. The study ran for 26 weeks within one general
practice located in Merseyside, with 93% of prescription items dispensed exempt from
charges. The study intervention enabled users exempt from paying prescription charges
to visit community pharmacies and access medicines free (from a pre-agreed formulary);
thus removing the financial incentive for these users to visit their general practitioner
(given that this is typically the only way to access free medicines)
Patients requesting either an urgent, same day appointment or a prescription (by visit or
telephone) for one of the 12 minor ailments included within the study were offered the
opportunity to visit one of eight local community pharmacies instead of the general
practice. Participating community pharmacists were paid £1.50 per patient, to offer
advice and/or a medicine concerning the minor ailment episode. Crucially, medicines
were provided free at the community pharmacist to users exempt from paying
prescription charges. This was key as research suggests that individuals weigh-up the
cost and benefits of seeking pharmacy or medical care and that, despite the time costs
associated with consulting general practitioners to obtain prescriptions, many patients
exempt from prescription charges, although able to self-treat, are unwilling to do so, due
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to the out-of-pocket expenses they would incur buying medicines over-the-counter at
community pharmacies (Hassell, Noyce & Rogers, 1999; Schafheutle, Cantrill &
Nicolson & Noyce, 1996; Hassell etal., 1998; Payne, Ryan-Woolley & Noyce, 1998).
Key findings of this study indicated that: a 38% uptake rate (576/1522) was achieved,
with over a third of the total workload for 12 minor ailment conditions referred to
community pharmacists; overall general practitioner workload was not reduced,
however, the proportion of total GP workload comprised ofminor ailments fell by about
a quarter, from 8.9% to 6.6%; there were no significant differences in patient
characteristics between users electing to consult general practitioners compared to
community pharmacists; users were no more likely to re-consult if they opted to visit a
community pharmacist - 6% of users opting to visit the community pharmacy re-
consulted (2.4% with general practitioners and 3.3% with community pharmacists)
compared to a 4% re-consulting among general practitioner visitors. User views were
generally positive, identifying time saved to both doctors and users and accessibility and
convenience factors as the key benefits. Statistical analyses to predict the patient's
choice between consulting either the community pharmacist or general practitioner
found that the choice was highly dependent upon the type of minor ailment e.g. patients
presenting with thrush or lice were much more likely to choose to consult a community
pharmacist, whereas patients with coughs, earaches and sore throats were more likely to
choose to consult a general practitioner (Bjoke et al., 2002).
Economic analysis of the implications of the 'Care at the Chemist Scheme' was
minimal. However, crude costs for community pharmacy consultations were estimated
to be between £1.44 and £1.85 (with an average consultation length of 3.4 minutes);
compared to between £2.91 and £6.87 per general practitioner consultation (with an
average consultation length of 4.2 minutes). Overall, prescription costs did not increase,
although the number of items prescribed did increase. These findings led the authors to
suggest that the community pharmacy option would be cheaper.
61
Overall, the study team concluded that the 'Care at the Chemist Scheme': demonstrated
equivalent user satisfaction; improved patient access; reduced general practice minor
ailment workload; encouraged more appropriate use of professionals' skills; with no
significant increases in drug costs; and patients no more likely to re-consult, having
visited a community pharmacist, rather than a general practitioner (Whittington et al.,
2001 a; Whittington et al., 2001 b; Hassell et al., 2001; Bjoke et al., 2002).
The 'Direct Supply of Medicines' pilot in Scotland (April 2001- March 2002) is the
other recent and important research contribution in this area. It investigated the impact
of directly supplying medicines (from a limited formulary) to users from community
pharmacists, across a defined range of conditions, again with medicines supplied free to
users exempt from prescription charges (Schafheutle et al., 2003; Sheehy & Jones,
2003). In this pilot, patients exempt from prescription charges were invited to register
with local participating community pharmacists, who were paid on the basis of volume
of registrations. The main findings of the scheme indicated that uptake of the scheme
was low in both areas, with only 4% and 23% of eligible users registering across the two
study areas (these figures subsequently rose to 5.6% and 26.9% in an extension period of
the pilot). None of the participating community pharmacists reached the upper limit of
the remuneration band of 750 registrations. Around half of the users who registered
actually used the scheme. Younger age groups were much more likely to use the
scheme. The pilot had only a small effect on the minor ailments workload in general
practice, which fell by only 1.5% and 2.6% in the pilot year. Head lice, pain and cough
were the most frequently presented conditions. Participating community pharmacists
consulted with between 21 to 205 users and were generally positive about the scheme
and reported noticing little perceptible impact on their overall workload. Users also
reported favourable opinions of the scheme, with enhanced convenience identified as
particularly beneficial. Average cost per consultation was estimated to be in the range
£1.49 to £2.40 (£2.07 to £2.87 in the pilot extension) (Schafheutle et al., 2003; Sheehy &
Jones, 2003).
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These two studies represent an important addition to the evidence base regarding
community pharmacist-general practitioner substitution in the management of minor
ailments. Their key contribution is that they investigate the practicalities of the
substitution, the impact on general practice minor ailment workload and the
acceptability to users. Overall, they appear to demonstrate that the burden of providing
advice and treatment for minor ailments can be successfully transferred from general
practitioners to community pharmacists. Their main weaknesses relate to their:
inadequate consideration of economic implications; inclusion of either a limited number
of conditions or only certain users; limited collection of personal level data; and
concerns over generalisability of their findings given their low uptake rates and very
specific settings. By comparison, the study reported in this research conducted extensive
economic analyses; included all patients and all P medicines; collected patient level
data; and reported on usual practice. Overall, though, the studies are complementary.
Largely in response to the Care at the Chemist and Direct Supply of Medicines pilot
schemes, there are now more than 20 similar schemes in operation throughout the UK
(Blenkinsopp, 2003; RPSGB, 2003a). The schemes operate in a variety of different
ways, for example: some are for specific groups, whereas others are for everyone;
referrals onto the scheme can come via practice receptionists, nurses, general
practitioners, community pharmacists or the patients themselves; written protocols
and/or formularies of medicines are agreed, with patient group directions, if needed; and
a variety of methods employed to remunerate community pharmacists including,
consultation or capitation fees, price of medicines, or a one-off annual fee (Blenkinsopp,
2003; RPSGB 2003a; RPSGB, 2003c).
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1.3.8 Gaps in the evidence base
The literature review outlined above demonstrates that there are general bodies of
literature and research, across a number of disciplines, generally relevant for considering
the impact of increasing availability of P class medicines and the extent to which this
facilitates substitution between general practitioners and community pharmacists in the
management of minor ailments within primary care. Research efforts investigating these
issues specifically are, however, rare.
For example, while a burgeoning literature exists on the use of medicines generally,
there is little on the use of P medicines, or medicines recently deregulated to P status,
specifically. Research investigating use of medicines typically dichotomises medicines
into either prescription or non-prescription categories only. Rarely, despite the policy
pertinence, does it differentiate between the general sales list (GSL) and pharmacy
available (P) classifications, thus making it difficult to tease out the more detailed
nuances in changing trends in medicines use and their potential implications. Likewise,
while good survey evidence exists that helps us to understand use of general practice and
community pharmacy services, it tends not to shed much light on increasing P medicines
utilisation in these contexts and consequent impacts for the structure and provision of
primary care services and the economic implications associated with this. This is
perhaps unsurprising as these utilisation data have been collected for other purposes e.g.
to inform the National Morbidity and General Health surveys.
As a result, despite current extensive use of both prescription and non-prescription, over-
the-counter drugs, we still do not have a clear picture of the kinds of people who use
them; the factors influencing users' consultation patterns; the extent of substitution or
complementary usage between POM and P drugs; the welfare implications associated
with the changing distributions of costs and benefits accruing as a result of changes to
POM and P medicines; and their impact upon changing structures of primary care.
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The available evidence suggests that there is no simple relationship between availability
of over-the-counter medicines and demand for NHS prescriptions. The assumption that
pharmacy available (P) drugs directly and only substitute for consultations with general
practitioners and prescription (POM) drugs in the management of minor ailments is
overly simplistic. The interface between self-medication and the NHS is likely to be
more complex (Thomas & Noyce, 1996). Complementary usage of some P drugs and
GP consultations undoubtedly exists. Thus, potential savings arising from reductions in
GP consultations may be less than assumed. Unfortunately, however, few P or over-the-
counter medicines have been evaluated in formal clinical trials in the settings in which
they are used and there has been no overall cost benefit analysis of policies to encourage
use of P medicines accessed from community pharmacists as a substitute for prescription
medicines obtained from general practitioners in the management of minor ailments, that
enable us to either challenge or confirm these assumptions (Bjoke et al., 2002).
Thus key gaps exist in the current evidence base that must be redressed. It is not enough
to simply accept that, because substitution between general practitioners and community
pharmacists appears intuitively obvious, it should be promoted; tempting as it may be
given that it coincides with prevailing policy and professional aspirations. In an
increasingly evidence-based world, it is incumbent upon policy analysts to explore the
details and investigate the implications to all concerned.
Support for research efforts investigating these issues comes from a number of
influential quarters. For example, in 1994, Mays produced a detailed critique of health
services research in pharmacy, within which he specifically identified: the need for
further research investigating patients' careers in medicines use; and the need for
economic analyses of the issues associated with deregulation, investigating its effects on
levels of use and costs to both the NHS and patients (Mays, 1994). This review was
well received and endorsed by both academic and professional organisations (RPSGB,
1998 a & b).
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Further, the Medical Research Council, in its 'Primary Care Topic Review', specifically
prioritised the need for research efforts to enhance understanding of: health seeking
behaviours within primary care; factors influencing demand, as opposed to need, for
primary care services, investigating appropriate efforts to modify demand; as well as
approaches to the assessment and management of undifferentiated and minor illness
within primary care and the outcomes of alternate ways of dealing with these (MRC,
1997). The study outlined in this thesis sought to address several of these identified
priorities which undoubtedly contributed to its success in attracting an 'MRC Special
Training Fellowship in Health Services Research' to fund the research.
The research presented in this thesis seeks to plug some of these gaps in current
knowledge, by undertaking detailed description and analysis of users' consultation
patterns in accessing P medicines drugs, assessing the extent of actual substitution
between general practice and community pharmacy in their use, and analysing changes
in the distribution of costs and benefits across key stakeholders as a result. This
information is urgently required to allow users, general practitioners, community
pharmacists, health commissioners and health policy makers to make more informed
choices about the appropriate provision of skills and medicines to manage minor
ailments within primary care. Thus, the research outlined in this thesis is timely and
highly relevant and is summarised in the aim and objectives specified next.
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Aim
The overall aim of this research project was to:
Assess the extent to which increasing availability of P class medicines has resulted in
substitution or complementary usage between general practice and community pharmacy
services; investigating the range of direct and indirect costs and consequences accruing
to users, general practitioners and community pharmacists as a result.
Objectives
Within this aim there were five distinct objectives including:
• Profiling the sample of users accessing P medicines, identifying patterns of P
medicine use among different socio-demographic and socio-economic groups;
• Mapping the routes adopted by users to access P class medicines;
• Assessing the extent of substitution or complementary usage between general
practice and community pharmacy services as a result;
• Developing a model aiming to predict users' choice of access; and
• Investigating the welfare implications, at both the micro (individual user and
professional) and macro (health policy) levels, of the changing distribution of costs





The aim of this chapter is to outline the methods applied within the research presented in
this thesis. It begins by stating the philosophical underpinnings of the research. Issues
related to the choice of study design adopted and sample selection procedures are then
outlined. Next, the development, piloting and conduct of the data collection are
summarised. Finally, the data analyses methods are described.
2.2 Philosophical underpinnings of the research
It is important for all researchers to consider the ways in which different research
methods produce data, their ontological, epistemological and methodological
underpinnings and what these mean for their interpretation.
Social science research has, for many years, been characterised by the existence of a
paradigmatic dichotomy between qualitative and quantitative research endeavours
(Mays & Pope, 1995). They adhere to very different views about the construction of
knowledge (Milburn et al., 1995; Brannen, 1992). Differential belief in single versus
multiple truths or realities is at the crux of the epistemological debates (Milburn et ah,
1995; Milburn et ah, 1994).
On balance, however, the paradigms are not as polarised as they might at first seem.
They are perhaps more productively viewed as existing on a continuum, ranging from
positive, scientific, quantitative approaches at one end, to constructive, interpretive,
qualitative approaches at the other (Coast, 1999; Steckler et ah, 1992). At the most basic
levels, they are similar in that they are both based on observations, data are central to
both approaches and both can generate theories inductively and test them deductively.
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The ontological, epistemological and methodological philosophies underpinning
economics and health economics are predominantly positivist (Coast, 1999). Two main
branches of economic theory are drawn upon in this research - demand and welfare
economics. Demand theory may be classed within the realms of positive economics in
which there is believed to be a discoverable (single) reality, or objective 'truth', about
which laws can be uncovered by research. Methodological individualism prevails (Begg,
Fischer & Dornbusch, 1991). Research proceeds through processes of falsification via
the development and testing of hypotheses, with theory derived mainly deductively,
from standard axioms and assumptions (Coast, 1999).
Welfare economics, on the other hand, is regarded as normative. It differs from positive
economics in that it is explicitly recognised as being value judgemental. Indeed, its
primary purpose may be regarded as offering prescriptions or recommendations the aim
of which is to inform how policy should proceed (Begg, Fischer & Dornbusch, 1991;
Coast, 1999). In welfare economics the concern is to maximize welfare through the
satisfaction of preferences (Coast, 1999). Preference elicitation and investigation of the
nature and content of utility functions among key stakeholders in the health sector
comprise a large body of the theory and research in this area of economics (Coast,
1999).
The methodologies (and specific methods) of demand theory (consumers' surplus
analysis) and economic evaluation (cost-minimisation analysis) are firmly rooted within
rationalist, positivist epistemology. So too are the data generation (questionnaire
survey) and analyses (descriptive and analytical statistics) techniques applied. As such,
the philosophy of science adopted in this research may be regarded as predominantly
rooted within the positivist tradition.
This approach was adopted as it was believed to offer a logical and practical first step in
exploring the key research questions outlined. In addition, it more readily
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complemented the disciplinary perspective, and experience of the researcher. It was not,
however, intended to indicate that the researcher believed this to be a superior, or indeed
the only, approach to investigating the study questions. On the contrary, the researcher
ascribes to a 'realist' world view, believing that behaviours have a reality for
individuals, that reasonably stable relationships can be identified and that from these
patterns it is possible to derive constructs that can be helpful in explaining individual
action (Miles & Huberman, 1994; Coast, 1999; Pawson & Tilley, 1998; Abercrombie,
Hill and Turner, 1988). Explanation, according to realists, is concerned with providing
an account of the structures, mechanisms, powers and tendencies that together produce
the phenomenon of interest (Coast, 1999; Pawson & Tilley, 1998). A strength of the
realist ontological perspective is that it embraces methodological pluralism (Pawson &
Tilley, 1998). Given the complex and contingent nature of consumer decisions regarding
use of medicines, the researcher believes that appropriate combinations of both
quantitative and qualitative, are likely to enhance our understanding. The potential for
mixing methods to build upon the current research in the future is an area that will be
returned in the discussion section of the thesis.
2.3 Selecting a study design
A descriptive study design was believed to be most appropriate to investigate the
research aim and objectives of interest in this study (Hennekens & Buring, 1987;
Beaglehole, Bonita & Kjellstrom, 1994). This study investigates user response to recent
policy initiatives encouraging increased self-medication in the management of minor
illness using P class medicines. Previous research efforts have investigated issues
relating to use of general practice and community pharmacy services by patients in the
management of minor illness episodes. However, these have tended to focus on use of
these services in isolation, viewing them almost as if they were mutually exclusive
options. To the researcher's knowledge, no other empirical studies have investigated the
choices users make in accessing P medicines. The outcome being studied (i.e. choice to
access P medicines from either the general practitioner or community pharmacist) is
70
relatively new and the important covariates are not known and associations with the
outcome not well understood. The general approach of this study is, therefore
exploratory and descriptive.
The research study outlined aims to explore potential covariates and consider them in
relation to existing theory, highlighting areas for future research. Thus, this research has
a predominantly pragmatic purpose and represents the beginning of efforts to appraise
the success or otherwise of current policy initiatives and potentially inform future policy
development in this area.
A primary research design was elected for the study. The researcher was unaware of
other research efforts investigating potential substitutions or complementary usage
between general practitioner and community pharmacist services in the use of P
medicines. Secondary data sources that could be used to investigate or describe this did
not exist. In addition, a key objective of the study was to consider the costs associated
with accessing P medicines to use in the treatment of minor illnesses, from a number of
perspectives - general practitioners, community pharmacists and users. Limited
amounts of secondary data sources were available to estimate costs accruing to general
practitioners e.g. national unit costs estimates (Netten, Dennett & Knight, 1998) and
there was one source of estimates for certain elements of community pharmacist time
taken up in related efforts (Savage, 1995). These were fairly crude, limited and the
appropriateness of their use within the context of the current study unknown. However,
there were no secondary data estimates or sources available regarding the resource and
time costs accruing to users of these services. Given that this was a key objective of the
study this was problematic. Thus, primary data collection was inevitable. Although
time consuming and expensive, it was, nonetheless, advantageous, enabling
investigation of the research questions in the context of a real population of users,
capturing actual, revealed preference data of users accessing P medicines, facilitating
detailed and reliable estimates of costs accruing to the stakeholders within the study
setting.
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2.4 Study design and setting
A cross-sectional descriptive study, with prospective follow-up of a sub-sample of users
was undertaken. Key advantages associated with cross-sectional studies are that they
are: useful for planning health care and resource allocation; valuable for describing
patterns; helpful in formulating hypotheses; and are generally cheaper and quicker to
perform. Prospective follow-up enabled data collection to be focused on answering the
specific research questions at hand and reliably capture utilisation and cost data as it
occurred, helping to minimise potential biases, particularly recall bias. The study was
based within the Lothian Health area in Scotland, UK.
Short interviews were conducted with users in pharmacies, at the point of purchase or
dispensing of P medicines. Follow-up telephone interviews were then conducted with
all willing users. Telephone follow-up was selected as it was felt to be less intrusive to
users and thus likely to generate better response rates, as well as being less time
consuming and more practical. The telephone interviews aimed to track users'
subsequent use (if any) of general practice or community pharmacy services, thus
collecting complete information on consultation routes adopted by users, within the
context of a specific illness episode. Deciding upon the optimal follow-up period was
tricky. Consideration of the minor nature of the conditions presented, alongside
practical concerns to minimise potential recall difficulties, resulted in a two to four week
follow-up period being adopted.
2.5 Sample selection(s)
2.5.1 Community pharmacies
The aim was to recruit a sample of community pharmacies into the study, covering as
broad an area of Lothian region as possible, in an effort to embrace a representative
population of users. Advice on the sample selection process was sought from the
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Lothian Health Pharmacy Facilitator, a local Consultant in Public Health and the
Information Co-ordinator for Lothian Health. In line with their recommendations,
community pharmacies were purposively sampled with key inclusion criteria as follows:
(a) community pharmacies spread across the whole geography of the Lothian Health
catchment population, including pharmacies in city centre, town, suburban and rural
areas; (b) community pharmacies reflecting the range of deprivation categories present
within Lothian Health (established after socio-demographic profiling); (c) a mixture of
both independent and chain pharmacies; and (d) both busier and quieter pharmacies. By
engaging in purposive sampling of this nature, the intention was to recruit a sample
broadly representative of the community pharmacies within the Lothian Health area
more generally.
Seventeen community pharmacies were identified according to the above inclusion
criteria. The main pharmacist was provided with a project information pack and invited
to participate (Appendix 2). General practices local to these pharmacies were informed
of the study via the Local Area Medial Committee (Appendix 2).
Two of the study community pharmacies were located in East Lothian, six in West
Lothian, two in Midlothian and five within the Edinburgh City area of Lothian.
2.5.2 Medicines
The study included all P class medicines simultaneously available from general
practitioners on prescription or over-the-counter direct from community pharmacists. A
P class medicine is defined as: "a medicinal product which is not a prescription-only
medicine and which is either: (a) not a medicinal product on a general sale list, or (b) a
product referred to in Regulation 8 of the Medicines (Sale or Supply) (Miscellaneous
Provisions) Regulations 1980" (RPSGB, 2004). Essentially a P medicine is any
medicinal product, other than those classified as GSL or POM products (Whittington et
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al., 2001; RPSGB, Lyndon Braddick, Director for the Scottish Department, Personal
Communmication, 2004). Pharmacy medicines can be sold or supplied from a registered
pharmacy by, or under the supervision, of a pharmacist, subject to certain exceptions
(Whittington et al., 2001). These P class medicines may be usefully distinguished in two
ways: either those that have been routinely available in the P class for some time; or
those recently deregulated from a prescription-only-medicine to pharmacy available (i.e.
POM to P switched medicines). It is important to note, however, that both are available
in mainly one of two ways: either from a general practitioner on prescription, or from a
community pharmacist in a supervised, over-the-counter sale.
Initially, it had been planned to review prescriptions and till receipts for all P medicines
dispensed or sold during fieldwork days. This would have facilitated assessment of the
representativeness of the community pharmacies' P medicines activity captured within
the study. However, the participating pharmacists were not in favour of making such
information available to the researcher due to its 'commercially sensitive' nature and the
time commitment involved in such an undertaking.
2.5.3 Users
The general population using community pharmacies to access 'P' class medicines
within the Lothian Health Board area was the study target population. It was
anticipated, however, that the results of the study were likely to be relevant further
afield. Evidence from the literature indicated that direct recruitment of community
pharmacy users at the point of sale was feasible, having been successfully tried
elsewhere (Bramstad et al., 1994; Bond et al., 1996; Hassell et al., 1996). The study
population was recruited by asking all users obtaining P class medicines, either on
prescription or over-the-counter, to participate. They were identified at the point of sale
or dispensing within community pharmacies, advised of the study and invited to take
part. Users who agreed to participate were given a leaflet outlining the study in more
detail (Appendix 2).
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Recruitment was planned to continue until a total sample size of 1500 users had been
achieved. Feasibility studies recorded dispensing and sales volumes of P class
medicines. The results indicated that recruitment of 1500 users would be feasible,
recruiting within six community pharmacies for five to seven days. However, early pilot
work suggested these recruitment figures were overly ambitious. More conservative
volume estimates indicated that fifteen community pharmacies would need to be
involved, for a period of 10 days each, if the target 1500 users were to be recruited.
Given the complex nature of the study, precise power calculations regarding the optimal
sample size were not possible. However, on the advice of a medical statistician it was
anticipated that the a sample size of over 1000 users would have sufficient power to
detect important differences between groups and to estimate population parameters with
good precision. The developmental nature of the proposed data collection methods
meant that it was also difficult to estimate sample attrition rates (for example from loss
to follow-up). Thus, this was reviewed in early pilot work to ensure that reasonable
follow-up could be achieved within the sample. Adequate sample follow-up (63% at 2
to 6 weeks) was attained in pilot work.
The purposive sampling methods outlined aimed to ensure that the sample was broadly
representative of the overall socio-demographic profile of the Lothian Health area. In
the absence of a random sample, selection biases could potentially arise (Greene, 2000;
Heckman, 1990; Vella, 1998). Consequently, a number of measures were built into the
study design in a bid to minimise potential sample selection bias and assist in assessing
the representativeness of the study sample.
Data were collected across a ten day period within each pharmacy, covering at least one
full week's business, across all opening times, including late nights and weekends. In
this way, all users of the community pharmacies had an equal chance of being included
within the sample. In addition, a 'non-responder minimum data collection form' was
designed to establish if non-responders were in any way systematically different from
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responders. Further, in order to assess the overall representativeness of the study
sample, it was compared to the overall demography of the Lothian health area and to the
individual catchment population areas within which each of the sample community
pharmacies were located. This was done using Lothian Health socio-demographic
profile data sources, including the Director of Public Health's annual report, as well as
other available comparative data sources (Lothian Health, 1996a). In particular, the
study sample was compared with the broader Lothian Health population according to
age, gender, deprivation category and population by postcode and 'depcat' breakdowns.
Finally, the study sample's characteristics were compared to other national data sources,
including for example, Census data and 'Scottish Health Survey' data (Scottish Office,
1997a). To aid this process, standard socio-economic questions, general health and use
of service questions used within larger national surveys were included in the study
questionnaires to indicate how the study sample compared to other populations in terms
of response and key respondent characteristics (Scottish Office, 1997a; ONS 1998a;
ONS 1998b; ONS, 1998c; ONS, 1998c; National Centre for Social Research, 1999).
Overall, these measures aimed to enable a judgement to be made about the
representativeness of the study population in relation to both the Lothian Health area and
national survey data and to assess the extent of potential selection biases present.
2.6 Development of data collection instruments
Three main data collection instruments were developed: a short pharmacy questionnaire
interview; a non-responders' minimum data collection form; and a telephone follow-up
questionnaire interview. These instruments aimed to: elicit users' routes to access P
class medicines; establish whether the users revisited the general practitioner or
community pharmacist concerning the illness episode for which they had obtained the P
medicine; map the logistics of their visit; and enumerate key time and resource costs
incurred by users and primary care providers. Guidance on the design and piloting of
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the research instruments was carefully adhered to (Streiner & Norman, 1995; Moser &
Kalton, 1973; Moser & Kalton, 1993; Oppenheim, 1993).
2.6.1 Community pharmacy questionnaire interview
The aim of this instrument was to describe the route adopted by users to access
deregulated 'P' class medicines and to ascertain the associated costs accruing to users
and other stakeholders as a result (Appendix 2).
The questionnaire interview (taking approximately 5 minutes to complete) was
administered by a researcher within community pharmacies, with consenting users,
immediately after the sale or dispensing of a P class medicine and covered socio-
demographic details of the user including, date of birth, marital status, employment
status, postcode, educational background and ethnic group, ft should be noted, however,
that the data on users' socio-economic status was indirect. Collection of more direct
socio-economic data e.g. on incomes was not possible as participating pharmacists
objected to this. The researcher was mindful of the ecological nature of the deprivation
status variable, derived from users' postcodes (acknowledging that being resident in a
deprived area does not equate to being poor) and thus exercised caution in its
interpretation.
The pharmacy questionnaire also collected details on: the route adopted by the user to
access the P medicine; the user's exemption status for prescription drugs and the retail
price of the P medicine, if obtained over-the-counter. Further, depending upon whether
the user consulted their general practitioner, a community pharmacist, or both, data was
also collected on: their method and distance of travel to the general practice/community
pharmacy and any time and financial costs accruing to users while attending
consultations (including, for example, waiting and consultation times and necessity to
take time off work or to arrange child care).
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At the end of the pharmacy interview, the researcher sought the user's permission to be
prospectively followed-up (by telephone) to answer a few questions regarding their
subsequent use (if any) of general practice and community pharmacy services. In
addition, respondents were asked two open questions to ascertain their views regarding
use of community pharmacies. Survey respondents were given the opportunity to
remain anonymous, unless they agreed to be followed-up. In this case the user's name
and a contact telephone number was collected.
2.6.2 Non-responders' minimum data collection form
This instrument aimed to collect a minimum amount of data about those users refusing
to participate in the study (Appendix 2). It collected information on pharmacy name;
interviewer name; day, date and time of refusal; gender; prescription or over-the-counter
sale; and any reason(s) given for the non-response. It was intended that this instrument
would enable the researcher to assess the existence and extent of any systematic
differences occurring in the sample between responders and non-responders that could
lead to bias.
2.6.3 Telephone follow-up questionnaire interview
The aim of this instrument was to follow-up participants in the short pharmacy
questionnaire interview (who gave consent) to ascertain their subsequent use (if any) of
general practice and community pharmacy services (Appendix 2). They were
conducted with users a minimum two weeks and maximum of 4 weeks after
participation in the initial pharmacy interview. The follow-up period was decided upon
in line with guidance within the literature regarding appropriate follow-up and recall
periods and consideration of the minor nature of the conditions presented (UK Working
Party on Patients' Costs, 1999).
The telephone follow-up interview established if any follow-up consultations occurred
regarding the same illness episode that the P medicine was obtained for and elicited
information on the key time and resource costs accruing to key stakeholders associated.
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By combining the information collected in both the pharmacy and telephone follow-up
interviews, it was possible to establish a complete history for the illness episode
concerned, for which the P medicine(s) were obtained. This also facilitated assessment
of the extent of substitution or complementary usage between general practice and
community pharmacy services within the sample, and the costs to users of accessing P
medicines via different routes.
2.7 Pilot work and refinement of data collection instruments
A pilot study was undertaken to assess the suitability and adequacy of the three data
collection instruments. It was conducted in three different community pharmacies
(including both chain and independent pharmacies) across a range of areas (residential
and shopping) within a variety of deprivation categories (affluent, mid-affluent and
deprived). The pilot was conducted in different community pharmacies from the fifteen
participating in the main study. 50 pharmacy and 20 telephone follow-up interviews
were piloted and re-piloted on four separate occasions.
2.7.1 Pilot of the community pharmacy questionnaire interview
Overall, the general administration of the short pharmacy questionnaire went well,
taking a maximum of five minutes to complete; generating encouraging telephone
follow-up rates; causing minimal disruption to the pharmacy business; and yielding the
desired data on routes to access P medicines and the associated costs to users.
As expected, however, a number of minor teething problems arose including: some
questions with apparently ambiguous language; inadequacy of the questionnaire to deal
with proxy responders; a tendency for responders to discuss 'personal' medical problems
due to the open nature of some of the questions; screening out of some potential
respondents (e.g. with learning disabilities) by pharmacy staff; and lower than expected
numbers presenting to the pharmacies for P medicines.
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A number of modifications were thus undertaken to improve the process of data
collection using the pharmacy questionnaire instrument. A project information pack was
developed to distribute to participating pharmacists and their assistants to ensure
maximum recruitment of all eligible respondents. This pack included: a brief summary
of the aims of the project; clear details on inclusion criteria; a standard introduction and
invitation to the project; and counter display materials (posters and leaflets) for
pharmacy staff and users to refer to.
A number of general modifications were also made to the questionnaire, including: use
of more user friendly 'lay' language; improvements to the wording of the ambiguous
questions; ensuring consistent use of language and terms throughout all sections of the
questionnaires; and improving the prompts and 'go to' instructions to improve the flow
of the questionnaire interview. In addition, the questionnaire was adapted to build in
sensitivity for 'proxy' responders, to avoid losing these interviews and data. Further, the
number of closed, pre-coded response questions was increased and the layout of the
questionnaire simplified to facilitate ease, speed and consistency of completion across
researchers and to facilitate data entry and management.
Adjustments were made to de-sensitise questions eliciting socio-demographic and other
personal information from users, by incorporating use of only 'yes' or 'no' answers,
developing show cards to anonymise responses and by asking such questions near the
end of the interview. Also, to facilitate comparison of the study sample with other local
and national data sets, standard socio-demographic questions were incorporated from
national surveys (Scottish Health Survey, 1995; ONS 1998a-d).
2.7.2 Pilot of the non-responder minimum data collection form
The non-responder minimum data collection forms worked well during the fifty pilot
interview stages, requiring no major changes. Non-responders were easily identified and
the form very quick and easy to complete.
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2.7.3 Pilot of the telephone follow-up questionnaire interview
The telephone follow-up questionnaire was piloted with users over a range of time
intervals following their initial pharmacy interview from two to six weeks. Respondents
identified quickly with the study and were happy to participate in the telephone follow-
up interview. Depending on whether the users had re-visited their general practitioner or
community pharmacist, or not, the telephone follow-up interview lasted between two to
five minutes. No problems emerged with this instrument, probably because most of the
questions within it mirrored those undertaken during the short pharmacy interview,
which was subjected to fairly extensive piloting.
2.8 Training and monitoring of support research staff
Increasing the number of participating community pharmacies from six to fifteen, to
achieve the target sample size, necessitated recruitment of three temporary support
research staff to assist with the pharmacy interviews. They each covered three
community pharmacies, with the lead researcher undertaking the data collection in the
remaining six.
A training day for the temporary research staff was developed and organised by the lead
researcher to ensure that they were fully cognisant of the study's aims, familiar with the
use of the pharmacy questionnaire, and consistent in its completion. To this end, a
'briefing pack' was prepared and circulated to the support researchers to read prior to
their training day, including: a summary of the projects aims; project summary leaflets;
user information leaflets; an alphabetical list of all P medicines; fieldwork instructions;
specimen study introductions to users; general notes on coding and completion of the
pharmacy questionnaires; luminous pharmacy counter display posters; the pharmacy
questionnaire and accompanying show cards; non responder minimum data collection
forms; fieldwork timetables; project contact details; and University of Edinburgh
identification badges and cards for use during fieldwork (Appendix 2).
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In addition, the temporary researchers shadowed the lead researcher for three days each
during the first two weeks of the fieldwork, receiving 'on the job'' training and resolving
any queries or difficulties they may have had, prior to them going into the field
independently. In this way, it was hoped to ensure data quality and consistency in the
administration of the questionnaire. The lead researcher also monitored the support
researchers' progress on an ongoing basis to identify and/or avert problems as they
arose. Extra training or assistance was provided where felt to be necessary. This was
undertaken in one case to iron out minor problems with incomplete questionnaires.
2.9 Data collection and entry
2.9.1 Ethical issues
Prior to commencement of data collection, ethical approval was sought from Lothian
Health's Ethics Committee. At the time of data collection (1998/9) ethical approval
was, however, deemed to be unnecessary. However, the research was conducted
following ethical principles, in that, questionnaires were anonymised, with respondent
identifiers kept separate from the data and in a secure location. Respondents were
assured confidentiality. Further, they were notified that any information they provided
to the researcher would not be shared with any health care professionals and that
participation in the study would not affect the treatment they received. Finally, they
were informed that the data would be anonymously stored, seen only by the researchers,
and reported in such a way that it would be impossible to identify them.
2.9.2 Community pharmacy questionnaire interview
Two weeks fieldwork was undertaken in 15 community pharmacies (30 weeks in total)
within the Lothian Health region. This comprised over 700 hours of fieldwork,
undertaken between June and November 1998.
No problems or complaints emerged during the data collection within the community
pharmacies. Users were generally very willing to take part and happy with the content
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of the pharmacy questionnaires, which neither they, nor the pharmacy staff, appeared to
find intrusive.
2.9.3 Non-responder minimum data collection form
As noted above, completion of the non-responder minimum data collection forms was
quick and effective.
2.9.4 Telephone follow-up questionnaire interview
The lead researcher undertook all of the telephone follow-up questionnaire interviews.
These were conducted between July and December 1998. A total of 718 follow-up
interviews were undertaken. No major problems were encountered in this data
collection effort.
Overall, the data collection progressed well, to time and on track to generate the data
required to achieve the specified aim and objectives of the project (as outlined at the end
of the literature chapter). The data collection effort did not realise the full 1500 target
sample size. However, the 1186 pharmacy and 718 telephone follow-up interviews
conducted were deemed adequate to address the aim and objectives of the research. The
primary data collection phase of the project was both costly and time consuming. For
these reasons it was not possible to continue further data collection to achieve the target
sample size.
2.9.5 Data entry





The core study data set comprised 273 variables, including: l user identifier code;
descriptions of consultation routes to access P class medicine(s); previous use of primary
care services and medicines; self reported health status; demographic and socio¬
economic characteristics. Variable name, type and description were summarised in a
data code-book.
2.10.2 Data management, quality and modification
Data were primarily managed and analysed using the Statistical Package for Social
Sciences (SPSS) Version 9. Respondents were identified by number only, thereby
securing user anonymity and confidentiality of record, in line with data protection
requirements.
Generally speaking, the data was of high quality and complete. Ideally, double entry of
all data would have been undertaken to fully check the accuracy of the data entry
process. This was impossible within the project time scale and resources. However,
literature indicates that this may not be necessary (Robin, Reynolds-Haert & McBride,
1992; Gibson et al., 1993). As a compromise measure, the first 400 questionnaires
(representing a third of all data collected) were double entered (by university data entry
clerks) and questionnaires randomly selected and checked thereafter (by the researcher).
Very few and only minor data entry errors were consequently detected. For example,
one case had been entered twice; another only partially; and data entry had been 'mixed
up' between two cases in the process of entering the follow-up telephone interview data.
2.10.3 Data cleaning
Exhaustive and detailed data cleaning was undertaken. Three main data cleaning
methods were used: graphical exposition; range checks; and logical validation.
Variables were charted to investigate their spread, looking out for any flat or uniform
distributions that may have indicated data entry errors. Range checks were then
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undertaken, using frequency counts, to identify and check for either nonsensical or
outlier values. Finally, logical validation exercises were conducted to check the data for
logical structure, ensuring that all questionnaire prompts and flows were adhered to and
that numbers of responses matched between related sections and questions. Apparent
errors or anomalies were identified, investigated and rectified. A detailed data cleaning
record was kept by the researcher, identifying and documenting any changes.
2.10.4 Missing values
Incomplete or missing information was excluded from the main data analyses, analysed
and written up separately and the potential implications of this, if any, for the overall
results identified.
For the most part, however, the data set was complete. Only one case was completely
excluded from subsequent analyses due to incompleteness. However, there was one
variable for which a significant number of cases exhibited missing values - the user
postcode variable (f6pcode). A number of users were reluctant to provide, could not
remember, or did not know their postcode. Postcode was used to create the 'depcaf
variable (f6depcat) indicating the area deprivation category within which users lived.
These data were missing from 112 users who, as a result, were initially excluded from
subsequent analyses using the f6depcat variable.
Discrete missing values were also detected within a limited number of cases. These
appeared to be missing at random. A number of strategies were employed to overcome
problems of missing data, in order to maximise the number of cases available to include
in subsequent analyses. Missing values were imputed in a number of ways. For
example, by substituting in mean or modal sample values; considering the distribution of
values across the sample and imputing a reasonable value; and exercising judgement
dependent upon the user's response to other questions. Detailed notes were kept of this
process within the data cleaning record. Data analyses were run both including and
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excluding the cases for which values were imputed in place of missing data. There was
no observable impact on the key results.
2.10.5 Data modifications
A number of the original variables specified in the data code-book was modified to
facilitate more sensitive and robust analyses. In the main, this involved recoding most
of the socio-economic and demographic variables collected in the pharmacy
questionnaire to either reduce the number of categories or compress variables that
included an open response category option to allow for individual user response out with
the pre-specified structure of the questionnaire. This was undertaken to fulfil a number
of pre-requisites necessary to facilitate appropriate analyses. For example, making
certain variables completely ordinal, categorical in nature; to make variables more
intuitive and easier to interpret in subsequent analyses; and, in particular, to limit the
number of cells violating the minimum data requirements of frequency counts of less
than five within Chi-square analyses of contingency tables. As before, a detailed
chronology of all data modifications and manipulations were recorded within a data
management diary.
2.11 Methods of data analyses
A mixture of descriptive and stochastic analyses was undertaken. The analytical
approach adopted embraced a mixture of exploratory and confirmatory analysis.
Exploratory in the sense that this was a completely new data set in an area of research of
which the researcher had limited prior knowledge. However, the analysis was also
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confirmatory to some extent in that the investigator tested a mixture of'common sense'
predictors expected to influence outcomes, as well as associations either expected on
theoretical grounds or previously identified within the literature.
The key data analyses methods employed to address the specific objectives of the study
are summarised below:
2.11.1 Describing the samples
The first step in the data analyses was to undertake basic description of the study
samples: profiling the sample of users accessing P medicines, identifying patterns in
terms of users from different demographic and socio-economic groups; summarising the
key characteristics of the community pharmacies included in the study; and enumerating
the different types of P medicines obtained by users.
Descriptive analyses incorporating the use of simple graphical techniques were used to
assess the distribution of the variables. Thereafter, basic descriptive statistics were used
to summarise variables and draw comparisons between inter (study sample and the
Lothian Health population) and intra (full and follow-up) sample characteristics,
including e.g. proportions, means, medians, ranks and ranges.
Analyses proceeded by investigating associations between variables and users' choice of
consultation route to access P class medicines, including: demographic and socio¬
economic characteristics; self-reported health status; access to and use of general
practice and community pharmacy services; cost and type of medicines.
Univariate analyses were then conducted investigating similarities and/or differences in
characteristics between users within the full (n=1185) and follow-up (n=7l8) samples;
and exploring associations between user characteristics and choice of consultation. The
main univariate analyses techniques included Chi-square analysis of contingency tables
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examining the relationships between binary outcome variables and categorical variables;
and Chi-square analyses of trend (i.e. the Mantel-Haenszel test for linear association)
applied to ordered categorical data (Kirkwood, 1996).
2.11.2 Mapping the routes adopted by users to access P class medicines
The next step in the analyses was to identify and describe the routes adopted by users to
access their P medicine(s). A typology of routes adopted by different groups of users
was outlined and analysed according to factors hypothesised to impact on their choices
including: socio-economic and demographic characteristics of users; type of drug; and
price of the P drug relative to the prescription fee. As before, a range of descriptive and
univariate probabilistic analyses were conducted to investigate these issues more fully.
2.11.3 Assessing the extent of substitution or complementary usage
between general practice and community pharmacy services
Using the data collected in both the pharmacy and telephone follow-up interviews it was
possible to detail the use of general practice and community pharmacy services for the
complete history regarding the minor illness episode for which the P medicine was
obtained. This data also made it possible to assess the extent of substitution or
complementary usage between general practice and community pharmacy services in the
use of P medicines to treat the particular episode of illness being investigated.
2.11.4 Developing a model aiming to predict users choice of access route
The next stage in the data analysis was to develop a model, identifying variables
predictive of users choice of route to access their P medicine - visiting either the general
practitioner or community pharmacist. Univariate (Chi-square analyses of categorical
variables within contingency tables) and multivariate (logistic regression) statistical
techniques were used to progress this analysis, investigating associations between user
characteristics and the access route adopted, once again including: demographic and
socio-economic characteristics; self-reported health status; access to and use of general
practitioner and community pharmacist services; and cost and type of medicines.
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2.11.4.1 Univariate analyses
Chi-square analyses were used to investigate associations between users' choice of
access route (general practitioner or community pharmacists first) and variables of
interest. The aim of this analysis was to ascertain if there were any statistically
significant differences in characteristics between those users who opted to go to the
community pharmacists to buy their P medicine over-the-counter, and those who
consulted the general practitioner to obtain a P medicine on prescription. Further, the
univariate analysis was undertaken to identify potential variables of interest to be
included within the multivariate logistic regression analysis.
Univariate analyses can be productively employed to investigate multiple variables
hypothesised to impact on users' choice to access P medicines from either the general
practitioner or community pharmacist. However, a limitation with the univariate
approach is that it ignores the possibility that a collection of variables, each of which is
weakly associated with the outcome, can become an important predictor of outcome
when taken together (Hosmer & Lemeshow, 1989). For this reason, it is also desirable
to try to take account of the relationships between the predictor variables in order to
determine their relative influence on users' route to obtain their P medicine. It could be
that only a small number of the predictors variables actually influence the choice of
consultation route adopted by the user and that other variables exhibit statistically
significant univariate relationships as a result of association with the key predictor
variables. Alternately, it may be that each variable has an independent effect upon
users' choice of method to access their P medicine.
2.11.4.2 Multivariate analysis
Multivariate analyses were then conducted to strengthen and extend the analyses,
investigating simultaneous interactions between explanatory variables. The aim was to
develop a model to predict users' choice of access route. Logistic regression modelling
was the multivariate method adopted.
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Logistic regression modelling
Logistic regression modelling is acknowledged as the standard method for regression
analysis if the relationship being investigated is between a dichotomous outcome
variable and a set of covariates (Hosmer & Lemeshow, 1989). It is a data analysis
technique used to derive an equation to predict the probability of an event, given one or
more predictor variables. It assumes the natural logarithm of the odds for an event ('the
logit') is a linear sum of weighted values of the predictor variables. The weights are
derived from data using the methods of maximum likelihood (Gold et al., 1996).
Logistic regression methods were chosen given the binary nature of the outcome
variable of interest - user's choice to access their P medicine from either a community
pharmacist or general practitioner. The strength of this method is that it accounts for the
complex, simultaneous interactions between explanatory variables, aiming to determine
the contribution of each to eventual outcome.
In line with other statistical model building techniques, the aim of logistic regression is
to find the best fitting and most parsimonious model to describe the relationship between
an outcome (dependent) variable and a set of independent (predictor) variables (Hosmer
& Lemeshow, 1989).
Given the non-linear characteristic of the dichotomous outcome variable of interest in
this study, the logistic regression model applies a logistic transformation of the
dependent variable in order that the substantive relationship remains non-linear but the
form of the relationship is linear. Put another way, the logistic transformation ensures
that the relationship is non-linear in terms of its variables and but linear in terms of its
parameters. In this way, a linear probability model is developed and can be analysed
using standard iterative regression techniques (Collett, 1999). In particular, maximum
likelihood techniques are used to maximise the value of a function, the log likelihood
function, which indicates how likely it is to obtain the observed values of the dependent
variable, given the values of the independent variables (Menard, 1995).
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A number of other methods are available to transform the data to facilitate regression
analysis (e.g. the probit or complementary log-log transformation). However, the
logistic transformation was selected for a number of reasons. From the mathematical
point of view, it is an extremely flexible and easily used function that is conceptually
more convenient (Hosmer & Lemeshow, 1989; Collett, 1999). More importantly,
however, it lends itself well to meaningful interpretation as it has a direct interpretation
in terms of the logarithm of the odds in favour of a success (Hosmer & Lemeshow,
1989; Collett, 1999). Hosmer and Lemeshow summarise the merits of the logistic
regression model noting: "unless we are dealing with a set of data where most of the
probabilities are very small or very large, or where fit is very poor in an identifiable and
systematic manner, it is unlikely that any alternative model will provide a better fit"
(Hosmer & Lemeshow, 1989).
Two main approaches to model building strategies using logistic regression techniques
were considered: purposeful selection of variables to be included in the model, moving
from general to specific models; and stepwise methods, referring to decisions made by
computer algorithms to select predictors for inclusion or removal from the model
(Menard, 1995). There are advantages and disadvantages associated with each of these
approaches to model building.
Advocates of the purposeful selection of variables by the researcher, argue that this
approach offers potential to include all scientifically relevant variables; pointing out that
it is less deterministic, according the researcher more control over the analysis; more
readily permitting him/her to consider a broader range of potential predictor patterns;
and facilitating as complete control of confounding as possible. However, these
advantages need to be balanced against the practical considerations that purposeful
selection and model building can be very time consuming (e.g. only ten pairs of
predictor variables yield a 1000 regression equations to consider) and can result in over-
fitting the model (Hosmer & Lemeshow, 1989).
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Proponents of stepwise procedures note that it is particularly suitable for predictive and
exploratory research (Hosmer & Lemeshow, 1989; Menard, 1995). They contend that in
purely predictive research, investigators are not concerned with causality but rather with
identifying a model that accurately predicts the outcome in question (Menard, 1995).
Further, they note that stepwise methods are particularly useful for exploratory research
in new areas of study where existing 'theory' amounts to little more than empirically
unsupported hunches (Menard, 1995). In these circumstances, stepwise approaches may
be concerned mainly with theory construction and development as opposed to theory
testing (Hosmer & Lemeshow, 1989; Menard, 1995). Another advantage of stepwise
procedures is that they offer a fast, effective way to screen a large number of variables,
simultaneously fitting a number of logistic regression equations. Further, they are
intuitively appealing in that they build models sequentially and facilitate examination of
a collection of models, which might not otherwise have been examined (Hosmer &
Lemeshow, 1989).
Critics of stepwise approaches believe them to be overly deterministic, resulting in
model development and choice by computer algorithms adhering to a fixed decision
rule, rather than researchers' judgement which some believe to be tantamount to an
admission of ignorance about the phenomenon being studied (Hosmer & Lemeshow,
1989; Menard, 1995). In particular, critics of stepwise procedures believe them to be
inappropriate for theory testing as they capitalise on random variations in the data
(Menard, 1995). Mechanical selection procedures, such as those employed in stepwise
approaches, can also select irrelevant or 'noise' variables and produce idiosyncratic and
implausible models, the results of which can prove difficult to replicate in other samples
(Hosmer & Lemeshow, 1989; Menard, 1995).
Notwithstanding these criticisms, stepwise logistic regression techniques were employed
in the analysis of the study data. There were four main reasons for this choice. The
general approach to the research study presented is exploratory. Whilst there is a
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significant amount of research on use of general practice services, investigation of user
response to the policy initiative to encourage increased self-medication using P class
medicines is relatively under-researched. Even less attention has been dedicated to
theoretically modelling social and cultural influences in this area. The outcome being
studied is relatively new and the important covariates are not known and associations
with the outcome not well understood. In the absence of theoretical frameworks, a more
'qualitative' approach was adopted. Further, the specific aim of the regression analysis is
to develop a model useful for predicting users' choice to visit either the general
practitioner or community pharmacist to access P class medicines, for the practical
purpose of appraising the success or otherwise of current policy initiatives and
potentially informing future policy development in this area. Theory construction and
development, while welcome, were secondary to this aim. Finally, while the researcher
acknowledges the potential dangers associated with the more mechanical stepwise
procedures for regression model building, the researcher also believes that these can be
overcome by critically reflecting throughout the model building process on the potential
pitfalls of the method and closely scrutinising resultant models, identifying their
strengths and weaknesses. For these reasons, stepwise techniques were adopted in the
logistic regression model building. More detail on the steps involved in building the
model and the results of checking its robustness are outlined in Chapter 4.
2.11.5 Investigating the changing distribution of costs and consequences
The next phase of data analysis involved: undertaking a costing analysis enumerating,
quantifying and valuing key stakeholder costs; modelling costs associated with varied
policy scenarios; conducting consumer surplus analyses investigating alternate prices
faced by users in accessing medicines; and conducting economic evaluation to assess the
relative efficiency to society associated with alternate routes to access P medicines.
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Two related economic methods were applied to address these questions: consumers'
surplus analyses and economic evaluation.
2.11.5.1 Consumers' surplus analyses
Consumers' surplus "measures the difference between what consumers have to sacrifice
(in terms of time and money) to consume a good and what they would be willing to pay.
It is, therefore, a measure of the net benefit an individual derives from consumption"
(Lipsey, 1987; Ryan & Yule 1990); i.e. it calculates the net consumption benefits to
users facing different time and money costs, depending on their route to access a P
medicine. This was the main application of consumers' surplus in this study -
examining the impact on both consumer's and consumers' surplus associated with the
different costs (change in relative prices) associated with accessing P class medicines in
the treatment of minor ailments via alternative access routes.
The basic principles of consumers' surplus were outlined in the literature review. In
summary, the key assumptions underpinning demand theory and consumer surplus
analysis are as follows:
• A linear demand function (Ryan, in Bond, 2000; Blaug, 1996);
• The commodity concerned is 'unimportant' and accounts for a small fraction of
the consumers' total purchases (Lipsey, 1987);
• The marginal utility of such a good is equal to its price, assuming that the
marginal utility of income is treated as a constant (Blaug, 1996);
• The marginal utility of consumption of all other goods is not affected by the
variations in the amount of money spent on the (unimportant) commodity
(Lipsey, 1987);
• Consumers' surplus addresses the collective gain or aggregate surplus of all
buyers in the market by assuming that most markets are homogenous with
respect to the income class of buyers (suggesting that the individual is a modal
representation of the group) thus ensuring additivity (Blaug, 1996);
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• All individuals face the same costs (prices) (Ryan & Yule, 1988;Ryan & Yule
1990);
• Costs can be broadly defined to include both monetary and non-monetary (e.g.
time) components (Ryan & Yule, 1988; Ryan & Yule, 1990);
• Users possess reasonably good information about the benefits and costs to them
from consuming the commodity in question (otherwise their demand function
would not be meaningful) (Blaug, 1996).
Data collected in both the pharmacy and telephone follow-up interviews elicited detailed
information on the differential time and resource costs faced by users, depending on the
route they adopted to access their P medicine(s). Actual cost to users of their chosen
method to access their P medicine was calculated, as was the potential cost to them had
they opted for the alternate route available to them; i.e. the changing cost to users of
substituting a general practitioner consultation in place of a community pharmacy visit
to access a P medicine (or vice versa) were estimated. The difference between the costs
faced by users in each of the two routes to access their P medicine represents their
individual consumer's surplus (this figure could be either positive or negative,
depending on whether the alternate decreased or increased the cost faced by the user).
A modelling exercise was then undertaken to compare the impact on net benefit to users
and the health sector resulting from numerous hypothetical consultation scenarios on our
sample including e.g. net benefit if all users had attended their general practitioner
exclusively to secure a prescription for their P medicines; or net benefit if all users had
attended their community pharmacy exclusively, buying a P medicine over-the- counter.
2.11.5.2 Economic Evaluation
Economic evaluation may be defined as: '"the comparative analysis of alternative courses
of action in terms of both their costs and consequences" (Drummond, O'Brien &
Stoddardt, 1987).
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The economic evaluation outlined in this study is concerned with identifying, measuring
and valuing the costs and consequences, and thus the relative efficiency, of alternate
ways to access P class medicines.
The study outlined employs both partial and full economic evaluation techniques. It
begins by undertaking a cost analysis, enumerating, quantifying and valuing the key cost
elements accruing to the main stakeholders.
A cost minimisation analysis (CMA) was then undertaken to extend the cost analysis to
a full economic evaluation. This step investigated the relative costs to different parties
of accessing P class medicines via one of two main access routes: either on prescription
from the general practitioner or purchased over-the-counter under the supervised sale of
a community pharmacist. In theory, the clinical outcomes experienced by any user
associated with using particular P class medicines to treat a particular episode of a minor
ailment should be identical, regardless of whether the medicine was obtained over-the-
counter from a community pharmacist or on prescription from a general practitioner.
For this reason, (approximate) equivalence in health outcome was assumed.
Finally, efforts were made to consider a broader range of indirect and/or intangible costs
and consequences that may also have been of relevance to the user's choice of
consultation route and their importance. In particular, the goal was to elucidate factors
(not readily captured within either consumers' surplus or economic evaluation
techniques) that influence consumers to choose the over-the-counter source of supply in
preference to the prescription route for selected medicines.
In the telephone follow-up interviews, users were asked two open questions aiming to
elicit their views on increased use of community pharmacies and P medicines. The
transcripts from these interviews were coded according to emergent themes, those within
the literature and their relevance to the study research questions considered. A pilot-
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coding frame was developed using a randomly selected 10% sample of follow-up
questionnaires. These were then recoded, blind, by the researcher to check the accuracy
of the coding scheme and ensure that codes had been applied consistently. A further,
randomly selected, 10% sample was selected and coded applying the modified coding
frame. This same sample was then given to a second researcher who coded them again
(blindly) and checked afterwards for sense and consistency in the application of the
codes. Inter-rater agreement was high. Thus, the remaining follow-up questionnaires
were coded and the data entered. Copies of the coding frames applied are included in
Appendix 2.
The general approach and key stages of economic evaluation were outlined in the
literature review and summarised in table A 1.1 in Appendix 1. Below is a summary of
the more detailed methodological decisions and assumptions applied in the economic
evaluation conducted in this study. For ease they are presented in the order of the key
stages, as outlined by Drummond et al., (1997).
The study question, alternatives compared and viewpoints for analysis
The economic evaluation outlined in this study was concerned with identifying,
measuring, valuing and comparing the costs and consequences (intermediate) and thus
the relative efficiency, of the two routes via which users can access P class medicines:
(1) through a general practitioner prescription, either issued in repeat prescription
mechanisms or in the course of a consultation; and (2) by buying a P medicine over-the-
counter in the course of a supervised sale within a community pharmacy.
This evaluation was undertaken in the context of an implicit shift in policy encouraging
people increasingly to self-medicate their minor illnesses using P class medicines,
accessed from community pharmacies, and formed part of broader demand management,
cost containment and graduated access strategies within primary care.
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The economic analysis adopted a societal perspective. This is generally acknowledged
to be the best perspective as it is the broadest and always relevant (Gold et al., 1996;
Drummond, O'Brien & Stoddart, 1997). Its strength is that it ensures that all key parties
affected by the intervention are represented, counting all significant costs and
consequences that results, regardless of to whom they accrue (Gold et ah, 1996). The
societal perspective was felt to be particularly relevant/useful in this study, given its
specific aim to investigate how costs may be shifted between sectors. While the study
adopted a general societal perspective, it also considered a range of other main
perspectives including those of patients, the health care system and specific sectors
within it (e.g. general practice and community pharmacy) (Reinhardt, 1997; Gold et ah,
1996). Thus, costs were identified, measured and valued separately, from each
perspective, and secondary analyses presented from the point of view of specific
interests and results compared (Gold et ah, 1996).
The options being evaluated
The economic analysis in this study investigates two alternative routes to access P
medicines for use in the treatment of minor illnesses: via prescription obtained from a
general practitioner, or purchased over-the-counter in the context of a supervised sale by
a community pharmacist. These two alternatives were selected for investigation as they
were the most pertinent. Accessing P medicines from the general practitioner on
prescription may be regarded as the traditional access route; and buying them over-the-
counter from the community pharmacist the newer option, which has been promoted in
recent years via the increasing deregulation of previously prescription only medicines
(POMs) to pharmacy available (P) status (i.e. POM to P shifts). This reflects a
government(s) policy shift encouraging increased use of community pharmacists in the
management of minor ailments, a central plank of broader demand management and
graduated access strategies within primary care, recently introduced. These two options
currently represent the main two routes via which users can access P class medicines
within primary care. They reflect 'real world' practice and were believed to be the most
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appropriate comparators relevant for assessing the relative costs of accessing P class
medicines.
Two other potential alternatives currently exist in which users can access P class
medicines: from a nurse prescriber and direct from a community pharmacist, still on
prescription, via pilot liaison schemes with general practitioners (Whittington et al.,
2001; Salisbury et al., 2002a; Schafheutle et al., 2003). These alternatives were,
however, excluded from consideration, for two main reasons. Firstly, they have
typically been introduced in pilot study developments, involving smaller number of
users and/or only specific medicines and conditions. This study wanted to investigate
current 'usual' practice. Further, it wanted to include all potential users of all P
medicines. Secondly, these developments have already, or are currently subject to
evaluation of their developments (Whittington et al., 2001; Salisbury et al., 2002a;
Schafheutle et al., 2003; Sheehy & Jones, 2003). Thus, these alternatives were excluded
from this study.
Often economic evaluations include a 'do-nothing' or 'status-quo' comparator option.
However, given the explicit promotion of the community pharmacy route within the
current policy environment, this was not considered appropriate. Effectively, the two
routes adopted currently constitute the 'defacto' statusquo, which, until now, has not
been evaluated.
Relative effectiveness of the two options
Full economic evaluations should consider issues relating to programme effectiveness
(Gold et al., 1996). A cost minimisation analysis is the main economic evaluation
methodology being applied. This technique requires the assumption that health
outcomes are presumed to be equal. This is the case in this study. This assumption is
predicated on the fact that there is no reason to expect that clinical efficacy of P
medicines is affected by the route via which users access them. Indeed, these and other
safety related considerations feature strongly in decisions by the Committee for Safety
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of Medicines in the licensing of P medicines (OTC Directory, 1995). Occasionally,
slightly different licensed indications are introduced for the same drugs (e.g. regarding
dosage, pack size and use of certain P medicines) which, in certain cases (e.g. large pack
sizes) may result in them being considered to re-enter the prescription only (POM)
category. This is the case, for example, in the availability of Hi antagonist medicines.
However, conditions of availability and appropriate use of medicines for the alleviation
of minor conditions, which come under a P classification, should be very similar (over
populations of users) whether bought over-the-counter or obtained on prescription. One
would expect them to be equally efficacious in the management of minor ailments, if
used appropriately, in line with their licensed indications.
The range of costs and consequences considered
Efforts were made in this study to at least outline, if not necessarily include, the whole
range of potential costs and consequences associated with the two alternatives under
investigation. Given the societal perspective adopted in the study, efforts were made to
cast the evaluation net as widely as possible to identify relevant cost and consequences
overall, but also to consider the particular groups to whom they potentially accrued -
namely society, the NHS (general practitioners and community pharmacists specifically)
and users and their families.
It was recognised at the outset that this study would involve investigating small
differences in costs to large numbers of individuals over significant volumes of health
care activity. Differences in cost between the two access routes were not expected to be
very large. Thus, considerable effort was devoted to identifying differences in resource
consumption at a micro level.
For these reasons, as well as financial and time constraints of the research, the study
'boundaries' were necessarily confined to identification of only the most important costs
likely to impact on results. The time horizon adopted for the collection of costs and
consequences information was determined in line with the nature of minor ailments
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concerned. On the advice of primary care professionals, an appropriate time window
was estimated to be within a range of between two to four weeks. Cost data were, thus
collected for this time period.
Calculation of long run marginal opportunity costs is the general theoretical ideal within
economic analyses (Netten & Beecham, 1993; Knapp, 1995; Gold et al., 1996).
However, an accepted costing convention is the use of short run average revenue costs,
supplemented with appropriate capital and overhead allocation, as a proxy for long run
marginal opportunity cost (Hallam et al., 1994; Drummond et al., 1997). This was the
costing approach adopted in the study.
Three main types of costs and consequences are generally considered relevant within
economic evaluation - direct, indirect and intangible. Methodological and time
constraints often mitigate against the inclusion of intangible costs and consequences
within economic evaluations. For exactly these reasons, they were excluded from
consideration in this study. The specific costs and consequences included in this study,
differentiated by type (direct and indirect) and relevance to various perspectives are
summarised in table 2.1 below.
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Adapted from Gold et al., 1996 p. 186 Table 6.1
"Direct cost
"Indirect cost
"Money transfers which do not reflect resource consumption are called transfer payments (Drummond et al., 1997).
'Transfer payments' (e.g. cash transfers from tax payers to welfare recipients) associated with an intervention, redistribute resources
from one individual to another. While the administrative costs of such transfers should be accounted for, the transfers themselves are
not since, by definition, their impact on the transfer and recipient cancel out (Gold et al.. 1996).
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Three main categories of health outcomes are usually relevant to economic evaluations -
physical, social and emotional functioning of individuals (Drummond et ah, 1997).
However, given the methodological and practical difficulties outlined earlier, health
outcomes are not explicitly considered in this study. Instead, intermediate outcomes
only are measured and compared. Given the doubts over the validity/appropriateness of
attempts to measure health outcomes in this study and the absence of available
instruments to do so, use of intermediate outcomes only was inevitable. However, this
need not be regarded as a limitation of the study. If the purpose of the evaluation is only
to guide allocation among options yielding approximately equivalent results and after
effects, then intermediate outcomes can be very useful (Gold et ah, 1996). Both of these
conditions are satisfied in the study outlined.
Measurement of costs and consequences
An 'ingredients' cost approach was adopted in the evaluation. The identification,
measurement and valuation of the costs and consequences was carried out in separate
steps. Once identified, they were measured in appropriate natural or physical units
(Drummond et ah, 1997). Primary data collection was undertaken to enable this
approach to the valuation of costs and consequences to be adopted. To facilitate
accuracy, respondents were explicitly asked to identify only the incremental costs and
consequences i.e. only those that they would not otherwise have incurred. This
enhances the usefulness of the study, making its key steps transparent and allowing
analysts to apply different valuations, if necessary, to reflect their particular decision¬
making context.
The boundaries set for the study, alongside some methodological considerations
explicitly constrained the analysis to include only the key direct and indirect costs and
consequences of relevance and felt likely to potentially influence any decisions. Further,
the collection was restricted to a one-month time horizon. As a result, certain costs and
consequences were omitted from consideration. Consequentially, consideration of
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adverse events and side effects and associated sequelae, as well as intangible costs and
consequences were excluded in subsequent analyses.
Given that primary data collection was conducted, no particular measurement difficulties
emerged. There were, however, some unavoidable uncertainties. The main example
concerns potential joint use of resources within both the general practice and community
pharmacy consultations. There were undoubtedly cases where the consultation dealt
with issues other than those related to the minor illness episode. Thus, attributing the
full cost of the consultation to the minor ailment may overestimate the cost. Given the
inability of the researcher to observe consultations, this was unavoidable. Thus, there
may be some issues regarding appropriate allocation of cost in such circumstances of
joint use of resources. This was not, however, felt to occur particularly frequently, or to
have a significant impact on the cost estimates. The analysis includes some differential
assumptions about the length of consultations, in a bid to try to account for such
uncertainty.
The valuation of costs and consequences
Prospective data collection allowed key time and financial costs to be estimated and
combined for each user's consultation route, resulting in an individually based
methodological approach (Donnelly et at., 1994). Market prices were mainly used to
proxy opportunity costs associated with resources depleted in the alternatives. Local or
patient specific data were used to calculate costs where possible. Where these were
unavailable, time and cost estimates were supplemented using national data sources (e.g.
Department of Transport and the Environment, 1997; Office for National Statistics, 1998
a-e) national unit cost estimates (e.g. Netten, Dennett & Knight, 1998; Office of Health
Economics, 1999) or previous estimates within the literature (e.g. Scottish Executive,
1999; BMA & RPSGB, 1998). In general though, robust time and cost estimates were
sourced via primary data collection from 'real' users. All cost data are reported in UK
pounds sterling, at 1998/9 prices, applying a range of high, medium and low cost
estimates.
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A range of different costing techniques may be applied to estimate long run marginal
opportunity costs. However, two main methodological approaches to costing exist -
micro and gross costing techniques (Gold et al., 1996). Micro costing may be regarded
as a 'bottom-up' approach (Gold et al., 1996). It is highly specific and involves
compiling a detailed inventory and measurement of all the inputs employed within an
intervention (Gold et al., 1996). By contrast, gross costing adopts a more 'top-down'
approach, seeking to derive a satisfactory estimate of 'typical' cost of the service in
question (Gold et al., 1996). It bases cost estimates on more aggregate level information
on resource use (Gold et al., 1996).
Both micro and gross costing techniques were utilised in this study. There were several
reasons for this. Differences in resource consumption, and therefore costs, between the
two alternatives under consideration were felt likely to be small. However, volume is
large. In these circumstances, only micro costing techniques would adequately
illuminate differences between the options (Gold et al., 1996). In addition consideration
of the distributional consequences to key stakeholders are more easily identified via
micro costing techniques. Further, micro costing methods are more appropriate for
programmes and events occurring in the present (Gold et al., 1996). In calculating costs
of the programmes, consideration also had to be given to both the time and effort
required to achieve robust results and also their generalisability, given the national
policy significance associated with the promotion of self-medication for minor illnesses.
Thus, a compromise or hybrid micro-gross costing approach was adopted in this study.
Time differences to key stakeholders (i.e. general practitioners, community pharmacists
and users) and their associated cost implications were perceived a priori to be the crucial
difference between the two access routes available to access P medicines. Although
involving fairly small time differences, within the context of single consultations, in
aggregate they are likely to be substantial. Further, in order to investigate the changing
distribution of costs across key stakeholders, detailed estimates are required. For these
reasons, a micro approach was adopting, identifying specific estimates from users
regarding key time costs associated with the consultation route adopted (i.e. travel,
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waiting, consultation, dispensing and advice-giving times). Acknowledging the national
policy pertinence of the study, gross cost estimates were applied (e.g. using national unit
costs to calculate the costs of general practitioner consultations). This approach
highlights resource implications on average, across different local contexts and settings.
However, efforts were made to sensitise gross costs. For example, although national
(average) unit costs for general practitioner consultations were used, a per minute
estimate for a general practitioner consultation was derived (Netten, Dennett & Knight,
1998). Staff costs were then calculated by multiplying the relevant per minute
consultation cost by the differential time estimates, thereby deriving a very sensitive
proxy cost for each element. This avoided simply attributing crude average cost
estimates.
User time costs were calculated a similar fashion. Whilst there has been some
methodological debate about the appropriateness of including user time costs, a
consensus has emerged that time resources supplied by users have a positive cost and
thus should be included and valued at their opportunity cost to society (Becker, 1965;
Propper, 1994; Santerre & Neun, 1996; Cauley, 1987; Dept. of Transport, 1997; Janssen,
1992). This approach is consistent with the theoretical foundations of economic
evaluation (Posnett and Jan, 1996). It is clear that when two interventions are very
similar, except that one requires more user time to obtain, they are not equally desirable
(Gold et al., 1996). This is the case in the present study. Time, like money, is a limited
resource that can be devoted to other uses (Gold et ah, 1996). For this reason, it was
crucial to include time costs in the analysis. Further, the societal perspective adopted in
the evaluation requires it.
Valuation of user time costs is also highly contentious. The proxy value attributed to
time depends on whether it is waged or unwaged; i.e. whether it relates to unpaid
employment or leisure time (Smith & Wright, 1994; Netten & Dennett, 1993; Ryan, in
Bond, 2000; Department of Transport & Environment, 1997). Different estimates are
available for each. Mindful of these controversies, the study used a number of different
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wage estimates, reflecting both waged and unwaged (leisure) time. As with estimates of
professional time, user time costs associated with alternative routes were estimated and
combined with the range of wage estimates deemed most appropriate. Given the macro
policy relevance of the study and the societal perspective adopted in the study, national
average hourly wage rate estimates were ultimately considered to be more appropriate
than age/gender specific ones. A key factor influencing this decision was
acknowledgement that, in this study, users of community pharmacy services were
predominantly women, who were often accessing P medicines on behalf of various
family members. In these circumstances, use of gender specific wage rates was felt
likely to underestimate the true cost of user time associated with use of community
pharmacy services. Thus, for both these reasons, use of national average wage rates
seemed methodologically more appropriate. It was not deemed appropriate or
acceptable to elicit users' wage levels within the context of a fairly public interview.
Further, community pharmacists objected to this suggestion. Ultimately, many of the
methodological nuances associated with attributing appropriate opportunity cost values
for lost working time may be a little academic, as only a small proportion of users in the
study actually attended services within work time. Nonetheless, user time costs were
enumerated and valued separately, thus making them transparent, allowing individual
decision makers to gauge their relevance (Drummond et al., 1997).
Thus, micro time and resource estimates were combined with sensitised gross cost
estimates. In this way, the methods aimed to encapsulate the subtle but important time
differences between the alternate access routes, applying cost estimates relevant from a
national policy perspective.
Other relevant costs, in particular, medicine(s), travel and childcare costs, also needed to
be included. Costs of medicines were calculated in three ways. If obtained on
prescription, the cost to the health sector was calculated using national average estimates
of the net ingredient costs of medicines per item obtained, or the average cost per item,
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depending on the classification the medicine was included under within the British
National Formulary (BMA & RPSGB, 1998). Costs to users of medicines purchased
over-the-counter were proxied by their market price. This is likely to overestimate these
costs to society, as the over-the-counter price inevitably includes a margin for profit
(although the profit margin within the price does represent a cost to the user).
Costs to users of obtaining medicines on prescription were estimated at the prescription
charge (£5.80 per item) if the user was eligible to pay for their prescription medicines
and zero if they were not. Cost of prescription medicines to users in possession of a
prescription season ticket, was estimated to be the monthly cost of their ticket. No cost
was attributed to prescription exempt users as prescription medicine benefits constitute a
transfer cost (i.e. payments made on, or on behalf of, individuals (usually by a
government body) that does not perform any service in return) (Gold et al., 1996). Such
transfer payments involve redistribution ofmoney, and as such, do not incur real costs to
society.
Two other categories of costs were calculated for users - travel and childcare costs.
Other research indicates that these are important indirect costs and can influence user
access to services (Pearson et al., 1993). User travel costs were estimated, depending on
the mode of transport used and the time taken travelling to access medicines. A range of
travel estimates was calculated for travel via public transport, train, taxi and private car.
Similarly, childcare costs were calculated by applying estimates of local childcare costs
or attributing a cost for leisure time forgone by family members providing childcare
necessary to allow the user to consult either the general practitioner or community
pharmacist to obtain a medicine.
Two other categories of cost that merited consideration for inclusion were capital and
overhead costs. They were, however, only partially embraced. The national unit cost
figures used for general practitioner consultations incorporate both capital and overhead
cost allocations in their estimates. Whether these national estimates reliably
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approximate the capital and overhead cost profiles of general practices visited by users
in this study is unknown. Doubtless variations exist.
Similarly, there is only limited consideration of the capital and overhead resources used
within the bottom-up cost estimates for community pharmacy included within the study.
Professional allowances paid to community pharmacies (e.g. for dispensing, advice and
on-cost allowances) presumably build in some consideration to cover the capital and
overhead costs associated with running them. At the time of analysis, dedicated
estimates for such costs were not, available within the literature. As such, they were
excluded due to the extreme difficulty in trying to apportion reliably a share of these
costs, particularly given the variation in size and types of community pharmacies
included in the study.
Partial and/or inadequate account for the capital and overhead costs associated with
running general practice and community pharmacy services introduces a potential
weakness in the cost calculated. However, this may not be a major limitation. There is
much debate over how to apportion such costs to particular services or elements of
practice or business. No unambiguous or right way is agreed upon. However, the
favoured approach is to employ marginal analysis; i.e. to assess which (if any) of these
costs would alter if a given programme was added or taken away (Drummond et al.,
1997). It seems unlikely that the capital cost base of general practices or community
pharmacies would alter as a result of potential changes in consultation preference to
access P medicines by users, as outlined in this study. Likewise, it seems unlikely that
such changes would significantly influence the overhead costs faced by these services.
Overhead costs usually increase with additional output. (Gold et al., 1996) However, if
users were not attending the general practitioner for a prescription for the P medicine,
those consultation slots would be filled by other users. Similarly, if more or less users
presented at the community pharmacy to access a P medicine, their opening hours and
business practice would also be likely to remain unchanged. Thus, assuming that general
practice and community pharmacy services were operating at, or near, capacity - and
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that this is unlikely to change drastically if users alter their route of access to P
medicines - the marginal capital and overhead costs directly attributable to particular
general practitioner or community pharmacy consultations are likely to be negligible.
Thus, limited consideration of capital and overhead costs were felt unlikely significantly
to influence total costs and thus results.
Indeed appraisal of recent national unit cost estimates for community pharmacy, appear
to confirm this. Low, mid and high gross national unit cost estimates for community
pharmacy resources range between £0.50, £0.55 and £0.62 per minute respectively
(including wage, training and overhead costs, at 2003 prices) (Netten & Curtis 2003).
These compare reasonably closely to the bottom-up cost estimates ranging between
£0.32, £0.45 and £0.59 per minute (including wage and professional allowances, at 1999
prices) calculated and applied in this study. The latter estimates are lower than the
national unit cost per minute estimates. However, a number of other elements
(professional fees and allowances) were separately identified and accounted for in this
study which, after accounting for inflation in the period between 1999 and 2003, bring
them within the same ballpark as the national unit cost estimates.
A summary of the units of resource consumption and the cost(s) per unit applied within
the economic evaluation, alongside the sources used to arrive at the estimates, are
summarised in table 2.2 below. Table 2.3 highlights the constituent cost elements
included within the user, general practice, community pharmacy and NHS cost
calculations in different access routes. The cost estimates were sensitised according to
the precise circumstances associated with route adopted by individual users to access
their P medicine. For example, medicine costs to the NHS were calculated according to
the type and amount of medicine obtained; time estimates were those reported by
individual users; and cost of medicines to users was calculated according to prescription
or pre-payment certificate charges incurred or the over-the-counter price paid for
medicines.
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TABLE 2.2: SUMMARY OF COST ESTIMATES AND SOURCES APPLIED IN THE ECONOMIC
ANALYSES
General practitioner Costs (Salary, Training, Overheads)
Low £0.83/minute Locum rate (Medeconomics,
1998)
Mid £1.25/minute Netten, Dennett & Knight, 1998
(General Practitioner without
specific training).
High £1,62/minute Netten, Dennett & Knight, 1998
(General Practitioner with
specific training).
Community Pharmacist Cost (Sa ary)















Community 'harmacist Cost (Professional Allowance)
Low £0.06 Scottish Executive, Drug Tariff,
1999.
RPSGB, 1999.
Mid £0.11 Scottish Executive, Drug Tariff,
1999.
RPSGB, 1999.
High £0.16 Scottish Executive, Drug Tariff,
1999.
RPSGB, 1999.
Community Pharmacist Cost (Dispensing Fee)
Low £0.94 Scottish Executive, Drug Tariff,
1999.
RPSGB, 1999.
Mid £0.94 Scottish Executive, Drug Tariff,
1999.
RPSGB, 1999.




Community Pharmacist Cost (On-Cost Allowance)
Low 17.5% ofNIC Scottish Executive, 1999.
RPSGB, 1999.
Mid 17.5% ofNIC Scottish Executive, 1999.
RPSGB, 1999.
High 17.5% ofNIC Scottish Executive, 1999.
RPSGB, 1999.
Community Pharmacist Time Cost (Dispensing)
Low 2.5 minutes/prescription Savage, 1995
Mid 3.5 minutes/prescription Savage, 1995.
High 5.0 minutes/prescription Savage, 1995.
Community Pharmacist Time Cost (Prescription Advice)
Low 0.2 minutes/prescription Savage, 1995.
Mid 0.3 minutes/prescription Savage, 1995.
High 0.4 minutes/prescription Savage, 1995.
Community Pharmacist Time Cost (Over-the-Counter Advice)
Low 0.5 minutes/customer Savage, 1995.
Mid 1.0 minutes/customer Savage, 1995.




Department of Transport &
Environment - leisure time/non-
working time estimate, 1997.
Mid £7.42/hour
£0.12/minute




Department of Transport &
Environment - national average
wage rate, 1997.
Cost of Prescription Medicines
Low £5.80 Scottish Executive, 1999 -UK
prescription charge per item,
1998.
Mid £8.74/prescription item Yuen, 1999 - Scottish average,
1999.
High £8.98/prescription item Yuen, 1999 - UK average, 1999.
Varied £ varied Yuen, 1999-Net Ingredient
Cost per prescription item per
BNF therapeutic group, 1999.
Cost of Over-The-Counter Medicines






































University of Edinburgh Finance
Dept. Private Car Allowances,
1999.
User Childcare Cost
Low £3/hour Local babysitting, childminder
and nursery rates. Personal
communications.
Mid £4/hour Local babysitting, childminder
and nursery rates. Personal
communications.
High £5/hour Local babysitting, childminder
and nursery rates. Personal
communications.
113
TABLE 2.3: CONSTITUENT COST ELEMENTS INCLUDED WITHIN USER, GENERAL PRACTICE,
COMMUNITY PHARMACY & NHS COST CALCULATIONS IN DIFFERENT ACCESS ROUTES
P medicines obtained on prescription in a general practitioner appointment
Medicine cost from name and quantity obtained on prescription *
Waiting time in general practitioner's surgery
Time in general practitioner appointment
Travel method to general practice surgery
Travel time to general practice surgery
Special arrangements to attend general practitioner appointment
Time for special arrangements to attend general practitioner appointment
Travel method to community pharmacy *
Travel time to community pharmacy
Waiting time in community pharmacy to obtain prescription
Special arrangements to visit community pharmacy to collect prescription "
Time for special arrangements to visit community pharmacy to collect prescription
Advice time with community pharmacist * & *
Professional fees and allowances paid to community pharmacist &ai
Prescription charge paid for prescription medicines (including pre-payment certificates)
P medicines obtained on repeat prescription from a general practitioner
Medicine cost from name and quantity obtained on repeat prescription
Travel method to general practice surgery to collect repeat prescription
Travel time to general practice surgery to collect repeat prescription
Waiting time in general practice surgery to collect repeat prescription
Other arrangement to obtain repeat prescription (e.g. via post)
Special arrangements to obtain repeat prescription
Time for special arrangements to obtain repeat prescription
Travel method to community pharmacy to collect repeat prescription
Travel time to community pharmacy to collect repeat prescription
Waiting time in community pharmacy to collect repeat prescription
Special arrangements to visit community pharmacy to collect repeat prescription
Time for special arrangements to visit community pharmacy to collect repeat prescription
Advice time with community pharmacist *& *
Professional fees and allowances paid to community pharmacist
Prescription charge paid for prescription medicines (including pre-payment certificates)
P medicine bought over-the-counter in a community pharmacy
Travel method to community pharmacy to buy over-the-counter medicine
Travel time to community pharmacy to buy over-the-counter medicine *
Waiting time in community pharmacy to buy over-the-counter medicine
Special arrangements to visit community pharmacy to buy over-the-counter medicine
Time for special arrangements to visit community pharmacy to buy over-the-counter medicine
Advice time with community pharmacist *"* s
Price paid for the over-the-counter medicine bought in community pharmacy
indicates the elements included in calculation of user costs
#
indicates the elements included in calculation of general practitioner costs
&
indicates the elements included in calculation of community pharmacy costs
$
indicates the elements included in calculation ofNHS costs
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Precise details of the units of resource expended (e.g. time, money costs etc.) in the
course of accessing P medicines were collected from users in the community pharmacy
questionnaire interview. These were operationalised to cost estimates using the
statistical software package SPSS, by multiplying the costs associated with each unit
(e.g. cost per minute of general practitioner, community pharmacist or user time) by the
number of units consumed by each user in the course of accessing their P medicine(s).
The prescription exemption status of individuals was also taken into account to ensure
accurate individual user costs were derived. Low, mid and high estimates for each
resource unit were collected and used to sensitise and yield a range of cost estimates for
consideration.
Having identified, measured and valued all relevant cost elements associated with the
two access routes, they were combined in various ways. They were reported according
to the access route adopted to obtain the P medicine (i.e. on prescription from a general
practitioner; on repeat prescription from a general practitioner; or over-the-counter at a
community pharmacy) as well as according to the costs accruing under varied
perspectives included within the analysis i.e. users, general practice, community
pharmacy, the NHS and society. The costs were also combined to calculate total costs
and average costs for individual users and aggregate costs at study population levels
(Gold et al., 1996). Next, key cost elements were broken down according to the main
categories outlined and assessed to identify the main drivers in the cost analysis.
Finally, incremental costs across the different perspectives were calculated subtracting
the costs associated with one access route alternative from the other (Gold et al., 1996).
Both point (means and medians) and range estimates (minimum, maximum and
confidence intervals) are presented.
In the telephone follow-up interview, users were asked about their perceptions of the
relative advantages, disadvantages, costs and benefits associated with general practice
and pharmacy consultations to obtain P medicines and the key attributes identified with
each which were important in determining their route. The transcripts from these
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interviews were coded according to emergent themes and those within the literature
generally and their relevance to the study research questions considered.
The timing of costs and consequences
It is considered good practice within economic evaluation to take account of any
differential timing of costs and consequences (Drummond et al., 1997; Gold et ah,
1996). This requires future costs and consequences to be 'discounted' to 'present
values'. However, given the relatively short time spans associated with the two
alternative programmes under consideration in this study, the application of discounting
techniques was not felt to be either necessary or appropriate.
Incremental consideration of costs and consequences
Analysts should investigate the sensitivity of their results of distinguishing between
total, average, marginal and incremental costs. Incremental analyses enable us to
examine the differences in cost or effect between rival programmes (Drummond et ah,
1997). It helps us to address the question 'how much extra benefit, at what additional
cost'? Clearly, however, opportunities to reallocate resources will differ from place to
place for rival programmes (Drummond & Jefferson, 1996). As such, analysts usually
present total and average costs as their baseline comparators within the primary analysis
and address marginal and incremental consideration within their discussion (Drummond,
1996). This will be the approach adopted in this study.
Consideration of uncertainty on the analysis
Robust economic evaluations will endeavour to account for uncertainty in their cost and
consequence estimates and probe the robustness of their methods and findings (Sloan,
1997). This is usually achieved by applying techniques of sensitivity analysis (Briggs,
Sculpher & Buxton, 1993). Various forms of sensitivity analysis were undertaken in the
present study, investigating potential uncertainties related to data and cost estimates and
methodological assumptions. Alternate data and methodological assumptions were
employed, assessing the sensitivity of the key study results to such change. (These were
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derived either from literature estimates, expert opinion or applying estimates from the
means within the data (Drummond et al., 1997).
Comprehensive discussion of the results
The results of economic evaluations should be made as transparent as possible. The
study presented endeavoured to achieve this by addressing a number of important
considerations in the presentation of the results, including: outlining potential limitations
and qualifications; clearly stating underlying assumptions and value judgements;
considering generalisability issues; considering distributive and ethical implications of
the findings; presenting meaningful qualitative description of the results and considering
policy implications emerging from the study.
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Chapter 3:
Sample Characteristics; Access; Extent of
Substitution; and User Views on Accessing P
Medicines from Community Pharmacies
3.1 Introduction
There are four key objectives within this chapter, to: (1) profile the samples (full and
follow-up) of users accessing P medicines, identifying patterns of use among
different demographic and socio-economic groups, as well as different types of
medicines; (2) map the routes adopted by users to access P class medicines; (3)
assessing the extent of substitution or complementary usage between general practice
and community pharmacy services as a result; and (4) outline general user views on




Fifteen of the seventeen community pharmacies approached agreed to participate.
Potential disruption to their business and inability to house a researcher, due to
limited physical space, were the reasons given by the two community pharmacies
declining to participate in the study. A total of 30 weeks or 700 hours of fieldwork
was undertaken in these fifteen pharmacies. All days of business (including
weekends) and opening hours (including late nights) were covered.
3.2.1.2 Users - pharmacy interview
A total of 1563 users were approached within the 15 community pharmacies and
invited to participate. Approximately 1 in 4 (378/1563) of the users approached
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(24%) declined to take part. A total of 1186 users agreed to participate (survey
response rate 1186/1563; 76%), and 760 users agreed to be followed-up (overall
survey follow-up rate 760/1563; 49%). Just under a third (31%) of participants were
visiting the pharmacy on behalf of, or as a ' proxy', for another person (this figure is
very similar to literature estimates that suggest that between 27-30% interactions
within community pharmacies involve proxy visits) (Rogers, Hassell & Nicolaas,
1999).
Total number of respondents within community pharmacies ranged between 20 to
164 users and non-response rates ranged, between 9% to 40%. The exact
breakdowns, alongside community pharmacy type and location are summarised in
table 3.1.
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TABLE 3.1: PHARMACY LOCATION AND TYPE, TOTAL NUMBER OF RESPONDENTS AND
RESPONSE RATES BY PHARMACY
Pharmacy Pharmacy Area Total No. of % o//o
Location Type Deprivation Respondents of Non
Category of Total Response
CP Sample Rate
Location*
Bathgate Chain Average 164 13.8 18 (37)
(4)
Blackburn Chain Deprived 131 11.1 16(25)
(5)
Livingston Chain Average 116 9.8 36(64)
(4)
Edinburgh Chain Average 114 9.6 30 (48)
Broughton St (4)
Balerno Independent Affluent 106 8.9 20 (27)
(2)
Edinburgh Chain Affluent 106 8.9 18 (24)
Comely Bank (2)
Edinburgh Chain Average 93 7.8 26 (33)
Corstorphine (3)
Bathgate Chain Average 78 6.6 20 (20)
(4)
North Independent Average 68 5.7 31 (30)
Berwick (3)
Dalkeith Chain Average 49 4.1 9(5)
(4)
East Linton Independent Affluent 41 3.5 21 (11)
(2)
Penicuik Chain Average 36 3.0 36 (20)
(3)
Edinburgh Independent Deprived 35 3.0 24(11)
Niddrie (5)
Edinburgh Chain Average 28 2.4 40(19)
Dairy Rd (4)
Fauldhouse Independent Deprived 20 1.7 17(4)
(5)
Totals N/A 1185 100 N/A
(378)
Note: * the figure in brackets represents the deprivation category from which the majority of
respondents within each pharmacy lived.
The Carstairs deprivation index was used (l-2=Aff!uent; 3-4=Average; 5-7=Deprived) (Lothian
Health, 1996a).
120
3.2.1.3 Users - telephone follow-up interview
760 (64%) users gave permission to be followed-up by telephone. 718 users were
successfully followed-up, representing 61% (718/1185) of the full sample. The loss
to follow-up of 42 users occurred for a number of reasons, including: provision of an
invalid telephone number; the user had moved away; the user was working away
from home long-term; or the user was repeatedly unavailable to participate.
3.2.2 Sample(s) descriptions
3.2.2.1 Sample description - community pharmacies
Figures 3.1 to 3.4 summarise the key characteristics and locations of the community
pharmacies included within the study. Lothian Health definitions of the geography
(west, mid, city and east) and location (town, city centre, suburban and rural) of













GEOGRAPHY OF LOTHIAN HEALTH
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FIGURE 3.3:
LOCATION OF COMMUNITY PHARMACIES
TOWN CITY CENTRE SUBURBAN RURAL
N= 6 N = 5 N = 2 N = 2
FIGURE 3.4:











Figure 3.1 highlights that the study pharmacies included ten that were part of a
multiple or small retail chain group and five that were independently owned. Three-
quarters of the sample were recruited within chain pharmacies and a quarter within
independently owned community pharmacies.
Figure 3.2 highlights the geographical spread of the 15 study community pharmacies
and demonstrates that the whole of the Lothian Health area was covered. The exact
locations the community pharmacies are pinpointed on an area map adjacent.
Figures 3.3 and 3.4 show that the pharmacies were located in a variety of different
area types and across all of the deprivation categories within the Lothian Health area.
3.2.2.2 Sample descriptions - users
Complete summaries of user responses to both the pharmacy and telephone follow-
up interview questions are reported in Appendix 3, which highlights modal and
ranked responses, broken down for both the full (n=l 185) and follow-up samples
(n=718).
Key characteristics of the full study sample (n=1185)
Tables 3.2 - 3.8 highlight the key characteristics of the full sample, grouped
according to variables potentially relating to users' choice of route to access the P
medicine, collected within sections E and F of the pharmacy questionnaire. The key
sample features are summarised below.
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Demographic characteristics
The demographic breakdown of users included a 2:1 female to male ratio in the
sample, which was almost exclusively white. There is a fairly even spread across the
age bands, although there are fewer users in the 16-19 years age group. However,
this is the case in other pharmacy practice research studies (Hassell et ah, 1996,
1997, 1998; Tully & Temple, 1999). There was a good mix of different marital
status groups in the sample, with just over half the sample married or co-habiting.
TABLE 3.2: DEMOGRAPHIC CHARACTERISTICS OF RESPONDENTS
(CHI-SQUARE TEST COMPARING FULL AND FOLLOW-UP SAMPLES)
Variable Full Sample Follow-up No Follow-
Sample up Sample d.f. X2 P
n=1185 n=718 n=467 value
n (%) n (%) n (%)
% % %
Sex
Male 440 (37) 266 (37) 173 (37) 1 0.02 0.880
Female 745 (63) 452 (63) 294 (63)
Ethnic Group
White 1171 (99) 704 (98) 462(99) 5 3.42 0.634
Non white 14(1) 14(2) 5(1)
Age Band
< 16 years 150(13) 101(14) 51(11) 7 4.31 0.743
16-19 29 (2) 14(2) 14(3)
20-29 123 (10) 72(10) 47(10)
30-39 188 (16) 115 (16) 73 (16)
40-49 175 (15) 108 (15) 70(15)
50-59 169(15) 108 (15) 61 (13)
60-69 181 (15) 108 (15) 75 (16)
70+ 170(14) 93(13) 75 (16)
Marital Sitatus
Married 581 (49) 359 (50) 219(47) 6 6.52 0.367
Living with 35 (30 22 (3) 14(3)
partner
Widowed 116(10) 65 (9) 56(12)
Divorced 72 (6) 36(5) 33 (7)
Separated 22 (2) 14(2) 9(2)
Single, never 216(18) 129(18) 84(18)
married
N/A child 143 (12) 93 (13) 51(11)
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Socio-economic characteristics
The full sample comprised 2:1 homeowners to renters. More than two-thirds of the
sample had access to a car or van. Two-fifths of the sample was in paid work and
three-fifths were not. Just over a quarter of the sample were retired. Over two-thirds
of the users had completed their full-time education at less than 18 years and one
sixth each of the sample were either still in full-time education or completed their
full-time education at over 18 years. The sample included a good mix of deprivation
category areas; with a third of the sample residing in areas classed as affluent, two-
fifths in average, and a quarter in deprived areas.
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TABLE 3.3: SOCIO-ECONOMIC CHARACTERISTICS OF RESPONDENTS
(CHI-SQUARE TEST COMPARING FULL AND FOLLOW-UP SAMPLES)
Variable Full Follow-up No Follow-up
Sample Sample Sample d.f. X2 P
(n=1185) (n=718) (n=467) value
% % %
Accommodation
With Mtg/Loan 479 (41) 294 (41) 182 (39) 8 25.52 0.001
Owned outright 301 (25) 208 (29) 93 (20)
Local authority 244 (21) 122(17) 126 (27)
Housing assoc. 70 (6) 36(5) 33 (7)
Private, unfurn. 40 (2) 14(2) 9(2)
Private, furn. 20 (3) 29 (4) 14(3)
From employer 5(0) 0(0) 0(0)
Other, paid 10(1) 7(1) 5(1)
Other, rent free 12(1) 7(1) 5(1)
Deprivation Category
Affluent 320 (27) 194 (27) 126 (27) 6 9.92 0.128
Average 652 (55) 388 (54) 266 (57)
Deprived 213 (18) 136(19) 75 (16)
Access to a Car or Van
Yes 843 (71) 546 (76) 299(64) 1 17.53 0.000
No 342 (29) 172 (24) 168 (36)
Employment Category
Paid work f/t 378 (32) 230 (32) 149 (32) 8 7.00 0.536
Paid work p/t 112(9) 72 (10) 42 (9)
Gvmt. scheme 1(0) 0(0) 0(0)
Retired 329 (28) 194 (27) 135 (29)
Unemployed 44 (4) 22 (3) 19(4)
Disabled/sick 52 (4) 36(5) 14(3)
Caring for home 66 (6) 36(5) 28 (6)
In f/t education 124(10) 79(11) 47(10)
Something else 79 (7) 50 (7) 33 (7)
Age Completed Full-Time Education
Still in f/t 190(16) 122(17) 75 (16) 2 25.56 0.000
education
< 18 years 805 (68) 460 (64) 336 (72)
> 18 years 190(16) 136(19) 56(12)
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Self-reported health status
Three-quarters of the sample rated their health as either very good or good. A fifth
rated their health as fair. Very few users considered their general health status to be
bad or very bad. In contrast, a third of the sample considered that they suffered from
a longstanding illness.
TABLE 3.4: SELF-REPORTED HEALTH STATUS
(CHI-SQUARE TEST COMPARING FULL AND FOLLOW-UP SAMPLES)
Variable Full Follow-up No Follow-up
Sample Sample Sample d.f. X2 P
(n=1185) (n-718) (n-467) value
% % %
General Health Status
Very 290 (25) 180 (25) 112(24) 4 10.55 0.032
good
Good 595 (50) 381 (53) 215 (46)
Fair 253(21) 136(19) 117(25)
Bad 36(3) 14(2) 19(4)
Very bad 11(1) 7(1) 5(1)
Longstanding Illness
Yes 435 (37) 273 (38) 168 (36) 1 0.50 0.480
No 749 (63) 445 (62) 299(64)
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Use of general practice and community pharmacy services
Overall, there was a mix of consultation rates with both general practitioners and
community pharmacists; broadly matching those identified in large, representative,
national surveys (Carr-Hill, Rice & Roland, 1996; Tully & Temple, 1999). One in
ten users had not seen their general practitioner at all in the previous year; two-fifths
had only visited the general practitioner once or twice; and two-thirds had consulted
the general practitioner between one and five times. A fifth (17%) of the users had
not consulted the community pharmacist at all in the last year; compared to between
6-20% reported in other survey findings (Tully & Temple, 1999; Rogers, Hassell &
Nicolaas, 1999). A quarter of users had consulted a community pharmacist only
once or twice; and two-thirds had visited the community pharmacy between one and
five times.
Over four-fifths of the sample had used the same community pharmacist regularly
and there was almost a 50:50 split in the sample between those receiving a regular
prescription medicine or not.
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TABLE 3.5: USE OF GENERAL PRACTICE AND COMMUNITY PHARMACY SERVICES
(CHI-SQUARE TEST COMPARING FULL AND FOLLOW-UP SAMPLES)
Variable Full Follow-up No Follow-up
Sample Sample Sample d.f. X2 P
(n=l 185) (n=718) (n=467) value
% % %
Number ofGeneral Practitioner Consultations Last Year
0 118 (10) 86(12) 42 (9) 4 6.06 0.194
1-2 498 (42) 287 (40) 205 (44)
3-5 296 (25) 172 (24) 126(27)
6-10 190(16) 122(17) 65 (14)
>10 83 (7) 50(7) 28(6)
Number of Community Pharmacist Consultations Last Year
0 261 (22) 122 (17) 145 (31) 4 50.31 0.000
1-2 320 (27) 172 (24) 145 (31)
3-5 438 (37) 309 (43) 126 (27)
6-10 154(13) 100(14) 47(10)
>10 12(1) 14(2) 5(1)
Use Same Community Pharmacist Regularl}
Yes 1022(86) 617(86) 406 (87) 1 0.18 0.675
No 163 (14) 100(14) 61 (13)
Regular Rx Medicine(s)
Yes 571 (48) 359(50) 210(45) 1 3.15 0.076
No 614(52) 359 (50) 257 (55)
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Access to general practitioner and community pharmacy services
User access to both general practice and community pharmacy services was fair.
Ninety percent of the sample could usually see a general practitioner within a week
and seventy percent within five days. This again broadly matches UK trends which
indicate that a quarter of people wait more than five days to see a general practitioner
(Leech, 2002). The vast majority of the sample lived within 2 miles of their general
practice surgery and the community pharmacy that they used most often.
TABLE 3.6: ACCESS TO GENERAL PRACTICE AND COMMUNITY PHARMACY SERVICES
(CHI-SQUARE TEST COMPARING FULL AND FOLLOW-UP SAMPLES)
Variable Full Follow-up No Follow-up
Sample Sample Sample d.f. X1 P
(n=1185) (n=718) (n=467) value
% % %
Usual Wait to See General Practitioner
Same day 237 (20) 136(19) 98 (21) 6 12.92 0.044
Next day 178 (15) 101 (14) 70(15)
2 days 201 (17) 136(19) 65 (14)
3-5 days 237 (20) 151 (21) 84(18)
> 5 days 332 (28) 194 (27) 149 (32)
Distance to General Practice Surgery
< a mile 545 (46) 330 (46) 205 (44) 4 5.43 0.246
1-2 miles 509 (43) 302(42) 205(44)
3-4 miles 95 (8) 50(7) 42 (9)
5 or more 36(3) 36(5) 14(3)
miles
Dis tance to Community Pharmacy
< a mile 758 (64) 452 (63) 308(66) 4 1.96 0.742
1-2 miles 344 (29) 215 (30) 126 (27)
3-4 miles 59(5) 36(5) 23 (5)




Two-fifths of the sample paid for prescription charges and three-fifths did not. One
in six users reported having been put off obtaining a medicine because of the cost at
some time in the past. This confirms previous research evidence that indicates that
medicine use is price sensitive (Leibowitz, Manning & Newhouse, 1985; Birch,
1986; O'Brien, 1989; Ryan & Birch, 1991; Huttin, 1994; Hughes & McGuire, 1995;
Gerdtham & Johannesson, 1996; Lundberg et al., 1998; Eversley & Sheppard, 1998;
Joyce, Escarce & Solomon, 2002);that not all prescriptions that are written are
dispensed (OHE, 2001); and that the costs of over-the-counter medicines are
prohibitive for some (Hassell et al., 1997; Rogers, Hassell & Nicolass, 1999).
TABLE 3.7: COST OF MEDICINES
(CHI-SQUARE TEST COMPARING FULL AND FOLLOW-UP SAMPLES)
Variable Full Follow-up No Follow-up
Sample Sample Sample d.f. X2 P
(n=1185) (n=718) (n-467) value
% % %
Exempt from Rx Charge
Yes 675 (57) 416(58) 271 (58) 1 0.04 0.838
No 510(43) 302 (42) 196(42)
Put Off by Cosi ofMedicines
Yes 190(16) 86(12) 98 (21) 1 15.49 0.000
No 995(84) 632 (88) 369(79)
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Types of medicines
Two-fifths of the medicines obtained by users in the sample were deregulated
medicines; i.e. they had been reclassified from prescription only status (POM) to
pharmacy available (P) under the supervised sale of a pharmacist. Three-fifths of the
medicines obtained by the users in the sample were ordinary P class medicines.
Two-fifths of the medicines obtained by users were included on the NHS blacklist of
products (i.e. those which health professionals are not technically permitted to write
prescriptions for).
TABLE 3.8: TYPE OF MEDICINES
(CHI-SQUARE TEST COMPARING FULL AND FOLLOW-UP SAMPLES)
Variable Full Follow-up No Follow-up
Sample Sample Sample d.f. X2 P
(n=1185) (n=718) (n=467) value
% % %
Deregulated i POM to P)
Yes 492 (42) 294 (41) 196 (42) 1 0.04 0.838
No 693 (58) 424 (59) 271 (58)
NHS Blacklisted
Yes 513(43) 302 (42) 215 (46) 1 2.21 0.137
No 672 (57) 416(58) 252 (54)
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Inter-sample characteristics
In order to assess the representativeness of the study sample, it was compared to the
results of other surveys within the research literature investigating utilisation patterns
within general practice and community pharmacy nationally (Carr-Hill, Rice &
Roland, 1996; Tully & Temple, 1999; Rogers, Hassell & Nicolaas, 1999; OHE,
2001; Scottish Executive, 2003). In addition, standard socio-economic and general
health questions were borrowed from national surveys to compare the key
characteristics of the study sample responders with both local and national data
sources (ONS, 1998a-d). In particular, the study sample was compared with the
broader Lothian Elealth population according to age, gender, deprivation categories,
and use of prescription medicines and self-reported general health status (Scottish
Office, 1998; Lothian Health, 1996a; Scottish Office, 1997a). These comparisons
are outlined in table 3.9.
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TABLE 3.9: COMPARISON OF KEY SAMPLE CHARACTERISTICS - STUDY SAMPLE AND
LOTHIAN HEALTH POPULATION
























Very good/good 77 75
Fair 18 21






This table indicates that the study sample includes broadly similar proportions of
users within the 0-9, 30-59 and 80+ years age groups. However, the study sample
included a smaller proportion of users in the 10-29 years range (-14%) and a higher
proportion of users in the 60-79 years age bands (+11%) compared to the Lothian
Health area profile. However, the age profile within the study sample broadly
approximates those found within other community pharmacy studies of
representative populations reported in the literature (Hassell et ah, 1996, 1997, 1998;
Rogers, Hassell & Nicolaas, 1999; Tully & Temple, 1999).
Sex
The study sample contains 12% more women and fewer men compared to the
Lothian Health area generally. Again, this would be expected as previous research
indicates that women are more frequent users of community pharmacy services than
men (Tully & Temple, 1999; Hassell et ah, 1998; Rogers, Hassell & Nicolaas, 1999).
Deprivation categories
The study sample includes a broadly similar profde of users resident in deprivation
categories similar to the Lothian Health breakdown overall; albeit with a slightly
smaller proportion of sample users resident within affluent areas and deprived areas
and a higher proportion resident within average deprivation areas.
Use ofprescription medicines
Higher proportions of users within the study sample were receiving regular
prescription medicines compared to the Lothian Health population generally. Again
this was expected given that the recruitment point for the study was within
community pharmacies. In both the study and Lothian Health sample, there was
increasing use of prescription medicines with increasing age, with use increasing
markedly in the over 40 years age groups.
General health status
Self-reported general health status was very similar between the two populations,
with three-quarters in each reporting either very good or good health; a fifth
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reporting fair health; and a very small proportion reporting either bad or very bad
health. Likewise, very similar proportions of users reported the presence of
longstanding illness in both populations (35% & 37%) and these were close to
national reported figures (40%) (Carr-Hill, Rice & Roland, 1996). Differences by
gender and longstanding illness were not reported.
Overall, the study sample was broadly similar to the Lothian Health population
across key variables. Likewise, key community pharmacy and general practice
utilisation and general health status figures were broadly comparable to those
reported in larger, national surveys. Where differences were identified, they were
intuitive and expected given the particular research questions and study design and
setting.
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Intra-sample characteristics: full and follow-up samples
Univariate Chi-square analyses of contingency tables were undertaken to investigate
the similarities and/or differences between the full and follow-up samples. The aim
of this was to ascertain if there were any statistically significant differences in user
characteristics between those users who consented to take part in the telephone
follow-up interview (n=718) and those users who did not (n=467). Another purpose
of this exercise was to ascertain the extent to which results from the follow-up
sample could be generalised to the full sample. This analysis again focused on the
groups of variables anticipated to impact on users' choice of consultation route to
access their P class medicine, collected in sections E and F of the pharmacy
questionnaire. The results of this analysis are also outlined within tables 3.2 - 3.8
and are summarised below.
Demographic characteristics
The full and follow-up samples exhibited very similar demographic profiles. There
were no statistically significant differences between the two samples in terms of sex,
ethnicity, age or marital status. However, statistically significant differences did
exist between users' accommodation type across the two samples (p = 0.001).
Homeowners were more likely to consent to take part in the telephone follow-up
interview.
Socio-economic characteristics
There were no statistically significant differences between those who elected to be
followed-up, or not, in terms of employment status or the deprivation category within
which they lived. However, users who agreed to be followed-up were more likely to
have access to a car or van (p = 0.000) and to have completed their full-time
education at over eighteen years (p = 0.000)
Self-reported health status
There were no differences in the two samples regarding proportions reporting the
presence of a longstanding illness. However, users who agreed to be followed-up
were more likely to report good to fair health compared to those who declined to
participate in the telephone follow-up interview (p = 0.032).
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Use of general practice and community pharmacy services
There were very few differences between the two samples in terms of use of general
practice and community pharmacy services. Both groups exhibited similar patterns
in use of general practice consultation in the previous year, use of the same
pharmacist regularly and receipt of regular prescription medicines. However, users
who agreed to be followed-up were significantly more likely to have consulted the
community pharmacist more frequently in the previous year (p = 0.000).
Access to general practice and community pharmacy services
There were no statistically significant differences in user distances to access general
practice and community pharmacy services. However, users who declined to be
followed-up were significantly more likely to experience longer usual waits to see
the general practitioner (p = 0.044).
Cost of medicines
There were no statistically significant differences between the two groups in terms of
prescription exemption status. However, users who declined to be followed-up were
significantly more likely to have reported being put off accessing medicines because
of the cost at some point in the past (p = 0.000).
Type of medicines
There were no statistically significant differences regarding the types of medicines
being accessed by users who did or did not consent to a follow-up interview, with
very similar proportions of deregulated and blacklisted medicines included within
each group.
In summary, the statistically significant differences identified between the users who
participated in the telephone follow-up interviews compared to those who did not,
suggest that users from higher socio-economic groups were more inclined to take
part in the follow-up telephone interview.
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3.2.2.3 Sample descriptions - medicines
P medicines accessed on prescription or over-the-counter?
Three-quarters of study participants bought their P medicine over-the-counter from a
community pharmacy under supervised sale arrangements. A quarter obtained their
P medicine on prescription from a general practitioner, with over two-fifths of these
obtained through repeat prescription systems. Identical access patterns were found
among the sub-samples of users who agreed and did not agree to take part in the
telephone follow-up interview.
Classification of P medicines in the study sample
A total of 1273 P medicines are included in the full study sample (n=1185). Table
3.10 outlines the distribution of the medicines included in the study, according to
their British National Formulary (BNF) classifications, and ranks their proportional
contribution within the sample.
TABLE 3.10: SAMPLE MEDICINES CLASSIFIED AND RANKED ACCORDING TO BNF
CLASSIFICATION
BNF Chapter n % Rank
4: Central nervous 362 28 1
3: Respiratory 261 21 2
10: Musculoskeletal & joint diseases 154 12 3
13: Skin 125 10 4
1: Gastro-intestinal 119 9 5
12: Ear, nose & oropharynx 80 6 6
7: Obs./gynae. & urinary tract 53 4 7
2: Cardiovascular 44 4 8
11: Eye 42 3 9
9: Nutrition and blood 27 2 10
5: Infections 3 - 11
6: Endocrine system 3 - 12
8: Malignant disease immunosuppression 0 0 -
14: Immunological products 0 0 -
15: Anaesthesia 0 0 -
Total 1273* 99 N/A
Note: * the total number ofmedicines in the sample exceeds the sample size as some users obtained
more than one.
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The modal classification is BNF chapter 4, which covers drugs for the treatment of
the central nervous system. Just under half of the study medicines (49%) fall within
the two BNF classifications central nervous system (BNF Chapter 4) and respiratory
system (BNF Chapter 3). Four-fifths of the study medicines came under the five
BNF classifications: central nervous system; respiratory system; muskuloskeletal and
joint diseases; skin; and gastro-intestinal system (BNF Chapters 4, 3, 10, 13 and 1
respectively). The most common conditions that prescriptions are written for are
those relating to respiratory tract, gastrointestinal tract and skin (Smith & Salkind,
1990). These ranked within the top five areas that P medicines were accessed for
within the study (ranking 2nd, 5th and 4lh respectively). Overall, the P medicines
included in the sample covered a broad range of conditions and BNF classifications.
Types of P medicines
Table 3.11 highlights proportions of the various medicines included within the full
and follow-up samples according to three different types: deregulated medicines
which have been reclassified from prescription-only-medicines (POMs) to pharmacy
available (P); regular pharmacy available P class medicines; and medicines included
on the NF1S blacklist of products, technically unavailable through the NHS
prescription system.
TABLE 3.11: BREAKDOWN OF MEDICINE TYPES WITHIN THE FULL AND FOLLOW-UP
SAMPLES
Type of Medicine Full Sample Follow-Up Sample
% (n*) % (n*)
Deregulated (POM to P) 42 41
(498) (294)




* Note: n* refers to the number ofmedicines and not users (some users accessed more than one P
medicine).
There is an almost identical breakdown across the different types of medicines within
both the full and follow-up samples. Two-fifths of the medicines obtained by users
in the samples were deregulated; three-fifths were regular P class medicines; and
two-fifths of the medicines obtained were included on the NHS blacklist of products.
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Very similar proportions of deregulated and regular P class products were obtained
by users, regardless of whether they were bought over-the-counter or obtained on
prescription. There were, however, a much smaller proportion of blacklisted
medicines obtained through prescription access routes (16% versus 43%). This was
to be expected as general practitioners are technically prohibited from prescribing
medicines included on the NHS blacklist.
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3.3 Users' routes to access P medicines and the extent of
substitution and complementary usage between general
practice and community pharmacy services
Two other key objectives of this research were to describe the routes adopted by the
sample of users to access P class medicines to treat a particular episode of illness;
assessing the extent of substitution or complementary usage between general practice
and community pharmacy services as a result.
For the sub-sample of users who participated in both the pharmacy and telephone
follow-up interview surveys (n=718) it was possible to map their routes to access P
medicines and assess the extent of substitution or complementary usage between the
general practitioner and community pharmacist in doing so. These are outlined in
table 3.12.
TABLE 3.12: USER ROUTES TO ACCESS P MEDICINES (N=718)
User Access Route No. of Users
First Visit Revisit N=718
(%)
Community Pharmacy None 418
(58)
General Practitioner None 134
(19)
Community Pharmacy General Practitioner 76
(11)
General Practitioner General Practitioner 46
(6)
Community Pharmacy Community Pharmacy 39
(5)
General Practitioner Community Pharmacy 5
(1)
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Just over three-quarters (N=552; 77%) of the users visited either the general
practitioner or community pharmacist only, with no subsequent revisits, in the
management of the illness episode that they accessed the P medicine for. One in four
users (N=161; 23%) did, however, revisit the general practitioner or community
pharmacist. Of those users adopting a pharmacy first route (N=533) to access their P
medicine, one in five (N=115; 22%) followed that up with a general practitioner
appointment. Among users opting to visit the general practitioner first (N=185) to
obtain a prescription for the P medicine, over a quarter (N=51; 28%) revisited either
the general practitioner or community pharmacist, although this was mainly the
general practitioner.
The proportion of users re-visiting either the community pharmacist or general
practitioner was considerably higher in this study (22% and 28% respectively)
compared to those within the Care at the Chemist study (6% and 4% respectively)
(Whittington et al., 2001). Further, much higher proportions of community
pharmacy users who made a follow-up visit consulted a general practitioner for
follow-up (14%) compared to within the Care at the Chemist study (2%)
(Whittington et al., 2001). These findings are important as the higher proportion of
revisits generally, alongside the higher proportion of revisits to general practitioners
specifically, among users visiting community pharmacies to access P medicines,
indicates that complementary usage was more and successful substitution between
services less prevalent than previous research had indicated. This has potentially
important implications for the costs and potential savings associated with policies
encouraging increased self-medication in the management of minor ailments within
primary care.
A quarter of participants used general practice and community pharmacy services in
a complementary fashion, visiting both in the management of the particular episode
of illness that they accessed the P medicine for. A sizeable proportion (22%) of
users who elected to try the pharmacist first failed in their attempt to self-medicate,
subsequently consulting a general practitioner. Overall though, the majority of users
adopting a pharmacy first access route (78%) appeared able to substitute a P class
144
medicine, obtained over-the-counter from a community pharmacist, in place of a
general practitioner consultation, in their attempt to self-medicate and manage a
particular episode of illness. Exactly how this 'substitution' may be interpreted,
however, is discussed fully in Chapter 6.
Finally, it should be noted that none of the findings outlined above rules out the
possibility that some or all of both groups could have successfully managed their
entire illness episode without either general practitioner or community pharmacist
input.
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3.4 User views on use of community pharmacies and
increasing availability of P medicines
At the end of the telephone follow-up interview, participants (n=718) were asked two
general questions regarding use of community pharmacies and increasing availability
of P medicines. User responses to these questions were coded. The top ten responses
to the two questions asked are summarised in table 3.13. A full summary of users'
responses is included in table A3.1 in Appendix 3.
TABLE 3.13: TOP TEN USER RESPONSES TO OPEN QUESTIONS REGARDING USE OF
COMMUNITY PHARMACIES
In what circumstances would you prefer to go to the pharmacist, rather than
the GP?
Reason n* (%)
Try to use the community pharmacist when 1 can 240 (33)
For minor complaints 211 (29)
When I feel confident about self treating 142 (20)
I prefer to see the doctor, better, safer 95 (13)
I don't like to bother the doctor or waste their time 65 (9)
Pharmacists are highly trained/give good advice 61 (8)
Convenience 50(7)
When I am familiar with the medicine 46 (6)
I don't like to go to the doctor 46 (6)
It is difficult to get an appointment with the GP 45 (6)
What do you think about making more medicines, whic i were in the past only
available on prescription, available from the pharmacist to buy?
Reason n* (%)
More convenient 231 (33)
No need to wait to see the doctor 132(18)
Cheaper over-the-counter 91 (13)
With monitoring and advice from the pharmacist 85 (12)
Risk of inappropriate, unnecessary or overuse of medicines 83 (12)
Relieves pressure on NHS/saves doctors' time 71 (10)
Dangers with strong medicines/safety issues 65 (9)
Better left in the control of doctors 61(8)
Potential abuses could arise 61(8)
Pharmacists are experts in medicines/give good advice 55 (8)
Note: n* refers to the number of responses and not users (respondents often gave multiple responses)
146
3.4.1 In what circumstances would you prefer to go to the pharmacist,
rather than the GP?
A third of users noted that they prefer to use the pharmacist, as opposed to the
general practitioner, whenever they could. Sizeable proportions also said that they
preferred to use the community pharmacy for minor complaints, that they felt
confident self-treating. However, just over a tenth of the users indicated that they
would always prefer to visit a general practitioner.
3.4.2 What do you think about making more medicines, which were in
the past only available on prescription, available from the pharmacist to
buy?
Users' most common responses regarding increased availability of P class medicines
from community pharmacies were that, it enhanced convenience, obviated the need
to see a doctor and would be cheaper. However, a fifth of the users also expressed a
number of potential concerns relating to inappropriate usage of medicines if more
routinely available.
User responses to the open questions eliciting their views on use of community
pharmacies and P medicines mirrored many of the advantages and disadvantages
identified within the broader literature, previously summarised in section 1.3.5 in the
literature review chapter (and table A1.3 in Appendix 1).
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3.5 Summary ofpolicy relevant results
BOX 3.1: SUMMARY OF POLICY RELEVANT RESULTS
• Over three-quarters of users visited either the general practitioner or
community pharmacist only, with no revisit, indicating that one consultation
was sufficient to support their use of a P class medicine.
• Approximately one-quarter of users did, however, revisit either the general
practitioner or community pharmacist for further advice and/or treatment in
their management of the same minor illness episode.
• One in five of the users who opted to access their P medicine direct from a
community pharmacist, followed up that visit with a general practitioner
consultation.
• Over a quarter of users who visited a general practitioner first to obtain their
P medicine, followed-up that visit with another visit to either a general
practitioner or a community pharmacist.
• The majority of users who adopted a community pharmacy first consultation
route appeared able to substitute this for a consultation with a general
practitioner to access a P class medicine.
• A third of users noted they would prefer to use the pharmacist as opposed to
the doctor whenever they could.
• Users were most comfortable using the pharmacist, rather than the doctor, for
minor complaints and when they felt confident self-treating.
• A tenth of users noted that they would always prefer to visit the doctor rather
than the pharmacist.
• Users were generally positive about increasing availability of medicines from
community pharmacies, noting it enhanced convenience, prevented having to
see a doctor and felt it would be cheaper.




What predicts user choice to access P medicines
from a general practitioner or community
pharmacist?
4.11ntroduction
The next stage in the data analysis was to develop a model, to identify variables
predictive of users' choice of route to access their P medicine. Univariate (chi-
square analyses of categorical variables within contingency tables) and multivariate
(logistic regression) statistical techniques were used to analyse the groups of
variables hypothesised to impact on the users' route to access P medicines, once
again including: demographic and socio-economic characteristics; self-reported
health status; access to and use of general practitioner and community pharmacist
services; and cost and type ofmedicines.
4.2 Univariate analyses
Chi-square analyses were used to investigate associations between users' route to
access P medicines (general practitioner or community pharmacist) and variables of
interest. The aim of this analysis was to ascertain if there were any statistically
significant differences in characteristics between those users who opted to go to the
community pharmacist to buy their P medicine over-the-counter, and those who
obtained a P medicine on prescription from a general practitioner. The results of the
univariate analysis are outlined in tables 4.1 - 4.7 and summarised below.
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4.2.1 Demographic characteristics
The sex and ethnicity profile was almost identical between users accessing their P
medicines from the general practitioner or community pharmacist. However,
statistically significant differences did exist between the two groups regarding their
age (p < 0.001) and marital status (p < 0.001). Users in the age range 30-59 years
were more likely to visit the community pharmacist first, whereas those over 60
years of age were more likely to consult the general practitioner to access their P
medicines. These findings concur with those identified by Payne et al., (1996) in
their postal survey investigating users willingness to pay for medicines. Users
accessing their P medicine from the community pharmacist were more likely to be
married/co-habiting compared to those obtaining their P medicine on prescription.
This trend has also been identified in previous surveys (Tully & Temple, 1999;
Rogers, Hassell & Nicolaas, 1999).
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TABLE 4.1: ASSOCIATIONS BETWEEN CHOICE OF ROUTE TO ACCESS P MEDICINES &
DEMOGRAPHIC CHARACTERISTICS
(Chi-square test comparing general practice and community pharmacy users)
Variable GP First CP First d.f. X P
n=303 n=882 value
n (%) n (%)
Sex
Male 120 (40) 320 (36) 1 1.06 0.302
Female 183(60) 562 (64)
Ethnic Group
White 299 (99) 872(99) 1 0.06 0.796
Non-white 4(1) 10(1)
Age Band
<16 years 43 (14) 107(12) 7 63.41 0.000
16-19 9(3) 20 (2)
20-29 32 (11) 91 (10)
30-39 29(10) 159(18)
40-49 26 (9) 149(17)
50-59 28 (9) 141 (16)
60-69 64 (21) 117(13)
70+ 72 (24) 98(11)
Marital Status
Married/living pt. 140 (46) 476(54) 4 11.63 0.020
Widowed 40(13) 76 (9)
Divorced/separated 30(10) 64 (8)
Single 50(17) 166(19)
N/A child 43 (14) 100(10)
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4.2.2 Socio-economic characteristics
The break down of socio-economic characteristics between users accessing P
medicines from the general practitioner or community pharmacist was markedly
different. Statistically significant differences (p < 0.001) existed in terms of users:
accommodation types; deprivation category of residence; access to a car or van;
employment status; and the age at which they had completed full-time education.
Users buying their P medicines over-the-counter were statistically significantly more
likely to: be homeowners; live within affluent deprivation category areas; have
access to a car or van; be in paid employment; and to have completed their full-time
education at a later age (>18 years).
Conversely, users accessing P medicines on prescription from a general practitioner
were statistically significantly more likely to live in rented accommodation; within
more deprived areas; to have no access to a car or van; not to be in paid work; and to
have completed full-time education at a younger age.
The findings regarding employment status, access to a vehicle and education were
also identified in surveys reported by Tully and Temple (1999) and Rogers, Hassell
and Nicolaas (1999).
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TABLE 4.2: ASSOCIATIONS BETWEEN CHOICE OF ROUTE TO ACCESS P MEDICINES &
SOCIO-ECONOMIC CHARACTERISTICS
(CHI-SQUARE TEST COMPARING GENERAL PRACTICE AND COMMUNITY PHARMACY USERS)
Variable GP First CP First d.f. X2 P
n=303 n=882 value
n (%) n (%)
Accommodation
With Mtg./Loan 64 (21) 415(47) 8 100.01 0.000
Owned outright 78 (26) 223 (25)
Local authority 107 (35) 137(16)
Housing assoc. 31 (10) 39(4)
Private, unfurn. 5(2) 32(2)
Private, furnished 8(3) 15(4)
From employer 1 (-) 4 (-)
Other, paid 6(2) 4(1)
Other, rent free 3(1) 9(1)
Deprivation Category of Postcode in which User Lived
Affluent 33(12) 260 (32) 2 125.03 0.000
Average 135(49) 455 (57)
Deprived 24 (39) 9(11)
Access to a Car or Van
Yes 169 (56) 674 (76) 1 46.80 0.000
No 134(44) 208(24)
Employment Category
In paid work 54(18) 441(50) 4 114.13 0.000
Retired 121(40) 212 (24)
Not in paid work 73 (24) 79 (9)
In f/t education 39(13) 88 (10)
Something else 16(5) 62 (7)
Age Completed f/t Education
Still in f/t 55(18) 141 (16) 2 21.38 0.000
education
< 18 years 224 (74) 573 (65)
> 18 years 24 (8) 168(19)
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4.2.3 Self-reported health status
Statistically significant differences existed between the two groups in terms of self-
reported health status. Users who bought their P medicine over-the-counter at the
community pharmacist were significantly more likely to report very good or good
general health (p < 0.001) and less likely to report the presence of a longstanding
illness (p < 0.001) compared to users who accessed their P medicine on prescription
from a general practitioner. This finding is interesting as associations between
existence of a longstanding illness and propensity to purchase P medicines over-the-
counter is not specifically identified within the literature.
TABLE 4.3: ASSOCIATIONS BETWEEN CHOICE OF ROUTE TO ACCESS P MEDICINES &
SELF-REPORTED HEALTH STATUS
Variable GP First CP First d.f. X5 P
n=303 n=882 value
n (%) n (%)
General Health Status
Very good/good 173(57) 712(81) 2 74.32 0.000
Fair 102(34) 151 (17)
Bad/very bad 28 (9) 19(2)
Longstanding Illness
Yes 182 (60) 255(29) 1 93.579 0.000
No 121(40) 627 (71)
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4.2.4 Use of general practice and community pharmacy services
Users accessing P medicines from the community pharmacist were, generally, less
frequent users of general practitioner and community pharmacist services. They
were significantly less likely to have seen the general practitioner as often in the last
year; be receiving regular prescription medicines; or using the same pharmacist
regularly. They were, however, more likely to have consulted the community
pharmacist more frequently in the last year. These findings corroborate those
identified by Payne et al., (1996) in their postal survey investigating user willingness
to pay for medicines.
TABLE 4.4: ASSOCIATIONS BETWEEN CHOICE OF ROUTE TO ACCESS P MEDICINES &
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4.2.5 Access to general practitioner and community pharmacy services
There were no differences between the two groups of users regarding usual wait to
see a general practitioner (p = 0.305) or in distance to their local pharmacy
(p = 0.081). The absence of an association between usual waiting times to see
general practitioners and accessing P medicines from community pharmacies is
interesting, given that user frustration with primary care waiting times has routinely
been identified as a key rationale underpinning policy initiatives to enhance and
graduate access to primary care services generally and make more use of community
pharmacies specifically.
Users accessing their P medicine from the community pharmacist were significantly
more likely to live a greater distance from their general practitioner surgery. This
finding seems to support evidence in the literature that indicates that distance from
services is generally predictive of utilisation rates, with an inverse relationship
between distance to facilities and utilisation (Campbell & Roland, 1996; Hopton,
Howie & Porter, 1992).
TABLE 4.5: ASSOCIATIONS BETWEEN CHOICE OF ROUTE TO ACCESS P MEDICINES &
ACCESS TO GENERAL PRACTICE & COMMUNITY PHARMACY SERVICES
Variable GP First CP First d.f. X2 P
n=303 n=882 value
n (%) n (%)
Usual Wait to See General Practitioner
< a week 288(91) 826 (93) 1 1.05 0.305
> a week 25 (9) 56(7)
Distance to General Practice Surgery
< 2 miles 280(92) 776(87) 1 4.65 0.031
> 2 miles 23 (8) 106(13)
Distance to Community Pharmacy
< 2 miles 288 (95) 811 (92) 1 3.052 0.081
> 2 miles 15(5) 71(8)
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4.2.6 Costs of medicines
Users accessing their P medicines on prescription from the general practitioner were
significantly more likely (p < 0.001) to be exempt from paying prescription charges
(an association also identified by Payne et al., 1996) and significantly less likely to
report ever having been put off obtaining medicines because of their cost.
TABLE 4.6: ASSOCIATIONS BETWEEN CHOICE OF ROUTE TO ACCESS P MEDICINES &
COST OF MEDICINES
Variable GP First CP First d.f. X* P
n=303 n=882 value
n (%) n (%)
Exempt from Rx Charge
Yes 274(90) 406(46) 1 181.33 0.000
No 29(10) 476 (54)
Put Off by Cost of Medicines
Yes 86 (28) 101 (12) 1 48.64 0.000
No 217(72) 781 (88)
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4.2.7 Types of medicines
There were no statistically significant differences between the proportions of users
obtaining deregulated medicines between the two groups (p = 0.358). However,
users electing to buy their P medicine over-the-counter from the community
pharmacist were statistically significantly more likely to be obtaining a medicine
included within the list ofNHS blacklisted products.
TABLE 4.7: ASSOCIATIONS BETWEEN CHOICE OF ROUTE TO ACCESS P MEDICINES &
TYPE OF MEDICINES
Variable GP First CP First d.f. X* P
n=303 n=882 value
N (%) n (%)
Deregulated (POM-to-P)
Yes 119(39) 373 (42) 1 0.84 0.358
No 184 (61) 509 (58)
NHS Blacklisted
Yes 47(15) 466 (53) 1 127.96 0.000
No 256 (85) 416(47)
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4.3Multivariate analysis
Seventeen of the 22 variables investigated to see if they might be predictive of users'
choice to access P medicines from either the general practitioner or community
pharmacist exhibited statistically significant associations in the univariate analyses.
However, a problem with the univariate approach is that it ignores the possibility that
a collection of variables, each of which is weakly associated with the outcome, can
become an important predictor of outcome when taken together (Hosmer &
Lemeshow, 1989). For this reason, it is also desirable to try to take account of the
relationships between the predictor variables in order to determine their relative
influence on users' route to access their P medicine. It could be that only a small
number of the predictor variables influence the choice of access route adopted by the
user and that other variables exhibit statistically significant univariate relationships
as a result of association with the key predictor variables. Alternately, it may be that
each variable has an independent effect upon users' choice of method to access their
P medicine. A logistic regression model was developed to explore these issues.
4.3.1 Logistic regression modelling
Multivariate logistic regression analyses were undertaken. It was conducted using
SPSS version 9. The dependent variable was the binary outcome variable general
practitioner or community pharmacist route to access P medicines (drphlst). The
regression model was organised to predict users electing to obtain their P medicine
over-the-counter from a community pharmacist. Independent variables entered into
the regression analysis were the groups of demographic, socio-economic, health
status, use of and access to general practitioner and community pharmacist services
and cost and type of medicines variables collected. These are summarised in table
4.8.
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TABLE 4.8: VARIABLES ENTERED INTO THE LOGISTIC REGRESSION ANALYSIS
DEPENDENT VARIABLE
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Distance to GP surgery from home






Put off obtaining medicines due to cost
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In receipt of regular Rx and
accommodation type
Use same CP regularly and Rx
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* indicates that the variable was entered as a categorical variable
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A forward stepwise procedure was selected with the criterion for entry into the model
based on the likelihood ratio (LR) statistic, based on maximum likelihood estimates.
This involves estimating the model with each variable added in turn and looking at
the change in results in the test statistic. The model solution is derived iteratively by
beginning with a tentative solution, revising it slightly to see if it can be improved
and repeating the process until the change in the likelihood function from one step to
another is non-significant (Menard, 1995). At any step, the most important variable
will be the one that produces the greatest change in the log likelihood relative to the
model not containing the variable (Hosmer & Lemeshow, 1989). The likelihood
ratio (LR test) was chosen as the test statistic, as it is believed to be superior to other
approaches, as the model is calculated with and without the variable being tested. It
takes longer to compute but it is more accurate (Menard, 1995).
All variables were entered in one block and coded using the default deviation
contrasts system, whereby each category of the predictor variable is compared to the
overall effect (Norusis, 1993). The default entry (0.05) and removal criteria (0.1) for
variables were selected; i.e. at each step, variables with the smallest significance
level for the score statistic (the LR test) are entered into the model, provided it is less
than 0.05; and variables with the largest significance levels are removed from the
model, provided they exceed 0.1.
A number of statistics and plots were requested to assess the goodness of fit of the
model, including: classification plots (with the default cut off set at 0.75); the
Hosmer-Lemeshow goodness of fit statistic; and histograms of observed and
expected probabilities. A number ofmeasures of influence were requested including,
Cook's distance and leverage values. Finally, key residual variables were generated
including, studentised, standardised and deviance.
A complete set of the logistic regression calculations, at the final step of the analysis
is included in Appendix 4. Key variables and their interpretation are summarised
next.
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4.4 Logistic regression results
A total of 1074 cases were initially included within the logistic regression model.
111 cases were initially rejected from the analysis because of missing data. These
111 excluded cases arise because postcode data was missing, making it impossible to
attribute the postcode (f6depcat) variable to them. However, using small area
Lothian Health statistics, it was possible to impute a postcode and thus deprivation
variable, as the catchment areas of the community pharmacies were relatively small
(Lothian Health, Information Officer, Personal Communication, 1999). Thus, all
1185 cases were, ultimately, included in the logistic regression analysis.
Table 4.9 summarises the final output equation and indicates that 11 of the 28
variables entered into the logistic regression were independently associated with the
outcome variable; i.e. were predictors of users' choice of route via which to access P
medicines.
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TABLE 4.9: ASSOCIATIONS BETWEEN USERS' ACCESSING P MEDICINES FROM COMMUNITY
PHARMACIES & VARIABLES WITHIN THE FINAL LOGISTIC REGRESSION MODEL








Pharmacy 7 -1.45 0.71 0.23 0.57 0.94 0.04
Pharmacy 13 -2.05 0.99 0.12 0.01 0.90 0.03
Demographic C laracteristics
Single, never married 0.52 0.23 1.69 1.07 2.68 0.02
Child -0.66 0.29 0.51 0.28 0.92 0.02
Socio-economic Characteristics
Deprived depcat -0.74 0.28 0.47 0.27 0.82 0.00
Self-reported General Health Status
Have a longstanding illness -0.27 0.12 0.75 0.58 0.98 0.03
Use of General Practice and Community Pharmacy Service
No. ofGP visits in last year -0.28 0.10 0.75 0.61 0.91 0.00
No. of CP visits in last year 0.67 0.14 1.96 1.49 2.59 0.00
Use the same CP regularly -0.57 0.19 0.56 0.38 0.83 0.00
Receive regular Rx meds. -0.44 0.14 0.64 0.48 0.84 0.00
Cost ofMedicines
Pay for Rx 0.52 0.20 1.69 1.14 2.51 0.00
Pay for Rx & use same CP 0.48 0.19 1.61 1.11 2.35 0.01
regularly
Type of IV edicine
Blacklisted 1.09 0.12 3.00 2.34 3.84 0.00
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As with standard linear regression coefficients, the logistic regression coefficients
can be interpreted as the change in the dependent variable associated with a one-unit
change in the independent variable (Menard, 1995). The results of the model
indicate that the odds of users accessing their P medicine over-the-counter from a
community pharmacist decrease significantly: within certain pharmacies; if the P
medicine was for a child (OR = 0.51); if the user lived in an area classed as deprived
(OR = 0.47); if the user reported the presence of a longstanding illness (OR = 0.78);
the more often users consulted with their general practitioner in the last year (OR =
0.75); if they had used the same community pharmacist regularly (OR = 0.56); and if
they received regular prescription medicines (OR = 0.64).
Conversely, the results of the model indicate that the odds of users accessing their P
medicine over-the-counter from a community pharmacist increase significantly: if
the user is single (OR = 1.69); the more often the user consulted with a community
pharmacist in the last year (OR = 1.96); if the user was eligible to pay for
prescription medicines (OR = 1.69); if they pay for prescriptions and use the same
pharmacist regularly (OR = 1.61); and if they were obtaining a medicine included on
the NHS blacklist (OR = 3.00).
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4.4.1 Comment on what stays in and drops out of the regression model
4.4.1.1 Variables remaining in the logistic regression model
Demographic characteristics
The only demographic variable to remain in the logistic regression model was
marital status. Single users were almost twice as likely (OR = 1.69) to choose to
access their P medicine over-the-counter at the community pharmacy. Interestingly,
this result changes from the univariate analysis and contradicts literature evidence
suggesting that those who are married/co-habiting are more likely to purchase over-
the-counter medicines (Tully & Temple, 1999; Rogers, Hasssell & Nicolaas, 1999).
Socio-economic characteristics
The deprivation category within which users lived was the only statistically
significant socio-economic predictor variable left in the regression model. Users
resident in deprived areas were almost two times less likely (OR = 1.60) to choose to
buy their P medicine over-the-counter from the community pharmacy. This finding
reinforces other research evidence that indicate that affordability of medicines may
be problematic among users in less advantaged situations (Hassell et al., 1997;
Rogers, Hassell & Nicolaas, 1999). Again, however, in the absence of a direct
income variable, caution should be urged in interpreting the socio-economic
variables given their ecological nature.
Self-reported health status
Illness burden appears to be an important predictor. The odds of users who reported
the presence of a longstanding illness buying their P medicine over-the-counter
decreased significantly, by a factor of two (OR = 2.13). The fact that this variable
remains in the model is interesting as, while there is evidence of association between
use of medicines generally and health status (i.e. those who are most ill, use most
medicines) the existence of an inverse relationship between presence of self-reported
longstanding illness and utilisation of over-the-counter medicines specifically was
not identified within the literature.
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Use of general practice and community pharmacy services
All variables relating to use of general practitioner and community pharmacy
services remained in the model. The more often users consulted their general
practitioner in the last year; receipt of regular prescription medicines; and use of the
same pharmacist regularly all decreased the probability of users accessing their P
medicine from the community pharmacist, again by nearly a factor of two.
Conversely, users who reported more frequently consulting the community
pharmacist in the last year were twice as likely to have visited a community
pharmacy to obtain their P medicine. These results may indicate that habit and/or
illness burden could be important predictors.
Cost of medicines
The cost of medicines to users also appears to be an important predictor. Users who
were not exempt from prescription charges were almost twice as likely to buy their P
medicine over-the-counter from a community pharmacist. This finding concurs with
the general weight of evidence regarding the existence of negative and inelastic price
elasticities for the demand of medicines generally and their affordability among less
affluent users specifically.
Type of medicine
The blacklist status of medicines seems influential. Users obtaining a P medicine
included on the NHS blacklist (Scottish Pharmaceutical General Council, 1997) were
three times more likely to buy it over-the-counter from the community pharmacist.
This may suggest that users are very product specific, or again that habits are
important.
Pharmacy
The community pharmacy variable remained in the model and was highly significant
overall. This suggests that there is something about the community pharmacies that
predicts user choice of whether to access P medicines from the general practitioner or
community pharmacy, even among people with the same individual level
characteristics. This may be a characteristic of the community pharmacies
themselves, features of the area they are located within, or perhaps linked to the
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general practices that they are closely associated with. More sophisticated statistical
analyses would be required to investigate this further, such asf multi-level-modelling
techniques (Carr-Hill, Rice & Roland, 1996). This was considered, however, on the
advice of a statistician, it was deemed to be methodologically difficult with only 15
pharmacies (Nigel Rice, personal communication, 1999). Exploring the relevance of
community pharmacy level variables is an important area for further research to
inform policy.
4.4.2 Variables dropping out of the logistic regression model
Table 4.10 highlights the non-significant variables not included within the final
logistic regression model. None of these variables was marginal, or even
approaching significance. For a full report of the variables not included in the final
regression equation, see table A4.1 in Appendix 4.
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TABLE 4.10: VARIABLES DROPPING OUT OF THE LOGISTIC REGRESSION MODEL
Community Pharmacy variables










Access to a car or van
Employment status






Self-reported general health status E12genht
Access to General Practice and Community Pharmacy Services
Usual waiting time for a GP apptmt.
Distance to GP surgery from home





Put off obtaining medicines due to cost




Recently deregulated P medicine G6pomtop*
Interaction Terms
Receiver regular Rx & accommodation




There were a couple of contrary findings regarding variables that were not included
in the final model. In particular, a key policy rationale for encouraging increased
self-medication, particularly using recently deregulated medicines, is that it would
reduce the wait, or indeed obviate the need, to consult a general practitioner. Usual
waiting time to get general practitioner appointment might have been expected to be
predictive of the decision by users to access P medicines from the community
pharmacist, buying them direct, over-the-counter. However, this variable was not a
significant predictor in either the univariate or multivariate analyses.
General health status did not predict users' choice of consultation route to access P
medicines. This variable exhibited a statistically significant association within the
univariate analyses but dropped out of the logistic regression model. This may have
been due to the fact that it did not appear to be a very sensitive variable, with very
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few users reporting bad or very bad health. Alternately, this variable may have been
strongly correlated with the longstanding illness variable that did remain in the
multivariate model.
An age effect might also have been expected but did not emerge. Similarly, the price
paid by the user for his/her medicine relative to the prescription fee, might have been
anticipated to be included in the model, yet was not. However, it may be that the
prescription exemption status variable was measuring similar features to these two
variables, given that both age and cost considerations are implicit to this variable.
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4.5 Extent of convergence between the univariate and
multivariate analyses
Table 4.11 summarises the significance, or otherwise, of key variables in both the
univariate and multivariate analysis, highlighting the changing significance status of
variables between the two steps. Variables that were statistically significant in the
univariate but not the multivariate analyses are highlighted in bold.
TABLE 4.11: CHANGING SIGNIFICANCE OF VARIABLES BETWEEN UNIVARIATE &
MULTIVARIATE ANALYSES (Y=YES; N=NO)






Marital Status Y Y
Socio-economic Characteristics
Accommodation type Y N
Postcode Y Y
Access to a car or van Y N
Employment status Y N
Age completed f/t Y N
education
Self-reported General Health Sta tus
Self-reported health status Y N
Any longstanding illness Y Y
Use of General Practice and Community Pharmacy Services
No. of GP visits in last year Y Y
No. ofCP visits in last year Y Y
Use the same CP regularly Y Y
In receipt of regular Rx Y Y
Access to General Practice and Community Pharmacy Services
Usual wait for a GP apptmt. N N
Distance to GP surgery Y N
Distance to CP N N
Cost ofMedicines
Exempt from Rx fee Y Y
Cost put-off obtaining Y N
med.
Type of Medicines
Deregulated P medicine N N
Blacklisted medicine Y Y
Eight variables were statistically significant within the univariate analysis which
subsequently lost their significance and dropped out of the multivariate logistic
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regression model, including: age; type of accommodation; access to a car or van;
employment category; age completed full-time education; general health status;
distance to the general practice surgery; and whether the user had ever been put off
accessing medicines due to their cost.
This is to be expected within multivariate analysis, the strength of which is its ability
to detect variables that remain independently statistically significant after their
simultaneous interaction with other variables are accounted for. The fact that these
variables do not enter the final regression model does not mean that they are
irrelevant to users' choice ofmethod to access P medicines, only that they cannot add
anything to the power of the model to predict the user's choice of consultation route
over and above that of the 11 variables that were included in the final model. If there
were compelling reasons to believe that there may be real affects associated with
variables excluded from the model, then there may be a case for forcing their entry
into the model. However, this was not felt to be the case.
Overall, there was good convergence between variables identified as statistically
significant in both the univariate and multivariate analyses. Further, most of the
variables included in the model moved in the directions one might have expected.
Similarly, where variables dropped out of the model, post hoc rationalisations
provided plausible explanations for this, after considering the variables remaining in
the model. Reassuringly, no variables emerged as significant in the multivariate
analyses that were not picked up in the univariate analysis. For these reasons, it was
reasonable to accept the results of the logistic regression stepwise procedure.
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4.6 Checking the specification and goodness of fit of the
logistic regression model
Whenever a statistical model is built, it is important to examine the adequacy of the
resulting model (Norusis, 1993; Hosmer & Lemeshow, 1989). This involves
checking that the model is appropriately specified and does not violate the
assumptions of logistic regression analysis methods. Further, it involves assessing
the model's goodness of fit in order to ascertain how effective it is at predicting the
outcome variable (Menard, 1995; Hosmer & Lemeshow, 1989).
4.6.1 Checking the model specification
Before discussing the findings of the model in detail and their relevance, it is
essential to ensure that the model is correctly specified and that model building
efforts were satisfactory (Hosmer & Lemeshow, 1989). There are two components
to this: being satisfied that the model includes all relevant independent variables and
no irrelevant independent variables; and that the functional form of the model is
correct (Hosmer & Lemeshow, 1989; Menard, 1995). Mis-specification of the model
may result in biased coefficients, inefficient estimates, and invalid statistical
inferences (Menard, 1995).
4.6.1.1 Inclusion of all relevant independent variables and exclusion of all
irrelevant independent variables
Given the relatively limited theory and knowledge of correlates regarding what
influences user behaviour in the management ofminor illness episodes using P class
medicines and the resultant exploratory nature of the research, it is difficult to know
the extent to which the model includes all relevant and no irrelevant independent
variables. Nonetheless, efforts were made to address the overall robustness and
stability of the model, re-running it in a number of different ways to check: whether
the model remained recognisable; if it included broadly the same variables; and
generally assessing the extent to which the stepwise method adopted 'creaked' under
closer scrutiny.
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4.6.1.2 'Jack-knifing' the sample
It is necessary to appreciate the kind of changes that could be expected from random
variation in data. One way to assess this is to 'jack-knife' the data set, excluding a
sub-sample of the study observations, developing a model based on the remaining
subjects, and then testing the model in the originally excluded subjects (Hosmer &
Lemeshow, 1989). The study data set is reasonably large, making it possible to
select random sub-sets of cases with which to re-estimate the model. Table 4.12
compares the variables included in the model for the full sample of cases and for two
randomly selected halves of the full sample. It shows that the top five-predictor
variables from the full model were also included in the models fitted to the random
halves of the data set. Further, the three models correctly predicted very similar
proportions of cases overall (83.39% to 85.93%). Three variables that featured in the
full model, yet not within the random halves models included, postcode (f6sunnm)
marital status (f4mstat2) and longstanding illness (e13lgill). However, these were
among the four least significant predictor variables within the full model. Only one
new predictor variable, not included in the full model, entered one of the random
halves models (e5sameph*g6pomtop) an interaction term of users who visited the
same community pharmacy regularly and accessed a recently deregulated medicine.
Generally though, the variables within the three models were broadly similar. This
result was also borne out when the regression analysis was conducted on a random
75%/25% selection of the cases.
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TABLE 4.12: VARIABLES INCLUDED WITHIN 'JACK-KNIFED' SUB-SAMPLE REGRESSION
ANALYSES
Full Model Random Random Random Random
50% 50% 25% 75%






































% Cases Correctly Classified by the Model
Full Model Random 50% Random Random Random 75%
50% 25%
GP 1st 88 GP 1st 90 GP 1st 83 GP 1st 89 GP 1st 87
CP 1st 85 CP 1st 84 CP 1st 83 CP 1st 84 CP 1st 85
Overall 86 Overall 86 Overall 83 Overall 86 Overall 86
174
4.6.1.3 Comparing forward and backward stepwise variable selection
procedures
Another way to assess the robustness of a statistical model and in particular to try to
ensure that all and only relevant variables are included, is to test out different model
building strategies e.g. forward and backward stepwise variable selection methods.
Forward stepping models start out including only the constant term, iteratively select
the most significant predictor variables and adds them to the model, one by one, until
none of the remaining terms offer any improvement in the predictive power of the
model. In contrast, backward stepping models start off by including all variables in
the model and iteratively remove the least significant variables, one by one, until
only significant terms are left in the model. Ideally, the results of the backward
elimination and forward inclusion methods of stepwise regression procedures will be
the same. However, this may not always be the case. Occasionally 'suppressor'
effects may arise. This is when a variable only reaches a statistically significant level
when another variable is controlled or held constant. Consequently, a potential
disadvantage to forward inclusion methods of stepwise regression is the possible
exclusion of variables involved in suppressor effects. With backward elimination,
because all variables are initially included in the model, there is less risk of failing to
find existing relationships (Menard, 1995). Thus, backward elimination techniques
may uncover relationships missed by forward inclusion. For this reason, both
forward inclusion and backward elimination stepwise models were undertaken. The
backward elimination stepwise approach yielded very similar results as the
previously conducted forward stepwise regression (See Appendix 4). This result is
reassuring, ruling out suppressor effects and validating the results of the forward
stepping regression analysis.
4.6.1.4 Relaxing the statistical significance criteria for including variables
within the regression model
Another way to try to ensure that all relevant variables are included within the model,
is to relax the statistical significance threshold determining variables entering the
regression model. The default inclusion criterion for variables within SPSS logistic
regression is set at the conventional p<0.05 level. However, some analysts believe
this to be too strict, running the risk of excluding important variables from the model.
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Instead, they recommend that the statistical criterion for inclusion be set in the range
0.15 to 0.20. This results in an increased risk of rejecting the null hypothesis when it
is true (finding a result that is not really there) but a lower risk of failing to reject the
null hypothesis when it is false (not finding a relationship when it is there). This is
particularly important within exploratory research, where there is a greater emphasis
on finding good predictors, than eliminating bad ones (Menard, 1995).
Thus, the regression model was re-run, relaxing the inclusion criterion within the
range 0.05 to 0.20. Table 4.13 summarises the result.
TABLE 4.13: VARIABLES ENTERING THE MODEL AFTER RELAXING THE DEFAULT INCLUSION
CRITERIA
N=1185 Model 1 Model 2 Model 3 Model 4
P=0.05 P=0.10 P=0.15 P=0.20
Model chi- 622.094 622.094 624.319 627.861
square (d.f.) (27) (27) (28) (30)
Significance 0.000 0.000 0.000 0.000
level
Variables e6farph e6farph
added to the prelrx
model e7regrx*
f5summ
Changing the inclusion criteria cut-off from p<0.05 to p<0.10 had no effect on the
variables included in the model. Increasing it further to p<0.15 and p<0.20 changes
the model very modestly, reducing the -2 log likelihood score change only
marginally by 2.25 and 5.767 respectively, with the overall statistical significance
remaining unchanged at the p<0.0001 level. When the inclusion criterion is set at
p<0.20 three extra variables enter the regression model, distance to the community
pharmacy (e6farph) price of P medicines relative to the prescription fee (prelrx) and
an interaction term relating to receipt of prescription medicines and accommodation
(e7regrx*f5summ). Otherwise, the model remains the same. Of these three
variables, one was highly significant (prelrx p<0.001) and another marginally non¬
significant (e6farph p=0.0831) in the univariate analyses. However, they only enter
the regression model when the inclusion criterion is relaxed considerably.
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Overall, relaxing the inclusion criterion threshold exerts little influence regarding
variable entering the regression model and the predictive performance of the model.
For this reason, adopting the conventional default inclusion criterion (p<0.05) did not
appear to be excluding potentially relevant variables from the model. Thus, the
results of the initial regression model were accepted and the default inclusion
criterion threshold (p<0.05) adopted in the analysis.
Analysis procedures to assess whether the forward inclusion stepwise technique
adopted was including only relevant variables suggest that the model remained fairly
robust and stable, in that it consistently identified and selected the same variables as
relevant to the model. Assessing the extent to which the regression model included
all relevant variables is more difficult. Given the exploratory nature of the research
and the relative lack of information regarding theoretically relevant variables,
omitted variable bias may be present (Menard, 1995). Further, detailed external
validation of the model would, however, be required to be able to conclude that the
model is indeed truly robust and includes all relevant variables and therefore useful
to predict users' choice of consultation route to access P medicines. This would
require obtaining new samples of data to assess the performance of the previously
developed model (Hosmer & Lemeshow, 1989). The aim of this process would be to
replicate the study results, simultaneously developing and testing theories that
potentially explain why certain variables emerge as predictors. Until that time, these
results must be regarded as tentative and inconclusive (Menard, 1995).
4.6.1.5 Testing the functional form of the regression model
The next stage in checking the model specification involves checking its functional
form. A key assumption underpinning the correct specification of logistic regression
models is that the form of the relationship is linear (Menard, 1995). Consequently,
the logistic regression model will be mis-specified if it is equal to a non-linear
combination of the independent variables or if the relationship between some or all
of the independent variables is multiplicative or interactive, rather than additive
(Menard, 1995). In order to ensure that the linearity and additivity assumptions hold,
a number of key considerations in the model building process include: selection of an
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appropriate transformation function; checking for linearity; and prior hypothesising
and investigating potential interactions within the model.
4.6.1.6 Choice of transformation function
Model mis-specification can result from inappropriate choice of transformation
function to facilitate the regression analysis of dichotomous data. However, mis-
specification as a result of using the logistic function as opposed to a different 'S'
shaped function is less likely to be a problem. Logit and probit models produce very
similar results (Menard, 1995; Collett, 1999). Further, Hosmer and Lemeshow note
that the logarithmic and other similar symmetric models are virtually identical in the
range 0.2 to 0.8 (Hosmer & Lemeshow, 1989). There is usually little theoretical
basis for preferring an alternative model
4.6.1.7 Checking for linearity
For continuous scaled variables, we should check the assumption of linearity in the
logit (Hosmer & Lemeshow, 1989). However, given that there are very few
continuous variables included within the regression model and no reason to expect
any non-linear relationships, formal tests of linearity were not undertaken. Re¬
running the model with all continuous variables re-coded to make them categorical
did not substantively alter the results. Linearity in the logit was, therefore, assumed.
4.6.1.8 Testing for collinearity andmulticollinearity
One further important characteristic of generalised linear models, such as logistic
regression model, is that they assume independent, or at least uncorrelated,
observations (McCullagh & Nelder, 1983). Collinearity or multicollinearity, is the
undesirable situation where the correlation among independent variables is strong.
Collinearity among the predictors can lead to biased estimates and inflated standard
errors (Norusis, 1993; Menard, 1995). A variety of collinearity diagnostics are
available in standard linear regression analysis (Norusis, 1993). One of these, the
'tolerance' statistic can also be applied to logistic regression models. Tolerance
statistics for individual variables can be used to determine the extent to which the
independent variables are linearly related to one another (multicollinear). The
tolerance statistic measures the proportion of a variable's variance not accounted for
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by other independent variables in the equation. A variable with very low tolerance
contributes little information to a model and can cause computational problems
(Norusis, 1993). A tolerance statistic less than 0.2 indicate cause for concern and if
it is less than 0.1 this is indicative of a serious collinearity problem (Menard, 1995).
Tolerance statistics can be obtained for logistic regression models by calculating a
standard linear regression model using the same dependent and independent
variables. As the main concern of this statistic is to investigate the relationship
between independent variables, the functional form of the model for the dependent
variable is irrelevant to the estimation of collinearity (Menard, 1995). Table 4.14
outlines the tolerance statistics calculated for the independent variables within the
logistic regression model. It shows that all the tolerance statistic for all the
independent variables exceed 0.50, indicating no serious problem of collinearity
(Menard, 1995).
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TABLE 4.14: TOLERANCE STATISTICS FOR INDEPENDENT VARIABLES, TESTING FOR
COLLINEARITY
INDEPENDENT VARIABLES TOLERANCE STATISTIC
Community Pharmacy variables
Community pharmacy 0.954









Access to a car or van 0.859
Employment status 0.519
Age completed f/t education 0.788
Self-reported General Health Status
Self-reported general health status 0.699
Any longstanding illness 0.631
Use of General Practice and Community Pharmacy Services
No. of GP consultations in the last year 0.780
No. ofCP consultations in the last year 0.863
Use the same CP regularly 0.962
In receipt of regular Rx 0.603
Access to General Practice and Community Pharmacy Services
Usual waiting time for a GP apptmt. 0.967
Distance to GP surgery from home 0.919
Distance to CP from home 0.968
Cost of Medicines
Prescription exemption status 0.801
Put off obtaining medicines due to cost 0.860
OTC price relative to the Rx fee 0.938
Type of Medicines
Recently deregulated P medicine 0.850
Medicine on NHS blacklist 0.963
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4.6.1.9 Investigating potential interactions between independent variables
Combinations of variables sometimes have a different effect than you would expect
from each of the variables alone within a model (Norusis, 1993). Interactions or non-
additivity occurs between variables that are not independent. The presence of
interaction terms means that the effect of one of the independent variables is not
constant over levels of the others i.e. when the change in the dependent variable
associated with a one-unit change in an independent variable depends on the value of
one of the other independent variables. (Hosmer & Lemeshow, 1989; Menard, 1995).
However, only interaction terms that one may have prior reason to believe might
exist should be investigated. To this end, a number of plausible potential interactions
between independent variables were tested. These were derived by considering, a
priori, whether individual variables weakly associated with the outcome might
become important predictors when taken together. Including terms in the model that
are a product of single terms did this (Norusis, 1993). For example, age and sex
were and were not respectively significantly associated with choice of access route in
the univariate analyses. However, other research indicates that these variables can
have a cumulative effect on illness burden and use of health services when taken
together. For this reason, age and sex were investigated to explore whether in
interaction they were significantly associated with the outcome. Other plausible
interaction effects were hypothesised and entered one at a time to assess if they
would emerge as significant predictor variables within the model. The interaction
terms tested are summarised in table 4.15.
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TABLE 4.15: INTERACTION TERMS ENTERED INTO THE LOGISTIC REGRESSION MODEL
Interaction Variable Interpretation
Flsex*f3age Sex and age
E7regrx*el31gill Regular prescription medicine and
longstanding illness
Elyrnogp*el31gill No. of times consulted the GP in last
year and longstanding illness
E4yrnoph*el31gill No. of times consulted the CP in last year
and longstanding illness
E5sameph*el 3 lgill Use same CP regularly and longstanding
illness
E5 sameph *e7 regrx Use same CP regularly and regular
prescription medicine
E5sameph*g6pomtop+ Use same CP regularly and
E5sameph*e8payrx
deregulated medicine
Use same CP regularly and pay for
prescriptions
E8payrx*f3age Pay for prescriptions and age
E8payrx*f8empcat Pay for prescriptions and employment
category
E8payrx*f5summ Pay for prescriptions and homeownership
El lctoffHSsumm Ever put off by the cost ofmedicines and
homeownership
E7regrx*f5umm+ Regular prescription and
homeownership
emerged as a significant predictor variable when added individually to the model
+ $ included in the final regression model as a significant predictor variable
Three of the thirteen interaction terms prior hypothesised to potentially predict
outcome emerged as significant predictors when added individually to the regression
model - e5sameph*g6pomtop, e5sameph*e8payrx and e7regrx*f5summ
(highlighted in bold). These three interaction terms were included in subsequent
regression analyses. However, only one of these interaction terms emerged as a
significant predictor variable in the final regression model - e5sameph*e8payrx.
Users who used the same pharmacist regularly and who paid for their prescriptions
were significantly more likely to try the community pharmacist first to access their P
medicine (OR=T.61). These may be users who, through time, have developed a
relationship with their community pharmacist whose advice they seek regarding
over-the-counter equivalents to prescription medicines, perhaps to save them either
time or money.
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4.7 Assessing the goodness of fit of the logistic regression
model
Once satisfied regarding the variables included and the functional form of the model
at the model building stage, the next step in assessing the model is to ascertain how
effective the model we have developed is at predicting the outcome variable (Hosmer
& Lemeshow, 1989). This involves assessing the 'goodness of fit' of the model.
Goodness of fit is, however, something of a misnomer, as what we are actually
measuring is how distant the model is from the data (Collett, 1999).
Fitting a model may be regarded as a way of replacing a set of data values with a set
of fitted values, derived from a model. However, the fitted values generated by the
model do not exactly reproduce the original data. The question is, how discrepant
they are? While a small discrepancy may be tolerable, a large one is not (McCullagh
& Nelder, 1983).
Thorough assessment of the goodness of fit of the model will involve both the
calculation of summary measures of distance between observed and predicted values,
as well as examination of the individual components of these measures, the aim of
which is to identify points or cases that the model does not fit well, or that exert a
strong influence on the coefficient estimates (Hosmer & Lemeshow, 1989; Norusis,
1993). A variety of diagnostic methods are available to investigate the fit of logistic
regression models including summary goodness of fit statistics and analysis of
residual measures, useful for investigating influential and outlier variables.
4.7.1 Summary goodness of fit measures
Three separate summary measures were used to investigate the overall goodness of
fit of the model, including: a classification table; the model chi-square, goodness of
fit statistic; and the Hosmer-Lemeshow goodness of fit statistic which assesses model
fit across sample deciles.
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4.7.2 The classification table
One way to assess how well the models fits is to compare its predictions to the actual
observed outcomes (Norusis, 1993). One method of determining how well the
logistic regression model performs is to consider the crude misallocation rate of the
model. This is done by examining the proportion of users that the model predicted
would consult the general practitioner, who actually did and the proportion of users
that the model predicted would consult the community pharmacist who actually did.
This is summarised in table 4.16.




GP first CP first %
Observed GP first 242 32 88
CP first 122 678 85
Three quarters of the recruited sample visited the community pharmacist first to
obtain their P medicine. For this reason, the cut value for the classification table was
set at 0.75. So, for each predicted group the table shows whether the estimated
probability is greater or less than 0.75.
The results indicate that 88.32% of users (242/274) who visited the general
practitioner first and 84.75% of users who visited the community pharmacy first
(678/800) were correctly predicted by the regression model to do so. Conversely,
122 users predicted by the model to visit the general practitioner first actually went
to the community pharmacy first and 32 users predicted by the model to visit the
community pharmacist first actually visited the general practitioner first to obtain
their P medicine.
Overall, the model correctly predicted 85.66% (920/1074) of the users and
misallocated 14.34% (154/1074) of users. Further, it correctly predicts membership
between the general practitioner and community pharmacy groups almost equally
well at 88.32% and 84.75% respectively.
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4.7.3 Model chi-square test
The classification table and histogram of estimated probabilities provide a useful
broad indication of how well, or otherwise, that the logistic regression model
classifies the observed data. However, we also need to test the model across the
whole range of probability estimates it produces. Considering the probability of
observed results, as measured by the 'likelihood" and related model chi-square
goodness of fit statistic does this (Norusis, 1993).
A good model generates high likelihood of the observed results. This translates into
a small value for the '-2 times the log of the likelihood' (-2LL) statistic. Ideally, the
improvement in the model between including only the constant term and the
significant predictor variables included within the final regression model, should
result in a decrease in the -2LL score. Indeed, the change in the -2LL score ({-2LL
for the model containing only the constant term} - {-2LL for the model containing
the significant independent variables}) constitutes the basis of the model chi-square
goodness of fit statistic. This tests the null hypothesis that the coefficients for the
independent variables included in the regression model are zero (Norusis, 1993). If
the model chi-square is statistically significant, then we can reject the null hypothesis
and conclude that information about the independent variables allow us to make
better predictions than without them (Menard, 1995; Norusis, 1993). Results of the
model chi-square goodness of fit statistic are summarised in table 4.17
TABLE 4.17: -2 TIMES THE LOG OF THE LIKELIHOOD (-2LL) SCORES & THE MODEL CHI-
SQUARE GOODNESS OF FIT TEST RESULTS
-2LL for model containing only the constant term a 1219.8311




Model chi-square = a - b
It indicates that the -2LL figure decreases markedly, from 1219.8311 for the model
including only the constant term, to 597.73 for the full model including the
significant independent variables. The model chi-square is the difference in the -
2LL between these two steps and is 622.094. This goodness of fit statistic is
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assessed using the chi-square distribution and is statistically significant at the
pO.OOOl level. Thus, we can conclude that the independent variables included in
the model allow us to significantly improve prediction of the outcome variable.
4.7.4 Hosmer-Lemeshow goodness of fit test
Hosmer and Lemeshow (1989) propose a more sophisticated method to assess the
goodness of fit of logistic regression models. They recommend grouping the users in
the sample into deciles, according to the value of their estimated probabilities, with
the first group having the smallest estimated probability values and the last group the
largest (Hosmer & Temeshow, 1989). Their goodness of fit statistic is then obtained
by calculating the Pearson chi-square statistic from a table of observed and expected
estimated frequencies across the sample deciles. SPSS output produces the Hosmer-
Lemeshow goodness of fit test. Results of applying the decile grouping strategy to
the estimated probabilities computed from the regression model are shown in table
4.18.
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TABLE 4.18: OBSERVED (OBS.) & ESTIMATED EXPECTED (EXP.) FREQUENCIES WITHIN EACH
SAMPLE DECILE FOR EACH OUTCOME (GP OR CP FIRST) USING THE FITTED LOGISTIC
REGRESSION MODEL
Group Decile Total



















































Total 107 107 107 107 107 108 107 107 107 110 1074
The Hosmer-Lemeshow test provides valuable descriptive information, facilitating
assessment of the fitted model over the sample deciles of estimated probabilities.
Comparing the observed and expected frequencies in each decile potentially
pinpoints regions where the model does not provide a good fit. Comparisons of the
observed and expected frequencies within the table's cells indicate similar values,
suggesting that the model fits within each of the sample deciles. Further, as
expected, the majority of users who adopted a general practitioner route appeared in
the lower estimated probability decile groupings and most of those adopting a
community pharmacist route are clustered in the higher estimated probability decile
groupings. These results are confirmed by a small value for the Hosmer-Lemeshow
goodness of fit statistic, 1.6592, the corresponding p value (computed from the chi-
square distribution with 8 degrees of freedom) for which is 0.9897, indicating a very
good overall fit.
4.7.5 Analysis of residuals
Analysing residuals using a variety of diagnostic methods offer another route via
which to assess the fit of a model, identifying cases for which the model works
poorly or that exert undue influence on the parameters of the model (Menard, 1995).
The residual is the difference between the observed and predicted probability of an
outcome based on the model (Norusis, 1993). For example, if the model predicts the
probability of visiting the community pharmacist first to be 0.9 for a user who does
use the community pharmacist, the residual is 0.1 (1.0 - 0.9). For large sample sizes,
certain residuals should be approximately normally distributed. This results from the
187
fact that the normal and binomial distributions are about the same for large samples.
If this is the case, we can be more confident in the inferential statistics derived from
the model (Norusis, 1993; Menard, 1995).
The standardised and deviance residuals, should be approximately normally
distributed for large samples, with means of zero and standard deviations of one
(Norusis, 1993; Menard, 1995). Standardised residuals are simply residuals divided
by the estimate of their standard deviation. Deviance residuals measure how well the
model fits individual cases. Large values for deviance residuals indicate a poor fit
with the model. Plotting histograms of the model standardised and deviance
residuals indicated that they were indeed approximately normally distributed, with
means very close to zero (0.02 and 0.07 respectively) and standard deviations
approaching one (0.85 and 0.74 respectively).
Analyses of residuals facilitate identification of influential variables and/or outlier
cases. Cases with unusually high or low vales on the independent variables, or with
unusual combinations of values on the dependent and independent variables, may
exert a disproportionate influence on the estimated parameters, if they have a big
effect on the slope of the regression line. Similarly, outliers can emerge if a case has
unusually high or low values on one variable or an unusual combination of two or
more variables. It is not always the case that outlier cases contain influential
variables.
In addition to the standardised residual and deviance measures, a number of other
residual analysis techniques are available to identify influential variables and outlier
cases, including: Cook's distance, leverage and studentised residuals.
Cook's distance measures the influence of a case. It indicates how much deleting
particular cases affect not only the residual for the case concerned, but also for the
remaining cases i.e. it is a measure of change in all residuals when an observation is
omitted (Norusis, 1993). Plots of the Cook's distance residual by case number
identified only one influential case, number 485.
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Leverage values are used to detect observations that have a large impact on predicted
values. Leverage values are bounded by zero and one. Cases with leverage values of
zero exert no influence, whereas if a leverage value equals one, the observation/case
is largely determining parameters in the model (Menard, 1995). The average leverage
value for a sample is p/n, where 'p' is the number of estimated parameters in the
model, including the constant, and 'n' is the sample size (Norusis, 1993). Thus, the
average leverage value for the model presented is 0.026 (28/1074). Plotting sample
leverage values by case number highlighted that case 545 exhibited a much higher
leverage value that the others.
The studentised residual for a case is the change in the model deviance if the case is
excluded (Norusis, 1993). Discrepancies between the deviance and studentised
residuals may identify unusual cases.
The standardised and deviance residuals are particularly useful for identifying cases
for which the model fits poorly. In particular, it is advisable to investigate cases with
standardised or deviance residuals greater or less than +2 or -2 . Given the normal
distribution of these residuals, 95% of cases should have values between -2 and +2
and 99% of cases between -2.5 and +2.5 (Menard, 1995). Indeed, SPSS can identify
cases with standardised residuals greater than 2. Table 4.19 reports the 10 cases with
the most discrepant fit (including cases 485 and 545) across a number of these key
residuals. It identifies the case number, the observed and predicted values of the
cases, the standardised residual, Cook's distance, leverage, studentised residual,
deviance, model chi-square excluding the case, and the difference between the model
chi-square value including and excluding the case (Menard, 1995).
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TABLE 4.19: LOGISTIC REGRESSION GOODNESS OF FIT DIAGNOSTIC SUMMARY
Case Obs. Pred. Std. Cook's Leverage Student Deviance Model Change





545 0 0.98 -7.33 0.373 0.006 -2.8 -2.82 627.7 5.6
485 0 0.96 -5.14 1.183 0.042 -2.6 -2.57 627.2 5.1
133 0 0.96 -4.92 0.416 0.016 -2.5 -2.54 626.2 4.1
853 1 0.04 4.61 0.351 0.016 2.5 2.49 628.0 5.9
561 0 0.95 -4.40 0.483 0.024 -2.4 -2.45 625.8 3.7
292 0 0.96 -5.30 0.307 0.010 -2.6 -2.59 626.4 4.3
287 0 0.96 -4.95 0.357 0.014 -2.5 -2.546 626.2 4.1
712 1 0.05 4.17 0.254 0.014 2.4 2.41 627.5 5.4
936 0 0.93 -3.89 0.212 0.013 -2.3 -2.35 625.1 3.0
1069 0 0.93 -3.71 0.219 0.015 -2.3 -2.32 624.9 2.8
Full Moc el Chi- 622.094 N/A
Square
(28d.f.)




The overall aim in analysing residuals is to identify cases to re-examine and make a
judgement about whether they should be retained or possibly excluded from the
model. Examining table 4.19, case number 545 stands out. The standardised
residual is large at -7.3315 and the studentised residual is just under -3 (-2.83924),
both indicators of a poor fit. In addition, this case was previously identified as
exhibiting the most discrepant leverage value in the sample. Deleting cases 545 from
the analysis would increase the model chi-square statistic by 5.656. Deleting each of
these poorly fit cases would improve the model chi-square between 2.872 and 5.982.
Further, deleting them all would improve the model chi-square by 47.642. However,
final decision regarding whether or not to remove these discrepant cases requires
closer scrutiny of the data It may be that, while these cases may be unusual, they
may also contain entirely plausible data, in which case they should be retained in the
analysis (Menard, 1995). Menard notes: "even cases with very large residuals do not
necessarily indicate problems in the model, in so far as we are dealing with non
deterministic models in which individual human choice and free will may naturally
provide less than perfect prediction of human behaviour" (Menard, 1995).
Ultimately, researcher discretion must be exercised. The ten most obvious outlier
cases were investigated further. This revealed that there were in fact plausible
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explanations as to why the model may have mis-specified them. Thus, the decision
was taken to keep them in the data set.
While it is important to examine goodness of fit, it is important to avoid 'over-fitting'
a model and keep in mind the distinction between getting a model to fit and
maintaining a conceptually sound model (Hosmer & Lemeshow, 1989). McCullagh
and Nelder caution that "all models are wrong", warning researchers to avoid "falling
in love with one model to the exclusion of all others" (McCullagh & Nelder, 1983).
Doubtless, there are several possible models. No one model can ever be termed the
'correct' model (Collett, 1999).
Overall, validation procedures examining both the specification and goodness of fit
of the model suggest that across the whole sample, the model performs relatively
well at predicting users' choice to visit either the general practitioner or community
pharmacist to access a P medicine. As expected though, the model is not able to
perfectly predict user choice. There are other factors, perhaps related to the
community pharmacies, the areas that they are in, or indeed the users themselves
which influences their choice to access P medicines from the general practitioner or
community pharmacist. The ultimate test of the model, however, concerns how well
it would work (i.e. whether it can correctly predict user choice) with another (out-of-
sample) data set. It was not possible to test this within this study. However, it
highlights an interesting area for further research.
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4.8 Summary ofpolicy relevant results
BOX 4.1: SUMMARY OF POLICY RELEVANT RESULTS
Users were significantly more likely to access a P medicinefrom a community
pharmacist rather than a genera/ practitioner if:
• Single; the more often they had consulted a community pharmacist in the last
year; if they paid for prescription medicines; if they used the same
community pharmacy regularly; and if they wished to receive a medicine
'blacklisted' from the NHS prescribing list.
Users were significantly less likely to access a P medicinefrom a community
pharmacist rather than a general practitioner if:
• The medicine was for a child; if they lived in a deprived area; if they reported
presence of a longstanding illness; the more often they had consulted with a
general practitioner in the last year; if they used the same community
pharmacy regularly; and if they received regular prescription medicines.
• Relative cost of medicines compared to prescription charges; burden of
illness (implying regular use of general practitioners); habit (using the same
community pharmacist and seeing a general practitioner regularly); as well as
being loyal to particular brands of medicines seem likely to be important
influences in attempts to self-medicate using a P class medicine obtained
from a community pharmacy.
• Usual waiting time to see a general practitioner was not predictive of users'
likelihood to attempt substitution, contrary to expectations.
• Neither age nor general health status were predictive of substitution.
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Chapter 5:
Time and resource costs of accessing P medicines from
general practitioners and community pharmacists
5.11ntroduction
The overall objective of this chapter is to investigate the welfare implications associated
with the changing distribution of time and resource costs accruing to stakeholders
associated with accessing P class medicines from general practitioners and community
pharmacists. Four sets of analyses were conducted to fulfil that objective, including: (l)
costing analysis, identifying the main costs (direct and indirect) accruing to stakeholders,
highlighting differences depending on the access route adopted; (2) consumer surplus
analyses, estimating the net consumption benefits (or costs) to users facing different time
and resource costs, dependent upon the access route adopted; (3) Modelling the impact
on net benefits to both users and the health sector resulting from numerous policy
scenarios; and (4) economic evaluation (cost minimisation analysis) assessing the
relative cost and efficiency to both users and the health sector of accessing P class
medicines via prescription or over-the-counter routes.
In the results that follow, estimates relating to users' initial choice of access route were
derived using data from the full study sample (n=ll85). Estimates referring to initial
and follow-up user visits were derived from the sub-sample of users who participated in
both the community pharmacy and telephone follow-up questionnaires (n=7l7).
Stakeholders refer to users, general practitioners and community pharmacists. Alternate
study perspectives (societal, user/family and health sector) comprise varied
combinations of these stakeholders. Key cost elements included under each were
outlined in Table 2.1 in Chapter 2 and the unit costs applied to value these resources
were summarised in Table 2.2 in Chapter 2.
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Time and resource costs are reported. Time costs highlight the time consequences to
stakeholders associated with the two routes for accessing P medicines. Resource cost is
a broader category, encapsulating all resources expended by stakeholders in the process
of accessing P medicines (i.e. time, travel, medicine and special arrangement costs).
Two main resource categories were costed - time and travel and medicine costs, with
total costs derived as the sum of both.
The cost of medicines represented the vast majority of the out-of-pocket financial costs
met by users and thus may be taken as a reasonable proxy for their actual money costs.
A small number of users also incurred monetary costs associated with their method of
travel to obtain their medicine. However, these were minor, with similar means and
ranges between different groups of users and were far outweighed by any medicine
costs. For those reasons, travel costs were not separately quantified, as they were felt
unlikely to change either the direction or magnitude of the key results.
All time and resource costs presented are mid-estimates, excluding costs associated with
any special arrangements made by users when accessing their medicine(s). High and
low cost estimates are presented within supplemental tables included in the appendices,
as are estimates including any special arrangement costs incurred by users (See tables
A5.1 - A5.24 in Appendix 5). Where differences emerged between these estimates, they
are reported. Finally, more detailed breakdowns of time and resource cost estimates
were summarised and reported in appendices where they were thought to represent a
useful reference source for future community pharmacy research.
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5.2 Costing analysis of varied user access routes
Summary time and resource costs incurred by stakeholders in each of the initial and
follow-up visits adopted by users to access P medicines are presented in table 5.1.
Monetary valuation of these resources is outlined in table 5.2. For simplicity, only mean
and total time and resource costs are presented. Actual time and resource costs to
stakeholders, broken down by the constituent elements of the varied routes to access P
medicines (travel, special arrangement(s), waiting and consulting time) are outlined in
tables A5.1 -A5.7 in Appendix 5, alongside relevant summary statistics. Tables A5.4 -
A5.7 in Appendix 5 also report the low and high money cost estimates calculated as part
of the sensitivity analyses undertaken to test the robustness of results.
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TABLE 5.1: SUMMARY TIME COSTS ACCRUING TO STAKEHOLDERS FOR INITIAL & FOLLOW-UP
VISITS TO ACCESS P MEDICINES
User Time Costs Mean Sum
(Inch Special Arrangements") (minutes) (hours)
Initial visit: P medicine on Rx in general practitioner apptmt. (n=176) 79 233
Initial visit: P medicine on Rpt Rx from general practitioner (n=127) 51 108
Initial visit: P medicine bought OTC at community pharmacy (n=882) 19 280
Total Initial visit 621
Follow-up visit: general practitioner follow-up apptmt. (n=122) 117 237
Follow-up visit: community pharmacist follow-up visit (n=44) 19 14
Total Follow-up visit 251
Overall Total User Time costs (initial & follow-up visits) 872
User Time Costs Mean Sum
(Excl. Special Arrangements ) (minutes) (hours)
Initial visit: P medicine on Rx in general practitioner apptmt.(n=l 76) 52 153
Initial visit: P medicine on Rpt Rx from general practitioner (n=127) 28 60
Initial visit: P medicine bought OTC at community pharmacy (n=882) 14 204
Total Initial visit 417
Follow-up visit: general practitioner follow-up apptmt.(n=122) 68 137
Follow-up visit: community pharmacist follow-up visit (n=44) 16 12
Total Follow-up visit 149
Overall Total User Time Costs (initial & follow-up visits) 566
General Practitioner Time Costs Mean Sum
(minutes) (hours)
Initial visit: P medicine on Rx in general practitioner apptmt.(n= 176) 12 35
Initial visit: P medicine on Rpt Rx from general practitioner (n=127) 5 11
Initial visit: P medicine bought OTC at community pharmacy (n=882) 0 0
Total Initial visit 45
Follow-up visit: general practitioner follow-up apptmt. (n=122) 13 27
Follow-up visit: community pharmacist follow-up visit (n=44) 0 0
Total Follow-up visit 27
Overall Total General Practitioner Time Costs (initial & follow-up visits) 72
Community Pharmacy Time Costs Mean Sum
(minutes) (hours)
Initial visit: P medicine on Rx in general practitioner apptmt. n=176) 4 11
Initial visit: P medicine on Rpt Rx from general practitioner (n= 127) 4 8
Initial visit: P medicine bought OTC at community pharmacy (n=882) 1 15
Total Initial visit 34
Follow-up visit: general practitioner follow-up apptmt. (n=122) 4 8
Follow-up visit: community pharmacist follow-up visit (n=44) 1 1
Total Follow-up visit 9
Overall Total Community Pharmacy Time Costs (initial & follow-up visits) 43
NHS Time Costs Mean Sum
(minutes) (hours)
Initial visit: P medicine on Rx in general practitioner apptmt. (n=176) 16 46
Initial visit: P medicine on Rpt Rx from general practitioner (n=127) 9 19
Initial visit: P medicine bought OTC at community pharmacy (n=882) 1 15
Total Initial visit 80
Follow-up visit: general practitioner follow-up apptmt. (n=122) 17 34
Follow-up visit: community pharmacist follow-up visit (n=44) 1 1
Total Follow-up visit 35
Overall Total NHS Time Costs (initial & follow-up visits) 115
"Special arrangements included mainly time-offwork and childcare.
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Mean user time costs ranged between 14-68 minutes overall. As expected, buying
medicines over-the-counter was the quicker and obtaining a prescription the slower route
through which users could access P medicines, with general practitioner access routes
increasing user time costs threefold compared to community pharmacist access routes.
Differences in mean time costs, depending on whether the user visited either the general
practitioner or community pharmacist, were statistically significant at the p<0.000 level
(t-test).
A rule of halves emerges. Buying P medicines over-the-counter from the community
pharmacist took between 14-16 minutes; approximately half as long as accessing a P
medicine on repeat prescription from a general practitioner (28 minutes on average);
which, in turn, took around half as long as accessing a P medicine during a general
practitioner consultation (52-68 minutes on average). For a summary of difference in
mean time costs across key study samples and associated summary statistics, see table
A5.8 in Appendix 5.
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TABLE 5.2: SUMMARY MONEY COSTS (£) ACCRUING TO STAKEHOLDERS IN INITIAL & FOLLOW-
UP VISITS TO ACCESS P MEDICINES
User Money Costs - Total1 Mean (£) Sum (£)
Initial visit: P medicine on Rx in general practitioner apptmt.(n=176) 6.14 1081
Initial visit: P medicine on Rpt Rx from general practitioner (n=127) 4.88 620
Initial visit: P medicine bought OTC at community pharmacy (n=882) 6.00 5296
Total Initial visit 6997
Follow-up visit: general practitioner follow-up apptmt. (n=122) 6.21 757
Follow-up visit: community pharmacist follow-up visit (n=44) 7.17 316
Total Follow-up visit 1073
Overall Total User Cost (initial & follow-up visits) 8070
User Money Costs-Time & Travel Costs Only Mean (£) Sum (£)
(Excl. Special Arrangements")2
Initial visit: P medicine on Rx in general practitioner apptmt. (n= 176) 6.93 1219
Initial visit: P medicine on Rpt Rx from general practitioner (n=127) 4.33 550
Initial visit: P medicine bought OTC at community pharmacy (n=882) 2.17 1912
Total Initial visit 3681
Follow-up visit: general practitioner follow-up apptmt. (n=122) 9.14 1115
Follow-up visit: community pharmacist follow-up visit (n=44) 2.58 114
Total Follow-up visit 1229
Overall Total User Time & Travel Cost (initial & follow-up visits) 4910
User Money Costs - Medicines Only 3 Mean (£) Sum (£)
Initial visit: P medicine on Rx in general practitioner apptmt. (n=176) 0.86 151
Initial visit: P medicine on Rpt Rx from general practitioner (n=127) 0.55 70
Initial visit: P medicine bought OTC at community pharmacy (n=882) 3.84 3390
Total Initial visit 3611
Follow-up visit: general practitioner follow-up apptmt. (n=122) 2.42 296
Follow-up visit: community pharmacist follow-up visit (n=44) 4.70 207
Total Follow-up visit 503
Overall Total User Medicine Costs (initial & follow-up visits) 4114
General Practitioner Money Costs 4 Mean (£) Sum (£)
Initial visit: P medicine on Rx in general practitioner apptmt. (n=176) 14.77 2599
Initial visit: P medicine on Rpt Rx from general practitioner (n=127) 6.48 823
Initial visit: P medicine bought OTC at community pharmacy (n=882) 1.23 1081
Total Initial visit 3422
Follow-up visit: general practitioner follow-up apptmt. (n=122) 16.29 1988
Follow-up visit: community pharmacist follow-up visit (n=44) 0.00 0
Total Follow-up visit 1988
Overall Total General Practitioner Costs (initial & follow-up visits) 5410
Community Pharmacy Money Costs 5 Mean (£) Sum (£)
Initial visit: P medicine on Rx in general practitioner apptmt. (n= 176) 13.49 2374
Initial visit: P medicine on Rpt Rx from general practitioner (n=127) 15.28 1941
Initial visit: P medicine bought OTC at community pharmacy (n=882) 0.45 397
Total Initial visit 4712
Follow-up visit: general practitioner follow-up apptmt. (n=122) 14.77 1506
Follow-up visit: community pharmacist follow-up visit (n=44) 0.45 20
Total Follow-up visit 1526
Overall Total Community Pharmacy Costs (initial & follow-up visits) 6238
NHS Money Costs 6 Mean (£) Sum (£)
Initial visit: P medicine on Rx in general practitioner apptmt. (n=176) 28.25 4972
Initial visit: P medicine on Rpt Rx from general practitioner (n=127) 21.76 2764
Initial visit: P medicine bought OTC at community pharmacy (n=882) 1.68 1478
Total Initial visit 9214
Follow-up visit: general practitioner follow-up apptmt. (n=122) 28.64 3494
Follow-up visit: community pharmacist follow-up visit (n=44) 0.45 20
Total Follow-up visit 3514
Overall Total NHS Costs (initial & follow-up visits) 12728
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1 includes the cost to users associated with: waiting time at the GP surgery; time in consultation with GP; travel time to the
GP surgery; special arrangements made to attend GP appointment; travel time to the pharmacy; waiting time in the
pharmacy; and special arrangements made to visit the pharmacy.
2 includes the cost to users associated with: waiting time at the GP surgery; time in consultation with GP; travel time to the
GP surgery; travel time to the pharmacy; and waiting time in the pharmacy (i.e. user costs, excluding special arrangement
costs).
3 includes the cost to users associated with: payment of prescription fees; payment for prescription exemption certificate;
and prices paid to buy over-the-counter medicines.
4 includes the costs to GPs associated with: time in consultations; signing repeat prescriptions; and administering repeat
prescription services.
5 includes the cost to pharmacists associated with: prescription dispensing; advice giving on prescription medicines, advice
giving on over-the-counter medicines, professional allowances and feels and the net ingredient costs of medicines
prescribed through the NHS.
6 includes the cost to the NHS associated with: general practitioner time; community pharmacy time; and the net ingredient
cost ofmedicines prescribed through the NHS (i.e. is the sum of general practitioner and community pharmacy costs).
Mean monetary valuation of the resources consumed by users accessing P medicine(s)
ranged between £4.88 and £7.17 overall. Mean total costs were lowest among users
accessing their P medicines on repeat prescription from a general practitioner. This is
because time and out-of-pocket money costs to users were typically lower in this access
route compared to attending an appointment with a general practitioner and buying a
medicine direct from a community pharmacist respectively. The monetary valuation of
total resources consumed by users buying their P medicines over-the-counter were very
similar to those accessing them during a general practitioner appointment for users in
both initial and follow-up access routes.
Straight comparison of mean total costs incurred by users accessing P medicines from
general practitioners (whether through appointments or repeat prescription systems)
compared to community pharmacists, revealed significantly higher costs within general
practitioner access routes in both full (n= 1185, p<0.023) and follow-up (n=717,
p<0.003) samples. For a summary of the mean total user money costs (mid-estimates)
across the key samples and associated summary statistics, see table A5.9 in Appendix 5.
Time and travel cost estimates represent the indirect costs met by users. Accessing P
medicines from general practitioners incurred higher time and travel costs (double if
accessed through repeat prescription systems and treble if users actually attended an
appointment with a general practitioner) compared to buying P medicines over-the-
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counter. These differences in mean time and travel costs incurred by users were
statistically significantly (p<0.000, t-test) across all key samples. For a summary of the
mean total time and travel costs (mid-estimate) to users, see table A5.10 in Appendix 5.
Medicine costs represent the main, and usually the only, out-of-pocket expenditure
incurred by users across the various access routes. As such, they can be seen as
representing the monetary cost actually met by users. Buying P medicines over-the-
counter incurred higher medicine costs in both initial and follow-up access routes and
again these differences were statistically significantly (p<0.000). For a summary of the
mean total medicine(s) cost (mid-estimate) met by users and associated summary
statistics, see table A5.11 in Appendix 5.
Resource costs to general practitioners of prescribing P medicines during an
appointment cost more than double that of issuing them through repeat prescriptions and
costs to community pharmacists increased hugely when dispensing P medicines on
prescription compared to selling them over-the-counter.
Overall, the pattern of results reported above were broadly replicated in sensitivity
analyses exploring the impact of both high and low mean user cost estimates, as well as
within the majority of sub-sample groupings (see tables A5.3 - A5.7 in Appendix 5).
In summary, monetary valuation of resources consumed indicates that users accessing P
medicines on prescription from general practitioners (whether in the course of an
appointment or through repeat prescription systems) incurred significantly higher
resource costs overall, compared to users buying their P medicines over-the-counter
from community pharmacies. However, the two main constituent resource cost elements
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consumed by users moved in opposite directions. Time and travel (i.e. indirect) costs
were significantly higher whereas medicine (i.e. direct) costs significantly lower among
users accessing P medicines on prescription compared to those buying them over-the-
counter. While users accessing prescription P medicines faced lower out-of-pocket
monetary costs, the overall value of the resources they consumed in accessing their P
medicine were significantly higher when the opportunity cost of their time was included.
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5.3 User time and resource costs - were any groups
disadvan taged?
Mean user costs might be expected to differ between different groups of people. T -
tests and ANOVA analyses were thus conducted, investigating potential differences
between people with differing: demographic and socio-economic characteristics; self-
reported health status; access to and use of primary care services; and types of
medicines. The results are summarised in tables 5.3 - 5.16 below. These results were
broadly replicated across the follow-up sample (n=717), as well as for time and resource
cost estimates including special arrangement costs (see tables A5.12 - A5.14 in
Appendix 5 for further details. Those results that changed, either moving into or out of
significance are highlighted in bold).
Four main user cost categories were investigated and are reported below: (1) total time
costs; (2) total mean costs; (3) travel and time; and (4) medicine costs.
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TABLE 5.3: USER TIME COSTS BY DEMOGRAPHIC CHARACTERISTICS (N=1185)
Variable N Mean t or P- 95% CI of
(minutes) F value Difference
Lower Upper
Gender
Male 440 21 -.179 .858 -11 10
Female 745 21
Ethnic Group
White 1170 21 .179 .858 -10 18
Non-white 15 27
Age Band
< 16 years 150 22 3.069 .003 19 26
16-19 29 18 12 24
20-29 123 21 17 25
30-39 188 19 16 23
40-49 175 18 15 21
50-59 169 24 15 21
60-69 181 25 21 28
70+ 170 21 22 29
Marital Status
Married 581 20 2.153 .045 19 22
Living with partner 35 20 12 28
Widowed 116 22 19 26
Divorced 72 24 18 30
Separated 22 34 19 48
Single, never married 216 20 17 22
N/A child 143 23 19 26
203
TABLE 5.4: USER RESOURCE COSTS BY DEMOGRAPHIC CHARACTERISTICS (N=1185)
Demographic Cost N Mean T or F P- 95% CI of
Variable Variable (£) value Difference
Lower Upper
Gender
Male Total 440 6.12 -.169 .866 -0.4571 0.3847
Female 745 6.16
Male Time & 440 3.16 .596 .552 -0.23 0.42
Female T ravel 745 3.06
Male 440 2.96 -0.725 .469 -0.50 0.23
Female Medicine 745 3.10
Ethnic Group
White Total 1170 6.13 -1.362 .174 -3.0789 0.5562
Non-white 15 7.38
White Time & 1170 3.08 -1.68 .093 -2.59 0.20
Non-white Travel 15 4.28
White 1170 3.05 -0.081 .935 -1.64 1.51
Non-white Medicine 15 3.11
Age Band
< 16 years 150 5.45 4.839 .000 5.09 5.82
16-19 29 5.89 4.71 7.08
20-29 123 6.58 5.95 7.21
30-39 Total 188 6.52 5.97 7.08
40-49 175 6.52 5.93 7.12
50-59 169 6.95 6.28 7.63
60-69 181 5.78 5.32 6.24
70+ 170 5.24 4.81 5.68
< 16 years 150 3.21 2.843 .006 2.79 3.63
16-19 29 2.67 1.90 3.43
20-29 Time & 123 3.03 2.55 3.51
30-39 Travel 188 2.85 2.42 3.27
40-49 175 2.70 2.33 3.07
50-59 169 2.79 2.41 3.17
60-69 181 3.49 3.09 3.90
70+ 170 3.68 3.21 4.14
< 16 years 150 2.24 16.292 .000 1.96 2.53
16-19 29 3.23 1.87 4.59
20-29 123 3.55 2.96 4.14
30-39 Medicine 188 3.68 3.25 4.11
40-49 175 3.82 3.32 4.32
50-59 169 4.16 3.56 4.77
60-69 181 2.28 1.89 2.68
70+ 170 1.57 1.29 1.84
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Marital Status
Married 581 6.39 4.576 .000 6.08 6.71
Live with partner 35 6.81 5.48 8.14
Widowed 116 5.27 4.73 5.81
Divorced 72 6.24 5.53 6.96
Separated Total 22 8.57 6.22 10.92
Single, never 216 6.00 5.54 6.47
married
N/A child 143 5.45 5.08 5.83
Married 581 3.07 2.284 .034 2.85 3.29
Live with partner 35 2.76 1.81 3.71
Widowed 116 3.20 2.72 3.68
Divorced 72 3.41 2.66 4.15
Separated Time & 22 4.79 2.73 6.86
Single, never Travel 216 2.77 2.42 3.13
married
N/A child 143 3.27 2.83 3.71
Married 581 3.33 5.722 .000 3.05 3.60
Live with partner 35 4.05 2.89 5.20
Widowed 116 2.07 1.59 2.54
Divorced Medicine 72 2.83 2.32 3.35
Separated 22 3.78 2.01 5.55
Single, never 216 3.23 2.83 3.63
married
N/A child 143 2.19 1.90 2.47
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5.3.1 User time and resource costs by demographic characteristics
5.3.1.1 Gender and ethnicity
Time and resource costs faced by users were broadly similar regardless of either gender
or ethnicity. No statistically significant differences existed.
5.3.1.2 Age band
Statistically significant differences in mean user time costs by age band did exist,
although no clear trend emerged. Children (<16 years) and older adults (50+ years)
appeared to incur higher mean time costs.
Trends in both mean total and mean medicine costs mirrored expected patterns. Users in
working age groups (16-59 years) incurred costs either similar to or greater than the
overall sample average; whereas users outwith usual working age ranges (who also
tended to fall within the age groups exempt from prescription charges (i.e. <19 years and
> 60 years) faced lower than average costs. Older users (60+ years) incurred greater
than sample average time and travel costs. Differences in both constituent and total user
costs by age band were statistically significant across the majority of estimates.
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5.3.1.3 Marital status
Statistically significant differences in mean user time costs were identified by marital
status. Divorced or separated users appeared to incur higher mean time costs.
Statistically significant differences also emerged in mean total and constituent money
costs between marital status groups, in both the full and follow-up samples. Clear trends
did not, however, emerge.
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TABLE 5.5: USER TIME COSTS BY SOCIO-ECONOMIC CHARACTERISTICS (N=1185)
Variable N Mean t or P- 95% CI of
(minutes) F value Difference
Lower Upper
Accommodation
Mortgage/loan 481 17 7.541 .000 15 19
Owned outright 301 20 18 22
Local authority 246 28 25 31
Housing association 70 29 23 34
Privately furnished 40 20 12 27
Privately unfurnished 20 23 12 35
From employer 5 14 -4 32
Other, with payment 10 30 9 51
Rent free 12 25 10 40
Deprivation Category*
Affluent (1) 88 17 4.047 .001 13 20
Affluent (2) 205 13 12 15
Average (3) 208 21 18 23
Average (4) 382 20 18 22
Deprived (5) 157 31 27 36
Deprived (6) 3 23 -7 55
Deprived (7) 30 30 23 36
Access to a Car or Van
Yes 843 19 -6.39 .000 -11 -5
No 342 27
Employment Category
Paid work f/t 377 16 7.937 .000 14 17
Paid work p/t 112 19 16 22
Gvmt. training scheme 1 10 N/A N/A
Retired 329 24 22 27
Unemployed 45 31 23 39
Disabled/perm. Sick 52 32 26 38
Caring for home/family 66 21 15 26
F/t education 124 22 18 26
Something else 79 23 18 27
Age Comp eted f/t Education
Still in f/t education 193 21 4.284 .014 18 24
< 18 years 801 22 21 23
> 18 years 191 17 14 20
*Note: categories (l)-(7) refer to the Carstairs deprivation classification applied to
Lothian Health postcodes
208
TABLE 5.6: USER RESOURCE COSTS BY SOCIO-ECONOMIC CHARACTERISTICS (N=1185)
Demographic Cost Variable N Mean t or P- 95% CI of
Variable (£) F value Difference
Lower Upper
Accommodation
Mortgage/loan 481 6.54 1.917 .054 6.19 6.88
Owned 301 5.90 5.51 6.29
outright
Local authority 246 5.82 5.43 6.21
Housing assoc. 70 5.32 4.72 5.92
Privately furn. Total 40 6.60 5.28 7.92
Private unfurn. 20 6.35 4.44 8.26
From employer 5 4.36 1.94 6.78
Other, paid 10 6.52 3.50 9.53
Rent free 12 6.49 4.15 8.83
Mortgage/loan 481 2.69 4.25 .000 2.48 2.90
Owned 301 3.02 2.71 3.33
outright
Local authority 246 3.80 3.42 4.18
Housing assoc. 70 3.71 3.00 4.42
Privately furn. 40 2.77 1.81 3.74
Private unfurn. Time & 20 3.11 1.73 4.49
From employer Travel 5 2.32 -0.58 5.22
Other, paid 10 4.09 1.45 6.73
Rent free 12 3.73 1.21 6.26
Mortgage/loan 481 3.85 3.56 4.14
Owned 301 2.88 2.54 3.22
outright
Local authority 246 2.02 1.69 2.35
Housing assoc. 70 1.61 1.20 2.03
Privately furn. 40 3.83 2.70 4.95
Private unfurn. 20 3.24 1.64 4.85
From employer 5 2.04 -0.36 4.44
Other, paid 10 2.43 0.50 4.35
Rent free 12 2.76 1.73 3.78
209
Demographic Cost Variable N Mean t or F P- 95% CI of
Variable (£) value Difference
Lower Upper
Deprivation Category
Affluent (1) 88 5.95 2.111 .050 5.33 6.58
Affluent (2) 205 5.77 5.30 6.25
Average (3) 208 6.03 5.56 6.50
Average (4) Total 382 6.14 5.77 6.51
Deprived (5) 157 6.76 6.14 7.38
Deprived (6) 3 7.27 -0.70 15.24
Deprived (7) 30 4.67 3.99 5.36
Affluent (1) 88 2.71 12.456 .000 2.18 3.25
Affluent (2) 205 2.08 1.84 2.31
Average (3) 208 3.10 2.76 3.44
Average (4) Time & 382 2.94 2.68 3.20
Deprived (5) Travel 157 4.28 3.77 4.79
Deprived (6) 3 5.47 1.94 8.99
Deprived (7) 30 3.78 2.95 4.61
Affluent (1) 88 3.14 5.181 .000 2.76 3.71
Affluent (2) 205 3.69 3.26 4.13
Average (3) 208 2.93 2.56 3.30
Average (4) Medicine 382 3.20 2.86 3.54
Deprived (5) 157 2.48 1.97 2.98
Deprived (6) 3 1.80 -5.94 9.54
Deprived (7) 30 0.89 0.27 1.51
Access to a Car or Van
Yes Total 843 6.29 2.193 .029 0.05 0.95
No 342 5.79
Yes Time & 843 2.89 -4.13 .000 -1.06 -0.38
No Travel 342 3.61
6.278 .000Yes Medicine 843 3.40 0.84 1.60
No 342 2.18
*Note: categories (1 )-(7) refer to the Carstairs deprivation classification applied to
Lothian Health postcodes
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Demographic Cost Variable N Mean t or F P- 95% CI of
Variable (£) value Difference
Lower Upper
Employment Category
Paid work f/t 377 6.79 4.192 .000 6.36 7.23
Paid work p/t 112 6.13 5.52 6.74
Gvmt. scheme 1 5.45 N/A N/A
Retired 329 5.57 5.22 5.91
Unemployed Total 45 5.71 4.83 6.59
Disabled/sick 52 5.87 5.21 6.52
Care for home 66 7.32 6.25 8.38
F/t education 124 5.64 5.18 6.10
Else 79 5.71 5.11 6.32
Paid work f/t 377 2.44 6.484 .000 2.20 2.68
Paid work p/t 112 2.91 2.47 3.35
Gvmt. scheme 1 1.20 N/A N/A
Retired 329 3.52 3.20 3.84
Unemployed
1 ime t\
' 1 ' yo \ 1
45 4.15 3.15 5.16
Disabled/sick
i ravei
52 4.44 3.69 5.20
Care for home 66 2.99 2.29 3.68
F/t education 124 3.19 2.71 3.67
Else 79 3.18 2.57 3.79
Paid work f/t 377 4.35 3.99 4.71
Paid work p/t 112 3.22
20.634 .000 2.79 3.65
Gvmt. scheme 1 4.25 NA N/A
Retired 329 2.04 1.78 2.31
Unemployed 45 1.56 0.91 2.21
Disabled/sick Medicine 52 1.42 0.86 1.98
Care for home 66 4.33 3.23 5.42
F/t education 124 2.45 2.05 2.85
Else 79 2.53 2.13 2.93
Age Completed f/t Education
Still f/t educ. 193 5.60 3.084 .046 5.24 5.96
< 18 years Total 801 6.20 5.94 6.46
> 18 years 191 6.46 5.93 6.99
Still f/t educ. Time & 193 3.10 4.08 0.17 2.72 3.47
< 18 years Travel 801 3.22 3.02 3.41
> 18 years 191 2.59 2.23 2.94
Still f/t educ. Medicine 193 2.51 10.13 .000 2.21 2.81
< 18 years 801 2.98 2.75 3.21
> 18 years 191 3.87 3.44 4.30
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5.3.2 User time and resource costs by socio-economic characteristics
5.3.2.1 Accommodation
Statistically significant differences emerged in both time and resource costs according to
users' accommodation type, although patterns were difficult to discern. However, users
resident in accommodation rented either from a local authority or housing association
appeared to incur considerably higher mean time costs.
T-tests investigating differences in mean costs between homeowners and renters
indicated that homeowners incurred higher mean total and medicine costs and lower
time and travel costs compared to users who rented their home. These results were
statistically significant.
5.3.2.2 Deprivation category
A monotonic relationship existed between mean user time costs and the levels of
deprivation associated with the area in which users lived. As level of deprivation of the
area within which a user lived increased, so too did their mean time costs to access P
medicines. Differences were statistically significant.
Total mean cost faced by users generally increased alongside level of deprivation of the
area in which they lived. The exception to this was for users resident in the most
deprived areas who incurred lower total mean costs than the overall sample average.
These trends were broadly replicated within the follow-up sample. These, differences
were, however, statistically significant in the full sample only.
A clear trend existed between the deprivation category within which users were resident
and the time and travel costs they incurred. Monotonic relationships existed between
deprivation category and time and travel costs. As deprivation increased, users' time
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and travel costs increased and vice versa. These differences were significant in both the
full and follow-up samples.
A statistically significant inverse relationship existed between mean medicine costs
faced by users and level of deprivation of the area in which they lived. As deprivation
level decreased, mean medicine costs increased and vice versa.
5.3.2.3 Access to a car or van
Users without access to a car or van incurred significantly higher time costs.
Users with access to a car or van incurred higher mean total and mean medicine costs.
However, the opposite result occurred regarding time and travel costs; users with access
to a car or van faced lower time and travel costs than those without access to a car or
van. Identified differences were statistically significant for all estimates and samples,
except one (mean total costs in the follow-up sample).
5.3.2.4 Employment category
Statistically significant differences in user time costs were also evident, contingent upon
users' employment category. Unemployed and disabled or permanently sick users
incurred higher mean time costs.
Mean total and medicine costs appeared higher for users in full-time paid work and for
those caring for a home or family and lower among the retired, unemployed and disabled
users. However, the opposite trend occurred concerning user time and travel costs.
Users in full-time paid work incurred lower than sample average travel and time costs;
whereas the retired, unemployed and disabled users incurred higher than average time
and travel costs. Again, identified differences were statistically significant across all
samples.
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5.3.2.5 Level of full-time education
Users who completed their full time education at over 18 years of age incurred lower
mean time costs compared to other groups. Differences between groups were
statistically significant.
Mean total and medicine costs were lower than the overall sample average for users still
in full-time education; approximately equal to the sample average for users who
completed their full-time education at <18yrs; and greater than the sample average for
users who completed their full-time education at >18 years.
Trends in user travel and time costs differed to those for mean total and medicine costs.
Users still in full-time education incurred travel and time costs close to the overall
sample average; whereas those users who completed their full time education at <18
years incurred higher than average travel and time costs; compared to users completing
their full-time education at >18 years. These differences were statistically significant for
all estimates and samples, except one (mean total costs in the follow-up sample).
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TABLE 5.7: USER TIME COSTS BY SELF-REPORTED HEALTH STATUS (N=1185)




Very good 290 17 16.407 .000 15 19
Good 595 20 18 21
Fair 253 26 23 28
Bad 36 42 31 53
Very bad 11 33 17 49
Longstanding Illness
Yes 436 26 5.967 .000 5 10
No 749 18
TABLE 5.8: USER RESOURCE COSTS BY SELF-REPORTED HEALTH STATUS (N=1185)




Very good 290 6.00 2.038 .087 5.64 6.37
Good 595 6.12 5.84 6.40
Fair Total 253 6.16 5.67 6.65
Bad 36 7.72 6.24 9.21
Very bad 11 5.35 2.90 7.80
Very good 290 2.65 14.631 .000 2.36 2.93
Good 595 2.88 2.68 3.08
Fair Time & Travel 253 3.71 3.33 4.09
Bad 36 5.51 4.15 6.87
Very bad 11 4.73 2.15 7.30
Very good 290 3.36 3.410 .009 3.06 3.65
Good 595 3.24 2.99 3.50
Fair Medicine 253 2.45 2.04 2.86
Bad 36 2.22 0.98 3.45
Very bad 11 0.62 -0.13 1.38
longstanding Illness
Yes Total 436 5.93 -1.556 .120 -0.76 0.09
No 749 6.27
Yes Time &Travel 436 3.71 5.98 .000 0.65 1.29
No 749 2.74
Yes Medicine 436 2.22 -6.001 .000 -1.89 -0.96
No 749 3.53
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5.3.3 User time and resource costs by self-reported health status
5.3.3.1 General health status
A statistically significant inverse relationship existed between self-reported general
health status and mean user time costs. As users' self-reported general health status
decreased, mean user time costs increased.
No statistically significant differences in user total mean costs were identified according
to user self-reported general health status in either the full or follow-up samples.
Statistically significant differences were, however, identified in constituent time and
travel and medicine costs.
Users reporting very good or good health incurred lower, whereas users reporting either
fair or bad to very bad general health incurred higher travel and time costs. Mean
medicine costs moved in the opposite direction. Users reporting either very good or
good health status incurred higher medicine costs than those reporting bad to very bad
general health. This general trend was replicated in the follow-up sample, however, the
differences were not statistically significant.
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5.3.3.2 Presence of a longstanding illness
Users reporting the presence of a longstanding illness incurred significantly higher mean
time costs than those who did not.
Users reporting no longstanding illness incurred higher mean total costs, although these
differences were not statistically significant. Statistically significant differences did,
however, exist in travel and time and medicine costs and moved in opposite directions.
Users with longstanding illnesses incurred higher mean travel and time costs but lower
mean medicine costs compared to users without a longstanding illness.
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TABLE 5.9: USER TIME COSTS BY USE OF GENERAL PRACTICE AND COMMUNITY PHARMACY
SERVICES (N=1185)
Variable N Mean t or F P- 95% CI of
(minutes) value Difference
Lower Upper
No. of General Practitioner Consultaltion in the Last Year
Not at all 124 12 18.883 .000 10-14 14
Once or twice 503 19 17-21 21
3-5 times 291 22 19-24 24
6-10 times 188 27 24-31 31
> 10 times 79 33 28-39 39
No. of Community Pharmacy Consultation in t le Last Year
Not at all 264 32 29.442 .000 29 36
Once or twice 313 21 19 23
3-5 times 443 16 15 17
6-10 times 149 17 14 20
> 10 times 16 17 10 25
Use the Same Community Pharmacy Regularly
Yes 1023 22 2.338 .020 1 8
No 162 18
Regular Prescription Medicines
Yes 572 25 5.983 .000 5 10
No 613 18
2 I 8
TABLE 5.10: USER RESOURCE COSTS BY USE OF GENERAL PRACTICE AND COMMUNITY
PHARMACY SERVICES (N=1185)
Variable Cost Variable N Mean t or F P- 95% CI of Difference
(£) value Lower Upper
No. Of General Practitioner Consultation in the Last Year
Not at all Total 124 5.79 .661 .619 5.18 6.40
Once or twice 503 6.24 5.92 6.55
3-5 times 291 6.08 5.70 6.46
6-10 times 188 6.34 5.74 6.93
> 10 times 79 5.88 5.22 6.54
Not at all Time & Travel 124 1.94 17.069 .000 1.64 2.24
Once or twice 503 2.84 2.61 3.06
3-5 times 291 3.15 2.82 3.47
6-10 times 188 3.82 3.38 4.25
> 10 times 79 4.65 3.93 5.37
Not at all Medicine 124 3.85 12.508 .000 3.28 4.43
Once or twice 503 3.40 3.14 3.66
3-5 times 291 2.93 2.59 3.27
6-10 times 188 2.51 2.02 3.02
> 10 times 79 1.23 0.81 1.66
No. of Community Pharmacy Consultation in the Last Year
Not at all Total 264 6.50 1.101 .355 6.02 6.98
Once or twice 313 6.05 5.67 6.43
3-5 times 443 5.95 5.65 6.26
6-10 times 149 6.21 5.57 6.85
> 10 times 16 6.58 4.29 8.86
Not at all Time & Travel 264 5.66 24.125 .000 4.02 4.87
Once or twice 313 3.91 2.74 3.34
3-5 times 443 3.25 2.32 2.69
6-10 times 149 3.35 2.18 3.01
> 10 times 16 3.83 1.86 3.96
Not at all Medicine 264 2.06 10.462 .000 1.69 2.42
Once or twice 313 3.01 2.69 3.34
3-5 times 443 3.45 3.18 3.72
6-10 times 149 3.62 3.05 4.18
> 10 times 16 3.67 1.25 6.10
Use the Same Community Pharmacy Rej'ularly
Yes Total 1023 6.11 -.793 .428 -0.83 0.35
No 162 6.35
Yes Time & Travel 1023 3.16 2.063 .039 0.02 0.93
No 162 2.68
Yes Medicine 1023 2.95 -2.757 .006 -1.23 -0.21
No 162 3.66
Regular Prescription Medicines
Yes Total 572 6.10 -.444 .657 -0.50 0.31
No 613 6.18
Yes Time & Travel 572 3.58 6.013 .000 0.64 1.25
No 613 2.64
Yes Medicine 572 2.51 -5.864 .000 -1.38 -0.69
No 613 3.55
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5.3.4 Time and resource costs by use of general practice and community
pharmacy services
5.3.4.1 Number of general practice consultations
A statistically significant monotonic relationship existed between mean user time costs
and the number of visits to the general practitioner in the last year. As the number of
general practitioner consultations increased, so too did mean user time costs.
No statistically significant differences existed between total mean user costs and the
number of general practitioner consultations attended by users in the last year, in either
the full or follow-up samples. Significant differences were, however, identified in mean
time and travel. Infrequent general practitioner attenders (0-2 visits) incurred lower, and
frequent attenders (6+ visits) higher, time and travel costs than the overall sample
average.
Mean medicine costs were also significantly different between infrequent and frequent
general practitioner attenders. Again, they moved in the opposite direction to time and
travel costs. Frequent general practitioner attenders incurred lower and infrequent
general practitioner attenders higher mean medicine costs than the overall sample
average.
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5.3.4.2 Number of community pharmacist consultations
Users who had not consulted a community pharmacist in the last year faced significantly
higher mean time costs compared to those that had.
No statistically significant differences were identified in total mean user costs and the
number of visits made by users to community pharmacists in the last year.
Statistically significant differences did exist in mean time and travel and medicine costs
in both full and follow-up samples. Users who had not consulted the community
pharmacist at all in the last year incurred higher than average mean time and travel costs,
compared to users who had consulted the community pharmacist more often. Again
mean medicine costs moved in the opposite direction, in that they were lower among
users who had never consulted the community pharmacist, compared to those that had
consulted the community pharmacist more frequently.
5.3.4.3 Use of the same community pharmacist regularly
Users who visited the same community pharmacist regularly incurred significantly
higher mean time costs compared to those that did not.
No statistically significant differences existed in the total mean user costs incurred by
users depending on whether they used the same community pharmacist regularly or not.
Users who used the same community pharmacist regularly incurred significantly higher
mean time and travel costs (full sample only). Whereas, mean medicine costs were
significantly higher among users who did not use the same community pharmacist
regularly, in both full and follow-up samples.
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5.3.4.4 Receipt of regular prescription medicines
Users in receipt of regular prescription medicines incurred significantly higher mean
time costs compared to those not in receipt of regular prescription medicines.
No statistically significant differences were identified in total mean user costs contingent
upon whether users were in receipt of regular prescription medicines.
Mean travel and time costs were significantly higher for users in receipt of regular
prescription medicines. In contrast, mean medicine costs were significantly higher for
users not in receipt of regular prescription medicines. These results held in both full and
follow-up samples.
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TABLE 5.11: USER TIME COSTS BY ACCESS TO GENERAL PRACTICE AND COMMUNITY
PHARMACY SERVICES (N=1185)
Variable N Mean t or P- 95% CI of
(minutes) F value Difference
Lower Upper
Usual Wait to See General 'ractitioner
Same day 233 22 1.661 .127 20 24
Following day 172 20 16 23
2 days 196 23 20 27
3-5 days 237 21 18 24
l week 262 20 17 22
1 -2 weeks 74 25 19 31
> 2 weeks 11 11 5 18
Distance to General Practitioner Surgery
Under a mile 541 24 4.303 .002 22 26
1-2 miles 515 19 17 20
3-4 miles 89 21 17 26
5-10 miles 34 17 11 23
> 10 miles 6 22 -13 57
Distance to Community Pharmacy
Under a mile 763 21 .308 .873 0 130
1-2 miles 337 21 5 100
3-4 miles 60 22 5 100
5-10 miles 20 21 5 75
> 10 miles 5 30 10 90
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TABLE 5.12: USER RESOURCE COSTS BY ACCESS TO GENERAL PRACTICE AND COMMUNITY
PHARMACY SERVICES (N=1185)
Variable Cost Variable N Mean t or P- 95% CI of
(£) F value Difference
Lower Upper
Usual Wait to See General Practitioner
Same day 233 5.64 3.056 .006 5.30 5.98
Following day 172 6.16 5.62 6.71
2 days 196 6.26 5.78 6.75
3-5 days 237 6.87 6.32 7.42
l week Total 262 5.89 5.46 6.33
1 -2 weeks 74 6.15 5.32 6.99
> 2 weeks 11 4.54 3.00 6.09
Same day 233 3.11 1.47 .185 2.78 3.43
Following day 172 2.85 2.46 3.25
2 days 196 3.45 3.02 3.88
3-5 days 237 3.08 2.71 3.45
1 week Time & Travel 262 2.95 2.66 3.23
1 -2 weeks 74 3.44 2.63 4.25
> 2 weeks 11 1.87 0.75 2.99
Same day 233 2.54 3.993 .001 2.24 2.83
Following day 172 3.31 2.83 3.79
2 days 196 2.81 2.43 3.20
3-5 days 237 3.78 3.31 4.26
1 week Medicine 262 2.95 2.56 3.34
1 -2 weeks 74 2.71 2.06 3.36
> 2 weeks 11 2.67 1.51 3.84
Distance to General Practice Surgery
Under a mile 541 6.14 .616 .651 5.83 6.44
1-2 miles 515 6.04 5.75 6.32
3-4 miles 89 6.58 5.58 7.59
5-10 miles Total 34 6.46 5.34 7.59
> 10 miles 6 7.07 2.46 11.67
Under a mile 541 3.31 2.131 .075 3.07 3.55
1-2 miles 515 2.84 2.62 3.07
3-4 miles 89 3.30 2.66 3.95
5-10 miles Time & Travel 34 2.87 2.00 3.73
> 10 miles 6 3.53 -1.12 8.19
Under a mile 541 2.83 1.408 .229 2.55 3.10
1-2 miles 515 3.19 2.95 3.44
3-4 miles 89 3.28 2.55 4.00
5-10 miles Medicine 34 3.60 2.61 4.58
> 10 miles 6 3.54 1.83 5.25
Distance to Community Pharmacy
Under a mile 763 5.89 3.092 .015 5.64 6.13
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1-2 miles 337 6.63 6.23 7.03
3-4 miles 60 6.71 5.60 7.82
5-10 miles Total 20 5.81 4.58 7.03
> 10 miles 5 7.08 1.75 12.40
Under a mile 763 2.97 1.311 .264 2.78 3.17
1-2 miles 337 3.27 2.98 3.56
3-4 miles 60 3.52 2.83 4.22
5-10 miles Time & Travel 20 3.41 2.28 4.53
> 10 miles 5 4.07 -1.21 9.35
Under a mile 763 2.91 1.482 .205 2.70 3.13
1-2 miles 337 3.36 3.01 3.71
3-4 miles 60 3.19 2.34 4.03
5-10 miles Medicine 20 2.40 1.74 3.06
> 10 miles 5 3.00 1.73 4.28
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5.3.5 User time and resource costs by access to general practice and
community pharmacy services
5.3.5.1 Usual wait to see the general practitioner
There were no statistically significant differences in mean user time costs and usual wait
to see a general practitioner.
Significant differences in total mean user costs existed depending on how long users
usually waited to see the general practitioner. However, the trends in the data were not
clear.
5.3.5.2 Distance to the general practitioner
Statistically significant differences did emerge in mean user time costs and distance to
the general practitioner, although no clear trend emerged.
No statistically significant difference existed in user travel and time costs and the
distance to the users general practitioner surgery.
5.3.5.3 Distance to the community pharmacist
There were no statistically significant differences in mean user time costs and distance to
the community pharmacist.
Significant differences in total mean user costs were identified according to the distance
users travelled to the community pharmacist. Users travelling over a mile to their local
community pharmacist incurred higher total mean costs overall. However, no
statistically significant differences were identified in either mean travel and time or
medicine costs by distance to the community pharmacist.
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TABLE 5.13: USER TIME COSTS BY COST OF MEDICINES (N=1185)
Variable N Mean t or P- 95% CI of
(minutes) F value Difference
Lower Upper
Exempt from Prescription Charge
Yes 679 26 -9.37 .000 -13 -9
No 506 15
Put Off by Cost of Medicines
Yes 187 30 6.305 .000 7 14
No 998 19
TABLE 5.14: USER RESOURCE COSTS BY COST OF MEDICINES N=1185)
Variable Cost Variable N Mean
(f)
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-2.504 .012 -1.10 -0.13
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5.3.6 Time and resource costs by cost of medicines
5.3.6.1 Exemption from prescription charges
Users exempt from prescription charges incurred significantly higher mean time costs.
Mean total and medicine costs were significantly higher for users who were eligible to
pay for prescription medicines. Whereas, travel and time costs were significantly higher
for users who were exempt from paying prescription charges.
5.3.6.2 Put off obtaining medicines due to their cost
Users who reported having been put off obtaining medicines in the past because of their
cost exhibited significantly higher mean time costs.
Total mean user costs were higher among users who reported having been put off
obtaining medicines in the past, in both the full and follow-up samples. However, these
differences in mean costs between the groups were not statistically significant.
Significantly higher time and travel costs were identified among users who reported
having been put off accessing medicines in the past due to their cost in both the full and
follow-up samples.
Mean medicine costs were significantly higher among users who reported never having
been put off obtaining medicines due to their cost (full sample only).
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TABLE 5.15: USER TIME COSTS BY TYPE OF MEDICINES (N=1185)
Variable N Mean t or P- 95% CI of
(minutes) F value Difference
Lower Upper
Deregulated (POM to P)
Yes 492 20 - .349 -4 1
No 693 22 .937
NHS Blacklisted
Yes 512 16 - .000 -12 17
No 673 25 7.87
TABLE 5.16: USER RESOURCE COSTS BY TYPE OF MEDICINES (N=1185)
Variable Cost Variable N Mean tor P- 95% CI of
(£) F value Difference
Lower Upper
Deregulated (PO VI to P)
Yes Total 492 6.97 6.846 .000 1.01 1.82
No 693 5.56
Yes Time & Travel 492 3.03 - .486 -0.43 0.20
No 693 3.14 0.697
Yes Medicine 492 3.94 8.64 .000 1.18 1.87
No 693 2.41
NHS Blacklisted
Yes Total 512 5.75 - .001 -1.10 -0.28
No 673 6.44 3.307
Yes Time & Travel 512 2.45 - .000 -1.45 -0.83
No 673 3.59 7.237
Yes Medicine 512 3.30 2.500 .013 0.10 0.81
No 673 2.85
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5.3.7 User time and resource costs by type of medicines
5.3.7.1 Deregulated medicines
User time costs were not significantly impacted depending on whether users were
accessing a deregulated medicine (switched from POM to P status) or a regular P class
medicine.
However, statistically significant differences emerged in mean total and medicine costs
incurred by users, depending on the type of P medicine obtained, in both full and follow-
up samples. Users accessing a P medicine recently deregulated from POM (prescription
only medicine) to P (pharmacy available) status incurred significantly higher total mean
costs than those who were accessing medicines available over-the-counter for some
time.
There were no statistically significant differences in mean travel and time costs to users
according to the deregulated status of the P medicine accessed.
5.3.7.2 NHS blacklisted medicines
Users accessing P medicine(s) blacklisted from the NHS prescribing list, incurred
significantly lower mean time costs.
Users obtaining medicines blacklisted from the NHS prescribing list incurred
significantly lower mean total and travel and time costs than users who obtained non-
blacklisted P medicines. Mean medicine costs faced by users obtaining NHS blacklisted
medicines were, however, higher (although this difference was significant in the full
sample only).
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5.4 Average time and resource costs accruing to stakeholders
across various access routes
Tables 5.17 and 5.18 below focus on the sample for which there is follow-up data
(n=718) and summarise the actual (average) time and resource costs accruing to
stakeholders across varied access routes, including both initial and follow-up visits (if
any).
TABLE 5.17: ACTUAL (AVERAGE) TIME COSTS (MINUTES) ACCRUING TO STAKEHOLDERS
ACROSS VARIED ACCESS ROUTES (N=718)
User access route N User General Community Total
Initial Follow-up Time Practitioner Pharmacy Time
Visit Visit Cost Time Cost Time Cost Cost
CP None 418 13 0 1 14
CP CP 39 33 0 2 35
GP None 134 40 9 4 53
GP CP 5 57 8 5 70
CP GP 76 76 14 5 95
GP GP 46 120 22 8 150
TABLE 5.18: ACTUAL (AVERAGE) RESOURCE COSTS (£) ACCRUING TO STAKEHOLDERS
ACROSS VARIED ACCESS ROUTES (N=718)
User access route N User General Community Total
Initial Follow-up Cost Practitioner Pharmacy Cost
Visit Visit Cost Cost
CP None 418 5.77 0.00 0.45 6.22
CP CP 39 14.69 0.00 1.19 15.88
GP None 134 6.49 11.12 14.35 31.96
GP CP 5 12.60 10.00 9.49 32.09
CP GP 76 17.93 17.60 12.57 48.10
GP GP 46 17.51 27.48 28.20 73.19
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Total average time and resource costs associated with accessing P class medicines are
generally lower to all concerned when users visited a community pharmacy first to
access P medicines (14 to 95 minutes and £6.22 to £48.10). As soon as the general
practitioner is involved, both time and resource costs go up appreciably (53 to 150
minutes and £31.96 to £73.19). (For a summary of low and high resource cost estimates,
see table A5.16 in Appendix 5).
Total mean time and resource costs were broadly similar for estimates of complete
access routes i.e. including both initial and follow-up costs as they were for estimates of
the individual initial and follow-up (if any) visits accruing to stakeholders. More detailed
time and resource cost estimates (alongside summary statistics) for the complete access
routes are presented in tables A5.15 and A5.17 respectively in Appendix 5.
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5.5 Proportional time and resource costs incurred by
stakeholders across varied access routes
It is useful to consider the burden of total time and resource costs incurred by
stakeholder groups across different access routes and how they might change in the
event of changes in policy. Tables 5.19 and 5.20 break down the proportion of total time
and resource costs incurred by stakeholder groups. Tables A5.18 to A5.23 in Appendix 5
present the proportional breakdown of time and resource costs, both including and
excluding user special arrangement costs, alongside more detail concerning the
proportions of total time and resource costs by key constituent elements.
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TABLE 5.19: PROPORTIONAL TIME COSTS (MINUTES) ACCRUING TO STAKEHOLDERS ACROSS
VARIED ACCESS ROUTES
Initial & Follow-Up Visits














First Visit: P medicine on Rx in General Practitioner Appointment (n=176)




First Visit: P Medicine on Repeat Rx from General Practitioner (n=127)




First Visit: P Medicine Bought OTC at Community Pharmacy (n=882)




Follow-up Visit: General Practitioner Appointment (n=122)




Follow-up Visit: Community Pharmacy (n=44)





TABLE 5.20: PROPORTIONAL RESOURCE COSTS (£) ACCRUING TO STAKEHOLDERS ACROSS
VARIED ACCESS ROUTES
Initial & Follow-Up Visits














First Visit: P Medicine on Rx in General Practitioner Appointment (n=176)




First Visit: P Medicine on Repeat Rx from General Practitioner (n=127)




First Visit: P Medicine Bought OTC at Community Pharmacy (n=882)




Follow-Visit: General Practitioner Appointment (n=122)




Follow-Up Visit: Community Pharmacy Consultation (n=44)





5.5.1 Proportion of total time and resource costs incurred by stakeholders
across varied access routes
Users incurred the vast majority of time costs, bearing over four-fifths (81-84%) of the
total time costs associated with accessing P medicines in initial and follow-up access
routes. By comparison, general practitioners contributed between 9-15% of total time
expended and community pharmacists 4-7%.
Resource costs were more evenly distributed between stakeholders. Users absorbed
between around a quarter to a half (23-46%) of total resource costs; general practitioners
between a quarter and two-fifths (23-43%); and community pharmacists around a third
(31-33%) overall.
These trends in the proportional breakdown of total stakeholder time and resource costs
were broadly replicated both in estimates including users special arrangement costs and
when aggregated across both initial and follow-up access routes (see tables A5.18 and
A5.20 in Appendix 5).
These proportions differed, depending on whether user access routes involved general
practitioners or community pharmacists primarily. Users incurred the vast majority of
both time and resource costs, 93-94%, in routes involving a community pharmacist
primarily, compared to between 76-80% of time and 18% of resource costs in access
routes involving mainly a general practitioner.
Clearly, access routes involving user visits to a general practitioner accounted for total
general practitioner time costs (9-15%). General practitioner resource costs translated
into between just under a quarter (24%) of total resource costs when P medicines were
obtained through repeat prescription mechanisms, to just under a half (43-47%) when
they were obtained within a general practitioner appointment.
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The proportion of total time costs consumed by community pharmacist activities were
broadly similar across different access routes, ranging between 5-10% of total time costs
in those primarily with the general practitioner, compared to 6-7% in consultation
primarily with the community pharmacist. The proportion of total resource costs
incurred by community pharmacists ranged from around a third (35-39%) if the
prescription was obtained in a recent general practitioner appointment to approximately
three-fifths (57%) if obtained through repeat prescription systems. The proportion of
total costs incurred by community pharmacists in over-the-counter sales was very small
in comparison, at between 6-7% only.
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5.5.2 Proportional breakdown of total costs across stakeholders by
constituent elements
Because of the amount of data, the proportion of total time and resource costs incurred
by users, broken down by the constituent elements of their varied access routes to P
medicines (both including and excluding special arrangement time costs) are
summarised in tables A5.19 and A5.21 in Appendix 5. The following summarises key
findings regarding how stakeholder time was expended across the different access
routes. Waiting times were the most important factor differentiating user time costs.
They were between two to four times greater for users accessing medicines on
prescription from a general practitioner, compared to users buying them over-the-
counter from a community pharmacy.
5.5.2.1 Key cost drivers
The proportion of total resource costs incurred by users, general practitioners and
community pharmacists, broken down by the main constituent elements of varied access
routes to P medicines are summarised in table A5.21 - A5.23 in Appendix 5.
Users
Waiting and travel time accounted for approximately two-thirds (57-69%) of total costs
accruing to users accessing their P medicine on prescription; compared to only a quarter
(26-28%) of total costs to users who bought their P medicine over-the-counter at a
community pharmacy.
Time spent consulting professionals represented 14-18% of total costs among those who
attended a general practitioner appointment; compared to between only 0-2% of total
costs faced by community pharmacy users.
Travel costs comprised a greater share of total user costs among those visiting the
general practitioner (8-19%) compared to those visiting the community pharmacy.
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Travel costs among users accessing P medicines through repeat prescription mechanisms
were double those associated with other access routes.
Medicine costs represented between a tenth to a quarter (11-23%) of total user costs in
access routes involving a general practitioner; compared to around two-thirds (64-67%)
in community pharmacy access routes.
In summary, the drivers of total user cost depended on the access route adopted. Where
P medicines were accessed on prescription from a general practitioner, the key drivers of
user costs were travel and waiting time; whereas medicine cost was the most significant
cost element among users buying P medicines from a community pharmacy.
General practitioners
General practitioner time consumed between 52 - 68% of total general practitioner costs
where users actually had an appointment with the general practitioner. When P
medicine(s) were obtained on a repeat prescription, general practitioner time costs
associated with administering and signing repeat prescriptions accounted for between
nearly a third (29%) and a half (45%) of total general practitioner costs.
Net ingredient cost (NIC) of medicines constituted between approximately a third (32%)
and a half (48%) of total general practitioner costs when medicines were obtained during
an appointment. Medicines obtained on repeat prescriptions cost between just over half
(55%) and nearly three quarters (71%) of total general practitioner costs.
In summary, general practitioner time was the key driver of total general practitioner
costs within appointments, whereas the cost of medicines were the main cost driver
within repeat prescription access routes.
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Community pharmacy
When P medicines were obtained by users on prescription, time spent dispensing
prescriptions accounted for between a fifth (19%) and a half (51%) of total costs to
community pharmacists.
Time spent by community pharmacists giving advice on P medicines obtained on
prescription constituted a negligible proportion of total cost to community pharmacists,
ranging between 1% and 4%. On-cost allowances paid to community pharmacists
represent between a quarter (28%) and half (50%) of the total costs to community
pharmacy and dispensing fees between approximately a fifth (18%) and a third (30%).
Where users bought P medicines over-the-counter, 100% of costs to the community
pharmacist were associated with giving advice on over-the-counter medicines
purchased.
In summary, there were three key drivers of total community pharmacist costs -
community pharmacist time, on-cost allowances and dispensing fee payments. Time
spent by the community pharmacist giving advice was the exclusive driver of costs in
over-the-counter sales. Time costs constituted a substantial proportion of total costs to
community pharmacy when P medicines were obtained through prescription routes,
specifically dispensing time. On-cost allowances and dispensing fees paid to
community pharmacists were also major drivers of total costs to community pharmacy.
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5.6 Consumer surplus analyses
5.6.1 Who wins or loses by switching access routes?
Consumers' surplus analysis investigates the net consumption benefits (or costs)
resulting if users switched their chosen access route to the alternate one available (e.g. if
those users who visited a general practitioner to access their P medicine on prescription
had, instead, visited the community pharmacy and bought their medicine over-the-
counter, and vice-versa). It considers the impact of any changes in time and resource
costs faced by users, and at the same time, it elucidates the changing distribution of costs
across stakeholders, identifying the 'winners' and 'losers' among stakeholders as a result
of such switches.
Changing time and resource costs accruing to stakeholders were estimated by applying
actual and modelled cost estimates (sensitised at the individual level to account for
factors affecting process e.g. prescription exemption status) to work out the differences
in costs resulting had users chosen to adopt the alternate access route available to them.
Change in stakeholder time and resource costs were, therefore, calculated as the
difference between the time and resource costs actually incurred associated with the
access route adopted by users minus the average time and resource costs to stakeholders
associated with the alternate access route.
Summary results of the consumer surplus analyses are presented in tables 5.21 and 5.22
below. A table outlining low and high modelled resource cost estimates is presented in
table A5.24 in Appendix 5.
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TABLE 5.21: MODELLED TIME SAVINGS ACCRUING TO STAKEHOLDERS WHEN USERS
SWITCHED THEIR INITIAL ACCESS ROUTE TO THE ALTERNATE ONE
Time savings: switching from general practice to community pharmacy access
routes (n=303)
Stakeholder/ Total time saving Ave. time saving per user
Perspective (hours) (minutes)
User 162 32
General practitioner 45 9
Community pharmacist 14 3
Society 221 44
Time costs: switching from community pharmacy to general practice access routes
(n=882)
Stakeholder/ Total time cost Ave. time cost per user
Perspective (hours) (minutes)
User -310 -21
General practitioner -132 -9
Community pharmacist -41 o-J
Society -483 -33
The costs calculated for general practice access routes were derived from a proportional combination of those associated with
accessing P medicines during a GP appointment and those associated with obtaining a repeat prescription via a GP.
TABLE 5.22: MODELLED RESOURCE SAVINGS ACCRUING TO STAKEHOLDERS WHEN USERS
SWITCHED THEIR INITIAL ACCESS ROUTE TO THE ALTERNATE ONE
Resource savings: switching from general practice to community pharmacy access
routes (n=303)
Stakeholder/ Total resource savings Ave. resource saving/user
Perspective (£) (£)
User 18 0.06
General practitioner 3422 11.29
Community pharmacist 4179 13.79
Society 7619 25.14
Resource savings: switching from community pharmacy to general practice access
routes (n=882)
Stakeholder/ Total resource costs Ave. resource cost/user
Perspective (£) (£)
User -2888 -3.27
General practitioner -9371 -10.62
Community pharmacist -12291 -13.94
Society -24550 -27.83
The costs calculated for general practice access routes were derived from a proportional combination of those associated with
accessing P medicines during a GP appointment and those associated with obtaining a repeat prescription via a GP.
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Had all users who obtained their P medicine on prescription from a general practitioner
(N=303) gone to the community pharmacy first instead, this would have this would have
saved them an average of 32 minutes each and a total of 162 hours (124 hours attending
appointments and 38 hours obtaining repeat prescriptions). This translated into average
and total user resource savings of £0.06 each and £18 respectively. Further, 45 hours
and £3422 of general practitioner time and resources would have been saved
(representing between 270-386 general practitioner consultation slots of between 7-10
minutes) and 14 hours and £4179 of community pharmacist time and resources. Total
saving in societal time and resource costs as a result of this switch would be 221 hours
and £7619.
Reorientation of demand and consultation patterns associated with the general
practitioner to community pharmacist switches outlined above would engender a win-
win situation, with stakeholder groups (and perspectives) benefiting overall as a result of
reduced average time and resource costs. However, resource savings from this switch
swing heavily towards the health sector, with users only very marginally better off, on
average.
The vast majority of users 96% (292/303) within the sample who obtained a prescription
for their P medicine from a general practitioner, would have been winners, facing lower
time costs had they switched their access route and visited the community pharmacist
instead to buy their P medicine over-the-counter; for 3% (9/303) users there was no
difference in time cost to them between the two alternate access routes; and 1% (2/303)
of users would have been worse off incurring higher time costs if they had switched.
In contrast, however, the majority of users 55% within the sample who adopted a
general practitioner first access route would have been financial losers, facing higher
money costs had they switched their initial access route and visited the community
pharmacist instead to buy their P medicine over-the-counter.
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The health sector would also have benefited from the switch, with 59 hours of
professional time and £7601 of resources freed for alternate uses (45 hours of general
practitioner time and £3422 of resources and 14 hours of community pharmacist time
and £4179 of resources).
For every 1000 users buying P medicines from the community pharmacy as opposed to
obtaining them on prescription from general practitioners, 533 hours of user time and
£60 of resources, 200 hours of health sector time and £25080 of resources - 150 hours
and £11290 of general practitioner time and resources (representing between 900-1286
general practitioner consultation slots) and 50 hours and £13790 of community
pharmacist time and resources - and 733 hours and £25140 of societal time and
resources would be saved overall.
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Had those users who visited the community pharmacy first (n=882) attended a general
practitioner appointment instead, this would have cost them an extra 21 minutes on
average and a total of 310 hours. This translated into extra average and total user
resource costs of £3.27 each and £2888 respectively. Further, an additional 132 hours
and £9371of general practitioner time and resources (representing between 792-1131
general practitioner consultation slots) and 41 hours and £12291 of community
pharmacist time and resources would have been required to deal with these users
accessing P medicines via prescription routes. Total additional costs incurred by society
as a result of this switch would be 483 hours and £24550.
Reorientation of demand and consultation patterns associated with the community
pharmacist to general practitioner switch outlined above would engender a lose-lose
situation, with stakeholder groups (and perspectives) losing out overall, as a result of
increased average time and resource costs.
The vast majority of users 92% (815/882) within the sample who bought their P
medicine over-the-counter at a community pharmacy would have been losers, incurring
extra time costs, had they switched their access route and visited the general practitioner
instead to obtain a prescription for their P medicine; for 1% of users (9/882) there was
no difference in time cost to them between the alternate routes; however, 7% of users
(58/882) would have saved time had they accessed their P medicine on prescription
obtained from a general practitioner.
The vast majority of users 83% within the sample who adopted a community pharmacy
first access route, buying their P medicine over-the-counter at a community pharmacist,
would have been losers, incurring extra costs, had they switched their access route and
visited the general practitioner instead to obtain a prescription for their P medicine.
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The health sector would also have incurred extra costs as a result of such a switch, with
an additional 173 hours and £21662 of professional time and resources required to meet
the demand for P medicines on prescription (132 and £9371 hours of general practitioner
time and resources and 41 hours and £12291 of community pharmacist time and
resources).
For every 1000 users accessing P medicines from general practitioners as opposed to
from community pharmacies, 350 extra hours and £3270 of user time and resources and
200 extra hours and £24560 of health sector time and resources - 150 hours and £10620
of general practitioner time and resources (representing between 900-1286 general
practitioner consultation slots) and 50 hours and £13940 of community pharmacist time
and resources - and 550 extra hours and £27830 of societal time and resource costs
would have been incurred.
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5.7 Time and resource cost implications of changes to policy on
accessing to P medicines
The next stage of the analyses was to undertake simple modelling exercises, comparing
the impact on net benefits to stakeholders (and perspectives) resulting from a range of
potential changes in policy in relation to access to and provision of P class medicines.
Included are: the resource consequences of status quo arrangements and the effect on
resources if users switched the route through which they access P medicines; costs of
accessing P medicines from general practitioners exclusively; making P class medicines
accessed routinely via repeat prescription mechanisms available from community
pharmacies direct (with a sub-scenario investigating the implication of paying
community pharmacists a fee for providing this service); and making P class medicines
available only from community pharmacies (with a sub scenario investigating the
implication of both paying community pharmacists a fee to provide this service and
requiring users not exempt from prescription charges to contribute to the costs of their
medicines via a user charge).
The scenarios modelled considered modifications to the status quo policy situation one
at a time. Ideally, it would have also been useful to consider simultaneous changes to
the access routes. Unfortunately, time pressures meant that this was not possible. This
is an area for future research efforts.
Analyses are summarised in tables 5.23 - 5.24. These were then compared to the actual
time and resource cost consequences resulting from the consultation patterns identified
within the study sample. Differences between actual and modelled time costs for the
study sample are highlighted, alongside benchmark estimates per 1000 users as a
reference source for both policy analyses and future research. Time costs are reported,
with the total value of all resources expended in brackets.
Table 5.1 summarised the average time, and table 5.2 the average resource, costs
incurred by stakeholders across each and both of the initial and follow-up routes adopted
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to access P medicines. Tables 5.23 and 5.24 extrapolate these estimates, modelling the
time costs that would have accrued to stakeholders and perspectives if users in the study
sample (n=l 185) had adopted access routes consistent with the various policy scenarios
outlined above.
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TABLE 5.23: CHANGING TIME COSTS TO STAKEHOLDERS AND PERSPECTIVES ASSOCIATED
WITH VARIOUS POLICY SCENARIOS FOR MANAGING THE PROVISION OF AND ACCESS TO P
MEDICINES
Stakeholder Actual Time Cost Modelled Difference Difference
Sample Time Per 1000 Sample Time Between Between















Policy Scenario 1: Time costs of the status quo arrangements for the provision of and access to P
medicines
Initial Visit
Total Time - 417a 352 N/A N/A N/A
User
Total Time - 80a 68 N/A N/A N/A
Health Sector
Total Time - 497a 420 N/A N/A N/A
Society
Policy Scenario 2: P medicines available only via prescriptions obtained during an appointment with a
general practitioner
Total Time - 153c 867 1027 610 515
User
Total Time - 46c 267 316 236 199
Health Sector
Total Time - 199c 1134 1343 846 714
Society
Policy Scenario 3: P medicines routinely obtained on repeat prescription available direct from community
pharmacy
Total Time - 60d 467 553 136 234
User
Total Time - 19d 150 178 98 83
Health Sector
Total Time - 79 d 617 731 234 317
Society
Policy Scenario 4: P Medicines available only from community pharmacies over-the-counter
Total Time - 204° 233 277 -140 -119
User
Total Time - 15e 17 20 -60 -51
Health Sector
Total Time - 219e 250 297 -200 -170
Society
User Perspective = User Cost
Health Sector Perspective = General Practitioner Cost + Community Pharmacist Cost
Societal Perspective = User Cost + General Practitioner Cost + Community Pharmacist Cost
time cost estimates derived from total cost for full sample across all initial access routes (n=l 185)
c time cost estimates derived from cost for users in the sample accessing their P medicine on prescription during a general
practitioner appointment (n=l 76)
Jtime cost estimates derived from cost for users in the sample accessing their P medicine on repeat prescription from a general
practitioner (n= 127)
"time cost estimates derived from cost for user in the sample accessing their P medicine over-the-counter from a community
pharmacy (n=882)
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TABLE 5.24: CHANGING RESOURCE COSTS TO STAKEHOLDERS AND PERSPECTIVES
ASSOCIATED WITH VARIOUS POLICY SCENARIOS FOR MANAGING THE PROVISION OF AND
ACCESS TO P MEDICINES
Stakeholder Actual Resource Cost Modelled Difference Difference
Sample Per 1000 Sample Between Between
















Policy Scenario 1: Resource (£) consequences of the status quo arrangements for the provision of and
access to P medicines
Initial Visit
Total Resources 6997" 5905 N/A N/A N/A
- User
Total Resources 8134a 6864 N/A N/A N/A
- Health Sector
Total Resources - 15131a 12769 N/A N/A N/A
Society
Policy Scenario 2: P medicines available only via prescriptions obtained during an appointment with a
general practitioner
Total Resources 1081c 6140 7276 279 235
- User
Total Resources 4973c 28260 33488 25354 21396
- Health Sector
Total Resources - 6054c 34400 40764 25633 21631
Society
Policy Scenario 3: P medicines routinely obtained on repeat prescription available direct from community
pharmacy
Total Resources 620d 4880 5783 -1214 2440
- User
Total Resources 2764 d 21760 25786 17652 6480
- Health Sector
Total Resources - 3384 3 26640 31569 16438 8920
Society
Policy Scenario 4: P Medicines available only from community pharmacies over-the-counter
Total Resources 5296e 6000 7110 113 95
- User
Total Resources 397e 450 533 -7601 -6414
- Health Sector
Total Resources - 5693e 6450 7643 -7488 -6319
Society
User Perspective = User Cost
Health Sector Perspective = General Practitioner Cost + Community Pharmacist Cost
Societal Perspective = User Cost + General Practitioner Cost + Community Pharmacist Cost
"resource cost estimates derived from total cost for full sample across all initial access routes (n=l 185)
c
resource cost estimates derived from cost for users in the sample accessing their P medicine on prescription during a general
practitioner appointment (n=176)
J
resource cost estimates derived from cost for users in the sample accessing their P medicine on repeat prescription from a general
practitioner (n= 127)
e
resource cost estimates derived from cost for user in the sample accessing their P medicine over-the-counter from a community
pharmacy (n=882)
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5.7.1 Policy Scenario 1: Time and resource cost of status quo
arrangements for the provision of and access to P class medicines
5.7.1.1 Time and resource costs
Total societal costs accruing across both initial and follow-up visits was 682 hours and
£19718 of resources (497 hours/£15131 in initial and 185 hours/£4587 in follow-up
visits). This comprised 566 hours/£8070 of user time (417 hours/£6997 in initial and
149 hours/£1073 in follow-up visits); 73 hours/£5410 of general practitioner time (46
hours/£3422 in initial and 27 hours/£1988 in follow-up visits); and 43 hours/£6238 of
community pharmacists' time (34 hours/£4712 in initial and 9 hours/£1526 in follow-up
visits).
A 1000 users accessing P medicines via a similar pattern of initial access routes would
consume 352 hours (£5905) of their own time, 39 hours (£2888) of general practitioner
time, 29 hours (£3976) of community pharmacy time and 420 hours (£12769) overall.
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5.7.2 Policy Scenario 2: P medicines available only via prescriptions
obtained during an appointment with a general practitioner
5.7.2.1 Time and resource costs
If sample users had all attended a general practitioner appointment to obtain their P
medicine on prescription: user time costs would have more than doubled (to 1027 hours)
taking up an extra 610 hours of users time, or an extra 31 minutes per user, on average.
However, the actual money costs incurred by users would increase only marginally, by
an extra £0.24 per user, on average. Health sector time costs would have almost
quadrupled (to 316 hours), consuming an extra 236 hours and £ 25354 in resources (191
hours (£14080) of general practitioner time and 45 hours (£11274) of community
pharmacy time), representing between 1146 and 1637 extra general practitioner
consultation slots (of between 7-10 minutes duration). Societal time costs would have
almost tripled (to 1343 hours), costing an extra 846 hours overall, while total resource
costs would increase by a factor of 2.5 to £40764. This represents a lose-lose situation
both for society overall, as well as for the constituent stakeholders, in that all their time
and resource costs would increase, although only marginally for users.
Per 1000 users accessing P medicines on prescription during a general practitioner
appointment compared to the access routes actually adopted by sample users under the
status quo policy arrangements, all stakeholder time costs would increase: user time
costs by 515 hours and £235 (or an extra 31 minutes each, on average); general
practitioners by 161 hours and £11882 (representing between 966 - 1380 extra general
practitioner consultation slots at between 7-10 minutes each); community pharmacy by
38 hours (£9514); and total societal costs by 714 hours (£21631).
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5.7.3 Policy Scenario 3: Repeat prescription P medicines available direct
from the community pharmacy
5.7.3.1 Time and resource costs
If, compared to the actual access patterns adopted, the 127 users who accessed their P
medicine via repeat prescription mechanisms through general practices had been able
instead to obtain them direct, over-the-counter from community pharmacies: user time
costs would have fallen by a half (to 30 hours), saving 30 hours, or an average of 14
minutes per user. Users' monetary costs would have decreased by half to £310, or an
average saving of £2.44 per user. General practitioner time costs would have been
reduced, saving 11 hours, potentially freeing up between 64-91 general practitioner
consultation slots (of between 7-10 minutes duration). Consequently, health sector
resource costs would be reduced, saving £823. Societal time costs would have
decreased by 41 hours overall and resource costs decreased, saving £1133 in resources
overall.
Per 1000 users, accessing repeat prescription P medicines over-the-counter from a
community pharmacy, as opposed to through general practice, would save 234 hours of
user time (or an average of 14 minutes each) and half user costs by £2440. 83 hours
(£6480) of general practitioner time, representing between 498-711 general practitioner
slots (of between 7-10 minutes duration) would be saved. It is unlikely that any
community pharmacy resources (time or medicine costs) would be saved under this
scenario, as the pharmacist would still be required to dispense the repeat prescription
medicines and offer advice as normal. A total of 317 hours and £8920 would be saved
overall.
Accessing repeat prescription medicines over-the-counter from community pharmacies,
as opposed to through general practice repeat prescription systems, potentially represents
a win-win situation for society overall, as well as for the constituent stakeholders, in that
time costs seem likely to decrease (for general practitioners and users) or remain the
same (in community pharmacy). Total societal costs would decrease overall and general
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practice resources potentially freed up for alternate uses. The impact on community
pharmacy resources is, however, less clear. Given that pharmacists would have been
dispensing these repeat prescriptions anyway, it is tempting to consider this scenario to
be resource neutral for community pharmacy. However, it is difficult to conclude this
with any certainty.
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5.7.4 Policy Scenario 3a: Repeat prescription P medicines available direct
from the community pharmacy, with community pharmacies explicitly
remunerated for providing this service
Note: this scenario is a derivative of scenario 3, outlined previously.
5.7.4.1 Time and resource costs
If, compared to the actual access patterns adopted, the 127 users who accessed their P
medicine via repeat prescription mechanisms through general practices had been able to
obtain them direct, from community pharmacies, with pharmacies explicitly
remunerated for providing this service (at various rates between £l .50, £2.00 and £2.50),
then user and general practitioner outcomes would be identical to those outlined in
scenario 3 above.
However, explicitly remunerating community pharmacies (between £1.50 to £2.50) to
offer advice on the use of the P medicines concerned would increase costs in community
pharmacy by between £191 and £318. This would, however, be offset against savings in
general practice resources (of £823) and result in a net saving of between £632 and £505
to the health sector overall.
Assuming an increase in advice giving and administration time within community
pharmacies of between 1 to 3 minutes to deal with this new role, time costs to
community pharmacy would increase between approximately 2 to 6 hours. Societal time
and resource costs would still, however, decrease overall, by between 35 to 39 hours and
£815 to £942 respectively.
Per 1000 users, 234 hours and £2440 and 83 hours and £6480 of user and general
practitioner time and resources would be released, as before. Time and money costs in
community pharmacies would increase by between 17 to 50 hours and £1500 to £2500
respectively. Overall, between 267 and 300 hours and £6420 and £7420 of societal costs
would still be saved after remunerating community pharmacies to provide this service.
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Enabling users to access repeat prescriptions for P medicines direct from community
pharmacies, via a system in which pharmacies were remunerated for this service,
potentially represents a win-win situation for society overall, as well as to the constituent
stakeholders. One would expect time and resource costs to decrease for users and
general practitioners and remain relatively constant in community pharmacies.
However, the development, regulation and administration of such a service is likely to
have an impact on the organisation and running of community pharmacies. However,
this could be accommodated if community pharmacies were explicitly remunerated as
outlined. Even after remuneration, resource savings could potentially be released,
relative to the status quo provision of services.
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5.7.5 Policy Scenario 4: P medicines only available over-the-counter from
community pharmacies
5.7.5.1 Time and resource costs
If, compared to the actual access patterns adopted, all users had opted to obtain their P
medicine by buying it over-the-counter at a community pharmacist: user time costs
would have fallen by a third (to 277 hours), saving 140 hours, or an average of 7 minutes
per user. However, user monetary costs would have increased slightly, costing £113
more, or an extra £0.10 per user, on average. Health sector time costs would have been
reduced by three-quarters (to 20 hours) and £7601 of resources freed for alternate uses
(46 hours (£3422) of general practitioner time potentially, freeing up between 276 and
394 general practitioner consultation slots, and 14 hours (£4179) of community
pharmacy time). Societal time costs would have almost halved (to 297 hours (£7643))
saving 200 hours (£7488) overall.
Per 1000 users buying P medicines over-the-counter from the community pharmacy,
rather than the routes adopted by sample users under the status quo policy arrangements,
user time costs would decrease by 119 hours (7 minutes each, on average) and resource
costs increased slightly (£95). However, 39 hours (£2888) of general practitioner time
(representing between an 234 - 334 extra general practitioner consultation slots at
between 7-10 minutes each), and 12 hours (£3526) community pharmacy time would be
freed up for alternate uses. Total societal time costs would be reduced by 170 hours
(£6319).
Compared to the actual time costs incurred across the initial access routes actually
adopted by users in this study to obtain P medicines, accessing them over-the-counter
from a community pharmacist represents a win-win situation both for society overall, as
well as for the constituent stakeholders, in that all their time costs would decrease if
users routinely accessed their P medicines in this way. However, costs faced by users
would increase slightly (on average), although considerable health sector and societal
resources would be released as a consequence.
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5.7.6 Policy Scenario 4a: P medicines only available over-the-counter from
community pharmacies, with community pharmacists explicitly
remunerated to provide this service and users contributing via user
charges depending on their prescription exemption status.
Note: this scenario is a derivative of scenario 4 outlined previously.
5.7.6.1 Time and resource costs
If, compared to the actual access patterns adopted, all users had obtained their P
medicine over-the-counter at a community pharmacy, with pharmacists explicitly
remunerated for providing this service and users contributing to the cost of obtaining
their P medicine, depending on their prescription exemption status, user time and
general practitioner time and money costs would be identical to those outlined in
scenario 4 above.
Assuming the same proportion of prescription exempt (57%) and non-exempt (43%)
users as in the study sample, with the former group able to access their medicines free as
before and the latter contributing to the cost of their medicines (at either the equivalent
of the prescription fee £5.80 or at the average sample cost for over-the-counter
medicines of £3.84) then users would have incurred additional money costs of £2958
and £1958 respectively.
Assuming advice giving and administration time costs for this scheme of between 1 to 3
minutes; a fee paid to pharmacists between £1.50 and £2.50; and that user contributions
are deducted from the costs of the medicines provided, community pharmacy time and
resource costs would be as follows:
Time costs to community pharmacies would decrease by 14 hours if they spent 1 minute
per consultation but increase between 6 to 25 hours if they spent 2 or 3 minutes in each
consultation. However, this scenario would still generate savings in societal time costs
of between 175, 194 and 214 hours overall.
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Fee payments to community pharmacy would be between £1778, £2370 and £2963.
Assuming average medicine costs of between £5.80, £8.74 and £11.00 for the P
medicines provided, then medicine costs would range between £6873, £10357 and
£13035 respectively. After accounting for user contributions to the costs of these
medicines, based on their prescription exemption status and applying a user charge of
£5.80 to users not exempt from prescription charges, these costs would decline to £3915,
£7399 and £10077. Assuming that the non-exempt users paid the lower average price
paid by users for over-the-counter medicines (£3.84) then the cost of the medicines
under this scheme would be £4915, £8399 and £11077. In total, community pharmacy
costs in this scenario would range between £5693, £9709 and £13040 (applying a £5.80
user charge) and between £6693, £10769 and £14040 (applying the £3.84 user charge).
Community pharmacy costs in this scenario would increase by between £981, £4997,
£8328 and between £1981, £6057, £9328 respectively. These extra costs would,
however, be partially offset by the savings in general practice cost of £3422.
Applying the low cost estimates, between £3704 and £4704 would be saved in societal
resources overall under this scenario. At the mid estimates, this scenario could either
slightly decrease (by £128) or increase (by £872) societal costs overall. Applying the
high cost estimates, societal costs would increase overall between £3643 and £4643.
Per 1000 users in this scenario, user time and general practitioner time and money costs
would again be identical to those outlined in scenario 4 above.
Users would have incurred additional costs for medicines of between £1651 and £2494.
Time costs to community pharmacies would decrease by 12 hours if they spent 1 minute
per consultation but increase between 4 to 21 hours if they spent 2 or 3 minutes in each
consultation. There would still, however, be savings in societal time costs of between
148, 165 and 181 hours overall.
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Fee payments to community pharmacy would be between £1500, £2000 and £2500.
Medicine costs would range between £5800, £8740 and £11000 respectively. After
accounting for user contributions to the costs of these medicines, these costs would
decline to between £3306, £6246, £8506 and £4149, £7089 and £9349 (if £5.80 or
£3.84 was recovered in user charges from those not exempt from prescription charges).
In total, community pharmacy costs in this scenario would range between £4806, £8246,
£11006 and £5649, £9089 and £11849. Community pharmacy costs in this scenario
would increase by between £826, £4226, £7026 and between £1669, £5109, £7869
respectively. These extra costs would, however, be partially offset by the savings in
general practice cost of £3422.
Applying the low cost estimates, between £3130 and £3973 would be saved in societal
resources overall under this scenario. At the mid estimates, this scenario could either
slightly decrease (by £111) or increase (by £732) societal costs overall. Applying the
high cost estimates, societal costs would increase overall between £3070 and £3913.
Compared to the actual time costs incurred across the initial access routes actually
adopted by the users in this study to obtain P medicines, accessing them over-the-
counter from a community pharmacist who is paid a fee for providing this service,
alongside cost recovery via user charges represents a win-win situation for society
overall. User costs would increase for medicines, probably because the user charges
applied were higher than the money costs actually paid by users in the study for their
medicines. The impact on societal resources was varied. At low cost and time
estimates, societal resources were still released overall. However, when high time and
cost estimates were applied, this situation was reversed and societal costs increased
overall.
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To this point in the analysis only partial economic evaluation has been conducted. This
stage in the economic evaluation, although partial is still very useful, particularly as
comprehensive cost estimates associated with accessing P class medicines within
primary care (general practice and community pharmacy) settings have not, until now,
existed. However, cost analysis, with its focus only on costs, while ignoring outcomes,
is inadequate to address efficiency issues. For this reason, the next stage was to extend




5.8.1 Cost minimisation analysis
If we assume that health outcomes among populations using P class medicines to treat
minor ailments are approximately equivalent - whether obtained from the general
practitioner on prescription or over-the-counter from the community pharmacy during a
supervised sale — then cost minimisation analysis is the economic evaluation method of
choice, as it focuses on difference in cost only between rival alternatives, with the least
costly alternative deemed to be the more efficient. Cost minimisation analyses are
particularly useful for considering the distribution of costs and the extent to which they
shift between interested parties.
Low, medium and high sample average costs per user accessing P medicines from either
the general practitioner or community pharmacist first were summarised in table A5.16
in Appendix 5. Stakeholder costs per 1000 users visiting either the community
pharmacist or general practitioner first to access their P medicine (with no subsequent
follow-up visits to primary care services required) are summarised in table 5.25 below.
TABLE 5.25: AVERAGE COSTS (£) TO STAKEHOLDERS & PER 1000 USERS IN COMMUNITY
PHARMACY FIRST AND GENERAL PRACTITIONER FIRST ACCESS ROUTED WITH NO FOLLOW-UP
VISIT
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Total cost per 1000 users accessing their P medicine over-the-counter from a community
pharmacist (with no subsequent follow-up visits to primary care services required) were
£4920, £6220 and £7870, compared to total costs of £24,640, £31960 and £38240 (low,
mid and high estimates respectively) for those accessing a P medicine on prescription
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from a general practitioner (with no subsequent follow-up visits to primary care services
required).
The table shows that cost minimisation analysis confirms that obtaining P medicines
over-the-counter during a supervised sale from a community pharmacist is a more and
efficient way to provide access to P medicines from all stakeholder perspectives
(societal, health sector and user) costing around only a fifth of the general practitioner
access route alternatives. The one exception was at low cost estimates for users, where
it was cheaper (on average) for users to access their P medicine from the general
practitioner.
It was also useful to compare the relative costs to stakeholders per 1000 users of
accessing P medicines assuming that equivalent proportions of users required to make
follow-up visits following their initial consultation with the general practitioner (28%) or
community pharmacy (22%) to that within the study sample. These are outlined in table
5.26 below.
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Table 5.26: COSTS (£) TO STAKEHOLDERS PER 1000 USERS ADOPTING COMMUNITY PHARMACY
FIRST AND GENERAL PRACTITIONER FIRST ACCESS ROUTES, ASSUMING PROPORTIONAL
FOLLOW-UP VISITS TO THAT IN THE STUDY SAMPLE
Consultation N Cost Est. User GP CP Total
Initial Follow-Up
CP None 780 Low 3713 0 125 3838
Mid 4501 0 351 4852
High 4984 0 1154 6139
CP CP 70 Low 858 0 43 898
Mid 1028 0 83 1112
High 1129 0 228 1357
CP GP 150 Low 1898 1754 1830 5481
Mid 2690 2640 1886 7215
High 3140 3422 2061 8622
Low 6469 1754 1998 10221
Total Mid 8219 2640 2320 13179
High 9253 3422 3443 16118
GP None 720 Low 2714 5306 9720 17741
Mid 4673 8006 10332 23011
High 5782 10382 11369 27533
GP CP 30 Low 262 199 251 712
Mid 378 300 285 963
High 443 389 359 1190
GP GP 250 Low 2445 4560 6823 13828
Mid 4378 6870 7050 18298
High 5408 8903 7430 21740
Low 5421 10065 16828 32289
Total Mid 9429 15176 17441 42272
High 11633 19674 19165 50463
Table 5.26 highlights that costs were almost exclusively lower, both from individual and
collective stakeholder perspectives, when P medicines were accessed from community
pharmacies under supervised sale arrangements.
In summary, the cost minimisation analysis confirmed that, from both individual and
collective stakeholder perspectives, it was more efficient for P medicines to be accessed
by visiting community pharmacies first. Importantly, this results held, even when
allowing for any subsequent primary care follow-up visits to either the general
practitioner or community pharmacy.
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5.9 Comparisons with other economic analyses
Unfortunately, it was not possible to compare the results of this economic analysis with
other literature estimates. To date, no economic evaluation of the policy encouraging
increased self-medication using P class medicines bought from pharmacies (and the
associated substitution between general practice and community pharmacists provoked
as a result) have been conducted. Likewise, detailed analyses investigating the
magnitude and distribution of costs incurred by stakeholders associated with this policy
do not exist.
Average cost per consultation figures are presented in two recent UK studies
investigating related issues (i.e. the Care at the Chemist and Direct Supply of Medicines
schemes). However, the estimates are presented in isolation and the methods they
adopted are not outlined, thus making any meaningful comparison impossible.
The economic data presented in this thesis, therefore, constitutes an important
contribution in this regard. It initiates efforts to explore the economic implications and
consequently, fuller appraisal this policy.
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5.9 Summary ofpolicy relevant results
BOX 5.1: TIME COSTS TO STAKEHOLDERS
• Total average time costs to all stakeholders ranged between 14-50 minutes, with
an overall sample average of 47 minutes.
• Mean user time cost ranged between 14-68 minutes.
• A rule of halves applied to user time costs. Buying a P medicine took half as long
(14-68 minutes on average) as obtaining them by repeat prescription (28
minutes), which took half as long as accessing them in a general practitioner
consultation (52-68 minutes on average).
• Primary care professionals' time costs were much lower when users visited the
community pharmacy. As soon as general practitioners were involved, time
costs to primary care professionals rose considerably.
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BOX 5.2: RESOURCE COSTS TO STAKEHOLDERS
• Total average resource costs to all stakeholders ranged from £6.56 to £82.82, with an
overall sample average of £30.94.
• Mean monetary valuation of total resource costs expended by users across different
access routes ranged between £4.88 and £7.17.
• Total average costs were significantly lower among users accessing P medicines via
repeat prescriptions.
• Mean total costs were significantly higher among users accessing P medicines from
general practitioners.
• User time and travel costs increased 100% across different access routes: by a factor of
three and two in general practitioners' and repeat prescription routes respectively,
compared to users who bought their P medicine at a community pharmacy.
• Accessing P medicines over-the-counter at a community pharmacy increased user
monetary costs by between 2-7 times.
• Users accessing their P medicines on prescription from general practitioners incurred
significantly higher resource costs overall, compared to those who bought them.
• Time and travel and medicine costs moved in opposite directions. Time and travel costs
were significantly higher and medicine costs significantly lower among users accessing
P medicine on prescription and vice versa for those who bought them from community
pharmacies.
• Users accessing P medicines on prescription incurred lower out-of-pocket money
expenditure. However, the overall value of the resources they expended accessing their
P medicine was higher when the opportunity cost of their time was included.
• Resource costs to general practitioners issuing P medicines on prescription during a
consultation were double those associated with issuing them by repeat prescription.
• Costs to community pharmacists increased appreciably when dispensing prescriptions
for P medicines, compared to selling them over-the-counter.
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BOX 5.3: WERE ANY USERS DISADVANTAGED?
• Status quo policy arrangements appear to increase time costs and disadvantage
users: who reported less favourable socio-economic circumstances; who
perceived themselves not to be in good health; and who were more frequent users
of primary care.
• Total resource costs were higher among users whose socio-economic
characteristics suggested they were more likely to be able to afford to bear higher
costs and lower among those who were not.
• Time and travel costs were higher among those reporting less favourable socio¬
economic circumstances, who were more frequent users of primary care services,
compared to those who were more affluent, in better health and who were less
frequent users of primary care services.
• Medicine costs were higher among relatively more affluent users; those in better
health; and less frequent users of primary care services. By comparison, less
affluent users, those who reported poorer health and more frequent users of
primary care services incurred lower medicine costs.
• In the context of current policy, opportunities to substitute may be limited for
groups that feel it is cost prohibitive.
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BOX 5.4: AVERAGE AND PROPORTIONAL SHARE OF COSTS TO STAKEHOLDERS
• Total average time and resource costs were generally lower when P medicines
were bought in community pharmacies (14-95 minutes and £6.22 - £48.10).
• As soon as general practitioners are involved, both time and resource costs
increase appreciably (53-150 minutes and £31.96 - £73.19).
• Users incurred the vast majority of time costs (81 -84%) compared to general
practitioners (9-15%) and community pharmacists (4-7%).
• Total resource costs were more evenly distributed, with users incurring between
a quarter to a half (23-46%); general practitioners between a quarter to two-fifths
(23-43%); and community pharmacists around a third (31%).
• Users incurred the vast majority of time and resource costs if they bought their P
medicine over-the-counter at a community pharmacy (93-4%); whereas in
General practitioner access routes, users incurred the majority of time (76-80%)
but not resource costs (18%).
• Waiting time was the key difference in user time expended different routes.
Waiting times were proportionally greater (2-4 times) in general practitioner
access routes.
• Key drivers of user total resource costs were travel and waiting time in general
practitioner routes but medicine costs in community pharmacy routes.
• General practitioner time was the key cost driver where P medicines were
accessed on prescription.
• Community pharmacy faced three main cost drivers - time, on-cost allowances
and dispensing fees.
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BOX 5.5: IMPACT OF CHANGING POLICY SCENARIOS
• Sample users switching from general practitioners to community pharmacies to
access P medicines would result in a win-win situation, with all stakeholders
incurring savings overall. However resource savings would be skewed heavily to
the health sector. Whilst on average users would be better off overall, over half
of them would be worse off in terms ofmoney costs.
• Accessing P medicines through repeat prescription mechanisms in community
pharmacies would generate a win-win situation overall. Total societal costs
would decrease. Health sector resources would be freed up for alternate uses.
However, costs would be shifted to users, who would face increased costs, on
average.
• P medicine available only to buy from community pharmacies would also result
in a win-win situation overall. However, average monetary costs faced by users
would increase. Considerable health sector resources would, however, be
released.
BOX 5.6: RELATIVE EFFICIENCY OF ALTERNATE ROUTES TO ACCESS P MEDICINES
• Cost minimisation analysis confirmed that it is more efficient for P medicines to
be accessed through community pharmacies, as opposed to through general






The aim of this chapter is to synthesise and reflect on the findings of the research
conducted in this thesis. It begins by outlining the limitations of the theory and method
applied in the research. It then considers the relevance of the results to current policy
debates, discussing the impact of encouraging increased self-medication using P
medicines and associated substitution between primary care professionals. It then
considers the winners and losers from the policy and concludes by identifying
implications for future research.
6.2 Limitations of the study
The key pros and cons of the study design and analytical techniques, alongside
justifications for the final choice of theory and methods adopted are outlined within the
literature and method chapters. Policy evaluations are typically pragmatic. However,
even in pragmatic evaluation it is important to have a clear understanding of the
implications of the underlying theoretical underpinnings of the methods adopted and the
potential implications of this for data generation, analysis and interpretation of results.
This chapter starts by considering the appropriateness of the consumer surplus and
economic evaluation methodologies applied in this study, highlighting potential
implications in considering the results and their interpretation. Two key areas of
limitation will be addressed: limitations of the theoretical foundations underpinning the
methods adopted; and general limitations or weaknesses inherent within the research, as
conducted.
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6.2.1 Limitations of the theory and method
6.2.1.1 Consumers' surplus analysis
There are two main limitations in estimating consumers' surplus resulting from different
routes, and thus prices, to access P medicines: first, uncertainty regarding the form of
demand curves for P medicines; and second, limitations of demand analysis in
explaining user behaviour
Uncertainty regarding the form of demand curves for P medicines
Key assumptions of neo-classical demand theory that underpin consumers' surplus
analysis include: linear, additive demand functions; constant marginal utility of money;
and the aggregation of individual consumer's surpluses.
The additivity assumption requires that the utility gained from consuming a P medicine
is a function of the quantity of the commodity consumed, independently of the amount
of other commodities consumed (Blaug, 1996). If this assumption is violated, the
demand schedule may not be linear and thus consumers' surplus analysis will be based
on an approximation, rather than actual, consumers' willingness to pay. If we know the
demand curve for P medicines, this should not be a problem (Pearce, 1983). However,
the UK P medicine market is relatively immature and in a state of flux, and the exact
shape and nature of the demand curves for P medicines are uncertain. Ryan and Yule
(1988) suggest, however, that because the maximum willingness to pay of individuals
within large groups typically varies widely, it is reasonably safe to assume that demand
schedules for P medicines broadly concur with the required linear additivity assumptions
(Ryan and Yule, 1988). Nonetheless, the findings presented should be regarded as an
approximate rather than an exact measure of consumers' surplus.
The assumption of constant marginal utility of income is necessary to ensure that a key
factor influencing demand, i.e. income, is not changing (Blaug, 1996). This may be
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assumed if the commodity concerned is 'unimportant', accounting for a negligible
proportion of consumers' total purchases (Blaug, 1996; Pearse, 1983; Call and Holahan,
1994; Lipsey, 1987). If this is not so, then the approximation of consumers' surplus may
be poor (Lipsey, 1987; Call and Holahan, 1983). Whether P medicines may be regarded
as unimportant may vary depending on individuals' income and the absolute and relative
price of P medicines obtained on prescription compared to those bought. P medicines
may well have been 'unimportant' in terms of their price and impact on income to some
users, however, this was unlikely to be the case for all users in the study. Indeed,
differential time and money price sensitivities were identified among different groups of
users, indicating that the 'unimportant commodity' assumption may not hold for all.
However, the existence of the prescription exemption system should, in theory,
ameliorate income impacts across users (albeit they are not directly income related or
proportional to income).
Consumers' surplus analysis requires aggregation of surpluses across individuals to
arrive at an aggregate estimate of benefit (Pearse, 1983). The placing of the apostrophe
in consumers' surplus tacitly assumes interpersonal comparisons of utility, yet,
individual consumer's surpluses may not be additive in this way. It is unlikely that all
individuals experience identical marginal utility from money income (Blaug, 1996) and
distributional considerations become relevant. Aggregated consumers' surplus estimates
should, therefore, be interpreted with caution (Blaug, 1996). Care should be taken to
consider both individual and group level surpluses and their distribution. These
potential limitations of the application of consumer surplus analysis in this study were
addressed by collecting proxy income data, identifying individual user costs, and
explicitly considering distributional issues. This enabled consideration of not only
sample average results, but also the impact to particular groups and even individual
users, making it much easier to assess the distribution of benefits.
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Limitations of demand analysis in explaining user behaviour
Demand theory is likely to offer only a partial explanation of user behaviour in
accessing P medicines. It progresses using 'comparative static techniques'; i.e. it alters
one parameter at a time, price, and compares the beginning and end equilibrium. Yet,
policy makers seeking to understand and refine policy levers will find the dynamic
process(es) of adjustment to changing prices at least, if not more, interesting. It also
operates on the 'ceteris paribus' assumption; i.e. that 'other things being equal',
everything that affects the quantity demanded, except price, is held constant (Stanlake,
1976). Consumer tastes are assumed to be stable and independent of prices. Yet, forms
of non-price competition, like advertising, are increasingly eroding this assumption and
changing the nature of demand. This applies to medicine markets also.
Multidimensional relationships exist between quantity demanded and a number of
factors, of which price is only one (Call and Holahan, 1983). The hedonistic premise
(i.e. the tendency to identify the desire that prompts an individual to purchase with the
underlying satisfaction derived from a purchase) underpinning demand analysis has been
critiqued for ignoring the habitual and conventional forces that shape desires and wants
(Blaug, 1996). Institutional economists are increasingly identifying the limitations of
traditional demand analysis and advocate consideration of broader socio-economic
theories of demand and consumption, contextualising individual action within broader
structural and institutional factors that influence consumption choices (Blaug, 1996).
This would serve to broaden our understanding of demand both for health services
generally and medicines specifically.
Another limitation of the consumers' surplus method is that it primarily focuses on net
benefits to users. It does not specifically encapsulate broader effects, such as knock-on
impacts on the health sector like changing demand for other services, or ripple effects in
the economy more widely. A broader economic evaluation, adopting a multi-sectoral or
societal perspective would be required to do that. For this reason, the analysis was
explicitly extended utilising economic evaluation methods to consider the changing
distribution of costs to users, the health sector and society more generally.
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Consumers' surplus is a useful but complex method of demand analysis (Blaug, 1996).
However, deviation from its underlying assumptions requires careful consideration and
necessary qualification of any conclusions drawn from such analysis. Care was taken to
do so in this research. Despite the potential limitations outlined, consumers' surplus
analysis provided a useful approach to analysing the impact of the changing prices
incurred by users who obtain P medicines via different access routes, the emergent
benefits and to whom they accrue.
6.2.1.2 Economic evaluation
Vilfredo Pareto's general equilibrium model underpins welfare economics (and thus
economic evaluation methods) and is applied to assess the impact of policies on societal
welfare (Call and Holahan, 1983; Gold et al., 1996). However, a number of concerns
have been raised regarding Pareto's model and its applications in economic evaluation.
First, the extent of acceptability of the Paretian ethical judgements have never been
tested empirically and it is unclear if they are generalisable, for example, across different
socio-economic groups (Nath 1973). For example, are individuals always the best judge
of their own welfare? When one considers the 'merit' good status attributed to health by
many economists (a good that society considers a virtual necessity, regardless of
income, yet which is often sub-optimally consumed if left to individual consumers)
individuals are perhaps not always the best judge of their own welfare (Begg, Fischer, &
Dornbusch, 1991; Earl-Slater, 1999; Tresch, 1994). This has led to an ' extra-welfarist'
perspective emerging, contending that social welfare should not be determined on the
basis of individuals' preferences for health or any other outcome in relation to other
commodities, but rather, that health policy should be based on the assumption that the
goal of health policy is to maximise health (Gold et al., 1996; Scott et al., 2003).
Second, many of the assumptions of perfect competition, upon which the model is
founded, do not hold generally, or in this study. For instance, the existence of taxes and
subsidies, alongside imperfect information in the demand and supply of medicines
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violate the perfect competition conditions necessary for Pareto optimal solutions to
prevail. Perfect competition theory is atomistic and requires that individuals are able to
assert 'free' choice in making judgements about their own welfare. Yet, choice may not
always be regarded as free, but often constrained by macro level institutional
considerations.
The chief objection to the Paretian model, however, concerns its implicit equity
implications. It effectively ignores distributional considerations (Nath, 1973). Given
that most societies are characterised by inequitable income distributions (Wilkinson,
1992; Wilkinson, 1995; Judge, 1995; Benzeval & Judge, 1996) this seems inappropriate.
Achieving Pareto improvements may, in theory, appear desirable. However, it does not
necessarily follow that members of society would be happy with the prevailing resource
distribution either at the start or end.
The modified Kaldor-Hicks-Scitovsky decision principle (upon which economic
evaluation methods are based) advocates acceptance of policy changes if overall welfare
is enhanced and winners can potentially compensate losers. However, the fact that, in
theory, the gainers can compensate the losers doesn't automatically make the infliction
of those losses socially desirable or acceptable (Coate, 2000). The policy outlined in
this thesis passes the compensation decision rule and would be regarded as promoting
social welfare. However, it is important to note that acceptance of policy on this basis
still implies that (economists') appraisal of policy change should be based on different
individual or groups' willingness and ability to pay for what they want, thus implying
tacit approval of the status quo distribution of resources.
The compensation principle is, however, an interesting one. In theory, the winners from
the policies widening access to P medicines and encouraging increased self-medication,
could compensate the losers. No obvious mechanism currently exists to facilitate this
between users. However, one could argue that in substituting a community pharmacist
in place of a general practitioner to access their P medicine, they have released valuable
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primary care resources (professional time and medicines) that become available to others
who are less fortunate than them.
The key limitations noted above are relevant to how policy makers should interpret the
findings of the economic evaluation in this study. Applying the objective welfare
criteria implicit in economic evaluation methodology suggested efficiency gains could
be realised and societal welfare enhanced (on average). However, even although
welfare was improved overall (i.e. on average) across the users, a majority faced
increased monetary costs and these were disproportionately borne by typically less
affluent users. Thus, in moving from considering objective (efficiency) to more
subjective (resource distribution) welfare criteria, it becomes much less clear if the
second, post-policy scenario (and its associated resource distribution) is preferred to the
first. It is difficult to divorce equity and efficiency considerations (Drummond et al.,
1997). The policy analyst is then left with the age-old dilemma of balancing individual
versus social welfare. Inevitably, economic evaluation is highly complex. It involves
numerous unresolved conceptual issues and questions of social justice (Reinhardt,
1997).
Thus, a number of potential limitations exist in applying the theory and methods of
consumers' surplus analyses and economic evaluation in this study. However, all theory
necessarily involves simplification and abstraction from reality. It is like a map -
drawing out in stark, crude outline the important relationship between variables.
(Wonnacott & Wonnacott, 1986). The challenge of this thesis has been to work out the
detail of the contours and grid lines and improve upon previous efforts to apply the
theory and method in this area. The potential limitations identified should, however, be
acknowledged in interpreting the results. These are more fully appraised in section 6.3.
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6.2.2 General limitations of the study
There are a number of general limitations to this study that should be acknowledged and
considered. These relate to: the cross-sectional nature of the study design; the absence
of health outcome measurement; considering all minor illness together; and limits to the
costing methods applied.
6.2.2.1 Limits of the cross-sectional study design
Cross-sectional study designs can be problematic, due to their uncontrolled nature and
the fact that they provide only 'snapshots' of data that can introduce sources of
uncertainty. Potential selection bias may have occurred i.e. the possibility that users
who chose to access their medicine from community pharmacies may be substantively
and/or systematically different from those who elect to access them from general
practitioners instead. Indeed, the sample description suggests that this was in fact the
case. Efforts were made to address this issue in presenting and interpreting the results by
examining whether there were differences between the full and follow-up samples
within the study and comparing the study sample with the broader Lothian Health
population, as well as to those of studies reporting upon related issues within the
literature. The study included some prospective elements. However, a fully prospective
design would have been preferable. Unfortunately, however, this was outwith the scope
and resources of the research.
Like most health services research, this study was designed amid an evolving and
somewhat implicit health policy development. In this context, and with the research
funds available, a cross-sectional design was considered the most pragmatic approach.
Nonetheless, caution should be urged in interpreting results and basing policy
interventions on inferences derived from cross-sectional findings.
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6.2.2.2 Absence of health outcome measurement
Outcome measurement was a contentious issue. Economic evaluations typically include
direct health outcome measurement. However, this was problematic and not undertaken
for a number of reasons. It is important to note, however, that this study was evaluating
the policy encouraging different routes to access P class medicines and not the impact on
users' health. It was not clear what the 'value added' to the policy evaluation would
have been of attempting to measure health outcome impacts. A key, if not the main,
rationale for promoting deregulation of medicines and encouraging increased self-
medication using P medicines obtained from community pharmacies, was to improve
access to first-contact services to deal with minor ailments, as opposed to improving
health outcomes per se. The conditions that the users presented with should, by
definition, have been self-limiting, and likely would have resolved themselves without
any professional intervention recommending use of a P class medicine. It seemed
unlikely, therefore, that discernible improvements in health outcome could realistically
be expected, or indeed attributed to a specific, one-off use of a P medicine, accessed
from a general practitioner rather than a community pharmacist. Particularly so, as these
often take place (and thus are potentially confounded by) in the context of a series of
ongoing self-care efforts and/or other health care contacts. For these, reasons efforts to
undertake measurement of changing health status in the current study were not
attempted.
It may be possible to undertake fuller economic evaluation of particular groups of clients
and/or conditions. However, this is likely to require a more complex, longitudinal study
design, taking baseline general health status measurements, as well as some related to
the specific minor illness concerned, and assessing any change over time, investigating
impacts on users' utilisation of different services and any differential results in health
outcomes. Arguably however, such a study is still likely to focus mainly on
intermediate or process outcomes, such as adherence to recommended treatment
strategies, incidence of adverse outcomes, user satisfaction with services, provision of
reassurance or information and changing patterns of service utilisation. Even if
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changing health status was discernible over time, it may be very difficult (unless one
was to apply an RCT design) to attribute effects to particular consultation or
management strategies. That said, it would be useful to explore more fully the
constituent elements of general practice and community pharmacy routes to access P
medicines to treat minor ailments, and their relative value to users of these services.
Validity of considering undifferentiated minor illness
It may not be appropriate to 'lump together' the diverse range of conditions (and their
varied severity and case mix) that users accessed P medicines for under the catch-all of
'minor ailments'. This is crude at best. In addition, the study was unable to take
account of differences in consultation processes between general practitioner and
community pharmacists generally, far less between particular professionals or users
specifically. Similarly, for some of the P medicines concerned, there are different
licensed indications for their use, depending if they are obtained over-the-counter or on
prescription. In theory, if they are being used appropriately, this should be irrelevant.
There should be no difference in their clinical efficacy within the context of their
appropriate use/application to treat the similar minor illness episodes for which they are
intended. However, again this may be uncertain. An RCT design could have helped to
address these issues. Unfortunately, however, this was not within the scope of the
present study.
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6.2.2.3 Limits of the costing methods
There are also some limitations to the costing methods applied within the economic
analyses. The study was restricted to calculating only the quantifiable direct and indirect
costs accruing to stakeholders. Yet, a broader range of costs and benefits are
undoubtedly relevant (Mooney, 1994). For instance, the study did not attempt to
measure or value process outcomes (e.g. reassurance). This may be considered as
potentially 'reductionist', negating broader costs and benefits of relevance (Jan, 1998)
but methodological and time constraints mitigated against this. Future research would
benefit from embracing a broader and more inclusive range of potential costs and
consequences.
A number of the assumptions made in the costing methods may also be subject to
contention. Over and underestimation of costs cannot be ruled out. Estimates were used
to calculate elements of the costs, where actual cost data were unavailable, for example,
using national reference costs (Netten, Dennett & Knight, 1998). However, these may
not have been representative of the local care situation (Smith & Wright, 1994). Further,
the cost data are sensitive to the time estimates provided by users. Generally, time
estimates provided by users were plausible. However, respondent inaccuracy cannot be
ruled out. Observational 'time and motion' type data would have been preferable for
collecting user time costs. This would have required a prospective design, which, as
noted previously, was not possible within the limited resources available to conduct this
research.
Valuation of user time was a particularly contentious issue. Yet, given that either small
or no money costs were typically incurred by users, time costs were the main
differential. Other research has indicated that those on salary often do not lose out if
they require to attend health services (i.e. their time costs are subsidised by their
employer) whereas people not in the formal labour force bear the full opportunity cost of
their time and consequently often face higher opportunity costs (Torgerson, Donaldson
& Reid, 1994). In policy terms, this reversal of the usual order of costs can have
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important implications i.e. people in lower socio-economic groups face greater access
costs and, as a result, may be subject to inequities (Torgerson, Donaldson & Reid, 1994).
This study found the same, highlighting the importance of not treating user time as a
'free input' to health care production processes and the potential implications of the
differential value of time within policy analyses. However, we have to acknowledge
that users themselves may not consider their time costs in this way.
National average wage estimates were applied to estimates of lost work time due to the
perceived infeasibility of collecting individual income data in the interviews and in the
interest of maximising the usefulness of the research for policy evaluation purposes.
However, these may be regarded as somewhat insensitive. For example, they fail to
account for differences in time costs between skilled and unskilled labour. However this
would not have had a major impact on user cost estimates as relatively small amounts of
the time costs calculated actually involved work time.
Accurate costing of primary care professionals' time was also difficult. At the time of
analyses, no unit cost estimates for community pharmacists' time existed within the
literature, yet important differences (e.g. variation in the employment status of
community pharmacists) are believed to impact these costs (Whittington et al., 2001).
Further, general practitioner time costs, may not have been completely attributable to
accessing the study P medicine(s) (e.g. if this occurred within a consultation in which
other issues were dealt with). The omission of overhead costs within community
pharmacies is a further weakness. In order to embrace potential variability, simple
sensitivity analyses were conducted, substituting alternative cost assumptions, to identify
a range of costs that might occur and to check the robustness of the results. The overall
pattern of results or associations did not change. Further, subsequent comparison of the
bottom-up cost estimates calculated for community pharmacy in the study with national
unit cost estimates (that became available after the analyses were conducted), indicated
that they were broadly similar.
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Clearly, a number of potential limitations exist regarding this study as designed and
conducted. It is difficult to gauge their significance. Efforts were made, wherever
possible, to ameliorate their effects. Overall, the results were intuitively plausible.
Unfortunately, no body of evidence exists in this area with which to compare the results
of the current economic analyses. However, there are uncertainties in all economic and
policy analyses. Limitations aside, the methods applied on this study are superior to
previous efforts in the area and this research is believed to offer a genuine and unique
contribution. It represents an important intermediate stage in beginning to understand the
costs associated with the two routes currently available to access P medicines within
primary care.
6.3 Implications for policy and practice
A number of findings emerge from this research, yielding potentially important
implications for policy and practice. These include: firstly, the extent and interpretation
of substitution; and secondly, equity and general policy implications to users, the
primary care sector and the NHS.
6.3.1 What do we mean by substitution and is it real?
In the results outlined, the substitution hypothesis was broadly affirmed. However, a
number of qualifications require to be considered in interpreting this finding. These
relate to whether substitution between general practitioners and community pharmacists
may be regarded as a one for one, perfect substitutes.
Community pharmacies certainly offer substitute access points for P medicines.
However, accessing a P medicine from a community pharmacy during a supervised sale
is a very different process compared to consulting a general practitioner for advice
(Hasseli et ah, 1996. Assuming them to be of equal value negates the potential
importance of the varied professional (and personal) attributes that differ between
community pharmacists and general practitioners and their interactions with users.
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These issues beg the question of whether it is misleading to promote general
practitioners and community pharmacists as substitutes in the management of minor
ailments using P medicines. Differences in how these primary care professionals are
currently used in the management of minor illness does not suggest they are substitutes -
users predominantly visit community pharmacies to access medicines (not advice) and
visit general practitioners to seek advice (as well as medicines) (Hassell et ah, 1998).
Policy deregulating and promoting P medicines have multiple potential outcomes. P
medicines may be used to directly substitute another service; they may be used as an
adjunct or complement, in tandem by users; they may generate additional or new
demand, with people presenting with problems they would otherwise have ignored or
dealt with themselves; or they may result in duplication between services, with users
attending for problems for which they have already sought advice from other health
professional and/or services. Each of these potential outcomes could be regarded
positively or negatively, depending on perspective.
Great care was taken in the study to ensure that any follow-up visits to services were
related to the minor illness episode discussed with users. Results indicated that one in
five of the users who were believed to be attempting to substitute, followed up their visit
to a community pharmacy with a general practitioner consultation, suggesting that their
substitution was not perfect or complete. How should one consider such complementary
usage between the general practitioner and community pharmacist? Follow-up care
could be regarded as a negative outcome. It could be argued that P medicines available
from community pharmacies should represent a direct substitute for the same P medicine
obtained from a general practitioner to treat the same minor ailment. Complementary
usage could, therefore, be regarded as potentially duplicative, generating new and
perhaps unnecessary demand, directly contravening the policy intention. Alternately, it
could be regarded positively. It may in fact indicate appropriate usage of P class
medicines; i.e. that they should be used in conjunction with advice from appropriate
primary care professionals, especially as most P medicine user information leaflets
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recommend visiting the general practitioner if the symptom persists, or if the user
experiences any adverse effects. Teasing out these nuances regarding what exactly
constitutes substitution is, however, extremely complex and was not addressed in this
study.
A related issue is the extent to which the substitution identified in the study is in fact
real. It may, in some circumstances, have been more perceived than real. For example,
should a P class cough medicine, obtained over-the-counter from a community
pharmacy be considered a substitute for a general practitioner consultation if the user
would never have considered attending a general practitioner to obtain it, or if the
general practitioner would never have considered prescribing it?
New versus old demand is a related issue. For example, if a user previously bought a
'general sales list' (GSL) medicine (e.g. Kaoline and Morphine) from a community
pharmacist and now buys P class 'Imodium' (after deregulation and advertising
promoting its availability), yet they would never consider consulting a GP to obtain
either, is this a substitution? A long-term prospective cohort study (again outwith the
scope of this research) would have been needed to disentangle the issues related to new
versus old demand.
Further, although we might presume that users were accessing a P medicine from
community pharmacies to self-medicate a minor illness episode (as per their licensed
indications) we do not know this for certain (although no major problems were revealed
at follow-up).
This study was unable to separate out some of these subtle nuances in substitution.
Consequently, such cases would have been classed as attempted substitutions and thus
may have overstated the impact on demand. A degree of uncertainty exists, therefore,
regarding what exactly was captured in this study and the extent to which it may be
regarded as substitution between general practitioners and community pharmacies.
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The time horizon of substitutions is also important. It is useful, and necessary, to
consider substitution issues in terms of either 'point' or 'period' substitution. Point
substitution refers to decisions to visit a community pharmacist 'on this occasion' to
obtain a P medicine to self-medicate, instead of consulting a general practitioner.
However, one cannot make the leap to assume that the user has ruled out consulting a
general practitioner for a similar minor illness episode or to obtain the same medicine in
future. Period substitution might be considered as occurring where users would always
and only visit the community pharmacist to obtain medicines for particular minor
ailments, of which they have experience, feel confident self-medicating and would never
consult a general practitioner about (acknowledging, of course, that decisions to consult
health professionals are usually more complex and contextual - depending on other
illnesses and worries etc.).
This study considers 'point' substitution over one maximum of a month only. The data
collected concerned only a snapshot of user decision-making regarding a particular
illness episode. It is not possible to say, therefore, that because a user either did or did
not attempt substitution on that occasion, that they would act in the same way in the
future.
Clearly, the substitution concept is a complex one. It appears intuitively sensible, but at
present, it is poorly defined and understood. Yet, it is frequently alluded to in health
policy debates. The substitution term is rarely defined and, more often that not, used
colloquially. Clearer definition of the substitution concept, its aims and the mechanisms
or processes considered most likely to achieve it is required to progress these debates.
In its absence, we are currently experiencing the inevitable problems consequent from
trying to transform the complex conceptual concept of substitution into an empirical
health policy reality. If we are to seriously consider substitution issues in health policy
we need to get beyond the use of the term as only a rhetorical device or politically
expedient rhetoric. In an increasingly evidenced based world there will and should be
pressure to better define and evaluate policies aiming to promote substitutions between
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care professionals and services within both health care generally and primary care
specifically.
6.3.2 Equity and general policy implications to key stakeholders.
Who were the winners and losers?
The results of this study overall suggest that encouraging increased self-medication and
the substitution from general practitioner to community pharmacists to access P
medicines in primary care generates a win-win situation, with all key stakeholders
benefiting. However, the results present the impact of the policy to stakeholder groups
on average. It is also necessary to identify relative advantage among the stakeholders,
identifying the winners and losers. Thus, the following sections specifically consider the
potential equity implications of the policy to users, alongside consideration of other
potential impacts to users, primary care, the NHS and policy debates generally.
6.3.2.1 Relevant equity implications to consider
Equity is a complex and multidimensional concept. It is important, therefore, to outline
the dimensions of equity of particular relevance to the policy under consideration.
At its simplest level, there is widespread agreement that equity implies notions of
'fairness' or 'equality'. Agreeing on equality of what is, however, more difficult.
Equity is most frequently defined in terms of Aristotelian principles, whereby,
'horizontal' equity implies the 'equal treatment of equals', and 'vertical' equity, the
'unequal treatment of unequals'. Definitions of equity posited of relevance within the
NHS are, however, typically more elaborate. For example, in 1979, a Royal
Commission specifically outlined eight equity principles upon which it recommended
that the NHS should be founded, including: universal entitlement; sharing financial
costs; free at the point of use; comprehensive in range; equality of geographical access;
same high standard care for all; selection on the basis of need and not ability pay; and
encouragement of a non-exploitative ethos (Merrison, 1979; Whitehead, 1994). Another
equity taxonomy commonly cited as relevant to care systems is offered by Mooney
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(1982, 1992, 1994) and includes: equality of expenditure per capita; equal inputs per
capita; equality of inputs for equal need; equality of access for equal need; equal
utilisation for equal need; equal marginal met need; and equal health.
Comprehensive appraisal of the equity implications of the policy examined in this thesis
is thus likely to be very complex and outwith the scope of this discussion. It is argued,
however, that equality of access is the most widely accepted and 'traditional' equity
principle referred to in the NHS (Powell, 2003) Indeed, Powell (2003) notes that recent
government policies reinforce this in their commitments to reduce 'unacceptable
variation' and provide a 'one nation' service characterised by 'fair access'.
The researcher believes that the policies to increase self-medication and the substitution
from general practitioners to community pharmacists to obtain P medicines were
predominantly intentioned to improve access to primary care (as part of the
government's broader goals of developing improved, graduated access services). For
this reason, appraisal of the policy will focus on equity of access considerations.
Equity of access, should, in Mooney's opinion, be the overriding aim of care systems,
given the impossibility of achieving equal health and difficulty in ensuring equal use of
services (Mooney, 1994). He suggests that it should consider the cost of gaining access
to potential users of services, noting that they should have the same opportunity to use
health care i.e. face the same opportunities and supply curves to use health care
(Mooney 1992, 1994).
Goddard and Smith (2001) in a recent review of the theory and evidence pertaining to
equity of access to health care services offer a more detailed and rigorous outline of
theory and evidence pertaining to equity of access to health services. They note that it is
a horizontal equity principle and a purely supply side consideration, addressing the
extent to which there exists equal access for equal need. They define access as referring
to: "the ability to secure a specified range of services, at a specified level of quality,
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subject to a specified maximum level of inconvenience and cost, whilst in possession of
a specific level of information"' (Goddard & Smith, 2001, p. 1185). In line with their
definition, they note that variations in supply side can arise due to differences in
availability, quality, cost and information. They caution, however, that it is difficult to
observe access directly and that it is usually utilisation that is observed which reflects
the extent to which 'potential access' is converted into 'realised access'. These are the
definitions and issues relating to access that are applied in considering the equity
implications to users of the policy studied in this thesis.
6.3.2.2 Implications to users
The results of this study suggest that users would benefit overall (i.e. on average) in
terms of time and resource costs if they substitute accessing P medicines over-the-
counter from community pharmacists as opposed to obtaining them on prescription from
general practitioners.
However, closer scrutiny of the findings indicated that current policy arrangements that
control access to P class medicines, yield mixed results, advantaging some and
disadvantaging other users, both in terms of their willingness to attempt substitution and
the total time and resource costs they incur in accessing P medicines. Generally
speaking, healthier, more affluent users were significantly more likely and less affluent,
iller users significantly less likely to attempt to substitute. Further, both total and time
costs were, generally, significantly higher among users reporting less favourable socio¬
economic circumstances; who perceived themselves not to be in good health; and who
were more frequent users of primary care. The crucial point is that in current policy
circumstances, already disadvantaged people are further disadvantaged, not in terms of
monetary, out-of-pocket expenses, but in terms of time and, consequently, total costs.
While the policy makes good sense overall (on average to all key stakeholders) users
fare least well. Resource savings swing heavily towards the health sector. It should be
acknowledged, however, that users are also taxpayers who pay for the NHS and thus
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have an interest in reducing its costs. That said, users would be only marginally better
off on average overall. They would face an increasing proportion of time and resource
costs. Over half (55%) of users would be worse-off in terms of money costs, which
would increase between two to seven times, with the majority of these increased costs
borne by users in less favourable socio-economic circumstances.
Different sensitivities regarding time and money prices existed among different user
groups. More affluent users appeared willing to pay higher money prices in order to
obtain P medicines from community pharmacies. There may be many reasons for this
including: preference to use the pharmacist whenever possible; reluctance to visit a
doctor; enhanced convenience, including reduced waiting times to access care and no
need to take time offwork; desire to obtain particular medicines e.g. those blacklisted on
NHS prescribing lists; and ability and willingness to pay. These reasons and others were
cited by users in this study when asked about use of community pharmacies. In contrast,
it appears as if money rather than time prices were key in discouraging substitution
attempts among less affluent users. Other research has shown that users who may find it
financially difficult to buy medicines over-the-counter, see general practitioner
consultations as a way to get medicines free (Hassell et al., 1997).
Equity implications to users
Having summarised the key findings to users, it is interesting to consider the potential
equity implications associated with them. For the reasons specified in section, this
section will focus on equity issues pertaining to access.
The results suggested that while users accessing P medicines on prescription from
general practitioners incurred lower out-of-pocket medicine costs, they incurred higher
costs overall when the value of their time was accounted for. This is interesting as it
suggests that these users were making seemingly 'irrational' choices, opting to pursue
consultation routes that consumed more of their resources overall, increased their
waiting times and delayed their access to care.
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This delay in accessing care is important when one considers the often minor and self-
limiting nature of the conditions concerned. Users whose only option is to consult a
general practitioner to obtain a prescription (which they receive free) must wait longer,
consigning them to suffer relative inconvenience and discomfort, compared to users who
can afford to buy the required P medicine immediately.
Thus, the key equity of access principle upon which the NHS is based may be being
violated under current primary care policy conditions. Contrary policy directions appear
to exist. The current government is committed to policies that enhance social justice,
reduce inequities and address social exclusion issues (Department of Health, 1997b;
Department of Health 2000). For example, recent government policy documents
propose that patients should get 'access to the NHS based on need alone and not on your
ability to pay' (Department of Health, 1997b). Yet, it appears as if access and equity
policy goals clash in their efforts to open up access to minor ailment care via medicine
deregulation and encouragement of self-medication and greater use of community
pharmacies. The policy appears to be sensible and well intentioned. However, it may
inadvertently be introducing inequities of access in the primary care system. An
important consideration at a time when government policy objectives aim to ensure, 'fair
access to consistently high quality, prompt and accessible services right across the
country' (NHS Executive, 2001).
Access is, of course, a complex and multidimensional concept (Rosen et al., 2001).
Gulliford et al (2002), like Goddard and Smith (2001) highlight the important distinction
between 'having access' and 'gaining access' (similar to Goddard and Smiths 'potential'
and 'realised' access). They note that gaining access is dependent upon financial,
organisational and social or cultural barriers. In theory, all users in the study 'had
access' to P medicines over-the-counter from community pharmacies. In reality,
however, many did not 'gain access' to them by actually buying them. Again though,
there may be many reasons that users opted to gain access to their P medicine from a
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general practitioner (as opposed to from a community pharmacist) making their choices
entirely reasonable, if not rational (Etzioni, 1988; Hargreaves and Heaps, 1992), many
of which relate to the potential barriers to utilisation identified by Gulliford, including:
inability to afford or unwillingness to pay for medicines over-the-counter; valuation of
personal time at less than the financial costs faced; prescription exemption status; and
preference to consult a general practitioner rather than a community pharmacist for
advice and medicines to treat minor ailments (Gulliford et ah, 1992; Gulliford et ah,
1992). Again, many of these issues were raised by users in this study when asked about
use of pharmacy and doctors' services.
Facilitating more expeditious access to P medicines for the treatment of minor ailments
is one of the key rationales underpinning deregulation trends for such medicines.
However, this improvement in access appeared only to be realised among certain groups
of users. In theory, access to P medicines was not denied to any group. It is difficult to
conclude this with any certainty however. The study design was not prospective and
involved users which, in the absence of a population denominator to ascertain level of
unmet need, made this impossible to determine. However, a twin-track system appeared
to be operating, with some users in a fast and others in a slower lane. Those users able
and willing to pay for P medicines over-the-counter, with no strong preference about
consulting a community pharmacist as opposed to a general practitioner to access P
medicines, were able to by-pass general practice and access P medicines faster (reducing
both their waiting time and total time overall). This could be regarded as the primary
care equivalent of queue jumping in secondary care services, or a form of covert
rationing - pay or spend much longer accessing medicines. Yet, theoretical and
empirical models suggest that the price elasticity of demand is likely to be higher for
lower income groups and that user charges are unlikely to promote equity or reduce
existing health status inequalities (US Congress, 1993; Eversley & Shepard, 1998; Mills
& Lee, 1993; Van Doorslaer, 1993; McPake, 1993; Lundberg et ah, 1998; Reutzel,
1993). Meeting monetary charges is always likely to be difficult for certain user groups,
who by default, therefore, are denied the opportunity to benefit from quicker access to P
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class medicines to manage their minor ailments. Further, public health principles
generally advocate against the levy of charges on primary health care services in view of
their 'gatekeeper role' (Mills & Lee, 1993). User charges should not hinder general
access or continuity of care.
It is important to consider, however, that while there did appear to be differences in
access, convenience and cost to users, how material and important are these differences
likely to be in terms of their health consequences, or in terms of NFIS resource
priorities? It is also important to remember that the potential inequities identified
concern the costs of access as opposed to access per se. To what extent does it matter
that people feel that they have no option but to spend more time consulting a general
practitioner to access a medicine or who choose to do this because they can access
medicine free that way? If such people put a low opportunity cost on their time, does
this reduce the need for the NHS to respond? Is it unfair for someone who is richer in
time to use that commodity while someone else with less time uses money to access a
service?
Potential emergence of inverse care
Thus, recent policy restructuring access to P medicines may be invoking what might be
regarded as a modern-day manifestation of the 'inverse care law'(Hart, 1971). Tudor
Hart (1971) hypothesized that 'the availability of good medical care tends to vary
inversely with the need for it in the population served'. He suggested that market
mechanisms for allocating health care result in inequitable access to medical care
services. A number of studies have subsequently investigated the operation of inverse
care laws within the UK, some of which confirm its existence (Benzeval et al., 1996;
Ben Schlomo et al., 1995; and Gillam 1992) and others that refute it (e.g. Powell, 1986
and 1990; and Wyke et al., 1992).
It is useful here to consider the contemporary relevance of the inverse care law, as well
as debates around its meaning or operation and its salience to this study. For example,
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Powell (1990) disputes the existence of an inverse care 'law', noting that key studies that
appear to confirm its existence inadequately define or measure key concepts associated
with its investigation e.g. need, availability and quality of care. In particular, he notes
that they narrowly adopt need as their only concept of social justice, disregarding others
including, for example, merit or common good (Powell, 1986). Further, he notes they
fail to differentiate between ascribed 'normative' need and personal 'felt' need, or to
consider the multidimensional nature of need.
Many of these issues are also relevant in considering whether policies aiming to enhance
access to P medicines have introduced inverse care within primary care. The inverse
care law as formulated by Hart is predominantly about access to care services. As noted
previously, a key aim of the policy under study is to enhance and expedite access to P
medicines. As such, Hart's inverse care law is of central relevance.
This study suggests differential access to P class medicines currently exists in primary
care (in that inequalities in access to P class medicines exist that are systematically
related to socio-economic status). It did not, however, find this to be operating at the
level of a 'law'. Results were not invariant. Rather, general trends emerged from the
data at the sample population level. Effects on individuals or groups of individuals
were, however, found to vary. Indeed, the study findings could be interpreted to
indicate that the neediest get access to equal if not better quality advice but at a higher
time costs and lower financial cost. Whether this amounts to confirmation of inverse
care is open for debate.
Major difficulties exist defining need and the 'appropriate response' of care systems to
needs (Powell, 1986; Carr-Hill and Sheldon, 1991; Sheldon et al., 1993). Inadequate
definition of central concepts such as need, availability and quality of care, pointed out
by Powell, are also evident in this study, making robust, meaningful comparisons about
relative access, use and outcomes across different users and groups difficult, if not
impossible.
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For example, if this study adopted common good as its main measure of social justice,
then the results at the societal level indicating overall improvements, on average, would
suggest that the policy was successful, even though certain groups of users appear to be
disadvantaged. Likewise, were it to be explicitly acknowledged that the NHS cannot
continue to provide all health care services free at the point of use, with users expected
to contribute to their care costs, then ascribed versus personal, felt need may be of key
relevance. Further, if an explicit policy decision was taken, de-prioritising access to
minor ailment care relative to more serious care needs, then the inverse care apparently
emergent from deregulation of medicines may be acceptable, even if regrettable. In
addition, this study is unable to make any judgement on the 'quality of the care'
accessed by users adopting different routes to access their P medicines. For example,
perceived differences among users regarding the quality of care obtained from the
general practitioner compared to the community pharmacist may be the main driver for
users to elect to obtain their medicine via prescription routes, rendering time or money
costs as either secondary or even unimportant. In the absence of knowledge of the
explicit policy intent of medicine deregulation for minor ailment care, or a fuller
understanding of user preferences and choices regarding different ways to access P class
medicines and minor ailment care, it is not possible to arrive at any final judgement on
these key issues.
Caution must, however, be urged in treating equity in provision of services as
synonymous with access. For example, community pharmacies currently provide access
to P medicines over-the-counter for anyone who wishes to buy them (within their
licensed indications). User choices are, however, rarely free from external constraints.
Recall Duesenberry's aphorism that, 'economics addresses how people make choices
and sociology about how they have none to make' (Etzioni, 1988; Baron, 1994). Poorer
access and/or outcomes among certain user groups may relate to multiple factors,
including economic and legislative structures and access to material resources in their
broadest sense e.g. adequate housing and education, or some combination thereof
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(Townsend & Davidson, 1982; Wilkinson 1992 and 1995; Kaplan et al., 1996; Kennedy,
Kawachi and Prothrow-Stith, 1996).
6.3.2.3 Implications for primary care
The implications of encouraging users to self-medicate using P medicines accessed from
community pharmacies, as opposed to general practices, appear to be generally positive.
At the sectoral, primary care level, economic analyses of the policy are generally
favourable. It appears as though the substitution hypothesis implicit in the policy is
broadly realised and that, in addition to providing improved access to P medicines, scope
exists to deal with minor illness episodes more efficiently within primary care.
If the aim of policy promoting self-medication for minor ailments is to facilitate more
expeditious access to care and reshape and move the NHS towards a more responsive,
customer friendly, immediate care system, that gets the right patients to the right
professional and place at the right time, one may consider the policy a success (albeit
with some qualifications). An alternative interpretation of the policy rhetoric could,
however, be that it is more about giving the health service what it wants, as opposed to
increasing consumer choice and responsiveness (Eyles & Woods, 1986). Whichever
interpretation, encouraging substitution between general practitioners and community
pharmacists is a core component in enabling delivery of the government's agenda of
'graduating access' to primary care services and matching users to the most suitably
qualified primary care professional to deal with them, as well as helping to assist in the
commitment to reducing waiting times to consult with professionals in primary care
(Department of Health, 2000).
However, a number of key questions remain unanswered and the full impact of this
service reorientation remains unclear. In particular, the true effect on primary care
professionals' time remains unknown. Economic evaluation methodologies generally
assume that freed resources are put to efficient, worthwhile, alternate uses (Drummond
et al., 1997) This may not be the case and little may change. If freed general practice
296
consultation slots are filled, the impact on the volume of medicines prescribed by
general practitioners and dispensed by community pharmacists is uncertain. Ideally,
such policy shifts would hope to reduce demand and/or effect changes in the case mix of
consultations, with general practitioners dealing with more serious clinical issues. The
Care at the Chemist and Direct Supply of Medicines pilots suggests, however, that the
impact on overall workload was very small, with general practitioners noting little
perceptible impact (Whittington et al., 2001; Schafheutle et al., 2003). Evidence from
research investigating national primary care skill mix experiments - NHS Direct and
Walk In Centres - also report limited impact on demand or the composition of workload
(Munro et al., 2000; Salisbury et al., 2002a; Salisbury et al., 2002b; Salisbury et al.,
2002c). Further, if one considers the 'symptom iceberg' (Hannay, 1979) that suggests
that only one in forty people with symptoms present for care, then this may not
necessarily hold. Freed general practitioner slots may equally be filled with previously
unmet minor illness need.
Further, while the policy may yield technical efficiency gains (i.e. getting the most out
of available resources) in the management of minor ailments in primary care, this does
not necessarily mean that it is allocatively efficient in terms of optimising the
distribution of resources within the primary care sector specifically or the NHS
generally. Within the resource constrained primary care sector, do the benefits of this
strategy outweigh the costs and how does it compare to other potential uses of scarce
primary care resources?
The contribution of this policy initiative to the overall efficiency of first-contact, NHS
care has not been fully explored and cannot be based only on changes in the direct cost
of providing access to P medicines. Rather, it needs to be put into the bigger picture,
relating also to what is happening in other care centres, with a more comprehensive
understanding of the level of additional or duplicative care provided and of the extent of
substitution and/or complementarity between services and professionals. For example,
what is the impact of increased self-medication not only on subsequent general practice
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utilisation but also on telephone consultation to NHS Direct or NHS24, general practice
out-of hours services, minor injury units and accident and emergency departments? As
the boundaries between different types of unscheduled, first contact care become
increasingly blurred, teasing out the issue of old versus new demand becomes
increasingly relevant, albeit difficult. It is crucial to remember that we are dealing with
new health care contacts, as well as those that already exist.
Even if such policy initiatives succeed in changing demand patterns, are they cost
offsetting? These questions are incredibly difficult to try to answer as any resultant costs
and savings occur across different budgets and care sectors. In addition, the impact of
such changes is situationally dependent upon capacity and demand issues across sectors.
For example, the marginal benefit of reducing demand for general practice consultations
may be negligible if practices face excess demand and freed consultation slots are
immediately filled. Related to this point is the importance of time horizon. Even if
costs or savings were incurred across services, they may not be obvious in the short-run
and only relevant if they permit long-run reconfiguration of service conducive to
improving both the technical and allocative efficiency of service provision overall.
Thus, the impact of such initiatives is often far from obvious and incredibly difficult to
trace or detect.
There may also be broader implications of the increased array of 'first access' or
'gateway' services within primary care on quality and continuity of care. Is there a
danger that consumerist, episode-based care systems might have a detrimental effect,
disrupting personal continuity of care, potentially resulting in fragmentation of care or
separation into service 'silos'? Also, what is the impact on quality of care? How do we
ensure consistent, evidence-based care and continuity of information across varied
providers? This has been difficult enough to achieve within single care settings in the
NHS; achieving this between sectors and professionals is likely to be fraught with
difficulties. Are there dangers inherent to diluting the skill mix among providers of first
contact care? A plethora of services and a mixed economy of care may provide several
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ways into the system however issues of consistency in training and advice inevitably
arise. Further, offering increased choice may not be a good thing, in the absence of
understanding how people make them. With enhanced choice comes the danger that
people make the wrong choice, with potentially adverse consequences. Ultimately, we
need to consider whether current policy aiming to graduate access to primary care - of
which medicine deregulation and encouraging increased self-medication using P
medicines for minor ailments are central strands - are meeting people's needs and, in
particular, are they reaching vulnerable groups? Ongoing attention must be devoted to
investigating emergent variation in use to ensure that no groups are routinely or
systematically disadvantaged. Consequently, future efforts to change or improve access
to P medicines in primary care would require us to learn more about users who either did
not consider substituting or those that were unsuccessful in their substitution, in a bid to
address these issues.
Finally, the economics of the consultation(s) remain unknown. The economic analyses
presented in this thesis assessed the economics of the two existing routes to access P
medicines, as opposed to the economics of user consultations with either general
practitioners or community pharmacists to access P class medicines. This is a fine but
extremely important distinction. This study has contributed to understanding of the
relative costs of general practice versus community pharmacy routes to access P
medicines. However, in the absence of direct benefit assessment of clinical and other
relevant outcomes (to both professionals and patients) it has not been possible to
undertake comprehensive economic evaluation of the two access alternatives. This work
remains to be done.
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6.3.2.4 Implications for the NHS overall
The results presented suggest that the policy encouraging increased self-medication for
minor ailments, utilising P class medicines obtained from community pharmacies,
appears to have been successful on many fronts. However, as with any policy or service
development, it should not be viewed in isolation. It is important to consider its
relevance not only to key stakeholders but also to adopt a more strategic, 'whole systems
view', considering its implications for the NHS overall and society generally. This
systemic view is crucial if, amid ongoing organisational change in the NHS, we are to
avoid conducting isolated policy analyses upon a disparate collection of services as
opposed to the health system as a whole. In this context, the broader implications of
this research in relation to access to care are also of relevance.
Community pharmacy and general practice services do not operate in a vacuum.
Consequently, a number of service level questions emerge from this policy development.
For example, where does community pharmacy feature on a complete patient pathway or
journey, within primary care and beyond? How does it fit in with the existing spectrum
of services? Might we be unintentionally building in contrary expectations, for example
between the primary and secondary care sectors, by increasing access for less serious
conditions at a time when there are genuine problems meeting access for more serious
ones? It is a perplexing irony that within the current NHS system the most seriously ill
often wait while services are developed to speed up access to minor ailment care.
Symptom and service icebergs are traditionally inverted i.e. with the vast majority of
resources dedicated to providing services and care for those with more serious needs and
vice versa. One could argue that investment in improving first contact care is overdue
and will go some way to redressing this historical trend. It has been argued that if equity
of access to health care services is, a desirable policy goal, this should also apply to self-
care and self-medication opportunities (Lowell & Levin, 1990). This begs the question
of whether it would be desirable for the NHS to be funded to provide an unlimited scope
of service on equitable access terms? Would encouraging increased access for minor
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ailment care be a good use of the resources available to the NHS overall? For example,
the cost of prescriptions for laxatives in primary care (which are routinely available as
both general sales and P medicines) are currently said to exceed the NHS spend on
cancer treatments overall (Bond, 2004, Personal Communication). Such examples may
make one consider whether the NHS should pay for P medicines at all?
Often focused policy evaluations begin with the tacit assumption that the objectives are
worth meeting (Drummond et ah, 1997). But are they? Do the benefits justify the
costs? Are there more efficient ways of achieving the same objective (e.g. by simply
increasing capacity in general practice)? In a society seemingly increasingly less
tolerant of illness, kquick-fix' solutions are popular. Again though, one should consider
at what cost? For example, what are the potential implications for appropriate use of
services and medicines? Indeed, this may be an argument for retaining a measure of time
and financial cost barriers in the minor ailments system. Finally, is there a danger that
we may decrease people's ability to self-care, with potentially damaging long-term
consequences (Bradley & Bond, 1995)?
A related issue, is the level of service that the NHS can reasonably be expected to
provide. Most people would welcome improvements in the process outcomes associated
with increased use of P medicines, such as quicker access, reassurance and convenience.
Indeed, economists increasingly recognise the value and necessity of incorporating such
process attributes of care within the cost-benefit calculus, thus avoiding an overly
consequentialist focus on health outcomes only (Ryan & Shackley, 1993). These are
worthy goals, but relative to what, and at what opportunity cost? There is no doubt that
process attributes were important in users' consultation choices in this study,
convenience particularly. How these process outcomes should weigh relative to other
outcomes remains a contentious issue and question for debate (Bond, 2003). The
convenience of a non-appointment service to access P medicines may seem a perfectly
reasonable way to improve access to medicines from the users' point of view. However,
there may be a fundamental difference between reasonableness from the users' point of
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view and efficient use of resources within the health care system overall. Improving
access to minor ailment care may indeed enhance users' experience of processes of care,
however, it may also increase total demand with little or no real health gain associated.
If, however, users are indeed substituting P medicines obtained from community
pharmacists in place of general practice consultations then, they may in fact be relieving
pressure on the NHS. However, if access is enhanced only among relatively healthier,
middle-class users, with fewer health needs, that can afford to pay (the health care for
working people critique) then inequities may be introduced.
Access is another key consideration at the system level. Improving access to resources
(community pharmacies and P class medicines) facilitating users' ability to self-manage
minor ailments was a key rationale underpinning efforts to encourage substitution
between primary care professionals and services. However, the 'access' concept goes
beyond individual access to individual services. Access issues concern the health
system as a whole. Efforts to improve first contact or immediate care should, in
principle, be applauded. However, once users are in the system what happens then? If
initial access is expedited, by enabling users to obtain certain medicines, only for users
to languish elsewhere in the system if further care is required, then there is the danger
that all that has been added is an additional and potentially duplicative layer of service,
elongating the patient pathway and complicating it. It is important to remember that
access is not synonymous with speed or quickness. Being seen quickly may not be
users' only priority, even if it is a major political priority in the UK. Access is also
about choice and varied routes into care. Ensuring appropriate access is key for all
concerned. For example, the evaluation of NHS Direct developments indicated that
15% of users were directed to a level of care more than they required (i.e. over-
management) and 1% to a level of care less than they required (i.e. under-management)
(James Munro, personal communication). Consideration of the appropriateness of users'
choice of consultation route to access their P medicine was not feasible in this study.
However, it is an important question, worthy of further study.
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Care must also be taken to minimise the development of perverse incentives in
introducing policies that result in increasing proportions of total time and resource cost
burdens being met by users. For example, e.g. charging for primary health care services
(direct or otherwise) may lead to over-utilisation of 'free' accident and emergency
services. Lack of information regarding the cross-price elasticities between health
services make such impacts difficult to estimate. However, reduction in inefficient use
of one service could be replaced by increased inefficient use of another. Further, there
may also be the danger that by encouraging more affluent, and usually healthier, users to
by-pass the prescription medicine system that we might encourage risk selection,
separating the healthy from the sick, potentially undermining the community insurance
basis that the NHS is based upon.
6.3.2.5 General policy implications
Finally, there are a number of general policy implications and lessons resulting from this
study. From a public policy perspective, the policy evaluated appears to be sensible and
consonant with the government's objectives of encouraging more graduated access to
first-contact care (Secretary of State for Health, 1997; Rogers, Entwistle & Pencheon,
1998). It would appear to promote a more technically efficient approach to expediting
access to P medicines, optimising lay and professional skill mix. At the same time, it
offers potential to enhance allocative efficiency by freeing up primary care resources for
relatively 'needier' patients, facilitating redeployment of saved resources to improve
existing, and develop new, primary care services.
This policy presents an interesting example of a policy that makes society better off, on
average, in that while it shifts an increasing proportion of the financial costs met by
users, it reduced the overall time costs they face in doing so, thus reducing overall costs
and speeding up their access to care. However, as with most policies, it makes some
users better off and others worse-off.
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It is almost impossible to introduce changes that disadvantage no one. Policies are,
however, more likely to be successful if the costs are diffused over large numbers of
people, as with the policy in this study (Getzen, 1997). The crucial question for policy
makers is whether the post-policy distribution of benefits and costs is preferable to the
pre-policy situation and even if it is not, is it acceptable? The answer to this question
will undoubtedly depend on balancing efficiency and equity alongside political
considerations (Sloan & Brabowski, 1997).
The policy is also interesting as it sheds light not only on how policy influences
behaviour (at the structural level) but also how behaviour influences policy (at the
agency level). It has successfully encouraged many users to substitute. However, the
policy has not completely altered behaviour. There remain substantial numbers of users
who have not changed how they access P medicines, continuing to consult general
practitioners to obtain them on prescription. Thus, the policy as currently formulated is
only partially efficient. A number of factors may explain this.
Previous research evidence and the results of this study indicate that demand for
medicines is price-elastic. There is no reason to think that P medicines are any different.
Thus, consideration of the pecuniary incentives inherent in the current policy is useful.
The policy currently appears to incentivise substitution where the resource-outcome
trade-off is favourable to the user concerned. This presupposes, of course, that the user is
happy to access their medicine from a community pharmacist rather than a general
practitioner.
The fact that the policy is not completely efficient is, perhaps unsurprising.
Consideration of the pecuniary incentives inherent in the policy is again useful.
Substituting from general practices to community pharmacies to access P medicines
would have resulted in over half of the study users facing increased financial costs but
reduced time costs. Whether users would perceive themselves to be better off in this
situation depends on how they value their time relative to the financial costs they faced.
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In this study, user time was explicitly valued in order to accord it an appropriate
opportunity cost and factor it into the cost-benefit calculus. However users' personal
time valuation is crucial. The monetary valuation attached to the resources consumed
may not necessarily match the actual money costs faced by users (e.g. users may have
incurred absolutely no direct financial cost if they walked to the general practitioner and
obtained a prescription for which they were exempt from payment). The opportunity
cost of time to users cannot be assumed to be equal. This has important implications. If
private costs to users are perceived to exceed private benefits, then compliance with
desired policy must be expected to be low (Posnett & Jan, 1996). Policies may seem to
benefit the majority of people according to objective evaluation criteria, but may not
benefit the majority according to self-assessment (Heckman & Smith, 1994). Thus, if
users do not consider their time to have an opportunity cost, or if they consider their time
to be less valuable than the financial cost they faced, then it makes sense that they would
still opt to access their P medicine on prescription from a general practitioner. Thus,
money rather than time prices may have dominated some users' choices. If a user
perceived him/herself unable to meet the financial cost of medicines, substitution may
not have been perceived to be a realistic option, or seriously considered. Among such
users, the current policy does not, nor does it ever seem likely to, incentivise
substitution. Indeed, the opportunity to substitute the community pharmacy in place of
the general practice as the access point for P medicines may have been effectively
denied to such users. Again, however, it is important to note that pecuniary incentives
present only one among a variety of alternate explanations regarding why users chose to
attempt substitution or not. For example, for users with longstanding illnesses, taking
multiple medications or who believe only doctors should dispense medicines, they may
never have considered visiting a community pharmacy to access a P medicine,
regardless of the time or resource costs they faced.
The challenge for health policy makers is to optimise the efficiency of the policy, in the
face of heterogeneous response, by maximising the substitution opportunities from
general practice to community pharmacy to access P medicines, among users happy to
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do so (Heckman, 2001). In order to achieve this, the policy must present win-win
scenarios to individual users and not only on average across the population of users.
There is little in the short run that policy makers can do to change the socio-
demographic and socio-economic characteristics of users. They can, however,
counteract the sub-optimal response by modifying the policy to remove any potential
obstacles to substitution among users willing to try to do so. The financial obstacle is,
perhaps, the most obvious one. This is, perhaps, fortuitous, as financial incentives are
generally the most direct (albeit crude) lever available to policy makers to influence
behaviour. Prescription exempt users may be more likely to consider substituting
between the general practitioner and the community pharmacist to access P medicines if
it is cost-neutral to them in money cost terms. Thus, were such users able to access P
medicines over-the-counter from community pharmacists free of charge, reflecting their
prescription exemption status, this would seem more likely to incentivise them to
substitute. This is an option that has been considered by policy makers and found to be
workable in pilot schemes (Pharmaceutical Journal, 1999; Whittington et al., 2001;
Schafheutle et ah, 2003). The modelling scenarios investigating the cost implications
associated with making medicines free over-the counter to prescription exempt users,
while paying pharmacists a fee to offer this service, also suggests that this would not
compromise the welfare improvements associated with the policy overall. This would
enhance the efficiency and equity of the current policy, in that inequities could
potentially be minimised and the welfare gains more evenly distributed.
Further, evidence from the literature indicates that there is broad support for increased
use of community pharmacies (Hassell et ah, 1998; PAGB, 1998). A third of users
participating in the telephone follow-up interview agreed, noting that they would prefer
to use the community pharmacy as opposed to general practice whenever they could. Of
course, unless it is made impossible to access P medicines from general practitioners, it
will never be possible to ensure that the substitution policy is totally efficient. There
will always be users who, for a variety of reasons, will always opt to access their
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medicines from a general practitioner. That said, removal of the financial cost obstacle
may go a long way to improving the efficiency of the policy. The results of this
hypothetical policy scenario indicated a win-win situation on average overall, and for the
vast majority of individual users (Whittington et al., 2001 a & b; Schafheutle et al.,
2003). Further, it has the advantage that it involves relatively minimal disruption to
other services and requires little new resource (Whittington et al., 2001 a & b).
This potential policy solution is not, however, without risk. It could potentially open-up
the floodgates and expose the NHS to massively increased medicine costs. Thus, a
system would require to be designed to minimise over-consumption (moral hazard) as
well as inappropriate consumption (Donaldson & Gerard, 1993). For example, making
P medicines available free over-the-counter to prescription exempt users could be an
option only available to users who had previously consulted their general practitioner
about the illness and medicine concerned and required a repeat prescription (for the
same medication). Similarly, the medicines may only be made available free on repeat
prescriptions from community pharmacies in the same quantities available in their over-
the-counter licensed indications. Further, limits could be set for the medicine, either in
terms of total consumption or number of requests, with users referred back to their
general practitioner once those limits were reached to ensure continued safe and
appropriate usage of the medicine concerned. Such efforts could help to improve the
efficiency of policy efforts to encourage substitution between general practitioners and
community pharmacists as access points for P medicines.
Continued attention to the policy of increasing use of community pharmacies will,
however, be necessary. For example, Rogers and colleagues highlight the importance of
'place' in the demand for and use of community pharmacies. They remind us that
inverse care can also arise related, not only to comparative use of community
pharmacies, but also in terms of the quality and level of services, the attention people
receive and the environment within which services are delivered. Consideration of these
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issues will become increasingly important as more services are devolved to community
pharmacy (Roger, Hassell & Nicolaas, 1999).
It is important to remember, however, that while eliminating differential access is the
prime safeguard against emergence of inequities, access is only one contributory factor
in understanding health and illness, minor illness included. While evidence exists to
suggest that health and illness are patterned by social structures there is little evidence
about the importance of access to health care services per se. Mildred Blaxter (1996)
highlights this, noting, 'no service can offer equal treatment for equal need, it can only
offer equal access to doctors who will inevitably apply different criteria of need and
different kinds of treatment. Equality of access does not necessarily mean equality in
either treatment or outcomes' (Blaxter, 1996). This is illustrated within the current study
also. Even if all users could access P medicines in equal time and free from their
preferred practitioner (for example if access to general practices was made more like that
in community pharmacy) one would not expect to achieve equality in treatment or
outcomes). Differences in treatment and outcome are still likely to emerge dependent
upon numerous factors associated with the consultation process (e.g. professional
expertise and experience, the exchange between user and care professional, format and
length of the consultation etc). It is important to acknowledge, therefore, that, whatever
the equity principle adopted and however hard we try to maintain equity of access to
services, trade-offs will always occur between efficiency equity and choice.
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6.4 Implications for future research
A number of implications for future research emerge from this study. There is much
still to learn about why different users access P class medicines in different ways.
Interdisciplinary, multi-level frameworks are required to understand user decisions to
access P medicines for minor ailment care. Research utilising a range of theoretical and
methodological approaches can help with this (Jesson, 1993; RPSGB, 2000). The
mainstream neo-classical, microeconomic theory underpinning the methods in this study
is uni-directional. While providing useful insights at the micro, individual user level, it
is less useful for understanding or predicting behaviour at the societal level. (Coast,
1999; Ormerod, 1994; Pescosolido, 1991; Pescosolido, 1992; Tudor Edwards, 2000).
Social structures are not irreducible to individual behaviour (Etzioni, 1988; Etzioni &
Lawrence, 1991). Thus, alternate theoretical perspectives, such as institutional
economics, may be usefully applied to further consider many of the micro-macro linkage
issues emerging in this study. The entrenched utilitarian, rationalistic, individualistic,
neo-classical economic paradigm trivialises the role of habit, culture and institutions
(Etzioni, 1988; Etzioni & Lawrence, 1991; Pescosolido, 1992; Baron, 1994; Lewin,
1996). To understand individual action, one must understand also social context. This
vision is one of 'homosociologicus' in contrast to 'homoeconomicus' (Etzioni, 1988;
Hargreaves & Heap, 1992). Institutional economists contend that policy programmes
cannot, and should not, be evaluated in isolation from the communities in which they are
set as this seriously limits the usefulness of policy appraisal undertaken on this basis
(Jan, 1998). An institutionalist approach would depart from the deductivist mode
characteristic of mainstream microeconomic theory and focus instead on historical and
institutional contexts underpinning the system, seeking structural evidence to explain
patterns of behaviour. (Coast, 1999; Blaug, 1996) It would investigate the
multidimensional relationship between demand for P medicines and factors other than
price, developing much needed, broader, socio-economic theories of self-care behaviour
generally and consumption of P medicines specifically; exploring economic,
infrastructural and cultural-cognitive contexts of self-medication (Geest & Hardon,
1990; Kirkbusch, 1990; Tudor Edwards, 2000). Mays et al (2001) reflecting on the
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'messy' process of evaluating evolving health policies agree, noting that consideration
of the impact of the context in which interventions are introduced on their potential
outcomes is essential and likely to increase the relevance of evaluations for policy
development (Mays, Wyke & Evans, 2001).
More micro level work is also required. There is currently an absence of developed
models of demand for individual or groups of drugs. This is required to progress more
macro level analysis (Bond, 2000). In addition, evidence on the cost effectiveness of
over-the-counter P drugs is scarce and desperately required (Richardson & Maynard,
1998) (e.g. to develop formularies for over-the-counter medicines to inform consumers
and ensure that the medicines they purchase are of evident effectiveness and least cost
(Bloor, 1997)).
A particularly contentious issue in this study, worthy of more attention, concerns the
inclusion of indirect costs and benefits within evaluation. Currently, there is little
consensus on whether, and if so, how, to impute shadow prices for non-marketed and
indirect care inputs generally, or to value the opportunity cost of user time, specifically.
(UK Working Party on Patients' Costs, 1999; Palmer & Raftery, 1999; Posnett & Jan,
1996; Koopmanschap & Rutten 1994; Torgerson, Donaldson & Reid, 1994). Yet, in
situations where user time inputs to care processes are a key, and perhaps the only,
difference between options, as in this study, it is crucial to decide. A macro level,
societal preferences approach versus a micro, individual user preferences approach
implies very different opportunity cost perspectives. Yet, ensuring appropriate
consideration of each approach is essential in policy appraisals. If we accept that equal
real resources (e.g. time) may not have equal opportunity costs to different groups in
society, then policy appraisals should investigate the full range of cost and benefits,
direct and indirect, accruing to all key actors, identifying differences between them, even
if small. Cumulative, small changes at the individual level potentially affect the
implementation and efficiency of policies at the societal level. Only when we include
such costs can we adopt a truly societal perspective and consider the distributional and
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equity implications of changing policies, and their likely effects on successful
implementation, alongside insight regarding how to better tailor and target future
policies.
There is also much scope to explore the relevance and importance of less tangible costs
and benefits in users' decisions to access medicines. The current study may be criticised
for being conducted in a narrow consequentialist manner, focusing only on tangible
effects. Yet, a much broader range of costs and benefits may be relevant within patients'
utility functions, often less tangible but still worthy of investigation (e.g. the value of
information, reassurance and anxiety) (Ryan, 1992; Tymstra, 1986; Tymstra, 1987;
Botkin & Alemango, 1992; Berwick & Weinstein, 1985; Mooney & Lange, 1991). It is
necessary to consider all potential sources of (dis)utility relevant to individual choices
about accessing medicines. Future research in this area must avoid tunnel vision and
cast the appraisal net wider to include these. Greater effort is required to identify
attributes important to users in their decisions about accessing medicines, the relative
weights they attach to them, potential trade-offs that exist between them and their
influence on decision making. The extent to which this might be expected to influence
the magnitude or direction of the current study is unknown. Regardless, such research
would improve our understanding is user behaviour and choice in this area.
Detailed economic appraisal of the role of community pharmacists is also necessary
(Bloor, 1997). Bero et al., (1997) highlight the lack of systematic reviews investigating
the effects of the extended roles of pharmacists on the process, costs and outcomes of
health service delivery. Questions regarding whether the profession can provide
equivalent care compared with other health professionals and the relative costs and
benefits of doing so are critical, yet unanswered (Bero et ah, 1997; Mays, 1994).
Redressing these gaps in the evidence will be crucial if the pharmacy profession is to
promote its enhanced role based firmly on evidence based practice (Bond, 2000).
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Mixed method approaches, combining both qualitative and quantitative tools, are likely
to be very useful in developing a fuller understanding of complex user preferences and
choices in accessing P medicines in primary care. Indeed, there is growing support in
the literature advocating the use of mixed methods in health services research (Baum,
1995; McKeganey, 1995; Brannen, 1992; Mason, 1994; Milburn et al., 1995). Baum
notes, 'given the complexities of most contemporary public health problems, researchers
need all the methodological variety they can muster to be effective' (Baum, 1995). A
recent review of research and development within community pharmacy concurs,
highlighting the important role multi-disciplinary research will play in the development
of the profession (Bond, 2003).
Qualitative methods could be productively applied to investigate the extent to which P
medicines are considered important or unimportant commodities by different user
groups; to tease out the importance of structural and institutional factors on individuals'
choices in relation to how they access P medicines; and more comprehensively identify
and measure the full range of costs and benefits relevant to different actors. They may
also be helpful in relating user preferences to context, within a broader institutional
analysis, providing rich understanding of the impact of policy on users. Further, they
may also assist in the design of more sensitive quantitative preference elicitation
instruments e.g. discrete choice experiments to investigate particular user preferences or
choices more fully (Ryan, 1996; Ben-Akiva, 1985).
Finally, future research investigating the relevance of time on user substitution decisions
in accessing P medicines would be useful. Data collection pertaining to complete
episodes and management of illness over time, as opposed to isolated snapshots
describing service use independent of illness, is necessary (Bentzen, 1989).
Longitudinal investigation of the use of P medicines in primary care would: assist in
teasing out the meaning of substitution, investigating the validity of the point versus
period substitution concepts across different users, minor illness and medicine groups;
thoroughly investigate new versus old demand issues; and more clearly define the
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substitution concept, its aims and processes, and the mechanisms considered most likely
to achieve it. It would also enable collection of fuller data sets facilitating out-of sample
testing and refinement of the existing model as well as more sophisticated analyses (e.g.
applying multi-level-modelling techniques, combining analysis of individual level
patient characteristics with small area level data, thereby potentially improving our
understanding of individual consumption behaviour). This would also enable increased
exploration of the relation between individual characteristics and the contextual and
institutional factors that shape individual behaviour; studying levels of influence and
multiple influence necessary to take forward theory development. In this way it will
become possible to explore the marginal effects of certain variables and their elasticities
of change, useful for considering the design of future policy.
Longitudinal analysis would also permit more in-depth consideration of issues, including
a more comprehensive 'whole-systems' analysis, focusing on not only first-order effects
associated with extending access to P medicines within primary care, but also second-
order, knock-on effects across the health care system more generally. This would
facilitate: more comprehensive analysis of any emerging variation in access and use
among different user groups and enable us to learn more about users who either do not
consider or who are unsuccessful in their efforts to substitute between general
practitioners and community pharmacists to access P medicines; consider in more detail
the true impact on primary care professionals' time; investigate impacts on patient-
professional relationships; and more fully analyse the distributional implications of
policies encouraging increased use of P medicines to self-medicate minor illnesses.




The substitution hypothesis implicit in recent policies such as deregulation of medicines
and encouraging increased self-medication is broadly affirmed. The majority of users
buying P medicines over-the-counter from a community pharmacist appeared able to
substitute this in place of accessing them from a general practitioner. Users' substitution
efforts were not, however, always successful. A sizeable proportion (one in five) of
users who bought their P medicine subsequently visited a general practitioner regarding
the same episode of illness. In addition, key questions remain regarding what exactly
constitutes substitution and its true impact on demand for primary care services. Clearer
definition of the substitution concept, its aims and the mechanisms and processes
considered most likely to achieve it is required.
Substitution away from general practitioners to community pharmacists to access P
medicines generates a win-win situation for society overall, with all key stakeholders
benefiting, on average. However, healthy more affluent users were significantly more
and less affluent, iller users significantly less likely to attempt to substitute. Both total
and time costs were significantly higher among those in less favourable socio-economic
circumstances, who perceived themselves to be not in good health, or who were frequent
users of primary care services. The crucial point is that in current policy circumstances,
already disadvantaged people are further disadvantaged.
Resource savings from the substitutions are concentrated in the health sector. Users are
only marginally better off, on average. They bear an increasing proportion of time and
money costs and more than half of the users within the study would actually have been
worse off in monetary terms. That said, their waiting times to access P medicines would
have been reduced. The cost minimisation analysis demonstrates that promoting
increased self-medication using P class medicines accessed from the community
pharmacy could, potentially, enhance both technical and allocative efficiency within the
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primary care sector, and optimise lay and professional skill mix. However, a number
key issues remain unanswered. The true impact on primary care costs is unknown, as is
the impact on the overall efficiency of providing first-contact care within the NHS. The
policy does facilitate better access for many users and is, therefore, consonant with the
government's policy objectives of encouraging enhanced, graduated access to first-
contact and immediate care services. However, it may, inadvertently, be promoting
differential access.
Currently, one may be forgiven for describing government efforts to enhance access to P
medicines by encouraging users to buy them 'Over-The-Counter, as policy making
'On-The-Cheap', with users 'Ok if They have the Cash'. If the policy goal is to shift the
resource burden associated with minor illness and first-contact care away from the NHS
and onto users, then the policy may be regarded as moderately successful. However, it
is not fully efficient and could potentially be introducing inequities regarding access to P
medicines. Differing time and money price sensitivities exist among users. Money,
rather than time prices appeared to dominate less affluent users' cost-benefit
calculations. For this reason the policy, as currently formulated, does not, nor is it ever
likely to, incentivise substitution among such users. The challenge facing policy makers
is, therefore, to optimise the efficiency of the policy simultaneously maximising
substitution potential yet avoiding the emergence of inequities in access. This may in
fact be possible, if the financial obstacle to prescription-exempt users is removed.
Making P medicines available free, over-the-counter at community pharmacies to
prescription exempt users (with certain provisos) could, potentially, realise both
objectives. Longitudinal, whole-systems analysis of any such initiatives, utilising a
range of theoretical and mixed method approaches would be required, facilitating
development of broader socio-economic theories of consumption for P medicines, which
in turn would yield much needed insight regarding how best to tailor and target future
policy initiatives in this increasingly important and pertinent health policy area.
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Appendix 1:
Chapter 1 - Literature
Literature Search Strategy
A literature search was undertaken using the electronic data bases 'BIDS' (Bath
Information and Data Services) and 'First Search'.
BIDS
The 'IBSS Online' international bibliography of the social sciences was searched
which covers the areas of economics; sociology; politics; and anthropology.
First Search
The 'Social Sciences', 'Medicine and Health Services' and 'Business and
Economics' subject area data bases was searched. Within these broad subject areas,
the specific data bases searched included 'WorldCat', 'Articles 1st', 'EconLit' and
'MEDLINE'.
'WorldCat' - Books and other material in libraries worldwide
'Article 1st' - Index of articles from nearly 12500 journals
'Econ Lit' - An index of economic literature
'MEDLINE' - Abstracted articles from medical journals
These databases were searched using a number of key words and authors including:
Key words/phrases: Non prescription drugs; medicine reclassifications; drug
reclassification; deregulated medicines; demand for non prescription drugs;
economics and prescribing; economics and pharmaceuticals; drug charges;
deregulated prescribing; drug policy; prescription drugs; drug co-payments; drug cost
sharing; drug price elasticity; self medication; drug switching; over-the-counter
drugs; and drug deregulation.
Key authors: Huttin, Temin, Leibowitz; Ryan; Birch; Newhouse; Noyce; Bond;
Bradley; Blenkinsopp; Britten; Blaxter; Cunningham-Burley; Ferner; O'Brien; Reez;
and Kennedy.
Literature Search Strategy continued
The literature search was continued, using the same electronic databases as before.
However, the focus of this search was methods/concepts/journals and so mainly
focused on the 'EconLit', 'Article 1st' and 'Contents 1st' data bases using BIDS and
First Search. The period of review was the whole span of the electronic databases.
In general though, this involved usually from 1990 onwards at least. For the search
of Journals contents pages through 'Contents 1st' the review period was often longer.
The key methods and concept terms searched under and the number of hits for each
are outlined below:
Economic substitution and health (25)
Medical firm (125)
Principal agent theory (193)
Health care demand functions (8)
Expected utility theory (789)
Costs and benefits and health (276)
Welfare economics (1240)
Welfare economics and health (8)
Consumer surplus analysis (115)
Economic decision-making (383)
Stated preference theory (13)
Conjoint analysis (55)
Substitution (25)
Search on journal contents pages as follows:
Pharmacoeconomics (1995-97, 43 issues)
Health Economics (1995-97, 87 issues)
Journal of Health Economics (1990-97, 34 issues)
Journal of Law and Economics (1992-97, 48 issues)
Bell Journal of Economics (1990-97, 32 issues)
Journal of Economic Theory (1993-97, 37 issues)
Journal of Political Economy (1993 -97, 96 issues)
American Economic Review (1992 -97, 27 issues)
Journal of Economic Literature (1986-97)
Search on authors included:
Christine Godfrey (7 hits); Graham Loomes (33 hits); John Hey (62 hits)
Quality Criteria Applied to the Literature
It was difficult to apply formal quality assessment criteria to the literature retrieved.
A diverse range of literature was searched and sourced and the researcher was keen
to be as inclusive as possible, including a range of papers (including various types of
primary and secondary research studies, comment, think and editorial pieces) both
published and unpublished (e.g. reports and other grey sources) as well as literature
from different subject areas and countries. Efforts to maintain quality of literature for
inclusion were, however, taken, by searching for literature in quality, peer reviewed
journals, by respected authors and canvassing colleagues views expert in related
subject areas. Thus, quality review of the literature included in the research was
ultimately at the discretion of the researcher, who was mindful of the hierarchy of
evidence and good practice principles applied by respected literature review
organisations (e.g. the Cochrane Collaboration).
TABLE A1.1: CHECKLIST FOR ASSESSING ECONOMIC EVALUATIONS
1. Was a well-defined question posed in answerable form?
1.1 Did the study examine both the costs and effects of the
service/programme?
1.2 Did the study involve a comparison of alternatives?
1.3 Was a viewpoint for the analysis stated and was the study placed in
any particular decision-making context?
2. Was a comprehensive description of the competing alternatives given?
2.1 Were any important alternatives omitted?
2.2 Was (should) a do-nothing alternative (be) considered?
3. Was the effectiveness of the programme or service established?
3.1 Was this done through a randomised, controlled clinical trial? If so, did
the trial protocol reflect what would happen in regular practice?
3.2 Was effectiveness established through an overview of clinical studies?
3.3 Were observational data or assumptions used to establish
effectiveness? If so, what are the potential biases in the results?
4. Were all the important and relevant costs and consequences for each
alternative identified?
4.1 Was the range wide enough for the research question at hand?
4.2 Did it cover all relevant viewpoints? (Possible viewpoints include the
community or social viewpoint, and those of patients and third-party
payers. Other viewpoints may also be relevant depending upon the
particular analysis).
4.3 Were capital costs as well as operating costs considered?
5. Were costs and consequences measured accurately in appropriate physical
units (e.g. hours of nursing time, number of physician visits, lost work¬
days, gained life years)?
5.1 Were any of the identified items omitted from measurement? If so,
does this mean that they carried no weight in the subsequent analysis?
5.2 Were there any special circumstances (e.g. joint use of resources) that
made measurement difficult? Were these circumstances handled
appropriately?
6. Were costs and consequences valued credibly?
6.1 Were the sources of all values clearly identified? (Possible sources
include market values, patient or client preferences and views, policy
makers' views and health professionals' judgements).
6.2 Were market values employed for changes involving resources gained
or depleted?
6.3 Where market values were absent (e.g. volunteer labour) or market
values did not reflect actual values (such as clinic space donated at a
reduced rate) were adjustments made to approximate market values?
6.4 Was the valuation of consequences appropriate for the question posed
(i.e. has the appropriate type or types of analysis - cost effectiveness,
cost benefit, cost utility - been selected)?
7. Were costs and consequences adjusted for differential timing?
7.1 Were costs and consequences which occur in the future 'discounted' to
their present values?
7.2 Was any justification given for the discount rate used?
8. Was an incremental analysis of costs and consequences of alternatives
performed?
8.1 Were the additional (incremental) costs generated by one alternative
over another compared to the additional effects, benefits, or utilities
generated?
9. Was allowance made for uncertainty in the estimates of costs and
consequences?
9.1 If data on costs and consequences were stochastic, were appropriate
statistical analyses performed?
9.2 If a sensitivity analysis was employed, was justification provided for
the ranges of values (for key study parameters)?
9.3 Were study results sensitive to changes in the values (within the
assumed range for sensitivity analysis or within the confidence interval
around the ratio of costs to consequences)?
10. Did the presentation and discussion of the study results include all issues of
concern to users?
10.1 Were the conclusions of the analysis based on some overall index or
ratio of costs to consequences (e.g. cost effectiveness ratio)? If so, was
the index interpreted intelligently or in some mechanistic fashion?
10.2 Were the results compared with those of others who have investigated
the same question? If so, were allowances made for potential
differences in study methodology?
10.3 Did the study discuss the generalisability of the results to other settings
and patient/client groups?
10.4 Did the study allude to, or take account of, other important factors in
the choice or decision under consideration (e.g. distribution of costs
and consequences, or relevant ethical issues)?
10.5 Did the study discuss issues of implementation, such as the feasibility
of adopting the 'preferred' programme given existing financial or other
constraints, and whether any freed resources could be redeployed to
other worthwhile programmes?
Sourced from Drummond et al., 1997





Highlighted the under-utilisation of the pharmacy
profession.
1980s Research efforts Expansion in pharmacy practice research
activities.
1980s Limited number of
drug deregulations
Increasing availability of proprietary medicines
e.g. ibuprofen and loperamide, terfenadine and
topical hydrocortisone reclassified from
prescription only to pharmacy available status in






Publicity campaign aiming to advice the general
public of community pharmacists' expertise in





Government sponsored the Nuffield Foundation to
consider the future of pharmaceutical services and,
in particular, to consider: the structure of the
profession; its potential contribution to the NHS
and health care; and to review pharmacists'
education and training.




Government compiled a list of the preparations to
be included and excluded from NHS prescribing.
1986 Nuffield Committee
Inquiry Report
Concluded that pharmacists were under-utilised.
Produced detailed suggestions regarding extending
and developing their role, recommending that their
contribution as: experts in medicines; advisers to
both patients and other professionals; providers of
specialist services; and engaging in health
promotion activities be increasingly utilised within
the NHS.
Around this time the primary care demand





Intention to harmonise the distribution of
medicines within Europe and achieve consistency





Endorsed the recommendations of the Nuffield
Inquiry and suggested closer involvement of
pharmacists in efforts to improve primary health
care service offered to patients. Key suggestions
included: delegating dispensing activities to
trained technicians, freeing up pharmacists to
undertake new roles including patient medication
reviews and providing pharmaceutical services to
nursing homes. Additional remuneration
recommended for these new roles.
1989 WHO report on the
role and function of
pharmacists in
Europe
Function and responsibility of pharmacists within
industrialised health care systems defined and





Proposals to improve patient health care,
enhancing access and choice of services, alongside
proposals to improve the satisfaction and
remuneration for NHS professionals responding to
local needs. Identified potential for pharmacists to
be involved in managing NHS drug expenditure.
1991 Health of the nation
(Department of
Health)
Advocated a primary care led NHS and outlined
the potential merits of encouraging community
pharmacy to become more actively involved in
health promotion activities.
1992 Pharmaceutical








Endorsed the extension of community pharmacy
roles as experts in medicines, in the provision of




Obliged member states to review the legal
classification of medicines every 5 years.
Prescription only classification to be enforced only
ifmedicines are dangerous, if used without
supervision; often used incorrectly; new medicines
(for 2 years and then reviewed); or normally
injected.
Deregulation criteria include that the drug should
be proven to be safe; of low toxicity in overdose;





An increasing number of medicines reclassified,
with over 40 POM to P deregulations up to 1995.
Enhanced consumer self-medication options.
1995 PIANA - Pharmacy




Professional engagement exercise: debating the
features shaping community pharmacy; agreeing
on future professional directions; and developing
an agenda for change. Supported the extension of
the role of pharmacists.
4 key areas where pharmacists' contribution
identified as vital including: management of
prescription medicines; management of chronic
conditions; management of common ailments; and
the promotion of healthy lifestyles.
Commitment to enhance the role of community
pharmacists within primary health care teams and
review alternative remuneration options with a
view to encouraging extended provision of




Written protocols outlining the procedure to be
followed in pharmacies when a medicine is





Each member of staff involved in the sale of
medicines now required to undertake specific
training.








Re-emphasis of the primary care led NHS.
Multidisciplinary team working to be a key feature
with community pharmacists included as an
integral member of primary health care teams.
Elnequivocal support for community pharmacy to






Scottish development programme for primary






Community pharmacy encouraged to become
involved in reducing drug wastage in the NHS.
Greater collaboration with patients and between
professionals to enhance concordance in medicine
usage.











Once again emphasising the pivotal role of
primary care in the NHS. Identified individuals as
partners in health care decision-making.
Supporting self-care via efforts to improve access
to primary care services e.g. through NHS Direct
and NHS 24.
Around the time of these White Papers, academic
and policy debates shift perceptibly, moving away
from narrow demand containment to broader
concerns to effect more appropriate, graduated
access to primary care services.
2000 The NHS plan: a
plan for investment,
a plan for reform
(Department of
Addressed the issue of a wider role for
pharmacists. Flagged up the necessity to change







Government proposals to modernise primary care
premises. Opportunity for pharmacists to improve
their premises, move to new ones or co-locate with
general practitioners and/or other primary care
professionals.






Outlined a number of proposals to improve access
to and quality of pharmacy services, including:
ensuring that people can get medicines or advice
from a pharmacist easily, at convenient times;
providing more support in using medicines; and
increasing public confidence in consulting with
pharmacists.
Specific improvements to include: increasing the
range of medicines available without a
prescription; management of repeat prescription
dispensing; improving out of hours access to
pharmacy advice e.g. via NHS Direct; increasing
the opening hours of community pharmacies; and
involving community pharmacists in one-stop care
centres.






community pharmacies to carry the NHS Scotland
logo; improving community pharmacy premises
e.g. increasing consultation areas; improving
access, especially out of hours; improving patient
medication records; electronic transfer of
prescriptions nationwide; management of repeat
prescription dispensing; enhancing therapeutic
roles; introducing supplementary prescribing
status; and developing remuneration systems to
allow health boards to contract directly with
community pharmacists for the provision of
specialist services.





Community pharmacies to become a more integral
part of the NHS to: be more engaged with primary
care trusts and involved in the planning and
development of local services; be more clearly
integrated with general practices and support the
new GMS contract; help deliver National Service
Frameworks; help redress health inequalities,
particularly for deprived groups; provide
diagnostic and monitoring services; and improve
public access to services.
2003 Office of Fair
Trading report
Call for controlled entry of community pharmacies
within areas to be scrapped. Government rejected.
However, proposed easing restrictions in large
shopping developments and for community
pharmacies planning to open for more than 100
hours per week.





Aim to assist the modernisation of community
pharmacy through the introduction of a new
contractual framework in 2004. Contract to be
designed to establish minimum standards and
outline essential, advanced and supplemental
services and appropriate remuneration for each.
The goal is to reward quality services and move
away from payment based solely on the volume of
prescriptions dispensed. Seeking to reward
broader professional activities associated with
community pharmacists' extended roles.
*
This table draws on and expands previous chronologies of related events outlined
by Bond, 2000 and Vallis, 1998. In addition, it draws on several policy documents,
including: Department of Health 1987; 1989; 1991; 1992a; 1992b; 1996a; 1996b;
1997a; 1997b; 1999; 2000; 2002a; 2002b; 2002c; 2003a; 2003b; Royal
Pharmaceutical Association of Great Britain 1986; 1992; 1994; 1996; 2001; Scottish
Executive 1997; 2003; Secretary of State for Scotland 1997; Secretary of State for
Wales 1997; Merrison, 1979; Harrison, 2001; and NHS Confederation, 2003.
TABLE A1.3: POTENTIAL ADVANTAGES AND DISADVANTAGES TO USERS, GENERAL
PRACTITIONERS AND COMMUNITY PHARMACISTS ASSOCIATED WITH THE INCREASING
AVAILABILITY OF MEDICINES, FROM A SOCIAL, CLINICAL AND ECONOMIC PERSPECTIVE.
SOCIAL DIMENSION: USERS
POTENTIAL COSTS POTENTIAL BENEFITS
Potential externality problems e.g.
increases in drug resistant organisms
(Hollis-Triantafillou, 1996; Temin,
1983).
Use of P drugs to contain symptoms as
an alternative to necessary lifestyle
modifications (Ross, 1996).
Changes in the culture and use of
medicines e.g. increased reliance on
drugs and 'pill for every ill' (Ferner,
1994; Bradley & Bond, 1995) or over
dependency on drugs with users
becoming 'slaves to medications.'
(Blaxter & Britten, 1996).
Loss of social interaction benefits
received during the GP consultation
process e.g. loss of doctors reassurance
and/or medical legitimation of users
illness (Blaxter & Britten, 1996;
Cunningham-Burley & MacLean, 1987).
Increased anxiety associated with
increased information available on P
drugs (Blaxter & Britten 1996).
Potential development of inverse care
scenarios in pharmacies, relating to
difference in the environment in which
community pharmacies are located and
organised, that influence the type of
services provided to local populations.
Concerns that large differentials in
range, quality and type of services
provided to users may emerge (Rogers,
Hassell & Nicolass, 1999).
Increase in user empowerment, choice
and autonomy (Blaxter & Britten, 1996;
Erwin, Britten & Jones, 1997; Bond and
Bradley, 1996; Bradley and Bond,
1995). Enhanced user knowledge and
value of information per se that is
potentially reassuring to users (Mooney
& Lange, 1993; Mooney, 1994).
Individuals have more opportunity to
take responsibility for their own health,
illness and symptoms resulting in
increases in users' self-legitimation and
confidence in self-diagnosis and
treatment (Blaxter & Britten, 1996).
Engagement of lay beliefs can
contribute to involving users in
evidence-based research, potentially
resulting in more effective services
(Blaxter & Britten, 1996).
Enhanced user convenience associated
with more direct access (Hassell et al.,
1996; Kennedy, 1996).
Convenience associated with users'
ability to increasingly engage in proxy
consultations for someone else (Temin,
1983; Hassell et al., 1996; Hassell et al.,
1997; Hassell et al., 1998; Rogers,
Hassell & Nicolass, 1999; Whittington
et el., 2001).
Redressing power relations between
users and health professionals.
Declining paternalism (Andersen &
Schou, 1994) and the potential to
develop more equal partnerships
(Blaxter & Britten, 1996) balancing self
and medical legitimation of symptoms
and illness (Cunningham-Burley &
McLean, 1987).
Medicines are seen as essentially
democratic which is particularly useful
for users with a low faith in traditional
medical services (Blaxter & Britten,
1996).
Pharmacists perceived to have more
time and empathy with users and there is
the advantage that users can remain
relatively anonymous in pharmacy
consultations (Blaxter & Britten, 1996;
Hassell et al., 1996; Hassell et al., 1997;
Griffin, 1994).
Potential to lead to more efficient and
appropriate utilisation of primary care
services (Hassell et al., 1996; Blaxter &
Britten, 1996;Temin, 1983).
Users encouraged to tap the expertise of
pharmacists in medicines, a currently
underused advice source. Ultimately
encouraging more rational use of
services via a 'stepping stone approach',
resulting in more appropriate utilisation
of services and the generation of caring
externalities associated with users
feeling good about not wasting or taking
up GPs time for those in more need
(Cunningham-Burley & MacLean, 1987;
PAGB, 1994; Hassell et al., 1997;
Hassell et al., 1998; Rogers, Hassell &
Nicolaas, 1999; Whittington et al.,
2001).
CLINICAL DIM ENSION: USERS
POTENTIAL COSTS POTENTIAL BENEFITS
Potential increases in the number of
adverse drug reactions, contra¬
indications and side effects (Bradley &
Bond, 1995;Temin, 1983).
Cynicism among users regarding the
efficacy of non-prescription medicines,
with many believing that medicines
from doctors are 'stronger' (Hassell et
al., 1998).
Concerns regarding inappropriate and/or
over utilisation ofmedicines leading to
concerns regarding developing
'immunities' in the population (Hassell
etal., 1998).
Potential masking of serious symptoms
and associated problems with late
diagnosis (Bond et al., 1993; Erwin,
Britten & Jones, 1997; Comment, 1994).
Reservations that pharmacists are not
trained to diagnose, alongside their
inability to consult users' medical
records (Vallis, Wyke & Cinningham-
Burley, 1997; Hassell etal., 1998).
Privacy concerns, as there are usually no
dedicated consulting areas within
community pharmacies (Hassell et al.,
1998; Whittington et al., 2001).
Inappropriate use of P products to
contain symptoms as an alternative to
necessary lifestyle modifications (Ross,
1996).
Doubts regarding user competence in
self-care (Blenkinsopp & Bradley,
1996). Danger of inadequate self-
diagnosis and inappropriate self
treatment (Erwin, Britten & Jones,
1997) e.g. via erroneous choice of P
drugs (Hassell at al., 1996). Concern
Encouragement of different approaches
to diagnosis and use of services (Blaxter
& Britten).
A 'stepping stone' approach
(Cunningham-Burley & MacLean,
1987) seeking legitimation of illness
before attending a GP (Blaxter &
Britten, 1996).
Using medicines to trial the meaning of
symptoms and for interrogating what
they understand about their doctor's or
their own diagnosis (Blaxter & Britten,
1996).
Increasing availability of information is
reassuring for users (Mooney & Lange,
1993; Mooney, 1994).
Ability to use the pharmacist as an
information source, tapping their
experience and expertise in medicines
(Hassell et al., 1996; Hassell et al,
1998).
More informal consultation process
within pharmacy (Hassell et al., 1996).
Users are able to remain more
anonymous and to ask advice without
feeling obliged to accept it (Temin,
1983).
More open consultation, leading to users
potentially revealing symptoms or side
effects that they would not reveal to
their doctor (Temin, 1983).
that information on P drugs is largely
promotional, making rational choice at
the point of sale is impossible for most
lay people Herxheimer & Britten, 1994).
• Danger of inadequate advice from the
pharmacists (Comment, 1994).
CLINICAL DIMENSION: GENERAL PRACTITIONERS
POTENTIAL COSTS POTENTIAL BENEFITS
• Potential for increases in drug resistant
organisms (Hollis-Triantiflllou, 1996;
Ward et al., 1997).
• Reductions in consultations mean
curtailed opportunities for GPs to pursue
opportunistic counselling about lifestyle
and other health promoting activities
(Blaxter & Britten, 1996; Kennedy,
1996; Bradley & Bond, 1995).
• Loss of the broader social interaction
process around the GP consultation
(Temin, 1983). Potential reduction in
traditional continuity of care aspect of
general practice. Change in the
traditional doctor-patient relationship.
• Surrendering a degree of professional
power that is often unwelcome (Erwin,
Britten & Jones, 1997; Blenkinsopp &
Bradley, 1996; PAGB, 1994).
• Uncertainty among GPs about the
appropriateness of pharmacy advice or
referral decisions (Hassell et ah, 1996).
• Potential decreases in GPs workload
(Kennedy, 1996) particularly for minor
ailments, leaving more time to spend on
needier patients (Ryan & Yule, 1990).
• More appropriate use of the relative
skills and knowledge base within
primary care (Erwin, Britten & Jones,
1997).
• Potential for pharmacists to become
proactive advisers of patients and
doctors with improvements in clinical
practice as a result (Kennedy, 1996).
CLINICAL DIMENSION: COMMUNITY PHARMACISTS
POTENTIAL COSTS POTENTIAL BENEFITS
• Concerns regarding the appropriateness
of referral and advice giving decisions
by pharmacists (Hassell et ah, 1996;
Griffin, 1994; Comment, 1994).
• Spot diagnosis, in the absence of user
history or access to medical records can
be very difficult. Danger of suspicion
rather than diagnosis (Hassell et ah,
1996). Adequacy of the training of
pharmacists to perform an extended
advisory and diagnostic role? (Hassell et
ah, 1996)
• Advice giving can be particularly
difficult if by proxy and more so if the
drugs concerned are the subject of
conjecture by the proxy (Hassell et ah,
1996).
• Danger that there is insufficient time
within a pharmacy consultation to
perform an advisory or diagnostic role to
a satisfactory standard. Typically,
pharmacies not set up for these roles e.g.
often a physical barrier of a counter
between the pharmacist and the user and
• Added value from pharmacy care and
advice, as they are the experts in
medicines. Becoming a more formal
player within a natural hierarchy of
advice (Hassell et ah, 1996) that is
leading to more appropriate use of the
relative skills and knowledge within
primary care (Ferner, 1994; Davey et ah,
1996).
• Pharmacists offer the potential to adopt
a more proactive gatekeeper role into
general practitioner services (Hassell et
ah, 1996).
• Pharmacy consultations tend to be more
open and less threatening to users and
their relative anonymity could be seen as
an advantage. Lay people perhaps more
willing to reveal symptoms and side
effects that they choose not to reveal to
their doctors (Blaxter & Britten, 1996).
• Increased opportunity to become more
involved in health promotion (Ross,
1996; Bond & Bradley, 1996) and to
extend their professional role more
the consultations tend to be of a very
public nature that can impede advice
giving (Hassell et al., 1996).
• Help on demand re P drugs can be a
barrier to the pharmacist's advisory role
(Hassell et ah, 1996; Temin, 1983; Reez
& Melzack, 1994).
• Danger of compromising pharmacists
professional relationship with users e.g.
in dealing with 'determined purchasers'
who are very difficult to advice. Danger
ofjeopardising relationship if the
pharmacist questions the
appropriateness of the users use of a
drug (Hassell et ah, 1996).
• P drug sales involve a product
recommendation that is complicated by
incentives for pharmacists to be tempted
to profit maximise (Hassell et ah, 1996).
• Pharmacists anxious about increasing
responsibility (Bradley & Bond, 1995).
Increasing consumer expectations of the
pharmacists. Can pharmacists
realistically be expected to meet them?
(Ashurst & Smith, 1997).
generally (Bradley & Bond, 1995;
Kennedy, 1996; Bond etah, 1993).
• Opportunity for pharmacists to develop
much closer partnerships with users
(Ashurst & Smith, 1997).
• Opportunities to facilitate closer
cooperation between pharmacists and
other primary health care professionals
(Ashurst & Smith, 1997).
• More job satisfaction (Ashurst & Smith,
1997).
• Increasing status for pharmacists within
the medical division of labour (Ward et
al., 1997).
ECONOMIC DIMENSION: USERS
POTENTIAL COSTS POTENTIAL BENEFITS
• Retail cost of the P product (Ryan &
Yule, 1990).
• Concerns regarding whether purchasing
medicines is affordable to all, especially
low- income groups (Rogers, Hassell &
Nicolaas, 1999; Whittington et ah,
2001).
• Travel costs to the pharmacy (Ryan &
Yule, 1990).
• Potential increases in morbidity and
associated loss of productive time if
users delay consulting a GP (Ryan &
Birch, 1991).
• Cost to consumer of switching or
substituting other health care services in
place of both the GP and the pharmacist
e.g. increased use ofA&E services
(Leibowitz, 1989).
• Savings to users in time costs in terms of
travel, waiting and consultation times.
Savings also in reduction in loss of time
at work (Bradley & Bond, 1995;
Kennedy, 1996; Ryan & Yule, 1990;
Temin, 1983).
• Savings to consumers in money costs
i.e. travel expenses and prescription
charges (for non-exempt users) and
through reductions in time lost at work
(Bond et al., 1993; Temin, 1983; Ryan
& Yule, 1990; Hassell et al., 1996).
• Enhanced user convenience (Thomas &
Noyce, 1996; Baines & Whynes, 1997;
Hassell et al., 1997; Hassell et al., 1998;
Varnish, Jesson & Wilson, 1998;
Rogers, Hassell & Nicolaas, 1999;
Whittington et al., 2001).
• Allows users to balance perceived costs
and benefits (Blaxter & Britten, 1996;
Cunningham-Burley & MacLean, 1987).
ECONOMIC DIMENSION: GENERAL PRACTITIONERS
POTENTIAL COSTS POTENTIAL BENEFITS
• Potential for duplication in advice and
consultation services between the GP
and the pharmacist.
• Increased volume ofwork and job stress
associated with keeping abreast of
patients' use of P as well as prescription
• Savings on the direct and indirect costs
of dispensed drugs e.g. on the practice
drug budget (Andersen & Schou, 1994).
• Reduction in workload associated with
minor ailments as pharmacist help to
keep this out of general practice (Hassell
drugs.
• Difficult for GPs to resist patients
demands for least cost effective, brand
drugs which they have previously
experimented with via P availability.
Danger that the users choice of drug is
sub-optimal both in clinical and cost
effectiveness terms (Bradley & Bond,
1995).
• Potential medico-legal implications of
increased P usage (Bradley & Bond,
1995; Thomas & Noyce, 1996; Griffin,
1994).
et al, 1996).
• More efficient division of labour and
skill mix (Hassell et al. 1996; PAGB,
1994). Opportunity to develop more
complementary service provision
between GPs and pharmacists, cutting
out any unnecessary duplication and
potentially reducing GPs workload
(Bond et al., 1993).
• Enhanced professional satisfaction
associated with the reduction in the
amount of self limiting, minor illness
presenting in general.
CLINICAL DIMENSION: COMMUNITY PHARMACISTS
POTENTIAL COSTS POTENTIAL BENEFITS
• Unpaid for their advice-giving role re P
drugs. So, opportunity costs of the
pharmacist's time (Hassell et al., 1996).
• Potential duplication of advice and
consultation services within primary
care.
• Exposure to more risk and responsibility
as a result of the increased advisory role
re P drugs (Ashurst & Smith, 1997).
• Anxieties about increased role (Bradley
& Bond, 1995).
• Medico-legal implications (Griffin,
1994; Baines & Whynes, 1977).
• Increased workload and stress for
pharmacists.
• Temptation to follow business interests
first i.e. pursue profit maximisation over
users welfare (Blenkinsopp & Bradley,
1995; Hassell et al., 1996).
• Benefit from typically increased profit
margins on P drug sales compared to the
prescription-dispensing fee (Ferner,
1994).
• More efficient division of labour and
skill mix. Opportunity to develop more
complementary services between GPs
and pharmacists and to cut out any
unnecessary duplication (Ferner, 1994;
Hassell et al., 1996).
• Added value of the pharmacist's advice
as an expert in medicines.
Appendix 2:
Chapter 2 - Methods
? April 1998
Dear ,
Deregulation of Medicines Research Project:
Request for Participation as a Study Pharmacy
I am writing to invite you to take part in a community pharmacy research project. I
telephoned your pharmacy when you were on holiday (07.04.98) and they suggested that I
send you on some information. I include a leaflet that summarises the research project and a
copy of the draft questionnaire that I hope to administer within your pharmacy. I also
enclose a leaflet that will be given to users following their interview.
I would like to spend ten days within your pharmacy to undertake this questionnaire. Your
participation would require the pharmacist/pharmacy assistant(s) introducing users of
deregulated 'P class' medicines to the study (whether obtained on prescription or over-the-
counter) and asking them to participate. In addition, it would be helpful if you could also tell
me directly the name of the deregulated medicine that I would be questioning the user about,
to ensure that I have an accurate record. Thereafter, I will undertake the short questionnaire
with the user. This will involve them answering a maximum of 26 short and mainly factual
questions. I anticipate that this should take no more than 5-10 minutes, maximum.
The project will begin in June and fieldwork undertaken in the following six months. The ten
days data collection period within your pharmacy will be arranged at convenient times, in
consultation with you.
Thank you very much for taking the time to consider participation in this study. I am on
holiday from 9th - 20th January. I shall telephone you on my return to discuss the project
with you further. The project is being undertaken with the support of Dawn Sykes, Lothian
Health's Pharmacy Facilitator. If you would like to discuss the project with Dawn she is







Deregulation of Medicines Research Project:
Proposed Fieldwork Dates
Further to our recent telephone conversation (20.04.98) I am writing to suggest
fieldwork dates to visit your pharmacy to undertake data collection. Based on your
planned holiday dates and preferred times, I propose that we visit you on the two
consecutive weeks of June 29th - 4th July and July 6th - 11th. I hope that these
two weeks will be convenient for you. If not, I can arrange alternate dates. I will
telephone you in the next week to confirm the dates. If they are suitable I will make
an appointment to visit you shortly before the data collection period to introduce the
member of the research team who will be visiting your pharmacy and to discuss any
queries you may have about the project.
I would like to thank you in advance for agreeing to take part in this study. Your
participation is of great value and is much appreciated by the research team.




MEDICINES FROM THE DOCTOR OR PHARMACIST?
AN ASSESSMENT OF THE COSTS AND BENEFITS
INTRODUCTION
Medicine deregulation has been enthusiastically embraced within the UK in recent
years. A key assumption underpinning this has been the belief that increasing the
availability of 'P' class medicines via deregulation offers potential to secure savings
for the NHS, as consumers increasingly self medicate and bear the cost of minor
illness. However, this assumption is unfounded in evidence. Research is necessary to
provide evidence on the impact of drug deregulation and the associated increase in
availability of 'P' class medicines, analysing changes in the distribution of costs and
benefits accruing to key stakeholders as a result. This information is urgently
required to help users, pharmacists, general practitioners and health policy makers to
make informed choices about the appropriate provision and classification of different
types of medicines. Thus, the Medical Research Council has funded the research
project outlined below, to investigate these issues. This research is being carried out
by the Department of General Practice at the University of Edinburgh, between
spring 1998 and autumn 2000.
STUDY AIM AND OBJECTIVES
AIM
The overall aim of this research project is to assess the extent to which increasing
availability of 'P' class medicines results in substitution or complementary usage
between general practice and community pharmacy services, investigating the direct
and indirect costs and benefits accruing to users, community pharmacists and general
practitioners as a result.
OBJECTIVES
• To describe the consultation career paths adopted by users to access 'P' class
medicines, assessing the extent of substitution or complementary usage between
general practice and community pharmacy services.
• To identify the full range of social, clinical and economic costs and benefits for
users, pharmacists and general practitioners associated with different consultation
career paths.
• To investigate the welfare implications, at both the micro (individual) and macro
(health policy) levels of the changing distribution of costs and benefits associated
with the increased availability of'P' class, medicines.
METHODS
A two year cross sectional descriptive study, with prospective follow up of users.
The study will be based within the Lothian Health Board area. Three key data
collection methods will be employed.
♦ Short interviews - conducted with users in community pharmacies, at the point of
purchase or dispensing of 'P' class medicines, to collect information on users'
consultation career paths through general practice and community pharmacy
services to date.
♦ Telephone interviews - following up users, to collect data on subsequent use of
general practice or community pharmacy services and to assess users' perceptions
of associated costs and benefits.
♦ Postal surveys* - across a representative sample of community pharmacists and
general practitioners within the Lothian Health Board area, to assess their
perceptions of the costs and benefits associated with the increased availability of
'P' class medicines.
DISSEMINATION
The full report will be available in October 2000. An interim report will be produced
in March 1999.
CONTACT
This research project is being undertaken by the Department of General Practice at
the University of Edinburgh. Any queries about the project should be addressed to
the lead researcher, Susan Myles, at the contact address below:
Susan Myles
Department of General Practice
University ofEdinburgh
20 West Richmond Street
Edinburgh
EH8 9DX
Tel: 0131 650 2682
Fax: 0131 650 9119
*Note: Postal surveys were not conducted.
MEDICINES FROM THE DOCTOR
OR THE PHARMACIST?
A RESEARCHSTUDY
Researchers from Edinburgh University are looking
at the costs and benefits to people of getting
certain medicines which can be got either from the
general practitioner on prescription, or bought from
the pharmacist over-the-counter.
This pharmacy has been chosen as a study site for
the research project. If you buy or collect a
prescription for certain medicines you may be
asked by the pharmacist or assistant to take part in
a short 5 minute interview with a researcher visiting
the pharmacy today.
PLEASE NOTE: all information you share with
the researcher will be strictly CONFIDENTIAL and
seen only by researchers. Taking part in the study
will not affect the treatment you receive.
Your opinions are very valuable to the research
and should help to guide new policy on medicines.
We hope that you will want to take part.
Thankyou very much foryour help
Deregulation of Medicines Project - Contact Details
In the event of any queries or problems arising please contact:
Susan Myles
Dept. of General Practice
Primary Care Research Group
20 West Richmond St
Edinburgh
EH89DX
Tel: 0131 650 2682
Fax: 0131 650 9119
Messages can also be left for Susan with Fiona Bell (Project
Secretary) on 0131 650 2680/2682






If Susan is unavailable then please contact:
Dr Sally Wyke
Senior Research Fellow
Dept. of General Practice
Primary Care Research Group








Notification of Research Project - "Reclassification of Medicines: An
Assessment of the Costs and Benefits"
I am writing to you to inform the LAMC and its members about a research project
about to begin within the Lothian area. I am an MRC Health Services Research
Training Fellow about to embark upon a pharmacy practice research project
investigating peoples' use of over-the-counter deregulated 'P' class medicines and
the extent to which they substitute them in place of a consultation with a general
practitioner to receive prescription drugs.
The research project has been cleared through the local ethical approval committee.
It will be undertaken in 14 pharmacies across Lothian and involves a short 5 minutes
interview with users at the point of collection of a P medicine within the pharmacy.
The pharmacists involved and the proposed fieldwork dates at each are attached. I
also enclose a copy of the project leaflets which summarise the research. If you




Research Project - Reclassification of Medicines: An Assessment of the Costs
and Benefits
Participating Pharmacies and Provisional Data Collection Timetable
Pharmacist Pharmacy Data Collection Dates
Mr Brian Ferguson B R & M L Ferguson
Chemist
66 High Street, North
Berwick
August 17th - 30th
Ms Julie Finneran J Smith Chemists
58 - 60 Niddrie Mains
Road, Edinburgh
September - to be
confirmed
Ms Claire Hutcheon Safeway Pharmacy
Almondvale Centre,
Livingston
June 22nd - July 5th i





Mr Robert Thomson Lindsay & Gilmour
105 Broughton Street,
Edinburgh
June 15th - June 28th
Ms Fiona McLaren Lindsay & Gilmour
14 Woodburn Avenue,
Dalkeith
August 3rd - 16th
Ms Ailsa Macdonald Moss Chemist
7-9 Sycamore Walk,
Blackburn
August 3rd - 16th
Ms Shireen Martin Linton Pharmacy
1 Bridge Street, East
Linton
September 21 st -
October 4th
Ms Elaine Craig Hills-Lloyd Chemist
Comely Bank,
Edinburgh
October 5th - October
18th
Ms Rhona McWhir Boots the Chemist
26-60 George Street,
Bathgate
August 31 st -
September 13th
Mr Ishtiaq Mohammed Hills-Lloyd Chemist
62/9 Gyle Loan,
Edinburgh
August 3rd - 16th
Ms Jean Flett Lindsay & Gilmour
65 Dairy Road,
Edinburgh
July 20th - August 2nd
Ms Fiona Ross Hills-Lloyd Chemist
34 John Street,
Penicuik
June 29th - July 12th
Ms Fay Spooner Spooner's Chemist
26 Main Street,
Balerno
July 6th - 19th
Varied (Locums) Hills-Lloyd Chemist
High Street,
Bathgate
July 20th - August 2nd
MEDICINES FROM THE DOCTOR OR THE
PHARMACIST? AN ASSESSMENT OF THE
COSTS AND BENEFITS
Edinburgh University is carrying out a study to find out the costs and benefits to
people of getting certain medicines which can be got either from your GP on
prescription, or which you can buy from the pharmacist over-the-counter.
WHY YOU?
We are approaching people collecting certain medicines within pharmacies, to ask
them for more detailed information about their method of obtaining those medicines.
WHAT'S INVOLVED?
The researcher will ask you some questions about how you got your medicine. The
idea is to find out the costs and benefits to you of obtaining the medicine. This
should only take 5 to 10 minutes of your time. Anything you say will be completely
confidential, and only seen by researchers. The information you give will not be
shared with your GP or the pharmacist you visited to collect the medicine. With
your permission, the researcher would contact you again, by telephone, to find out if
you used general practice or pharmacy services in the couple of weeks after
collection of your medicine today.
Your opinions are very valuable. The results of the study will be very useful in
determining the costs and benefits to people using medicines and should help to
guide new policy on medicines.
MORE INFORMATION
If you would like to know anything more about the study, or taking part, please
contact Susan Myles on 0131-650-2682 or write to us at:
Department of General Practice
University of Edinburgh
20 West Richmond Street
Edinburgh
EH8 9DX
Thankyou very much foryour help
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Edinburgh University is carrying out a study to find out the costs and benefits to people of getting
certain medicines which can be got either from your GP on prescription, or which you can buy from
the pharmacist over-the-counter.
WHY YOU?
We are approaching people collecting certain medicines within pharmacies, to ask them for more
detailed information about their method of obtaining those medicines.
WHAT'S INVOLVED?
The researcher will ask you some questions about how you got your medicine. The idea is to find
out the costs and benefits to you of obtaining the medicine. This should only take 5 to 10 minutes of
your time. Anything you say will be completely confidential, and only seen by researchers. The
information you give will not be shared with your GP or the pharmacist you visited to collect the
medicine. With your permission, the researcher would contact you again, by telephone, to find out if
you used general practice or pharmacy services in the couple of weeks after collection of your
medicine today.
Your opinions are very valuable. The results of the study will be very useful in determining the costs
and benefits to people using medicines and should help to guide new policy on medicines.
MORE INFORMATION
If you would like to know anything more about the study, or taking part, please contact Susan Myles






Thank you very much foryour help
Department of General Practice
Primary Care Research Group




Chain or Independent: Code:
Name of Interviewer: Code:
Date of Interview: Code:
Day of Interview: Code:
Time of Interview: Code:
1
Section A: P Medicine obtained and how?
I'd like to begin by asking you a couple ofquestions about the medicine which you
collected today.
Al. Name of P medicine(s) collected?:





Note: where more than one P medicine obtained, write down the names, amount and dosage of them all
If respondent can't answer - ask, 'do you mind if I just get that information from the pharmacist
at the end?'
A2. Is the medicine you are collecting today for you?
Circle only one
Yes, for me No, for someone else
1 2
If yes go to A4 If no go to A3
A3. Who is the medicine(s) for?
Circle only one
Wife/ Child Parent Grandchild Other Non- Other Don't know
husband/ family relative (specify)
partner member
1 2 3 4 5 6 7 8
A4. Did you (they) get the medicine that you collected today on prescription from a GP, or
direct from the pharmacist?
Circle only one
Prescription from GP Direct from pharmacist Don't know
1 2 8
Go to Bl, page3 Go to Dl, pagelO Discontinue interview
2
Section B: Medicines obtained on prescription during a recent GP
appointment
The next few questions are about how you got the prescription for the medicine
which you collected today.







Go to B2 Go to CI, p7
B2. How long did you (they) have to wait for an appointment to see the GP to get the
prescription for the medicine you collected today?
Circle only one
Same day Following day 2 days 3-5 days >5 days (specify
days)
Don't know
01 02 03 04 88
B3. How long did you (they) have to wait in the doctor's surgery before you (they) were
seen by a GP?
No wait 0-5 mins 6-10 mins 11-15 mins >15 mins
(specify mins)
Don't know
01 02 03 04 88
B4. How long were you (they) in with the GP during your (their) recent appointment?
<5 mins 5-10 mins 11-15 mins 16-20mins >20 mins
(specify mins)
Don't know
01 02 03 04 88
B5. How did you (they) get to the GP surgery?
Circle only one
Walked Bus Train Taxi Car Other (specify) Don't know
1 2 3 4 5 6 8
3
B6. How long did it take you (them) to get there?
Circle only one
<5 mins 5-10 mins 11-15 mins 16-20 mins >20 mins
(specify mins)
Don't know
01 02 03 04 88










Go to B8 Go to B10 Go to B10
B8. What were they?








1 1 1 1
B9. How long did you (they) have to make those arrangements for?
Circle only one
1-2 hours 3-4 hours 5-6 hours 7-8 hours >8 hours
(specify hrs)
Don't know
01 02 03 04 88
The next few questions are about your visit to the pharmacy today
BIO. Did you come straight from your (their) GP to the pharmacy just now?
Yes No
1 2
Bll. How did you get here?
Circle only one
Walked Bus Train Taxi Car Other
(specify)
1 2 3 4 5 6
4
812. How long did it take you to get here?
Circle only one
<5 mins 5-10 mins 11-15 mins 16-20 mins >20mins
(specify mins)
01 02 03 04
B13. How long have you waited to pick up your (their) prescription?
Circle only one
____
No wait 0-5 mins 6-10 mins 11-15 mins >15 mins
01 02 03 04
(specify mins)
B14. Did you have to make any special arrangements to come to pick up your (their)
prescription?
Prompt - for example, time off work, childcare or any other arrangements?
Yes No
1 2
Go to B15 Go to B17
B15. What were they?








B16. How long did you have to make those arrangements for ?
Circle only one
_____ _____
1-2 hours 3-4 hours 5-6 hours 7-8 hours >8 hours
(specify hrs)
01 02 03 04
B17. Did you (they) know that you can buy the medicine that you (they)
prescription direct from the pharmacist, over the counter?
got on
Yes No Don't know
1 2 8
5
B18. In the future, would you (they) consider buying this medicine direct from the
pharmacist?
Circle only one
Yes No Don't know
1 2 8
Go to B19 Go to B20 Go to B19
B19. What would encourage you (them) to buy the medicine you (they) received on
prescription today direct from the pharmacist?
Less More No need to Don't need to Other Don't know
expensive convenient to wait for a GP see the GP (specify)
than on get from appointment
prescription pharmacy
1 1 1 1 1 1
B20. What puts you (them) off buying the medicine you (they) received today on
prescription direct from the pharmacist?
Circle all that apply
Too More Prefer to get Exempt from Don't think Other Don't know
expensive convenient to the GP's prescription should have (specify)
from get from the opimon charge to pay
pharmacy GP
1 1 1 1 1 1 1
GO TO SECTION E, QUESTION El, PAGE 14
6
Section C: Medicines obtained on repeat prescription
The next few questions are about how you (they) got the repeat prescription for
the medicine which you collected today.
CI. Did you (they) visit your (their) GP surgery to pick up your (their) repeat prescription?
Yes No
1 2
Go to C2 iiMiiiiliii!
IfNo - researcher need to make a judgment about which questions appropriate to ask
C2. How did you (they) get to the GP surgery ?
Walked Bus Train Taxi Car Other
(specify)
Don't know
1 2 3 4 5 6 8
C3. How long did it take you (them) to get there ?
Circle only one
<5 mins 5-10 mins 11-15 mins 16-20 mins >20 mins
(specify mins)
Don't know
01 02 03 04 88
C4. How long did you (they) have to wait at the GP surgery when picking up your (their)
repeat prescription?
no wait 0-5 mins 6-10 mins 11-15 mins >15 mins Don't know
01 02 03 04
(specify mins)
88
C5. Did you (they) have to make any special arrangements to pick up your (their) repeat
prescription from the GP surgery?
Prompt - for example, time offwork, childcare or any other arrangements?
Yes No Don't know
1 2 8
Go to C6 Go to C8 Go to C8
7
C6. What were they ?








1 1 llll 1
C7. How long did you (they) have to make those arrangements for ?
Circle only one
1-2 hours 3-4 hours 5-6 hours 7-8 hours >8 hours Don't know
01 02 03 04
(specify hrs)
88
The next few questions are about your visit to the pharmacy today
C8. Did you come straight from your (their) GP to the pharmacy just now?
Yes No
1 2
C9. How did you get to the pharmacy ?
Circle only one
Walked Bus Train Taxi Car Other
(specify)
Don't know
1 2 3 4 5 6 8
CIO. How long did it take you to get here ?
Circle only one
<5 mins 5-10 mins 11-15 mins 16-20 mins >20 mins
(specify mins)
01 02 03 04
Cll. How long have you had to wait to pick up your (their) repeat prescription?
No wait 0-15 mins 6-10 mins 11-15 mins >15 mins
(specify mins)
01 02 03 04
C12. Did you have to make any special arrangements to come to the pharmacy to pick up
your (their) repeat prescription today?
Prompt - for example, time offwork, childcare or any other arrangements?
Yes No
1 2
Go to C13 Go to C15
8
C13. What were they ?








C14. How long did you have to make those arrangements for ?
Circle only one
1-2 hours 3-4 hours 5-6 hours 7-8 hours >8 hours
(specify hrs)
01 02 03 04
C15. Did you (they) know that you can buy the medicine that you (they) got on repeat
prescription today direct from the pharmacist over the counter?
Yes No Don't know
1 2 8
C16. In the future, would you (they) consider buying this medicine direct from the
pharmacist?
Circle only one
Yes No Don't know
1 2 8
Go to C17 Go to C18 Go to C17
C17. What would encourage you (them) to buy the medicine you (they) received on
prescription direct from the pharmacist?
Less More No need to Don't need to Other Don't know
expensive convenient to wait for a GP see the GP (specify)




1 1 1 1
C18. What puts you (them) off buying the medicine you (they) received on repeat
prescription today direct from the pharmacist?
Circle all that apply
Too More Prefer to get Exempt from Don't think Other Don't know
expensive convenient to the GP's prescription should have (specify)
from get from the opimon charge to pay
pharmacy GP
1 1 1 1 1 ill 1
GO TO SECTION E, QUESTION El, PAGE 14
9
Section D: Medicines obtained over the counter direct from the pharmacist
The next few questions are about this visit to the pharmacy to obtain the
medicine(s) you have just bought and whether you (they) have been to your (their)
GP about them.
Dl. How much did your (their) medicine(s) cost you (them)?
Medicine 1 Medicine 2 Medicine 3 Medicine 4
£ £ £ £
Note: Important to get the individual cost of each P medicine bought
D2. How did you get to the pharmacy today?
Circle only one
Walked Bus Train Taxi Car Other
(specify)
Don't know
1 2 3 4 5 6 8
D3. How long did it take you to get here?
Circle only one
<5 mins 5-10 mins 11-15 mins 16-20 mins >20 mins
01 02 03 04
(specify mins)
D4. How long have you had to wait to pick up your (their) medicine?
No wait 0-5 mins 6-10 mins 11-15 mins >15 mins
(specify mins)
01 02 03 04
D5. Did you have to make any special arrangements to come to the pharmacy today to buy
this medicine?
Prompt - for example, time offwork, childcare or any other arrangements?
Yes No
1 2
Go to D6 Go to D8
10
D6. What were they?








D7. How long did you have to make those arrangements for?
Circle only one
1-2 hours 3-4 hours 5-6 hours 7-8 hours >8 hours
(specify
hours)
01 02 03 04
The next few questions are aboutwhether you (they) have visited the GP about
the symptoms for which you bought your (their) medicine today
D8. Have you (they) consulted your (their) GP this time about the symptoms you've
(they've) got just now which you bought the medicine for?
Yes No Don't know
1 2 8
Go to D9 Go to D19 Go to D19
Emphasise that we are interested in this episode of symptoms if respondent is unsure
D9. When was that?
Circle only one
Today Yesterday In the last In the last > 2 weeks ago Other Don't know
week fortnight (specify)
1 2 3 4 5 11!! 1111 (111111' 8
D10. How long did you (they) have to wait for your (their) appointment to see the GP?
Same day Following day 2 days 3-5 days >5 days
(specify days)
Don't know
01 02 03 04 88
Dll. How long did you (they) have to wait in the doctor's surgery before you (they) were
seen by a GP?
No wait 0-5 mins 6-10 mins 11-15 mins >15 mins Don't know




D12. How long were you (they) in with the GP during your (their) recent appointment?
<5 mins 5-10 mins 11-15 mins 16-20 mins >20 mins
(specify mins)
Don't know
01 02 03 04 88
D13. How did you (they) get to the GP surgery?
Circle only one
Walked Bus Train Taxi Car Other
(specify)
Don't know
1 2 3 4 5 6 8
D14. How long did it take you (them) to get there?
Circle only one
<5 mins 5-10 mins 11-15 mins 16-20 mins >20 mins
(specify mins)
Don't know
01 02 03 04 88
D15. Did you (they) have to make any special arrangements to go for your (their) GP
appointment?
Prompt - for example, time offwork, childcare or any other arrangements?
Yes No Don't know
1 2 8
Go to D16 Go to D18 Go to D18
D16. What were they?








1 1 1 1
D17. How long did you (they) have to make those arrangements for?
Circle only one
1-2 hours 3-4 hours 5-6 hours 7-8 hours >8 hours
(specify hrs)
Don't know
01 02 03 04 88
D18. Did the doctor write you (them) a prescription for a medicine to help with the
symptoms you bought your (their) medicine for today?
Yes No Don't know
1 2 8
12
D19. In the future, would you (they) consider attending the GP to obtain a prescription for
the medicine which you bought direct from the pharmacist today?
Yes No Don't know
1 2 8
Go to D20 Go to D21 Go to D20
D20. What would encourage you (them) to attend the doctor to obtain a prescription for the
medicine you bought direct from the pharmacist today?
Less More Prefer to get Exempt from Other Don't know
expensive on convenient to the GP's prescription (specify)
prescription get from the opinion charge
GP
1 1 1 1 1111 1
D21 What puts you (them) off going to the doctor to get a prescription for the medicine
that you bought today direct from the pharmacist?
Too More Need to wait Don't need to Other Don't know
expensive on convenient to for a GP see the GP (specify)
prescription get from the appointment
pharmacist
1 1 1 1 1 1
D22. Why did you (they) decide to buy your (their) medicine direct from the pharmacist








1 1 III 1
GO TO SECTION E, QUESTION El, PAGE 14
13
Section E: Use of general practice and pharmacy services and prescription
and other medicines
These next few questions are about how easy it is for you (them) to see your
(their) GP and pharmacist, your (their) use ofmedicines and a couple of questions
about your (their) general health.
El. In the last year, how many times have you (they) consulted or spoken to your (their) GP
about yourself (themselves)?




01 02 03 04 88
E2. How long do you (they) usually have to wait to get an appointment with your (their)
GP?
Circle only one
Same day Following 2 days 3-5 days >5 days Don't know
day (specify days)
01 02 03 04 88
E3. How far do you (they) live from your (their) GP surgery?
Circle only one
< a mile 1-2 miles 3-4 miles 5 or more Don't know
(specify miles)
01 02 03 88
E4. In the last year, how many times have you (they) consulted or spoken to a pharmacist
about yourself (themself)?
Not at all Once or twice 3-5 times 6-10 times >10 times Don't know
(specify no.
01 02 03 04
times)
88
E5. Do you (they) use the same pharmacist regularly?
Yes No Don't know
1 2 8
14
E6. How far do you (they) live from the pharmacy you (they) use most often?
< a mile 1-2 miles 3-4 miles 5 or more Don't know
(specify miles)
01 02 03 88
Prompt - the next question requires only a yes or no answer
E7. Do you (they) currently get any medicines, pills, ointments, puffers or injections
regularly on prescription from your (their) GP?
Yes No Don't know
1 2 8
E8. Do you (they) currently pay for your (their) prescriptions?
Yes No Don't know
1 2 8
Go to E9 Go to E10 Go to Ell
E9. Do you (they) purchase a four or twelve month pre-payment certificate to pay for your (their)
prescriptions?
Circle only one
Yes, Yes, No Don't know
4 months 12 months
1 2 3 8
Now go to Now go to Now go to Now go to
Ell Ell Ell Ell
E10. Could you just tell me why you (they) are exempt from prescription charges?
Circle only one
Under 16 16-18 in FT 60 years or Maternity Prepaid War/MoD Receiving a Other Don't
educ over or medical certificate pensioner benefit (specify) know
exempt
01 02 03 04 05 06 07 08 88
15
Ell. We are interested in the cost of medicines and prescriptions and whether it stops
people getting them. Do you mind telling me whether you (they) ever don't get medicines
you (they) feel you (they) need because of their cost or the cost of the prescription?
Yes No Don't know
1 2 8
E12. In general/ how would you (they) describe your (their) health?
Circle only one
Very good Good Fair Bad Very bad Don't know
1 2 3 4 5 8
Prompt - the next question requires only a yes or no answer
E13. Do you (they) have any longstanding illness, disability or infirmity? By longstanding
1 mean anything that has troubled you (them) over a period of time, or that is likely to affect
you (them) over a period of time.
Yes No Don't know
1 2 8
GO TO SECTION F, QUESTION Fl, PAGE 17
16
Section F: Demographic details of the respondent
In order to give me a picture of the people I've spoken to in this survey, these next
few questions ask for a little more information about yourself and where you live.
Again, I should stress that all the information you share with me will be treated
in the strictest of confidence and will not be divulged to anyone.
Fl. Sex of respondent (person the medicine for)?
Male Female
1 2
Prompt - "Could I ask you to look at this card (A) and read out the number of the ethnic group you feel
you belong to?"











01 02 03 04 05 06 07 08 09 88
F3. Do you mind telling me your date of birth?
Date of Birth Don't
know
888888 Researcher - please circle correct age band below
Note: ask for age band if reluctant
<16 years 16-19 20-29 30-39 40-49 50-59 60-69 70 or over Don't
know
01 02 03 04 05 06 07 08 88
F4. What is your (their) marital status?
Circle only one
Married Living with Widowed Divorced Separated Single, Not Don't know
partner never applicable
married (child)
1 2 3 4 5 6 7 8
17
Prompt - "Could I ask you to look at this card (C) and read out the number next to the group that best
describes your accommodation?"
F5. Can I just ask about your (their) accommodation. Which of the following best

























03 04 05 06 07 08 09 88




F7. Is there a car or van normally available for use by you or any members of the
household?
Yes No Don't know
1 2 8
Prompt - "Could I ask you to look at this card (B) and read out the number next to the group that best
describes what you're doing now?"
F8. Can I just ask about your (their) employment? Which of the following applies to you



























01 02 03 04 05 06 07 08 09 88
F9. At what age did you (they) finish your (their) continuous full-time education at school






I would like to follow people up who have taken part in this interview by
telephone, to ask them a few questions about their subsequent use of general
practice and pharmacy services. Again, I should stress that it would be
completely confidential and would only take about 5 minutes. Would you be








Ifyes, name and contact telephone number
Name Telephone No.
Is there a convenient time to contact you by telephone?





1 1 1 1
If no, any reason given?
I'll leave you with a short leaflet outlining the study and my contact telephone
number in case you have any queries about taking part.
THANK YOU VERYMUCH INDEED FOR YOUR TIME AND HELPWITH THIS SURVET
19
Card A
Could you please read out the number of
the ethnic group to which you consider
you belong?
White 1
Black - Caribbean 2
Black - African 3





None of these 9
Card B
Could you please read out the number of
the group below which best describes
what you are doing now?
in paid work - full time 1
in paid work - part time 2
on a government training scheme 3
retired 4
unemployed 5
disabled, invalid or permanently sick 6
caring for home and family or dependants 7
in full time education 8
something else (please specify) 9
Card C
Could you please read out the number of
the group below which best describes
your accommodation?
owned - with a mortgage 1
owned - outright 2
rented - from the local authority 3
rented from a housing association 4
rented - privately, furnished 5
rented - privately, unfurnished 6
rented - from employer 7
other - with payment 8
rent free 9
SM/Pharm/July98
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Pharmacy Name: Pharmacy Code:
Interviewer Name: Interviewer Code:
Date of Interview: Date Code:
Day of Interview: Day Code:







/2se II:®1I non response?:
SM/Telfup/July98
Department of General Practice
Primary Care Research Group
Medicines from the Doctor or the Pharmacist?








Section G: Follow up visit to the GP or pharmacist?
Can / begin by asking aboutyour use ofgeneral practice and
pharmacy services since we last talked?
Gl. Have you (they) visited the GP about the symptoms for which you (they)
got the medicine that we talked about last time?




If yes, go to Section H, Qu. HI, Page
3
If no, go to Question G2
G2. Have you (they) visited the pharmacist about the symptoms for which you
(they) got the medicine that we talked about last time?




If yes, go to Section I, Qu. 11, Page 7 If no, go to Section J, Page 9
If Yes, prompt - Can I just double check then, you went back to the pharmacy only
and not
to the doctor at all?
IfNo, prompt - Can I just double check then, you haven't needed to visit either the
GP or a
pharmacist for any more advice about the symptoms you were
treating the
last time we talked?
GO TO SECTION J, QUESTION Jl, PAGE 9
Section H: Follow up visit to the GP to obtain additional
medicines or advice
These next few questions are about your (their) follow up visit to the
GP since the last time we spoke.
HI. Your (their) follow up visit to the GP, was that for an appointment or to




Go to Question H2 Go to Question H5







2 days 3-5 days >5 days (specify
days)
Don't know
01 02 03 04 88
H3. How long did you (they) have to wait in the doctor's surgery before you
(they) were seen by a GP?
Circle only one
No wait 0-5 mins 6-10 mins 11-15 mins >15 mins
(specify mins)
Don't know
01 02 03 04 88
H4. How long were you (they) in with the GP during your (their) follow up
appointment?
Circle only one
<5 mins 5-10 mins 11-15 mins 16-20 mins >20 mins
(specify mins)
Don't know
01 02 03 04 88
H5. How did you (they) get to the GP surgery?
Circle only one
Walked Bus Train Taxi Car Other (specify) Don't know
1 2 oJ 4 5 6 8
H6. How long did it take you (them) to get there?
Circle only one
<5 mins 5-10 mins 11-15 mins 16-20 mins >20 mins
(specify mins)
Don't know
01 02 03 04 88
H7. Did you (they) have to make any special arrangements to go for your
(their) follow up GP appointment?
Prompt - for example, time offwork, childcare or any other arrangements?





Go to H8 Go toHIO Go toHIO
H8. What were they?
Circle all that apply




1 1 1 1
H9. How long did you (they) have to make those arrangements for?
Circle only one
1-2 hours 3-4 hours 5-6 hours 7-8 hours >8 hours
(specify hrs)
Don't know
01 02 03 04 88
H10. During your (their) follow up appointment with the GP, did the doctor





Hll. Did you (they) visit a pharmacy to pick up other medicine(s) after your




If yes, go to H12 If no, go to Section J, Page 9
The nextfew questions are aboutyour (their) visit to the pharmacy
afteryour (their) follow up GP appointment
H12. At your (their) follow up visit to the pharmacy, did you (they) get other




Go to Question HI3 Go to Question HI6
H13. How many other medicines did you (they) get?
Circle only one
One Two Three Four Five > Five
(specify)
01 02 03 04 05
H14. Were the medicines you (they) got on prescription, or did you (they) buy




If Prescription, go to HI6 IfOTC, go to Question HI 5
HI 5. How much did the medicine(s) that were bought over-the-counter cost
you (them)?
Medicine 1 Medicine 2 Medicine 3 Medicine 4
£ £ £ £
H16. How did you (they) get to the pharmacy?
Circle only one
Walked Bus Train Taxi Car Other
(specify)
1 2 3 4 5 6
H17. How long did it take you (them) to get to the pharmacy?
Circle only one
<5 mins 5-10 mins 11-15 mins 16-20 mins >20 mins
(specify
mins)
01 02 03 04
HI8. How long did you (they) have to wait in the pharmacy to pick up your
(their) medicine(s)?
Circle only one
No wait 0-5 mins 6-10 mins 11-15 mins >15 mins
(specify
mins)
01 02 03 04
H19. Did you (they) have to make any special arrangements to pick up the
medicine(s)?




Goto HI9 Go to
Section J,
Page 9
H20. What were they?
Circle all that apply





H21. How long did you (they) have to make those arrangements for ?
Circle only one
1 -2 hours 3-4 hours 5-6 hours 7-8 hours >8 hours
(specify hrs)
01 02 03 04
GO TO SECTION J, QUESTION Jl, PAGE 9
Section I: Follow up visit to the pharmacy to obtain
additional over-the-counter medicines or advice
The next few questions are about your (their) follow up visit to the
pharmacy.
II. At your (their) follow up visit to the pharmacy, did you (they) have to get
any other medicine(s) or did you (they) just get advice?
Circle only one
Other Medicines Advice Only
1 2
Go to Question 12 Go to Question 14
12. How many other medicines did you (they) get?
Circle only one
One Two Three Four Five > Five
(specify)
01 02 03 04 05
13. How much did the medicine(s) that you (they) bought over-the-counter cost
you (them)?
Medicine 1 Medicine 2 Medicine 3 Medicine 4
£ £ £ £
14. How did you (they) get to the pharmacy?
Circle only one
Walked Bus Train Taxi Car Other (specify) Don't know
1 2 3 4 5 6 8
15. How long did it take you (them) to get to the pharmacy?
Circle only one
<5 mins 5-10 mins 11-15 mins 16-20 mins >20 mins
(specify mins)
01 02 03 04
16. How long did you (they) have to wait to get the additional medicine(s) or
advice in the pharmacy?
Circle only one
No wait 0-5 mins 6-10 mins 11-15 mins >15 mins
(specify mins)
01 02 03 04
17. Did you (they) have to make any special arrangements to go to the
pharmacy to get your (their) additional medicine(s) or advice?









18. What were they?









19. How long did you (they) have to make those arrangements for?
Circle only one
1-2 hours 3-4 hours 5-6 hours 7-8 hours >8 hours
(specify
hours)
01 02 03 04
GO TO SECTION J, QUESTION Jl, PAGE 9
Section J: User views on availability of medicines
These last two questions ask for your (their) general views on
availability of medicines and about the circumstances in which you
would choose to use the GP or the pharmacist.
Jl. In what circumstances would you (they) prefer to go to the pharmacist,
rather than the doctor?
J2. What do you (they) think about making more medicines which were in the
past prescribed, available from the pharmacist to buy?
That's the interview finished now. I'd just like to thank you for
helping us out. We really appreciate your time. Your views will be
important in informingfuture policy on medicines .
Thanks once again for allyour help
Medicines From (he Doctor or the Pharmacist?
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J1. In what circumstances would you prefer to go to the pharmacist, rather than the CP?
J2. What do you think about making more medicines, which were in past prescribed,
from the pharmacist to buy?
3 June 1998
Dear
Deregulated Medicines Research Project - Briefing Pack for Training
Session on 11th June 1998, 4pm - 6pm in Department Library
I enclose a briefing pack for your training session on 11th June. I'd be grateful if
you could set aside a couple of hours to familiarise yourself with the information
prior to the training session, particularly the questionnaire (although all of the
materials are still in draft form and may be subject to change). I have arranged for
you to be paid for your reading time and for the training day (4 hours in total).
I hope that the information contained in the briefing pack is helpful. We'll have a
chance to go over it all on the 11 th.






Primary Care Research Group
Deregulated Medicines:




Deregulated Medicines Research Project
Contents of Training Session Briefing Pack
• Training session programme
• Project summary leaflet
• User information leaflet
• List of all deregulated P medicines
• Fieldwork instructions
• General notes on coding & completion of the questionnaire
• Information poster to display on the pharmacy counter
• Tips on how to get that interview!
• Questionnaire
• Questionnaire show cards
• Non responders minimum data collection form
• Overall fieldwork timetable
• Individual researchers' fieldwork timetables
• Fieldworker's essential survival kit
• Project contact details
• Travel expenses form
• Researcher time sheets
Fieldwork Materials Still to Follow:
• Identification badge and card
• Full list of deregulated P medicines
• Clip board and pens
• Wallet to hold all the materials
• Laminated pharmacy poster
• Laminated questionnaire show cards
Deregulated Medicines:
From the GP or Pharmacist?
Interviewers Training Day - Programme
Thursday June 11th 1998
1. Background and introduction to the project
2. The questionnaire - aims & administration
3. Interview training - role play
4. Administration - contacts, time sheets,
expenses
5. Confirmation of training and fieldwork dates
6. Discussion & questions
Fieldwork Instructions
1. Background and purpose of the study
The "Deregulated Medicines: From the GP or the Pharmacist?" study is being funded
over three years by an MRC (Medical Research Council) Special Training
Fellowship in Flealth Services research, held by Susan Myles and supervised by Dr
Sally Wyke, both from the Department of General Practice, Primary Care Research
Group, University of Edinburgh.
The aim of the study is principally to assess the extent to which deregulation of
prescription only medicines (POMs) to pharmacy available status (Ps) results in
substitution or complementary usage between general practice and community
pharmacy services, investigating the direct and indirect costs and benefits accruing
to users, community pharmacists and generalpractitioners as a result.
The key objective of the first stage of data collection, via the short interviews with
users collecting deregulated (P) medicines within pharmacies, is to describe the
consultation career paths adopted by users to access deregulated (P) medicines. For
example a number of possible consultation career paths for accessing deregulated (P)
medicines exist. For example,
(1) User consults their GP and obtains a prescription for a deregulated (P) medicine
which they pick up from a pharmacy
(2) User does not consult their GP this time but picks up a repeat prescription for a
deregulated (P) medicine from their GP surgery which they then pick up from a
pharmacy
(3) User obtains a prescription either during a GP appointment or on repeat
prescription and then visits the pharmacy. Flowever, instead of collecting their
prescription medicine, they opt rather to buy a similar or equivalent deregulated (P)
medicine involving a supervised sale by a pharmacist. This route is most likely to be
pursued when the deregulated (P) medicine prescribed by the GP is available over-
the-counter from the pharmacist at a cheaper cost than paying the flat £5.80
prescription charge fee.
(4) User goes direct to the pharmacist and purchases a deregulated (P) medicine,
over-the-counter during a supervised sale. The user has not consulted their GP to
obtain a prescription or collect a repeat prescription for this medicine this time
The short pharmacy questionnaire aims to establish exactly what route the user took
to access the deregulated (P) medicine they are picking up and will allow us to assess
the extent of substitution or complementary usage between general practice and
pharmacy services by users when obtaining deregulated (P) medicines.
Definitions of Different Classes of Medicines
1. Prescription Only Medicines (POMs)
Prescription Only Medicines (POMs) are those medicinal products supplied in
accordance with a prescription given by an appropriate practitioner e.g. registered
doctors, dentists and nurse prescribers. They are medicines which can only be
obtained with a prescription.
2. Pharmacy Medicines (Ps)
Pharmacy medicines (Ps) are not available for general sale. The sale of P medicines
must be supervised by a pharmacist. A prescription may be presented for P class
medicines.
3. General Sales List Medicines (GSL)
Are medicinal products that are available for general sale which do not require a
prescription or the supervision of a pharmacist at the point-of-sale.
For this study we are interested specifically in deregulated (P) pharmacy available
medicines. Two main options exist for users trying to get these medicines: (i) they
can visit their GP who can write them a prescription for a pharmacy available P
medicine; or (ii) they can buy them direct from a pharmacist, involving a supervised
sale.
For a full list of all deregulated pharmacy available (P) medicines, see sheet entitled,
"Full List of All Deregulated Pharmacy Available (P) Medicines".
2. Introducing the study
Be friendly and polite. Emphasise that it only takes 5 minutes and that all
information given is strictly confidential, seen only by researchers and will not affect
the treatment they receive or be shared with the pharmacist of the persons GP.
Keep the introduction as brief as is consistent with securing agreement.
See "Specimen Study/Interview Introductions" sheet. While it is important to cover
the key points made in these, it will be easier if you customise them into language
that you would use and feel comfortable with.
3. Common questions and answers
(a) What is the purpose of the survey?
Its main aim is to get a picture of how people get certain medicines and to understand
the services they use to do so.
It will also help us to understand how much it costs different groups of people to get
medicines.
It will be used to produce helpful information that may be used to inform future
health care policy e.g. on decisions about how best to set up services to make
medicines readily available to different groups in the population.
(b) Who is it for?
The research project is being funded by the Medical Research Council and is being
conducted for them by Edinburgh University Medical School
All the information that you share with me will be treated in the strictest of
confidence and will not be seen or given to anyone else except researchers at
Edinburgh University. The information will not be shared with your doctor or the
pharmacist and will not affect the treatment you receive.
(c) What does it involve?
It involves a very short 5 minute questionnaire about how you got your medicine
today, how easy it is for you to see the doctor and the pharmacist, a couple of
questions about your general health and some general questions about you, to give us
a picture of all the people we've spoken to in our survey.
With your permission, I would also like to follow you up by telephone in the next
week to ten days. This will involve a five minutes conversation, the aim of which is
to find out whether you visited either a GP or a pharmacist after collecting the
medicine that you got today. This would be arranged at a convenient time for you
and would again be strictly confidential.
(d) How/why was I selected?
We asked 14 pharmacies across Tothian to take part in the study. We are visiting
each of these fourteen pharmacies for two weeks. During this time, we are asking
everyone buying or collecting a prescription for certain medicines to take part in our
survey, by answering a short 5 minutes questionnaire.
We want to collect information from all different kinds of people so that the results
of our survey reflect the Lothian area as a whole. We're hoping to speak to 1500
people in total. So, we'd really appreciate it if you would agree to take part.
(e) What about confidentiality?
Complete confidentiality is guaranteed. Your name would not be held with the
answers you gave to our questions and it would be impossible to identify you
personally. The information you give us will not be shared with any one else,
including your doctor or the pharmacist. It will only be seen by researchers from the
University of Edinburgh Medical School. You don't even have to give your name if
you would prefer to remain anonymous.
(f) I may not know the answer to your questions
The questions are straightforward and not intended to be difficult or tricky. If there
are any questions that you are unsure about, that is fine, or if there are any that you
would prefer not to answer then that too is okay.
(g) The medicine is not for me
That's okay. I'd still like the opportunity to ask the questions on behalf of the person
that you are collecting the medicine for. If there are a few questions that you are
unsure about, that's fine. It'd be really helpful to us if you could still take part.
(h) Why should I bother taking part?
We're hoping to talk to as many and as broad a selection of people within Lothian as
possible. Information is needed about all the different sections of the population;
people who consult their GP to get medicines on prescription, people who visit the
pharmacy to get medicines, single people, married people, retired people, disabled
people and those in work and not in work, and so on. Your views and circumstances
are important. By taking part, you and other people in similar circumstances have an
opportunity to be represented within our research.
The results of this study may be used to inform future health care policy.
Specimen Study/Interview Introductions
Below are noted a couple ofpotential introductions that you could use to give the
user some information about the study and hopefully entice them to want to take part.
It's probably best to keep your introduction both simple and brief to avoid scaring
offpotential respondents. Also, as noted before, while you should try to include the
key points as outlined below, it is probably better ifyou have a bash at putting them
into your own words, that you wouldfeel comfortable using.
My name is Susan Myles. I am a researcher with Edinburgh University Medical
School. (Show identification card) We are undertaking a research project looking
into the way in which people get hold of medicines that can be got, either from the
general practitioner on prescription, or purchased over-the-counter direct from the
pharmacist. I'd like to ask you a few questions about the medicine(s) you got at the
pharmacy today and about your use of general practice and pharmacy services. It
should only take about five minutes of your time. All the information you share with
me is will be completely confidential and can also be anonymous if you wish. This
information cannot be linked back to you personally and will not be shared with
either your GP or the pharmacist. Have you got five minutes just now?
Hi, my name is Susan Myles, I am a researcher with Edinburgh University Medical
School. (Show identification card). We are doing a study about how people access
certain medicines that used to only be available on prescription, but which can now
be got from the pharmacist direct, over-the-counter. You picked up one of these
medicines today. Would you mind if I asked you a few questions about it? It should
only take about 5 minutes of your time. All the information you share with me
would be completely confidential and will be seen only by researchers. Have you
got five minutes just now?
We would like to find out what extra money and time you had to spend to obtain
your medicine. Your answers are important because they will give those who make
decisions about patient treatment within the National Health Service and idea of how
much it costs you to use health services (UK Working Party on Patients' Costs,
1999).
Note if user unsure about participation, offer them a leaflet to read that explains the
study.




This will be a four digit number, already on the questionnaire after final printing e.g.
0001, 0002, etc.
Pharmacy Name:
Write in the pharmacy name and enter its code number as below:

















Write in your name and interviewer code as below:






Write in date and code with 6 digits as follows e.g. 1st June 1998 = 010698
Day of Interview:
Write in the day and code as follows:









Write in the time of interview and code using 4 digits and 24 hour clock e.g. 4.10
p.m. = 1610
General Points on Questionnaire Completion
• Clearly circle the code numbers and make sure that you have circled one for every
question
• Where see 'Other (specify)' take care to fill these in (although the limit is usually
10 characters)
• 'Don't know' is always coded as number 8
• Where any extra (interesting/potentially useful) information is given by the
respondent, write it down for me to have a look at later
• If unsure which code to circle write down the respondent's answer (try to avoid
this where possible though)
• Try to write clearly and legibly
• Remember to ask all respondents at the end of the questionnaire if they would be
happy to be followed up?
• At end of questionnaire remember to always offer respondents an information
leaflet
Get that Interview!
1. Introduce yourself and show your authorisation card
2. Introduce the project
3. Explain why this person approached
4. Don't say too much
5. Be positive. Believe in yourself and the survey. Act as if you have
never had a refusal
6. Build rapport. Smile. Look and listen. Relate to your respondent but
don't be so chummy that they think that you are being insincere
Fieldworker's Essential Survival Kit
1. Sufficient questionnaires (probably 15 max. a day - let's hope for a
rush)!
2. Prompt cards
3. Non-respondent minimum data collection forms
4. Identification card and badge
5. Clip board and couple of pens
6. Supply of user information leaflets
7. Pharmacy information poster (first day)
8. Pharmacist/pharmacy assistant's information packs (first day)
9. Something to read, eat and drink
10. A good sense of humour and a smile
Coding frames for user responses to open questions
J1 and J2 in the telephone follow-up interview
Question J1:
"In what circumstances would you prefer to go to the pharmacist, rather than
the GP?"
Broadly Positive Responses Code
No.
For minor things/not too serious 1
Convenience 2
Cheaper OTC 3
Prefer/try to use the pharmacist when I can 4
Good for specific groups of users 5
Good relationship with the pharmacist 6
Pharmacist highly trained/give good advice 7
Try to use the pharmacist first 8
When want a quick solution/relief 9
When I feel confident self treating or know what's wrong or what to do 10
I like to help myself whenever possible/trial & error/know own body 11
Relieves pressure on the doctors/NHS/saves Drs time/NHS resources 12
Don't need to see or have a doctor diagnose 13
When I'm familiar with the medicine/know what it does 14
Frees up time with Dr for more needy/ill 15
Broadly Negative Responses Code
No.
Difficult to get an appointment/no need to wait for appointment with GP 16
Don't like to bother the doctor/waste their time 17
Too expensive/cost prohibitive/cost a concern 18
Reluctant/don't like to go to the doctor 19
Shouldn't mix medicines/Rx and OTC drugs 20
Pharmacists not expert enough 21
I would never go to the pharmacy to buy a medicine 22
Better/safer/prefer to see the doctor/get a repeat Rx 23
No, wouldn't, as get free prescription 24
What Dr prescribed doesn't work 25
Equivocal Responses Code
No.
Reluctant to use either the GP or the pharmacist 31
Don't like to use medicines at all 32
With monitoring and advice 33
Don't know 88
Question J2:
" What do you think about making more medicines, which were in the past
prescribed, available from the pharmacist to buy"
Broadly Positive Responses Code No.
More convenient 1
Cheaper OTC 2
Relieves pressure on doctors/NHS/users/saves Drs time 3
Encourages more selfmanagement ofminor illness 4
Provides information and education on medicines 5
Allows autonomy/choice in decision making/promotes self help 6
Pharmacist expert in medicines/highly trained/give good advice 7
Saves bothering the doctor/wasting their time 8
Frees up time with doctors for more needy/ill 9
For minor, routine things/recurrent or chronic 10
No need to wait to see the doctor/saves or no need having to see Dr 11
When confident/like to self treat/know what's wrong/what I need 12
Broadly Negative Responses Code No.
Too expensive/cost prohibitive/cost concern 16
Side effects/wary ofmixing medicines 17
Danger of strong medicines/safety concerns/addiction/immunity 18
Pharmacist not expert enough/not enough time or advice given 19
Prefer/better to see/left in control of the GPs 20
Potential abuses could arise/exist 21
Inappropriate or unnecessary use or overuse of medicines 22
Danger may suppress more serious/other symptoms 23
Certain groups of people really should see their GP 24
Adequacy of self diagnosis/should see a professional/proper consult. 25
Too many/enough medicines already available 26
Users have inadequate information to self diagnose and prescribe 27
Medicine not available from the GP 28
Just a way for ph and drug cos. to make money 29
Equivocal Responses Code No.
With monitoring and advice from the ph 31
If demonstrated safe/min side effects/used cautionary/non addictive 32
Only for some conditions/medicines 33
Enough medicines already available 34
With doctor's sanction/advice first/had before 35
Increases pressure on pharmacists 36
Don't know 88
Appendix 3:
Chapter 3 - Results
Table A3.1: When would users prefer to use a community pharmacist?
In what circumstances would you prefer to go to the pharmacist, rather
then the GP?
User Responses 1st 2nd 3rd 4th 5th
N N N N N TOTAL
(%) (%) (%) (%) (%)
N (%)
Try to use the pharmacist when I can 160 48 24 8 0 240
(14) (4) (2) (1) (-) (33)
For minor complaints 173 29 8 1 0 211
(15) (2) (1) (-) (-) (29)
When feel confident self-treating or 90 37 11 4 0 142
know what is wrong (8) (3) (1) (-) (-) (20)
Better/safer/prefer to see the doctor 66 26 3 0 0 95
(6) (2) (-) (-) (-) (13)
Don't like to bother the doctor/waste 6 35 22 0 2 65
their time (1) (3) (2) (-) (-) (9)
Pharmacist highly trained/give good 10 28 11 9 3 61
advice (1) (2) (1) (1) (-) (8)
Convenience 21 17 9 2 1 50
(2) (1) (1) (-) (-) (7)
When I am familiar with the medicine 13 24 7 2 0 46
and know what it does (1) (2) (-) (-) (-) (6)
Don't like to go to the doctor 10 20 13 3 0 46
(1) (2) (1) (-) (-) (6)
Difficult to get an apptmt./ no need to 0 30 10 5 0 45
wait for an apptmt. with the GP (-) (3) (1) (-) (-) (6)
Like to help myselfwherever possible 14 19 6 2 0 41
(1) (2) (1) (-) (-) (6)
Cheaper OTC 11 12 9 4 0 36
(1) (1) (1) (-) (-) (5)
Good for specific groups of users 8 9 10 2 0 29
(1) (1) (1) (-) (-) (4)
I wouldn't go as I get my 19 6 2 1 0 28
prescriptions free (2) (1) (-) (-) (-) (4)
Don't need to see a doctor/have a 4 19 1 0 1 25
doctor diagnose (-) (2) (-) (-) (-) (3)
I would never go to the pharmacist to 20 2 0 0 0 22
buy a medicine (2) (-) (-) (-) (-) (3)
Shouldn't mix medicines/prescription 4 14 1 2 0 21
and OTC drugs (-) (1) (-) (-) (-) (3)
When want quick solution/relief 7 8 "3J 0 1 18
(1) (1) (-) (-) (-) (3)
Too expensive/cost a concern 6 8 2 0 0 16
(1) (1) (-) (-) (-) (2)
Frees up doctors time for more needy 11 0 2 0 0 13
or ill/Pharmacist not expert enough (1) (-) (-) (-) (-) (2)
Relieves pressure on doctors & 0 9 2 0 0 11
NHS/saves doctor time and resources (-) (1) (-) (-) (-) (2)
Good relationship with/trust the 2 2 4 0 0 8
pharmacist (-) (-) (-) (-) (-) (1)
Don't like to use medicines at all 4 1 0 0 0 5
(-) (-) (-) (-) (-) (1)
What doctor prescribes/ what 1 3 0 0 0 4
available from pharmacist didn't work (-) (-) (-) (-) (-) (1)
Reluctant to use either the GP or the 2 1 0 0 0 3
pharmacist (-) (-) (-) (-) (-) (-)
Don't know 1 0 1 0 0 2
(-) (-) (-) (-) (-) (-)
With monitoring or advice 1 0 0 0 0 1
(-) (-) (-) (-) (-) (-)
Pharmacist not expert enough 0 0 1 0 0 1
(-) (-) (-) (-) (-) (-)
Table A3.1: User views on making more medicines available from community
pharmacies
What do you think about making more medicines, which were in the past
prescribed, available from the pharmacist to buy?
User Responses 1st 2nd 3rd 4th 5th
N N N N N TOTAL
(%) (%) (%) (%) (%)
N
(%)
More convenient 168 38 19 4 2 231
(14) (3) (2) (-) (-) (32)
No need to wait to see the 43 66 18 3 2 132
doctor/saves having to see the doctor (4) (6) (2) (-) (-) (18)
Cheaper OTC 56 25 7 2 1 91
(5) (2) (1) (-) (-) (13)
With monitoring and advice from the 30 33 16 4 2 85
pharmacist (3) (3) (1) (-) (-) (12)
Inappropriate or unnecessary or 36 36 9 0 2 83
overuse of medicines (3) (3) (1) (-) (-) (12)
Relieves pressure on 29 24 13 4 1 71
doctors/NHS/saves doctors time (2) (2) (1) (-) (-) (10)
Danger of strong medicines/safety 34 20 9 1 1 65
concerns/addiction issues/immunity (3) (2) (1) (-) (-) (9)
Better left in the control of the GP 25 21 11 2 2 61
(2) (2) (1) (-) (-) (8)
Potential abuses could arise 26 22 9 2 2 61
(2) (2) (1) (-) (-) (8)
Pharmacists experts in 20 22 10 3 0 55
medicines/highly trained/good advice (2) (2) (1) (-) (-) (8)
If demonstrated to be safe 26 14 5 1 0 46
(2) (1) (-) (-) (-) (6)
Saves bothering the doctor/wasting 10 23 5 2 0 40
their time (1) (2) (-) (-) (-) (6)
Too expensive/cost a concern 18 17 5 0 0 40
(2) (1) (-) (-) (-) (6)
Adequacy of self-diagnosis/should see 18 13 2 1 0 34
a professional (2) (1) (-) (-) (-) (5)
For minor routine things/ recurrent or 21 8 1 0 1 31
chronic conditions (2) (1) (-) (-) (-) (4)
When confident/like to self-treat 13 12 4 0 0 29
(1) (1) (-) (-) (-) (4)
Encourages more self-management of 12 6 5 2 0 25
minor illness (1) (1) (-) (-) (-) (4)
With doctors sanction or advice first/if 10 6 2 4 0 22
have had the medicine before (1) (1) (-) (-) (-) (3)
Allows autonomy/choice in decision 6 11 2 0 2 21
(1) (1) (-) (-) (-) (3)
Concerned about side effects/wary of 5 10
->
J 2 1 21
mixing medicines (-) (1) (-) (-) (-) (3)
Only for some conditions or medicines 12 6 3 0 0 21
(1) (1) (-) (-) (-) (3)
Enough medicines available already 9 7 2 2 0 20
(1) (1) (-) (-) (-) (3)
Don't know 12 0 0 0 0 12
(1) (-) (-) (-) (-) (2)
Pharmacist not expert enough/not 3 4 5 0 0 12
enough time or advice given (-) (-) (-) (-) (-) (2)
Certain groups of people really should 8 0 2 1 0 11
see their GP (1) (-) (-) (-) (-) (2)
Just a way for pharmacists and drug 1 5 4 0 0 10
companies to make money (-) (-) (-) (-) (-) (1)
Danger may suppress more serious or 3 3 1 1 0 8
other symptoms (-) (-) (-) (-) (-) (1)
Too many medicines already available 3 2 0 2 0 7
(-) (-) (-) (-) (-) (1)
Frees up more time with doctors for 1 4 2 0 0 7
more needy/ill (-) (-) (-) (-) (-) (1)
Provides information and education on 2 3 1 0 0 6
medicines (-) (-) (-) (-) (-) (1)
Increases pressure on pharmacists 1 1 2 1 0 5
(-) (-) (-) (-) (-) (1)
When embarrassed and don't want to 1 3 0 0 0 4
talk to the doctor about the problem (-) (-) (-) (-) (-) (1)
Users have inadequate information to 1 1 0 0 0 2
self-diagnose and prescribe (-) (-) (-) (-) (-) (-)
Appendix 4:
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Number of selected cases: 1185
Number rejected because of missing data: 111









jhton St 1 103 - 1.000 -1 .000
lgston 2 109 1.000 . 000
:uik 3 30 .000 1 . 000
mo 4 102 . 000 . 000
s Lloyds 5 71 . 000 .000
fRd 6 24 . 000 . 000
cburn 7 108 .000 . 000
Dhns 8 91 . 000 .000
jith 9 43 .000 . 000
cwick 10 • 57 . 000 .000
iBOOtS «■»•>— 11 151 . 000 .000
rie Mains 12 34 .000 . 000
iton 13 41 . 000 .000
ihouse 14 16 .000 . 000
Ly Bank 15 94 .000 .000
3
(3) (4) (5)
ghton St 1 -1.000 -1.000 -1.000
agston 2 . 000 . 000 .000
ruik 3 . 000 . 000 . 000
rno 4 1.000 . 000 . 000
s Lloyds 5 .000 1.000 .000
/ Rd 6 . 000 . 000 1 . 000
tburn 7 .000 . 000 . 000
Dhns 8 . 000 . 000 .000
»ith 9 .000 . 000 .000
rwick 10 .000 . 000 . 000
s Boots 11 . 000 . 000 . 000
rie Mains 12 .000 . 000 . 000
aton 13 . 000 . 000 . 000
dhouse 14 . 000 . 000 . 000
ly Bank 15 .000 . 000 .000
E
(6) (7) (8)
ghton St 1 -1.000 -1.000 -1. 000
ngston 2 . 000 . 000 . 000
cuik 3 . 000 . 000 . 000
rno 4 . 000 . 000 . 000
e Lloyds 5 . 000 . 000 . 000
y Rd 6 . 000 . 000 . 000
kburn 7 1.000 . 000 . 000
ohns 8 .000 1. 000 . 000
eith 9 . 000 . 000 1.000
rwick 10 . 000 . 000 . 000
e Boots 11 . 000 . 000
. 000
rie Mains 12 .000 . 000 . 000
nton 13 .000 . 000 . 000
dhouse 14 . 000 . 000 .000




ghton St 1 -1.000 -1.000
-1.000
ngston 2 .000
. 000 . 000
cuik 3 . 000 . 000 . 000
rno 4 . 000 . 000
. 000
8 .000 . 000 . 000
9 . 000 . 000 .000
10 1 .000 . 000 .000
11 .000 1 . 000 .000
12 . 000 . 000 1 .000
13 .000 .000 .000
14 .000 . 000 .000
15 . 000 .000 .000
(12) (13) (14)
1 -1 .000 -1 . 000 -1 .000
2 . 000 .000 .000
3 .000 . 000 .000
4 .000 .000 .000
5 . 000 . 000 .000
6 . 000 . 000 .000
7 .000 .000 .000
8 .000 .000 .000
9 . 000 . 000 . 000
10 .000 .000 .000
11 . 000 .000 .000
12 . 000 .000 .000
13 1 .000 .000 .000
14 . 000 1 . 000 . 000




1. 00 566 -1.000 -1.000
2 . 00 107 1.000 . 000
3 .00 87 . 000 1.000
4 . 00 187 . 000 . 000






























































1.00 293 -1.000 -1
2 . 00 591 1 . 000
3 . 00 190 . 000 1
1 169 1. 000
2 731 . 000 1












































le 1 403 1.000
male 2 671 -1.000
UMM
me owner 1.00 722 1.000
nting 2 .00 352 -1.000
UMM
ite 1.00 1060 1.000
















ice paid less than or eq^ial to the Rx charge 1.00 968 1.000









1 E7REGRX(1) by F5SUMM(1)
2 E5SAMEPH(1) by E8PAYRX(1)
3 E5SAMEPH (1) by G6POMTOP (1)
\
JCLUJLCLL L, V CXX. AQUiC . . uXV. WA Wi. fit 1.XA. wv. <vW«.
ginning Block Number 0. Initial Log Likelihood Function
Log Likelihood 1219.8311
Constant is included in the model.
ginning Block Number 1. Method: Forward Stepwise (LR)
Improv. Model Correct
2P Chi-Sq. df sig Chi-Sq. df sig Class % Variable
1 301.280 14 .000 301.280 14 000 73 .46 IN: PHCODE
2 122 .673 1 .000 423.954 15 . 000 78.40 IN: E8PAYRX
3 97.857 1 .000 521.810 16 . 000 82 . 68 IN: G7BLACKL
4 34 .057 1 .000 555.867 17 000 82.31 IN: E7REGRX
5 15.312 1 .000 571.179 18 . 000 83 .24 IN: E4YRNOPH
6 12.100 1 . 001 583.279 19 . 000 82 . 77 IN: E1YRNOGP
7 10.823 1 .001 594.102 20 . 000 84.17 IN: E5SAMEPH
8 8.083 2 .018 602.184 22 . 000 84.08 IN: F6SUMM
9 5.303 1 .021 607.488 23 000 84.54 IN: E5SAMEPH * E8PAYRX
L0 10 .123 4 .038 617.611 27 . 000 85.29 IN: F4MSTAT2
LI 4 .483 1 .034 622.094 28 . 000 85 . 66 IN: E13LGILL
more variables can be deleted or added.
i Block Number 1 """PIN »
lal Equation for Block 1
.0500 Limits reached.
:imation terminated at iteration number 7 because












Hosmer and Lemeshow Goodness-of-Fit Test
\ DRPH1ST = Doctor first ccp DRPH1ST = Ph first ccp






> < V WW
30.000
> • TC XW
29.188
AV / . V/W
107.000
3 50.000 48.305 57.000 58.695 107.000
4 28.000 25.296 79.000 81.704 107.000
5 11.000 11.930 96.000 95.070 107.000
6 6.000 6.324 102.000 101.676 108.000
7 3.000 2 . 856 104.000 104.144 107.000
8 1.000 1.303 106.000 105.697 107.000
9 . 000 .499 107.000 106.501 107.000
10 .000 .095 110.000 109.905 110.000
Chi-Square df Significance
3dness-of-fit test 1.6592 8 .9897
ossification Table for DRPH1ST







Doctor first ccp Ph first ccp Percent
D P
242 32 88 .32%
122 678 84 . 75%
Overa! .1 85.66%
Variables in the Equation
riable B s.e. Wald df Sig R
:ode 58.4382 14 .0000 . 1580
icode(1) 1.1908 . 8809 1.8273 1 . 1764 . 0000
icode(2) 6.7147 8.9604 .5616 1 .4536 . 0000
icode(3) .4135 . 8323 .2468 1 .6194 . 0000
icode(4) -.8067 . 7369 1.1982 1 .2737 . 0000
icode (5) . 9528 1.0858 .7700 1 , .3802 .0000
icode(6) -1.4672 .7592 3.7344 1 .0533 -.0377
icode(7) -1.4553 .7144 4.1494 1 .0416 - .0420
icode(8) .0864 .8207 . 0111 1 . 9161 .0000
icode(9) 1.0341 .8099 1.6304 1 .2016 . 0000
icode(10) .2881 . 7259 .1575 1C .6915 . 0000
icode(11) -1. 1347 . 8244 1.8947 1 . 1687 .0000
icode(12) -1.5453 .8361 3.4155 1 .0646 -.0341
*code(13) -2.0591 . 9994 4.2449 1 . 0394 - . 0429
code (14) -1.2460 .7418 2.8210 1 . 0930 - . 0259
(RNOGP -.2877 . 1032 7.7663 1 .0053 -.0688
fRNOPH .6764 . 1407 23.1150 1 . 0000 . 1316
3AMEPH(1) -.5707 . 1978 8.3274 1 . 0039 -.0720
IEGRX(1) -.4459 . 1430 9.7179 1 . 0018 -.0795
3AYRX(1) . 5280 .2019 6.8425 1 . 0089 . 0630
SLGILL(1) - .2745 . 1298 4.4749 1 . 0344 - . 0450
ILACKL(1) 1. 0989 . 1267 75.2441 1 .0000 .2450
3UMM 10.1243 2 . 0063 . 0709
SSUMM(1) - . 0572 . 1899 .0906 1 .7634 . 0000
3SUMM(2) - . 7476 .2811 7 . 0742 1 . 0078 - . 0645
ISTAT2 11.3466 4 . 0229 . 0524
IMSTAT2(1) .2148 .2716 .6251 1 .4291 . 0000
IMSTAT2(2) - .4281 .3381 1.6035 1 .2054 . 0000
1MSTAT2(3) .5277 .2343 5.0742 1 .0243 . 0502
IMSTAT2(4) -.6626 .2972 4.9691 1 . 0258 -.0493
r_2 .4816 . 1909 6.3624 1 .0117 . 0598
istant 2 .0926 .7849 7.1086 1 . 0077
riable Exp(B) Lower Upper
10de(1) 3.2899 .5852 18.4942
:ode(2) 824.4239 .0000 3 . 4 93e+10
:ode(3) 1.5120 .2959 7.7275
:ode(4) .4463 .1053 1.8921
:ode (5) 2 .5931 .3087 21.7814
:ode (6) .2306 .0521 1.0211
:0de(7) .2333 .0575 . 9464
30de (8) 1.0903 .2182 5 .4471
:ode (9) 2.8125 .5751 13 .7548
;ode(10) 1.3338 .3215 5.5329
:ode(ll) .3215 .0639 1.6177
:ode(12) .2132 . 0414 1.0980
30de(13) .1276 .0180 . 9046
lode (14) .2877 .0672 1.2312
frnogp .7500 . 6126 . 9182
frnoph 1.9668 1.4928 2.5913
3AMEPH(1) .5651 .3835 .8327
1egrx(1) .6403 .4837 .8474
?ayrx(1) 1.6956 1.1416 2 .5186
ilgill(1) .7599 .5893 . 9800
3lackl(1) 3 .0010 2 . 3411 3.8468
3UMM (1) . 9444 .6509 1.3703
3UMM(2) .4735 .2729 .8214
^gtat2 (1) 1.2396 .7279 2.1110
3tat2(2) .6517 .3360 1.2643
1stat2(3) 1,6950 1.0710 2.6827
1stat2(4) 75155 .2879 .9231
r 2 1.6187 1.1134 2 .3534
TABLE A4.1: VARIABLES NOT INCLUDED IN THE FINAL LOGISTIC REGRESSION EQUATION
Variable Score d.f. Sig. R
Chainind 0.07 1 0.78 .000
E2uswtgp 0.99 1 0.31 .000
E3fargp 1.01 1 0.31 .000
E6farph 2.27 1 0.13 .015
Ellctoff 0.70 1 0.40 .000
E12genht 1.36 1 0.24 .000
Flsex 0.06 1 0.79 .000
F3age 0.50 1 0.47 .000
F7carvan 1.63 1 0.20 .000
F9fted 0.07 1 0.77 .000
G6pomtop 0.17 1 0.67 .000
F2summ 0.28 1 0.59 .000
F5summ 0.56 1 0.45 .000
F8summ 2.50 0.64 .000
F8summ(l) 1.04 1 0.30 .000
F8summ(2) 0.16 1 0.68 .000
F8summ(3) 1.03 1 0.31 .000
F8summ(4) 0.95 1 0.32 .000
E7regrx(l) by 1.46 1 0.22 .000
F5summ
E5sameph(l) by 1.05 1 0.30 .000
G6pomtop (1)
Prelrx 1.39 1 0.23 .000























e5sameph e6farph e7regrx e8payrx
e11ctoffe12genhte13lgill flsex
f6summ
f4mstat2 f7carvan f9(ted g6pomtop



































Number of selected cases: 1185
Number rejected because of missing data: 111










roughton St 1 103 -1.000 -1.000
ivingston 2 109 1.000 .000
enicuik 3 30 .000 1.000
alerno 4 102 .000 . 000
gate Lloyds 5 71 . 000 . 000
airy Rd 6 24 . 000 . 000
lackburn 7 108 . 000 . 000
t Johns 8 91 . 000 . 000
alkeith 9 43 . 000 . 000
Berwick 10 57 . 000 . 000
Gate Boots ■*" ~ 11 151 .000 .000
iddrie Mains 12 34 .000 .000
Linton 13 41 .000 .000
auldhouse 14 16 . 000 . 000
omely Bank 15 94 . 000 . 000
(3) (4) (5)
CODE
roughton St 1 -1.000 -1.000 -1.000
ivingston 2 . 000 . 000 .000
enicuik 3 . 000 . 000 . 000
alerno 4 1.000 . 000 . 000
gate Lloyds 5 . 000 1.000 . 000
airy Rd 6 . 000 .000 1.000
lackburn 7 . 000 . 000 .000
t Johns 8 . 000 . 000 . 000
alkeith 9 . 000 . 000 . 000
Berwick 10 . 000 . 000 . 000
Gate Boots 11 .000 . 000 . 000
iddrie Mains 12 .000 . 000 . 000
Linton 13 . 000 . 000 . 000
auldhouse 14 . 000 . 000 .000
omely Bank 15 . 000 .000 .000
(6) (7) (8)
CODE
roughton St 1 -1.000 -1.000 -1.000
ivingston 2 .000 . 000 .000
enicuik 3 . 000 . 000 . 000
alerno 4 . 000 . 000 . 000
gate Lloyds 5 .000 . 000 .000
airy Rd 6 .000 . 000 . 000
lackburn 7 1.000 .000 . 000
t Johns 8 .000 1. 000 . 000
alkeith 9 .000 . 000 1. 000
Berwick 10 .000 .000 . 000
Gate Boots 11 .000 . 000 . 000
iddrie Mains 12 . 000 . 000 . 000
Linton 13 . 000 . 000 . 000
auldhouse 14 . 000 . 000 . 000







1 -1.000 -1.000 -1.000
2 .000 . 000 . 000
3 . 000 . 000 .000
4 . 000 . 000 . 000
8 . 000 .000 .000
9 . 000 . 000 . 000
10 1.000 .000 .000
11 .000 1.000 .000
12 . 000 . 000 1.000
13 .000 .000 .000
14 .000 . 000 . 000
15 .000 .000 .000
(12) (13) (14)
1 -1.000 -1.000 - 1. 000
2 .000 .000 . 000
3 .000 .000 .000
4 . 000 .000 . 000
5 .000 . 000 .000
6 . 000 . 000 . 000
7 .000 .000 .000
8 .000 .000 .000
9 .000 .000 . 000
10 .000 .000 . 000
11 . 000 . 000 . 000
12 . 000 . 000 . 000
13 1.000 .000 .000
14 . 000 1. 000 .000




1.00 440 -1.000 - 1.000
2 .00 150 1.000 .000
3.00 306 . 000 1.000
4 . 00 104 . 000 . 000






























































1.00 293 -1.000 -1.000
2.00 591 1.000 .000
3.00 190 .000 1.000
1 169 1.000 .000
2 731 .000 1.000


































rice paid less than or equal to the Rx charge
rice paid more than Rx charge
Interactions:
r_l E7REGRX(1) by F5SUMM(1)
r_2 E5SAMEPH(1) by E8PAYRX(1)
























pendent Variable.. DRPH1ST Dr or Ph first CCP
ginning Block Number 0. Initial Log Likelihood Function
Log Likelihood 1219.8311
Constant is included in the model.
ginning Block Number 1. Method: Backward Stepwise (LR)
riable(s) Entered on Step Number
PHCODE pharmacy name
CHAININD chain or independent pharmacy
E1YRN0GP no times seen gp in last year
E2USWTGP usual wait to see a gp
E3FARGP how far live from gp surgery
E4YRNOPH no times consulted ph in last year
E5SAMEPH use the same ph
E6FARPH how far live from ph
E7REGRX any regular medicines on rx from gp
E8PAYRX pay for rx
E11CT0FF ever put off by cost of medicines
E12GENHT description of general health
E13LGILL any longstanding illness
F1SEX sex
F6SUMM dep. cat. summ
F4MSTAT2 m stat combined - marr./lvg tgthrv& div./sep.
F7CARVAN car or van ownership
F9FTED -—ager completed f/t education
G6P0MT0P pom to p med
G7BLACKL med NHS blacklisted
F2SUMM ethnic group - summary
F5SUMM accom.type - summary




PRELRX Price paid realtive to Rx chg
F3AGE age
:imation terminated at iteration number 7 because
3 Likelihood decreased by less than .01 percent.
I Log Likelihood
3odness of Fit
















issification Table for DRPH1ST
; Cut Value is .75
Predicted






D 242 32 88.32%






























































































































































Wald df Sig R
5893 14 . 0000 . 1420
0348 1 .3090 . 0000
6151 1 .4329 . 0000
0003 1 . 9858 .0000
4038 1 . 5251 . 0000
8896 1 . 3456 . 0000
1176 1 .2904 . 0000
2490 1 .2637 . 0000
0093 1 . 9234 . 0000
1558 1 . 6931 . 0000
0651 1 . 7986 . 0000
3516 1 .5532 . 0000
8010 1 . 3708 . 0000
9295 1 .3350 .0000
3430 1 .2465 . 0000
0176 1 . 8944 . 0000
8400 1 . 0089 - . 0630
1038 1 .2934 . 0000
0284 1 . 8662 . 0000
4544 1 . 0000 . 1357
2184 1 . 0024 -.0769
2768 1 . 1313 -.0151
3983 1 . 0007 -.0878
1447 1 . 0762 . 0306
8604 1 .3536 . 0000
6097 1 . 2045 . 0000
9297 1 . 0474 - . 0398
0050 1 . 9437 . 0000
2598 2 . 0059 . 0716
0242 1 . 8763 . 0000
8533 1 . 0051 -.0693
2201 4 . 1247 . 0000
0000 1 1.0000 . 0000
7303 1 . 1884 . 0000
0555 1 . 0245 . 0500
5542 1 .4566 . 0000
9987 1 . 1574 . 0000
0098 2 . 9951 .0000
0067 1 . 9346 . 0000
0013 1 . 9708 . 0000
6235 1 . 4297 . 0000
0216 1 . 0000 .2396
3635 1 . 5466 . 0000
8206 1 . 1772 . 0000
5922 4 .6282 . 0000
6563 1 .4179 . 0000
0124 1 . 9115 . 0000
3255 1 . 5683 .0000
3610 1 . 5480 . 0000
1208 3 .4848 1 . 0619 - . 0349
2007 5 . 9445 1 . 0148 . 0569
1990 1.7807 1 . 1821 . 0000
2461 2 . 4358 1 .1186 -.0189
0115 . 0530 1 .8180 . 0000
3189 2.9180 1 . 0876
Exp(B) Lower Upper
3.8522 .2866 51.7867
1072.1189 . 0000 4.007E+10
1.0384 .0163 66.0968
.4620 . 0427 5.0010
4 .1239 .2171 78.3342
.2760 .0254 3 .0023
. 2571 . 0237 2.7841
1.1315 .0913 14.0308
2 .2616 .0393 130.1117
1.3664 . 1242 15.0291
.2791 .0041 18.9625
. 1500 .0024 9.5569
.1192 .0016 9.0016
.2345 .0202 2.7252
.8234 . 0467 14.5049
.7510 .6060 . 9308
1.0836 . 9329 1.2586
.9714 .6928 1.3620




1.5192 . 9569 2 .4119
. 8580 .6207 1.1859
1.2286 . 8939 1.6887
.7536 .5697 .9968
1.0087 .7928 1.2835




1.7952 1. 0780 2.9898
.6577 .2182 1.9821
.8273 .6360 1.0760
. 9531 .3022 3.0059
1.0124 .5240 1.9558
. 8513 . 5710 1.2694
3 .2446 2 .4724 4.2581
. 7425 .2821 1.9545
1.2115 .9168 1.6009
. 7413 .3592 1.5295
1. 0489 .4523 2.4320
1.3604 .4726 3 . 9161




1.6313 1.1007 2 .4176
1. 3042 . 8830 1.9263
.6811 .4205 1.1032
1.0027 . 9803 1.0255














DDPP PP P PPPPPPPPP
sdicted 1
Prob: 0 —-—.25 .5 .75 1
3roup: DDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDPPPPPPPPPPPPPPP
Predicted Probability is of Membership for Ph first ccp
The Cut Value is .75
Symbols: D - Doctor first ccp
P - Ph first ccp
Each Symbol Represents 25 Cases.
Improv. Model Correct
sp Chi-Sq. df sig Chi-Sq. df sig Class % Variable
2 - . 010 2 . 995 640.677 47 000 86.13 OUT: F9FTED
3 - . 005 1 . 943 640.672 46 000 86.22 OUT: F1SEX
4 - . 017 1 . 896 640.655 45 . 000 86 . 22 OUT: CHAININD
5 - . 028 1 . 867 640.627 44 000 86.13 OUT: E3FARGP
6 - . 071 1 .791 640.556 43 000 86 .31 OUT: F3AGE
7 -3 .104 4 .541 637.453 39 . 000 86.03 OUT: F8SUMM
8 - .487 1 .485 636.966 38 . 000 86 . 03 OUT: F2SUMM
9 - . 689 1 .406 636.277 37 . 000 86.31 OUT: G6POMTOP
10 - . 916 1 .338 635 .361 36 . 000 86 . 03 OUT: E11CTOFF
11 -1 . 063 1 .303 634.298 35 000 86 .13 OUT: E2USWTGP
12 -1.329 1 . 249 632.969 34 . 000 86.22 OUT: E12GENHT
13 -1.246 1 . 264 631.722 33 . 000 85.85 OUT: E5SAMEPH
14 -2.155 1 . 142 629.567 32 . 000 85 . 94 OUT: PRELRX
15 -2 . 173 1 . 140 627.394 31 . 000 85 . 94 OUT: E6FARPH
16 -2.268 1 . 132 625.126 30 . 000 85.66 OUT: F5SUMM
17 -1 .400 1 .237 623 .726 29 000 85.29 OUT: E7REGRX *
18 -1 . 632 1 .201 622.094 28 . 000 85 . 66 OUT: F7CARVAN
more variable S ican be deleted or added.
i Block Number 1 PIN =
nal Equation for Block 1
.0500 Limits reached.
Limation terminated at iteration number 7 because
j Likelihood decreased by less than .01 percent.
2 Log Likelihood 597.737
Dodness of Fit 782.942
jx & Snell - RA2 .440





622.094 27 . 0000
622.094 28 . 0000
-1.632 1 .2014
ioDii-J-i.ai.iuu idJJXC LUI iJlfniD i
2 Cut Value is .75
Predicted
served
Doctor first ccp D
Ph first ccp P
Doctor first ccp Ph first ccp Percent
D P
242 32 88.32%
122 678 84 . 75%
Overa: .1 85.66%
Variables in the Equation
triable B S.E. Wald df Sig R
20DE 58 .4382 14 .0000 . 1580
3C0DE (1) 1.1908 . 8809 1.8273 1 . 1764 . 0000
3C0DE(2) 6.7147 8.9604 .5616 1 .4536 . 0000
3C0DE{3) .4135 . 8323 .2468 1 . 6194 . 0000
3C0DE (4) -.8067 .7369 1.1982 1 .2737 .0000
3C0DE(5) .9528 1.0858 .7700 1 .3802 . 0000
ICODE(6) -1.4672 .7592 3.7344 1 . 0533 -.0377
3CODE(7) -1.4553 .7144 4.1494 1 .0416 - .0420
3C0DE(8) .0864 . 8207 . 0111 1 . 9161 .0000
3C0DE(9) 1 .8099 1.6304 1 .2016 .0000
ICODE(10) .2881 .7259 .1575 1 .6915 . 0000
3C0DE(11) -1.1347 .8244 1.8947 1 . 1687 . 0000
3C0DE(12) -1.5453 .8361 3.4155 1 . 0646 -.0341
aCODE (1.3) -2.0591 . 9994 4 .2449 1 . 0394 -.0429
aC0DE(14) -1.2460 .7418 2.8210 1 . 0930 -.0259
fRNOGP - .2877 .1032 7.7663 1 .0053 -.0688
iTRNOPH .6764 . 1407 23.1150 1 . 0000 . 1316
3AMEPH(1) -.5707 . 1978 8.3274 1 .0039 -.0720
R.EGRX (1) -.4459 . 1430 9.7179 1 .0018 -.0795
?AYRX(1) .5280 .2019 6.8425 1 .0089 .0630
3LGILL(1) -.2745 . 1298 4.4749 1 . 0344 - . 0450
3UMM 10.1243 2 , .0063 . 0709
SSUMM(l) -.0572 . 1899 .0906 1 . 7634 . 0000
5SUMM(2) -.7476 .2811 7 . 0742 1 . 0078 - . 0645
4STAT2 11.3466 4 .0229 .0524
iMSTAT2 (1) .2148 .2716 .6251 1 .4291 . 0000
1MSTAT2(2) - .4281 .3381 1.6035 1-' .2054 . 0000
1MSTAT2 (3) .5277 .2343 5.0742 1 .0243 . 0502
1MSTAT2 (4) - .6626 .2972 4.9691 1 . 0258 - . 0493
3LACKL (1) 1.0989 . 1267 75.2441 1 .0000 .2450
r_2 .4816 . 1909 6.3624 1 . 0117 . 0598
istant 2.0926 . 7849 7.1086 1 • .0077
riable Exp(B)
95% CI for Exp(B)
Lower Upper
-ode(1) 3 .2899 .5852 18 .4942
:ode (2) 824.4239 .0000 3 .493e+10
20de (3) 1.5120 .2959 7.7275
:0de(4) .4463 .1053 1.8921
20de(5) 2.5931 .3087 21.7814
20de (6) .2306 . 0521 1. 0211
:ode(7) .2333 .0575 . 9464
20de(8) 1.0903 .2182 5.4471
lode (9) 2 . 8125 .5751 13 .7548
30de(10) 1.3338 .3215 5.5329
;ode(ii) .3215 .0639 1.6177
30de(12) .2132 . 0414 1.0980
30de(13) . 1276 .0180 .9046
30de(14) .2877 .0672 1.2312
frnogp .7500 .6126 . 9182
frnoph 1.9668 1.4928 2.5913
3ameph(1) .5651 .3835 . 8327
s.egrx (1) .6403 .4837 . 8474
payrx (1) 1.6956 1.1416 2.5186
3lgill(1) .7599 .5893 .9800
3umm(1) . 9444 .6509 1.3703
3umm(2) .4735 .2729 .8214
4stat2(1) 1.2396 .7279 2.1110
4stat2(2) .6517 .3360 1.2643
"1stat2 (3) 1.6950 1.0710 2 .6827
*1stat2 (4) .5155 .2879 . 9231
3lackl(1) 3tdbt0 2.3411 3 .8468
r 2 1.6187 1.1134 2.3534
Appendix 5:
Chapter 5 - Results
Constituent user, GP, CP and NHS time costs (minutes) across the
range of consultation routes adopted by users to access P medicines
TABLE A5.1: USER TIME COSTS (MINUTES) IN EACH OF THE INITIAL AND FOLLOW-UP
CONSULTATION ROUTES
First Consultation: P medicine on Rx in GP Appointment (N=176)
Activity
Mean
Median Mode Range Min Max
Sum
(Hrs)
Waiting time in GP surgery 14 10 5 90 0 90
4- O
Consulting time with GP 12 10 10 35 5 40 2079
(35)




180 120 120 360 120 480 3000
(50)
Travel time to CP 8 5 5 35 5 40 1480
(25)




200 120 120 360 120 480 1800
(30)
First Consultation: P Medicine on Repeal Rx from GP (N=127)
Activity
Mean
Median Mode Range Min Max
Sum
(Hrs)
Travel time to GP surgery 12 10 10 85 5 90 1320
(22)




223 120 120 720 120 840 1560
(26)
Travel time to CP 10 10 10 55 5 60 1220
(20)




264 120 120 720 120 840 1320
(22)
First Consultation: P Medicine Bought OTC al CP (IV=882)
Activity
Mean
Median Mode Range Min Max
Sum
(Hrs)
Travel time to CP 10 10 10 85 5 90 9195
(153)




145 120 120 120 120 240 2040
(34)
Waiting time in GP surgery 13 10 5 90 0 90 975
(16)
Consulting time with GP 11 10 10 55 5 60 865
(14)




5 120 120 1320 120 1440 2520
(42)
Follow Up Consulta tion: GP Appointment (N=122)
Activity Mean Median Mode Range Min Max
Sum
(Hrs)
Waiting time in GP surgery 28 15 15 90 0 90 3445
(57)
Consulting time with GP 13 10 10 55 5 60 1590
(27)




182 120 120 360 120 480 5280
(88)
Travel time to CP 8 5 5 15 5 20 775
(13)




120 120 120 0 120 120 720
(12)
Follow Up Consultation: CP Consultation (N=44)
Activity Mean Median Mode Range Min Max
Sum
(Hrs)
Travel time to CP 12 10 5 30 5 35 520
(9)




120 120 120 0 120 120 120
(2)
Note: the key figures of interest are the mean and total time costs accruing to users.
These are highlighted in bold. Other summary statistics are included as a reference
source for future researchers interested in costing the provision of P medicines in
primary care.
TABLE A5.2: GP TIME COSTS (MINUTES) IN EACH OF THE INITIAL AND FOLLOW-UP
CONSULTATION ROUTES
First Consultation: P medicine on Rx in GP Appointment (N=176)
Activity Mean Median Mode Range Min Max Sum
(Hrs)
Consulting time with GP 12 10 10 35 5 40 2079
(35)
First Consultation: P Medicine on Repeat Rx from GP (N=127)
Activity Mean Median Mode Range Min Max Sum
(Hrs)
Administration of posting by
GP




5 5 5 0 5 5 635
(11)
First Consultation: P Medicine Bought OTC al CP (N=882)
Activity Mean Median Mode Range Min Max Sum
(Hrs)
Consulting time with GP 0 0 0 0 0 0 0
(0)
Follow Up Consulta tion: GP Appointment (N=122)
Activity Mean Median Mode Range Min Max Sum
(Hrs)
Consulting time with GP 13 10 10 55 5 60 1590
(27)
Follow Up Consultation: CP Consultation (N=44)
Activity Mean Median Mode Range Min Max Sum
(Hrs)
Consulting time with GP 0 0 0 0 0 0 0
(0)
Note: the key figures of interest are the mean and total time costs accruing to users.
These are highlighted in bold. Other summary statistics are included as a reference
source for future researchers interested in costing the provision of P medicines in
primary care.
TABLE A5.3: CP TIME COSTS (MINUTES) IN EACH OF THE INITIAL AND FOLLOW-UP
CONSULTATION ROUTES
First Consultation: P medicine on Rx in GP Appointment (N=176)
Activity Mean Median Mode Range Min Max Sum
(Hrs)
Prescription dispensing (low) 2.5 2.5 2.5 0 2.5 2.5 440
(7)
(mid) 3.5 3.5 3.5 0 3.5 3.5 616
(10)
(high) 5.0 5.0 5.0 0 5.0 5.0 880
(15)
Prescription advice (low) 0.2 0.2 0.2 0 0.2 0.2 35
(1)
(mid) 0.3 0.3 0.3 0 0.3 0.3 53
(1)
(high) 0.4 0.4 0.4 0 0.4 0.4 70
(1)
First Consultation: P Medicine on Repeal Rx from GP (N=127)
Activity Mean Median Mode Range Min Max Sum
(Hrs)
Repeat Rx dispensing (low) 2.5 2.5 2.5 0 2.5 2.5 318
(5)
(mid) 3.5 3.5 3.5 0 3.5 3.5 445
(7)
(high) 5.0 5.0 5.0 0 5.0 5.0 635
(11)
Repeat Rx advice (low) 0.2 0.2 0.2 0 0.2 0.2 25
(0.5)
(mid) 0.3 0.3 0.3 0 0.3 0.3 38
(1)
(high) 0.4 0.4 0.4 0 0.4 0.4 51
(1)
First Consultation: P Medicine Bought OTC al CP (IV=882)
Activity Mean Median Mode Range Min Max Sum
(Hrs)
Advice P meds. OTC (low) 0.5 0.5 0.5 0 0.5 0.5 441
(7)
(mid) 1.0 1.0 1.0 0 1.0 1.0 882
(15)
(high) 2.5 2.5 2.5 0 2.5 2.5 2205
(37)
Follow Up Consulta tion: GP Appointment (N=122)
Activity Mean Median Mode Range Min Max Sum
(Hrs)
Prescription dispensing (low) 2.5 2.5 2.5 0 2.5 2.5 305
(5)
(mid) 3.5 3.5 3.5 0 3.5 3.5 427
(7)
(high) 5.0 5.0 5.0 0 5.0 5.0 610
(10)
Prescription advice (low) 0.2 0.2 0.2 0 0.2 0.2 24
(0.5)
(mid) 0.3 0.3 0.3 0 0.3 0.3 36
(1)
(high) 0.4 0.4 0.4 0 0.4 0.4 48
(1)
Advice on P med. OTC (low) 0.5 0.5 0.5 0 0.5 0.5 2
(-)
(mid) 1.0 1.0 1.0 0 1.0 1.0 4
(-)
(high) 2.5 2.5 2.5 0 2.5 2.5 10
(-)
Follow Up Consultation: CP Consultation (N=44)
Activity Mean Median Mode Range Min Max Sum
(Hrs)
Advice on P med. OTC (low) 0.5 0.5 0.5 0 0.5 0.5 22
(0.5)
(mid) 1.0 1.0 1.0 0 1.0 1.0 44
(1)
(high) 2.5 2.5 2.5 0 2.5 2.5 110
(2)
Note: the key figures of interest are the mean and total time costs accruing to users.
These are highlighted in bold. Other summary statistics are included as a reference
source for future researchers interested in costing the provision of P medicines in
primary care.
TABLE A5.4: SUMMARY MONEY COSTS (£) ACCRUING TO KEY STAKEHOLDERS IN EACH OF
THE INITIAL AND FOLLOW-UP CONSULTATION ROUTES
First Consultation: P medicine on Rx in GP Appointment (N= 176)
Stakeholder Mean Median Mode Range Min Max Sum
User incl. special arr. (1) 5.88 3.60 2.40 64.72 1.20 65.92 1035
User incl. special arr. (m) 10.41 7.10 4.80 128.12 2.40 130.52 1832
User incl. special arr. (h) 12.98 9.00 6.00 155.90 3.00 158.90 2284
User excl. special arr. (1) 4.62 3.95 3.79 30.39 0.30 30.69 813
User excl. special arr. (m) 6.14 5.19 4.39 32.39 0.60 32.99 1081
User excl. special arr. (h) 7.03 5.90 4.50 33.79 0.75 34.54 1237
General practitioner (1) 9.80 8.30 8.30 29.05 4.15 33.20 1726
General practitioner (m) 14.77 12.50 12.50 43.75 6.25 50.00 2599
General practitioner (h) 19.14 16.20 16.20 56.70 8.10 64.80 3368
Community pharmacist (1) 12.64 10.97 7.68 40.30 6.97 47.28 2225
Community pharmacist (m) 13.49 11.82 8.52 40.30 7.82 48.12 2374
Community pharmacist (h) 14.91 13.24 9.94 40.30 9.24 49.54 2624
National Health Service (1) 22.44 19.27 15.98 44.45 11.12 55.58 3950
National Health Service (m) 28.25 24.32 21.03 56.44 14.07 70.51 4972
National Health Service (h) 34.04 29.44 26.15 69.39 17.34 86.73 5991
First Consultation: P Medicine on Repeal Rx from GP (N=127)
Stakeholder Mean Median Mode Range Min Max Sum
User incl. special arr. (1) 4.37 2.20 2.30 155.46 0.30 155.76 555
User incl. special arr. (m) 7.62 4.40 1.20 290.76 0.60 291.36 968
User incl. special arr. (h) 9.53 5.70 4.50 362.45 0.75 363.20 1210
User excl. special arr. (1) 2.81 2.10 1.50 19.70 0.30 20.00 357
User excl. special arr. (m) 4.88 4.20 3.00 22.00 0.60 22.60 620
User excl. special arr. (h) 6.09 5.40 4.50 23.55 0.75 24.30 774
General practitioner (1) 4.29 4.15 4.15 0.88 4.15 5.03 545
General practitioner (m) 6.48 6.25 6.25 1.48 6.25 7.73 823
General practitioner (h) 8.43 8.10 8.10 2.08 8.10 10.18 1070
Community pharmacist (1) 14.43 1 1.79 9.68 34.43 0.86 35.29 1833
Community pharmacist (m) 15.28 12.64 10.52 34.43 1.71 36.14 1941
Community pharmacist (h) 16.76 14.11 12.00 34.43 3.19 37.61 2128
National Health Service (I) 18.72 15.94 13.83 34.43 5.01 39.44 2378
National Health Service (m) 21.76 18.89 16.77 34.43 7.96 42.39 2764
National Health Service (h) 25.18 22.11 20.10 34.43 11.29 45.71 3198
First Consultation: P Medicine Bought OTC altCP (IV=882'
Stakeholder Mean Median Mode Range Min Max Sum
User incl. special arr. (1) 5.24 4.29 3.79 90.78 0.95 91.73 4623
User incl. special arr. (m) 6.62 5.15 4.39 187.68 1.25 188.93 5839
User incl. special arr. (h) 7.41 5.69 4.69 230.25 1.40 231.65 6536
User excl. special arr. (1) 4.94 4.29 3.79 29.74 0.95 30.69 4358
User excl. special arr. (m) 6.00 5.10 4.39 31.74 1.25 32.99 5296
User excl. special arr. (h) 6.65 5.65 4.69 33.14 1.40 34.54 5867
General practitioner (1) 0.00 0.00 0.00 0.00 0.00 0.00 0.00
General practitioner (m) 0.00 0.00 0.00 0.00 0.00 0.00 0.00
General practitioner (h) 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Community pharmacist (1) 0.16 0.16 0.16 0.00 0.16 0.16 141
Community pharmacist (m) 0.45 0.45 0.45 0.00 0.45 0.45 397
Community pharmacist (h) 1.48 1.48 1.48 0.00 1.48 1.48 1301
National Health Service (1) 9.61 8.46 8.46 0.16 5.31 49.96 859
National Health Service (m) 14.68 12.95 12.95 0.45 6.80 75.45 1478
National Health Service (h) 19.92 17.68 17.68 1.48 9.58 98.68 2702
Follow-up Consulta tion: GP Appointment (N=122)
Stakeholder Mean Median Mode Range Min Max Sum
User incl. special arr. (1) 12.20 7.95 2.80 70.76 1.30 72.06 1488
User incl. special arr. (m) 20.39 12.40 5.60 121.96 2.60 124.56 2488
User incl. special arr. (h) 25.07 14.50 7.20 151.60 3.45 155.05 3058
User excl. special arr. (1) 4.42 3.99 1.80 16.79 0.90 17.69 539
User excl. special arr. (m) 6.21 5.17 3.60 17.14 1.25 18.39 757
User excl. special arr. (h) 7.24 6.00 4.50 17.85 1.40 19.25 883
General practitioner (1) 10.82 8.30 8.30 45.65 4.15 49.80 1320
General practitioner (m) 16.29 12.50 12.50 68.75 6.25 75.00 1988
General practitioner (h) 21.11 16.20 16.20 89.10 8.10 97.20 2576
Community pharmacist (1) 14.69 11.23 11.23 56.66 10.38 67.04 1498
Community pharmacist (m) 14.77 11.30 11.30 56.44 10.67 67.11 1506
Community pharmacist (h) 14.90 11.40 11.40 55.81 11.40 67.21 1520
National Health Service (1) 23.10 19.53 19.53 71.19 4.15 75.34 2818
National Health Service (m) 28.64 23.80 23.80 80.05 6.25 86.30 3494
National Health Service (h) 33.57 27.60 27.60 100.50 8.10 108.60 4096
Follow-up Consultation: CP Consultation (N=44)
Stakeholder Mean Median Mode Range Min Max Sum
User incl. Special arr. (1) 5.90 5.45 4.85 18.00 1.59 19.59 260
User incl. Special arr. (m) 7.22 6.57 6.57 18.09 2.10 20.19 318
User incl. Special arr. (h) 7.96 7.33 5.75 20.10 2.25 22.35 350
User excl. special arr. (1) 5.86 4.64 4.55 20.69 1.60 22.29 258
User excl. special arr. (m) 7.17 5.58 3.65 22.90 2.69 25.59 316
User excl. special arr. (h) 7.96 6.30 4.20 24.25 2.99 27.24 350
General practitioner (1) 0.00 0.00 0.00 0.00 0.00 0.00 0.00
General practitioner (m) 0.00 0.00 0.00 0.00 0.00 0.00 0.00
General practitioner (h) 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Community pharmacist (1) 0.16 0.16 0.16 0.00 0.16 0.16 7
Community pharmacist (m) 0.45 0.45 0.45 0.00 0.45 0.45 20
Community pharmacist (h) 1.48 1.48 1.48 0.00 1.48 1.48 65
National Health Service (1) 0.16 0.16 0.16 0.00 0.16 0.16 7
National Health Service (m) 0.45 0.45 0.45 0.00 0.45 0.45 20
National Health Service (h) 1.48 1.48 1.48 0.00 1.48 1.48 65
Note: '1' denotes low estimate; 'm' denotes mid estimate; 'h' denotes high estimate
TABLE A5.5: USER MONEY COSTS (£) IN EACH OF THE INITIAL AND FOLLOW-UP
CONSULTATION ROUTES
First Consultation: P medicine on Rx in GP Appointment (N=176)
Activity Mean Median Mode Range Min Max Sum
Waiting time GP surgery (1) 0.82 0.60 0.30 5.40 0.00 5.40 144
Waiting time GP surgery (m) 1.64 1.20 0.60 10.80 0.00 10.80 289
Waiting time GP surgery (h) 2.05 1.50 0.75 13.50 0.00 13.50 361
Consulting time with GP (1) 0.71 0.60 0.60 2.10 0.30 2.40 125
Consulting time with GP (m) 1.42 1.20 1.20 4.20 0.60 4.80 250
Consulting time with GP (h) 1.77 1.50 1.50 5.25 0.75 6.00 312
Travel method to GP (1) 0.23 0.00 0.00 3.00 0.00 3.00 40
Travel method to GP (m) 0.41 0.00 0.00 4.00 0.00 4.00 72
Travel method to GP (h) 0.59 0.00 0.00 5.00 0.00 5.00 104
Travel time GP surgery (1) 0.62 0.60 0.60 3.60 0.00 3.60 108
Travel time GP surgery (m) 1.23 1.20 1.20 7.20 0.00 7.20 217
Travel time GP surgery (h) 1.54 1.50 1.50 9.00 0.00 9.00 271
Special arr. attend GP (1) 10.15 7.07 7.00 21.56 7.00 28.56 162
Special arr. attend GP (m) 17.40 12.42 10.00 49.36 10.00 59.36 278
Special arr. attend GP (h) 21.94 15.60 13.00 59.80 13.00 72.80 351
Travel method to CP (I) 0.14 0.00 0.00 0.50 0.00 0.50 25
Travel method to CP (m) 0.26 0.00 0.00 0.80 0.00 0.80 47
Travel method to CP (h) 0.30 0.00 0.00 1.20 0.00 0.00 68
Travel time to CP (1) 0.50 0.30 0.30 2.10 0.30 2.40 89
Travel time to CP (m) 1.01 0.60 0.60 4.20 0.60 4.80 178
Travel time to CP (h) 1.26 0.75 0.75 5.25 0.75 6.00 222
Waiting time at CP (1) 0.48 0.30 0.30 5.40 0.00 5.40 84
Waiting time at CP (m) 0.96 0.60 0.60 10.80 0.00 10.80 169
Waiting time at CP (h) 1.20 0.75 0.75 13.50 0.00 13.50 211
Special arr. attend CP (1) 12.54 7.00 7.00 21.56 7.00 28.56 113
Special arr. attend CP (m) 21.00 10.00 10.00 49.36 10.00 59.36 189
Special arr. attend CP (h) 26.58 13.00 13.00 59.80 13.00 72.80 239
Prescription fee (1) 6.90 5.80 5.80 5.80 5.80 11.60 145
Prescription fee (m) 6.90 5.80 5.80 5.80 5.80 11.60 145
Prescription fee (h) 6.90 5.80 5.80 5.80 5.80 11.60 145
First Consultation: P Medicine on Repeat Rx from GP (N=127)
Activity Mean Median Mode Range Min Max Sum
Travel method to GP (1) 0.22 0.00 0.00 3.00 0.00 3.00 24
Travel method to GP (m) 0.41 0.00 0.00 4.00 0.00 4.00 44
Travel method to GP (h) 0.60 0.00 0.00 5.00 0.00 5.00 64
Travel time GP surgery (1) 0.74 0.60 0.60 5.10 0.30 5.40 79
Travel time GP surgery (m) 1.48 1.20 1.20 10.20 0.60 10.80 158
Travel time GP surgery (h) 1.85 1.50 1.50 12.75 0.75 13.50 198
Waiting time GP surgery (1) 0.16 0.00 0.00 1.80 0.00 1.80 16.80
Waiting time GP surgery (m) 0.31 0.00 0.00 3.60 0.00 3.60 34
Waiting time GP surgery (h) 0.39 0.00 0.00 4.50 0.00 4.50 42
Special arr. attend GP (1) 17.75 7.00 7.00 42.98 7.00 49.98 71
Special arr. attend GP (m) 33.47 10.00 10.00 93.88 10.00 103.88 134
Special arr. Attend GP (h) 41.60 13.00 13.00 114.40 13.00 127.40 166.40
Travel method to CP (1) 0.37 0.00 0.00 3.00 0.00 3.00 47
Travel method to CP (m) 0.57 0.00 0.00 4.00 0.00 4.00 72
Travel method to CP (h) 0.76 0.00 0.00 5.00 0.00 5.00 97
Travel time to CP (1) 0.57 0.60 0.60 3.30 0.30 3.60 73
Travel time to CP (m) 1.15 1.20 1.20 6.60 0.60 7.20 146
Travel time to CP (h) 1.44 1.50 1.50 8.25 0.75 9.00 183
Waiting time at CP (1) 0.39 0.30 0.30 1.20 0.00 1.20 48
Waiting time at CP (m) 0.76 0.60 0.60 2.40 0.00 2.40 96
Waiting time at CP (h) 0.94 0.75 0.75 3.00 0.00 3.00 120
Special arr. Attend CP (I) 25.39 7.00 7.00 91.98 7.00 98.98 127
Special arr. Attend CP(m) 42.77 10.00 10.00 163.88 10.00 173.88 214
Special arr. Attend CP (h) 54.08 13.00 13.00 205.40 13.00 218.40 270
Prescription fee (1) 8.70 5.80 5.80 11.60 5.80 17.40 70
Prescription fee (m) 8.70 5.80 5.80 11.60 5.80 17.40 70
Prescription fee (h) 8.70 5.80 5.80 11.60 5.80 17.40 70
First Consultation: P Medicine Bought OTC at CP (N=882)
Activity Mean Median Mode Range Min Max Sum
Travel method to CP (1) 0.24 0.40 0.40 3.00 0.00 3.00 210
Travel method to CP (m) 0.45 0.75 0.80 4.00 0.00 4.00 395
Travel method to CP (h) 0.65 1.00 1.20 5.00 0.00 5.00 581
Travel time to CP (1) 0.63 0.60 0.60 5.10 0.30 5.40 552
Travel time to CP (m) 1.25 1.20 1.20 10.20 0.60 10.80 1103
Travel time to CP (h) 1.56 1.50 1.50 12.75 0.75 13.50 1379
Waiting time at CP (1) 0.02 0.00 0.00 0.90 0.00 0.90 20
Waiting time at CP (m) 0.05 0.00 0.00 1.80 0.00 1.80 41
Waiting time at CP (h) 0.06 0.00 0.00 2.25 0.00 2.25 51
Special arr. Attend CP (1) 9.50 7.14 7.14 7.28 7.00 14.28 114
Special arr. Attend CP(m) 18.98 14.84 14.84 19.68 10.00 29.68 228
Special arr. attend CP (h) 23.40 18.20 18.20 23.40 13.00 36.40 281
Waiting time at GP (1) 0.77 0.60 0.30 5.40 0.00 5.40 59
Waiting time at GP (m) 1.54 1.20 0.60 10.80 0.00 10.80 117
Waiting time at GP (h) 1.92 1.50 0.75 13.50 0.00 13.50 146
Consulting time with GP (1) 0.68 0.60 0.60 3.30 0.30 3.60 52
Consulting time with GP (m) 1.37 1.20 1.20 6.60 0.60 7.20 104
Consulting time with GP (h) 1.71 1.50 1.50 8.25 0.75 9.00 130
Travel method to GP (1) 0.33 0.40 0.40 3.00 0.00 3.00 25
Travel method to GP (m) 0.60 0.80 0.80 4.00 0.00 4.00 45
Travel method to GP (h) 0.86 1.20 1.20 5.00 0.00 5.00 65
Travel time GP surgery (1) 0.69 0.60 0.60 2.10 0.30 2.40 53
Travel time GP surgery (m) 1.40 1.20 1.20 4.20 0.60 4.80 106
Travel time GP surgery (h) 1.75 1.50 1.50 5.25 0.75 6.00 133
Special arr. attend GP (1) 18.74 7.14 7.14 78.54 7.14 85.68 150
Special arr. attend GP (m) 38.96 14.84 14.84 163.24 14.84 178.04 312
Special arr. attend GP (h) 47.78 18.20 18.20 200.20 18.20 218.40 382
OTC medicine price (1) 3.84 3.29 3.19 28.04 0.35 28.39 3388
OTC medicine price (m) 3.84 3.29 3.19 28.04 0.35 28.39 3388
OTC medicine price (h) 3.84 3.29 3.19 28.04 0.35 28.39 3388
Follow Up Consultation: GP Appointmenl (N=122)
Activity Mean Median Mode Range Min Max Sum
Waiting time GP surgery (1) 1.69 0.90 0.90 5.40 0.00 5.40 207
Waiting time GP surgery (m) 3.39 1.80 1.80 10.80 0.00 10.80 413
Waiting time GP surgery (h) 4.24 2.25 2.25 13.50 0.00 13.50 517
Consulting time with GP (1) 0.78 0.60 0.60 3.30 0.30 3.60 95
Consulting time with GP (m) 1.56 1.20 1.20 6.60 0.60 7.20 191
Consulting time with GP (h) 1.95 1.50 1.50 8.25 0.75 9.00 239
Travel method to GP (1) 0.42 0.40 0.40 3.00 0.00 3.00 51
Travel method to GP (m) 0.70 0.80 0.80 4.00 0.00 4.00 85
Travel method to GP (h) 0.98 1.20 1.20 5.00 0.00 5.00 119
Travel time GP surgery (1) 0.69 0.60 0.60 2.40 0.30 2.70 84
Travel time GP surgery (m) 1.38 1.20 1.20 4.80 0.60 5.40 168
Travel time GP surgery (h) 1.72 1.50 1.50 6.00 0.75 6.75 210
Special arr. time GP (I) 19.98 14.14 14.14 49.56 7.00 56.56 379
Special arr. time GP (m) 34.62 24.84 24.84 89.36 10.00 99.36 1004
Special arr. time GP (h) 43.58 31.20 31.20 111.80 13.00 124.80 1264
OTC medicine price (1) 4.60 4.70 1.20 6.60 1.20 7.80 18.40
OTC medicine price (m) 4.60 4.70 1.20 6.60 1.20 7.80 18.40
OTC medicine price (h) 4.60 4.70 1.20 6.60 1.20 7.80 18.40
Travel method to CP (1) 0.13 0.00 0.00 3.00 0.00 3.00 13
Travel method to CP (m) 0.23 0.00 0.00 4.00 0.00 4.00 23
Travel method to CP (h) 0.33 0.00 0.00 5.00 0.00 5.00 33
Travel time to CP (1) 0.46 0.30 0.30 0.90 0.30 1.20 47
Travel time to CP (m) 0.91 0.60 0.60 1.80 0.60 2.40 93
Travel time to CP (h) 1.13 0.75 0.75 2.25 0.75 3.00 116
Waiting time at CP (1) 0.60 0.60 0.30 5.40 0.00 5.40 62
Waiting time at CP (m) 1.21 1.20 0.60 10.80 0.00 10.80 123
Waiting time at CP (h) 1.51 1.50 0.75 13.50 0.00 13.50 154
Special arr. attend CP (1) 7.09 7.14 7.14 0.14 7.00 7.14 43
Special arr. attend CP (m) 13.23 14.84 14.84 4.84 10.00 14.84 79
Special arr. attend CP (h) 16.47 18.20 18.20 5.20 13.00 18.20 99
Prescription fee (1) 8.53 5.80 5.80 29.00 5.80 34.80 290
Prescription fee (m) 8.53 5.80 5.80 29.00 5.80 34.80 290
Prescription fee (h) 8.53 5.80 5.80 29.00 5.80 34.80 290
Follow Up Consultation: C 5 Consultation (N=^ \4)
Activity Mean Median Mode Range Min Max Sum
Travel method to CP (1) 0.21 0.20 0.00 0.50 0.00 0.50 9
Travel method to CP (m) 0.40 0.38 0.00 0.80 0.00 0.80 17
Travel method to CP (h) 0.58 0.50 0.00 1.20 0.00 1.20 26
Travel time to CP (I) 0.71 0.60 0.30 1.80 0.30 2.10 31
Travel time to CP (m) 1.42 1.20 0.60 3.60 0.60 4.20 62
Travel time to CP (h) 1.77 1.50 0.75 4.50 0.75 5.25 78
Waiting time at CP (1) 0.25 0.30 0.30 1.20 0.00 1.20 11
Waiting time at CP (m) 0.50 0.60 0.60 2.40 0.00 2.40 22
Waiting time at CP (h) 0.63 0.75 0.75 3.00 0.00 3.00 28
Special arr. time CP (1) 7.14 7.14 7.14 0.00 7.14 7.14 7.14
Special arr. time CP (m) 14.84 14.84 14.84 0.00 14.84 14.84 14.84
Special arr. time CP (h) 18.20 18.20 18.20 0.00 18.20 18.20 18.20
OTC medicine price (I) 4.57 4.20 4.57 18.30 0.69 18.99 201
OTC medicinejirice (m) 4.57 4.20 4.57 18.30 0.69 18.99 201
OTC medicine price (h) 4.57 4.20 4.57 18.30 0.69 18.99 201
Note: '1' denotes low estimate; 'm' denotes mid estimate; 'h' denotes high estimate
TABLE A5.6: GP MONEY COSTS (£) IN EACH OF THE INITIAL AND FOLLOW-UP
CONSULTATION ROUTES
First Consultation: * medicine on Rx in GP Appointment (N=176)
Activity Mean Median Mode Range Min Max Sum
Consulting time with GP (1) 9.80 8.30 8.30 29.05 4.15 33.20 1726
Consulting time with GP (m) 14.77 12.50 12.50 43.75 6.25 50.00 2599
Consulting time with GP (h) 19.14 16.20 16.20 56.70 8.10 64.80 3368
Net ingredient cost Rx meds. 9.14 7.80 5.00 32.70 4.40 37.10 1608
First Consultation: P Medicine on Repeat Rx from GP (N=127)
Activity Mean Median Mode Range Min Max Sum
Admin, of posting by GP (1) 0.88 0.88 0.88 0.00 0.88 0.88 18
Admin, of posting by GP (m) 1.48 1.48 1.48 0.00 1.48 1.48 30
Admin, of posting by GP (h) 2.08 2.08 2.08 0.00 2.08 2.08 42
Signing repeat Rx GP (1) 4.15 4.15 4.15 0.00 4.15 4.15 527
Signing repeat Rx GP (m) 6.25 6.25 6.25 0.00 6.25 6.25 794
Signing repeat Rx GP (h) 8.10 8.10 8.10 0.00 8.10 8.10 1029
Net ingredient cost Rx meds 10.65 8.50 6.70 22.30 4.60 26.90 1342
First Consultation: P Medicine Bought OTC at CP (N=882)
Activity Mean Median Mode Range Min Max Sum
Consulting time with GP (1) 9.45 8.30 8.30 45.65 4.15 49.50 718
Consulting time with GP (m) 14.23 12.50 12.50 68.75 6.25 75.00 1081
Consulting time with GP (h) 18.44 16.20 16.20 89.10 8.10 97.20 1401
Follow Up Consultation: GP Appointmen
S2!II >—'
Activity Mean Median Mode Range Min Max Sum
Consulting time with GP (1) 10.82 8.30 8.30 45.65 4.15 49.50 1320
Consulting time with GP (m) 16.29 12.50 12.50 68.75 6.25 75.00 1988
Consulting time with GP (h) 21.11 16.20 16.20 89.10 8.10 97.20 2576
Net ingredient cost Rx meds. 11.43 8.70 8.70 43.50 8.70 52.20 1166
Follow Up Consull ation: CP Consultation (N=44)
Activity Mean Median Mode Range Min Max Sum
Consulting time with GP (1) 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Consulting time with GP (m) 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Consulting time with GP (h) 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Note: T denotes low estimate; 'm' denotes mid estimate; 'h' denotes high estimate
*
GP consulting costs are reported in this route because as small number of users visited a GP before buying a P medicine over-
the-counter from a community pharmacy
TABLE A5.7: CP MONEY COSTS (£) IN EACH OF THE INITIAL AND FOLLOW-UP
CONSULTATION ROUTES
First Consultation: P medicine on Rx in C 5 Appointment (N=176)
Activity Mean Median Mode Range Min Max Sum
Prescription dispensing (I) 0.80 0.80 0.80 0.00 0.80 0.80 141
(m) 1.58 1.58 1.58 0.00 1.58 1.58 277
(h) 2.95 2.95 2.95 0.00 2.95 2.95 519
Prescription advice (1) 0.06 0.06 0.06 0.00 0.06 0.06 11
(m) 0.14 0.14 0.14 0.00 0.14 0.14 24
(h) 0.18 0.18 0.18 0.00 0.18 0.18 32
CP on-cost allowance 1.60 1.37 0.88 5.72 0.77 6.49 281
CP dispensing fee 1.04 0.94 0.94 1.88 0.94 2.82 183
Net ingredient cost Rx meds. 9.14 7.80 5.00 32.70 4.40 37.10 1608
First Consultation: P Medicine on Repea Rx from GP (N=127)
Activity Mean Median Mode Range Min Max Sum
Repeat Rx dispensing (1) 0.80 0.80 0.80 0.00 0.80 0.80 102
(m) 1.58 1.58 1.58 0.00 1.58 1.58 200
(h) 2.95 2.95 2.95 0.00 2.95 2.95 375
Repeat Rx advice (1) 0.06 0.06 0.06 0.00 0.06 0.06 8
(m) 0.14 0.14 0.14 0.00 0.14 0.14 17
(h) 0.24 0.24 0.24 0.00 0.24 0.24 30
CP on-cost allowance 1.86 1.49 1.17 3.90 0.81 4.71 235
CP dispensing fee 1.16 0.94 0.94 1.88 0.94 2.82 147
Net ingredient cost Rx med. 10.65 8.50 6.70 22.30 4.60 26.90 1342
First Consultation: P Medicine Bought OTC a tCP(N=882)
Activity Mean Median Mode Range Min Max Sum
Advice P medicines OTC (1) 0.16 0.16 0.16 0.00 0.16 0.16 141
(m) 0.45 0.45 0.45 0.00 0.45 0.45 397
(h) 1.48 1.48 1.48 0.00 1.48 1.48 1301
Follow Up Consultation: GP Appointment (N=122)
Activity Mean Median Mode Range Min Max Sum
Prescription dispensing (1) 0.80 0.80 0.80 0.00 0.80 0.80 78
(m) 1.58 1.58 1.58 0.00 1.58 1.58 154
(h) 2.95 2.95 2.95 0.00 2.95 2.95 289
Prescription advice (1) 0.06 0.06 0.06 0.00 0.06 0.06 6
(m) 0.14 0.14 0.14 0.00 0.14 0.14 13
(h) 0.24 0.24 0.24 0.00 0.24 0.24 23
Advice P medicines OTC (1) 0.16 0.16 0.16 0.00 0.16 0.16 1
Cm) 0.45 0.45 0.45 0.00 0.45 0.45 2
(h) 1.48 1.48 1.48 0.00 1.48 1.48 6
CP on-cost allowance 2.00 1.52 1.52 7.61 1.52 9.13 204
CP dispensing fee 1.24 0.94 0.94 4.70 0.94 5.64 122
Net ingredient cost Rx meds. 11.43 8.70 8.70 43.50 8.70 52.20 1166
Follow Up Consultation: CP Consultation (N—44)
Activity Mean Median Mode Range Min Max Sum
Advice P medicines OTC (1) 0.16 0.16 0.16 0.00 0.16 0.16 7
Cm) 0.45 0.45 0.45 0.00 0.45 0.45 20
CO 1.48 1.48 1.48 0.00 1.48 1.48 65
Note: '1' denotes low estimate; 'm' denotes mid estimate; 'h' denotes high estimate
TABLE A5.8: DIFFERENCE IN MEAN TIME COSTS (MINUTES) ACCRUING TO USERS,
DEPENDING ON WHETHER THEY VISITED THE GP OR CP FIRST TO OBTAIN THEIR P
MEDICINE
Full Sample N=1185
Variable Group N Mean t P- 95% CI of
(mins) value Difference
Lower Upper
1st cons. rte. incl. SA GP 1st 303 67 8.37 .000 37 60
CP 1st 882 19
1st cons. rte. excl. S.A. GP 1st 303 42 24.88 .000 26 30
CP 1st 882 14
Follow Up Sample N=718
Variable Group N Mean t p- 95% CI of
(mins) value Difference
Lower Upper
1st cons. rte. incl. SA GP 1st 185 64 9.19 .000 38 58
CP 1st 532 16
1st cons. rte. excl. S.A. GP 1st 185 40 19.65 .000 24 29
CP 1st 532 14
No Follow Up Sample N=468
Variable Group N Mean t p- 95% CI of
(mins) value Difference
Lower Upper
1st cons. rte. incl. SA GP 1st 118 73 3.98 .000 25 73
CP 1st 350 24
1st cons. rte. excl. S.A. GP 1st 118 45 15.57 .000 27 35
CP 1st 350 14
Revisit Sample N=165
Variable Group N Mean t p- 95% CI of
(mins) value Difference
Lower Upper
1st cons. rte. incl. SA GP 1st 51 64 3.72 .000 23 75
CP 1st 114 15
1st & 2nd cons. rte. GP 1st 51 175 3.24 .000 30 125
incl. S.A. CP 1st 114 98
1st cons. rte. excl. SA GP 1st 51 41 9.30 .000 20 31
CP 1st 114 15
1st & 2nd cons. rte. GP 1st 51 114 8.38 .000 41 66
excl. S.A. CP 1st 114 61
TABLE A5.9: DIFFERENCE IN TOTAL MEAN RESOURCE COSTS (£) TO USERS (MID-
ESTIMATES) DEPENDING ON WHETHER THEY VISITED THE GP OR CP FIRST TO OBTAIN
THEIR P MEDICINE
Full Sample N= 1185
Total Mean Group N Mean t P- 95% CI of
Resource Cost (£) value Difference
Lower Upper
1st cons. rte. incl. SA GP 1st 303 9.24 3.273 .001 .8674 .9003
CP 1st 882 6.62
1st cons. rte. excl. S.A. GP 1st 303 6.54 2.278 .023 .07496 1.0052
CP 1st 882 6.00
Follow Up Sample N=718
Total Mean Group N Mean t P- 95% CI of
Resource Cost (£) value Difference
Lower Upper
1st cons. rte. incl. SA GP 1st 185 8.71 3.967 .000 1.2586 3.7255
CP 1st 532 6.22
1st cons. rte. excl. S.A. GP 1st 185 6.40 3.004 .003 1.2999 6.2026
CP 1st 532 5.95
No Follow Up Sample N=468
Total Mean Group N Mean t P- 95% CI of
Resource Cost (£) value Difference
Lower Upper
1st cons. rte. incl. SA GP 1st 118 10.05 l .585 .114 -.6806 6.3451
CP 1st 350 7.22
1st cons. rte. excl. S.A. GP 1st 118 6.77 1.738 .083 -.0895 1.4581
CP 1st 350 6.09
Revisit Sample N=165
Total Mean Group N Mean t P- 95% CI of
Resource Cost" (£) value Difference
Lower Upper
1st cons. rte. incl. SA GP 1st 51 8.13 1.262 .209 -.8601 3.9044
CP 1st 114 6.61
1st & 2nd cons. rte. GP 1st 51 25.71 .611 .542 -5.2647 9.9863
incl. S.A. CP 1st 114 23.35
1st cons. rte. excl. SA GP 1st 51 6.17 -.744 .458 -1.6032 .7259
CP 1st 114 6.61
1st & 2nd cons. rte. GP 1st 51 17.03 .213 .831 -2.4838 3.0850
excl. S.A. CP 1st 114 16.73
*Total Mean Resource Cost = Mean Time & Travel Cost + Mean Medicine Cost
TABLE A5.10: DIFFERENCE IN MEAN TIME AND TRAVEL COSTS (£) TO USERS (MID-
ESTIMATES) DEPENDING ON WHETHER THEY VISITED THE GP OR CP FIRST TO OBTAIN
THEIR P MEDICINE
Full Sample N==1185
Mean Time Group N Mean t P- 95% CI of
& Travel Cost (£) value Difference
Lower Upper
1st cons. rte. incl. SA GP 1st 303 8.51 7.391 .000 4.2125 7.2571
CP 1st 882 2.77
1st cons. rte. excl. S.A. GP 1st 303 5.82 24.579 .000 3.3641 3.9478
CP 1st 882 2.16
Follow Up Sample N=718
Mean Time Group N Mean t p- 95% CI of
& Travel Cost (£) value Difference
Lower Upper
1st cons. rte. incl. SA GP 1st 185 7.87 9.587 .000 4.3329 6.5644
CP 1st 532 2.42
1st cons. rte. excl. S.A. GP 1st 185 5.55 19.643 .000 3.0658 3.7467
CP 1st 532 2.15
No Follow Up Sample N=468
Mean Time Group N Mean t p- 95% CI of
& Travel Cost (£) value Difference
Lower Upper
1st cons. rte. incl. SA GP 1st 118 9.51 3.507 .000 2.7261 9.6748
CP 1st 350 3.31
1st cons. rte. excl. S.A. GP 1st 118 6.23 15.197 .000 3.5246 4.5715
CP 1st 350 2.18
Revisit Sample N=165
Mean Time Group N Mean t p- 95% CI of
& Travel Cost (£) value Difference
Lower Upper
1st cons. rte. incl. SA GP 1st 51 7.45 4.399 .000 2.723 7.159
CP 1st 114 2.51
1st & 2nd cons. rte. GP 1st 51 23.54 2.140 .034 .6115 15.232
incl. S.A. CP 1st 114 15.61
1st cons. rte. excl. SA GP 1st 51 5.49 8.257 .000 2.2676 3.6929
CP 1st 114 2.51
1st & 2nd cons. rte. GP 1st 51 14.85 6.917 .000 4.1882 7.535
excl. S.A. CP 1st 114 8.99
TABLE A5.11: DIFFERENCE IN MEAN MEDICINE COSTS (£) TO USERS (MID-ESTIMATES)
DEPENDING ON WHETHER THEY VISITED THE GP OR CP FIRST TO OBTAIN THEIR P
MEDICINE
Full Sample N==1185
Mean Group N Mean t P- 95% CI of
Medicine Cost (£) value Difference
Lower Upper
1st cons. rte. GP 1st 303 0.73 - .000 -3.4799 -2.7538
CP 1st 882 3.84 16.886
Follow Up Sample N=718
Mean Group N Mean t p- 95% CI of
Medicine Cost (£) value Difference
Lower Upper
1st cons. rte. GP 1st 185 0.85 12.540 .000 -3.4191 -2.4937
CP 1st 532 3.80
No Follow Up Sample N=468
Mean Group N Mean t p- 95% CI of
Medicine Cost (£) value Difference
Lower Upper
1st cons. rte. GP 1st 118 0.54 - .001 -3.9468 -2.7807
CP 1st 350 3.90 11.338
Revisit Sample N=165
Mean Group N Mean t p- 95% CI of
Medicine Cost (£) value Difference
Lower Upper
1st cons. rte. GP 1st 51 0.68 -7.299 .000 -4.3438 -2.4940
CP 1st 114 4.10
1st & 2nd cons. rte. GP 1st 51 2.18 -5.025 .000 -7.7464 -3.3756
CP 1st 114 7.74
TABLE A5.12: SUMMARY OF COMPARISON OF MEAN TIME COSTS (INITIAL CONSULTATION

















Gender NS NS NS NS NS NS
Ethnic group NS NS NS NS NS NS
Age band ** * NS NS NS NS
Marital status * NS *** * NS NS
Socio-economic
Accommodation * * * NS
Deprivation cat. *** *** **** * **
Access car/van * * * NS NS NS
Employmt. Cat. **** NS *** NS * NS
Level f/t educ. * NS ** NS * NS
Health Status
General health NS =i= NS * * M= * NS
L/standing **** * *** NS *** NS
illness
No. GP cons. * * * * * NS
No. CP cons. * * * * **** **** * * * * NS NS
Use same CP * NS NS NS *** NS
Regular Rx * * * H= * * * NS
meds.
Access to G 3/CP Services
Wait to see GP NS NS NS NS NS NS
Distance to GP ** * NS NS NS NS
Distance to CP NS NS NS NS NS NS
Cost of Vledicines
Exempt Rx chg. ** NS *** NS
Put off cost **** * * * * * * * * * NS
meds.
Type of Vledicines
Deregulated NS * NS NS NS NS
NHS blacklisted * * * * *** **** * * * NS
Significance levels: * p<.05; ** p<.01; *** p<.001; **** p<.0001
SA: Special Arrangements
NS: Not significant
TABLE A5.13: SUMMARY COMPARISONS OF TOTAL AND CONSTITUENT MEAN RESOURCE
COSTS (MID-ESTIMATES) ASSOCIATED WITH USERS' INITIAL CONSULTATION ROUTE







Characteristics User User User User User User







Gender NS NS NS NS NS NS
Ethnic group NS NS NS NS NS NS
Age band ❖ * * * * * * * * * * * NS * * >k *
Marital status * ** **
Socio-economic
Accommodation NS * * * * * * * * * * * * * * * * *
Deprivation cat. * * * >k * * * * * NS * * * * **
Access car/van * NS *
Employmt. cat. * * * * * * * * * * * * * * * * * * * * ** *
Level f/t educ. * * * * * * NS ** * * * *
Health Status
General health NS * * * * NS ** NS
L/standing NS NS
illness
Use of GP/CP Services in the Last Year
No. general NS * * * * * * * * NS * * * *
practitioner
cons.
No. community NS * * * * * * * * NS
pharmacist cons.
Use same NS * ** NS NS *
community
pharmacist
Regular Rx NS * * * * * * * * NS **** ****
meds.
Access to GP/CP Services in .he Last Year
Wait to see * * * NS * NS *
general
practitioner
Distance to NS NS NS NS NS NS
general
practitioner




Exempt Rx chg. **** **** * * *
Put off cost
meds.
NS * NS **** NS
Type of Medicines
Deregulated NS NS ***
NHS blacklisted *** **** * ** NS
Significance levels: * p<.05; ** p<.01; *** p<.001; **** p<.0001
SA: Special Arrangements
NS: Not significant
TABLE A5.14: SUMMARY OF COMPARISONS OF TOTAL AND CONSTITUENT MEAN MONEY
COSTS (MID-ESTIMATES) ASSOCIATED WITH USERS' INITIAL CONSULTATION ROUTE







Characteristics User User User User User User







Gender NS NS NS NS NS NS
Ethnic group NS NS NS NS NS NS
Age band * NS *** NS * * * *
Marital status NS NS * *
Socio-economic
Accommodation NS NS NS *
Deprivation cat. NS * * * * * k *** **
Access car/van NS ** * * * * NS NS * * * *
Employmt. cat. NS NS ** NS
Level f/t educ. NS NS NS NS
Health Status
General health NS NS NS NS NS
L/standing NS * **** NS NS
illness
Use of GP/CP Services in the Last Year
No. GP cons. NS NS * * * * NS * * * * *
No. CP cons. k **** * * * * k k **** * * * *
Use same CP NS NS ** NS NS *
Regular Rx NS NS * =H * * NS * * * * *
meds.
Access to GP/CP Services in he Last Year
Wait to see GP NS NS **** NS NS *
Distance to GP NS NS NS NS NS NS
Distance to CP NS NS NS NS NS NS
Cost of Medicines
Exempt Rx chg. NS * NS
Put off cost k ** * kkkk **** NS
meds.
Type of Medicines
Deregulated * * * * k * * * * *** NS ***
NHS blacklisted * ** * ** jjc k * * NS
Significance levels: * p<.05; ** p<.01; *** p<.001; **** p<.0001
SA: Special Arrangements
NS: Not significant
TABLE A5.15: SUMMARY TIME COSTS (MINUTES) ACCRUING TO KEY STAKEHOLDERS
ACROSS INITIAL AND FOLLOW-UP CONSULTATION ROUTES
Full Sample (N=1185)








29 15 10 205 5 210 33954
(566)
General practitioner (GP) 11 10 10 80 0 80 5169
(86)




7 1 1 87 1 88 7710
(129)
Follow-Up Sample (N=718)








33 15 10 205 5 210 23560
(393)
General practitioner (GP) 11 10 10 80 0 80 3635
(61)




8 1 1 87 1 88 5378
(90)
No Telephone Follow-U p Sample (N=467)








22 10 10 125 5 130 10394
(173)
General practitioner (GP) 10 10 5 55 5 60 1534
(26)




5 1 1 60 1 61 2332
(39)
GP Only Sample (N=134)








40 35 30 105 10 115 5310
(89)
General practitioner (GP) 9 5 5 25 5 30 1175
(20)




13 9 9 25 9 34 1684
(28)
CP Only Sample (N=418)








13 10 10 90 5 95 5485
(91)
General practitioner (GP) 0 0 0 0 0 0 0
(0)




2 1 1 60 1 61 713
(12)
GP to GP Sample (N=46)








120 120 60 160 50 210 5530
(92)
General practitioner (GP) 22 20 15 70 10 80 1010
(17)




30 28 23 70 18 88 1360
(23)
GP to CP Sample (N=5)








57 65 65 30 40 70 285
(5)
General practitioner (GP) 8 10 10 5 5 10 40
(1)




13 15 15 5 10 15 64
(I)
CP to GP Sample (N=76)








76 70 45 155 20 175 5765
(96)
General practitioner (GP) 14 10 10 35 5 40 1070
(18)




19 15 15 35 10 45 1436
(24)
CP to CP Sample (N=39)








33 30 15 90 10 100 1285
(21)
General practitioner (GP) 0 0 0 0 0 0 0
(0)




4 2 2 15 2 17 137
(2)
Note: the key figures of interest are the mean and total time costs accruing to users.
These are highlighted in bold. Other summary statistics are included as a reference
source for future researchers interested in costing the provision of P medicines in
primary care.
TABLE A5.16: AVERAGE RESOURCE COSTS (£) ACCRUING TO KEY STAKEHOLDERS




User General Community Total
First Follow-up Cost Practitioner Pharmacist Cost
Consultation Consultation Cost Cost
Community None 418 4.76 0.00 0.16 4.92
Pharmacist 5.77 0.00 0.45 6.22
6.39 0.00 1.48 7.87
Community Community 39 12.26 0.00 0.61 12.83
Pharmacist Pharmacist 14.69 0.00 1.19 15.88
16.13 0.00 3.25 19.38
General None 134 3.77 7.37 13.50 24.64
Practitioner 6.49 11.12 14.35 31.96
8.03 14.42 15.79 38.24
General Community 5 8.73 6.64 8.36 23.73
Practitioner Pharmacist 12.60 10.00 9.49 32.09
14.76 12.96 11.96 39.68
Community General 76 12.65 11.69 12.20 36.54
Pharmacist Practitioner 17.93 17.60 12.57 48.10
20.93 22.81 13.74 57.48
General General 46 9.78 18.24 27.29 55.31
Practitioner Practitioner 17.51 27.48 28.20 73.19
21.63 35.61 29.72 86.96
TABLE A5.17: SUMMARY RESOURCE COSTS (£) ACCRUING TO KEY STAKEHOLDERS
ACROSS INITIAL AND FOLLOW UP CONSULTATION ROUTES
Full Sample ( \=1185)
Stakeholder Mean Median Mode Range Min Max Sum
User incl. Special arr. (1) 6.72 4.39 4.29 155.46 0.30 155.76 7961
User incl. Special arr. (m) 9.66 5.68 4.39 290.76 0.60 291.36 11444
User incl. Special arr. (h) 11.34 6.49 6.00 362.45 0.75 363.20 13439
User excl. special arr. (I) 5.57 4.29 4.29 57.30 0.30 57.60 6597
User excl. special arr. (m) 7.58 5.59 4.39 68.20 0.60 68.80 8987
User excl. special arr. (h) 8.74 6.39 6.00 74.45 0.75 75.20 10360
General practitioner (1) 8.99 8.30 8.30 66.40 0.00 66.40 4308
General practitioner (m) 13.55 12.50 12.50 100.00 0.00 100.00 6491
General practitioner (h) 17.57 16.20 16.20 129.60 0.00 129.60 8415
Community pharmacist (1) 4.81 0.16 0.16 93.36 0.16 93.52 5704
Community pharmacist (m) 5.26 0.45 0.45 93.99 0.45 94.44 6237
Community pharmacist (h) 6.45 1.48 1.48 94.48 1.48 95.96 7638
National Health Service (1) 20.61 18.76 8.30 109.96 0.16 110.12 9871
National Health Service (m) 25.74 23.38 12.50 139.47 0.45 139.92 12331
National Health Service (h) 30.80 27.60 16.20 169.56 1.48 171.04 14752
Follow-Up Sample (N=718)
Stakeholder Mean Median Mode Range Min Max Sum
User incl. Special arr. (1) 7.47 4.65 4.29 78.64 0.60 79.24 5353
User incl. Special arr. (m) 10.78 6.15 3.79 130.60 1.20 131.80 7726
User incl. Special arr. (h) 12.70 6.95 4.50 160.94 1.50 162.74 9106
User excl. special arr. (I) 6.14 4.55 4.29 57.00 0.60 57.60 4405
User excl. special arr. (m) 8.45 6.00 3.79 67.60 1.20 68.80 6057
User excl. special arr. (h) 9.77 6.90 4.50 73.70 1.50 75.20 7006
General practitioner (1) 9.27 8.30 8.30 66.40 0.00 66.40 3030
General practitioner (m) 13.96 12.50 12.50 100.00 0.00 100.00 4566
General practitioner (h) 18.10 16.20 16.20 129.60 0.00 129.60 5920
Community pharmacist (1) 5.74 0.16 0.16 93.36 0.16 93.52 4113
Community pharmacist (m) 6.20 0.45 0.45 93.99 0.45 94.44 4444
Community pharmacist (h) 7.41 1.48 1.48 94.48 1.48 95.96 5315
National Health Service (1) 21.58 19.53 0.16 109.96 0.16 110.12 7058
National Health Service (m) 26.82 23.80 0.45 139.47 0.45 139.92 8771
National Health Service (h) 31.96 27.60 1.48 169.56 1.48 171.04 10457
No Telephone Follow-Up Sam ale (N=467)
Stakeholder Mean Median Mode Range Min Max Sum
User incl. Special arr. (1) 5.57 4.19 3.79 155.46 0.30 155.76 2608
User incl. Special arr. (m) 7.94 5.31 4.39 290.76 0.60 291.36 3718
User incl. Special arr. (h) 9.26 5.99 6.00 362.45 0.75 363.20 4333
User excl. special arr. (1) 4.68 4.09 3.79 20.30 0.30 20.60 2192
User excl. special arr. (m) 6.26 5.20 4.39 21.60 0.60 22.20 2929
User excl. special arr. (h) 7.17 5.95 6.00 24.54 0.75 25.29 3354
General practitioner (1) 8.41 8.30 4.15 45.65 4.15 49.80 1278
General practitioner (m) 12.66 12.50 6.25 68.75 6.25 75.00 1925
General practitioner (h) 16.42 16.20 8.10 89.10 8.10 97.20 2495
Community pharmacist (1) 3.40 0.16 0.16 35.13 0.16 35.29 1592
Community pharmacist (m) 3.83 0.45 0.45 35.69 0.45 26.14 1793
Community pharmacist (h) 4.96 1.48 1.48 36.14 1.48 37.61 2322
National Health Service (1) 18.51 16.60 8.30 48.71 4.15 52.86 2813
National Health Service (m) 23.42 21.65 12.50 68.75 6.25 75.00 3560
National Health Service (h) 28.30 26.15 16.20 89.10 8.10 97.20 4301
GP Only Sample (N=134)
Stakeholder Mean Median Mode Range Min Max Sum
User incl. Special arr. (1) 5.12 2.90 0.60 65.32 0.60 65.92 687
User incl. Special arr. (m) 8.94 5.80 1.20 129.32 1.20 130.52 1 198
User incl. Special arr. (h) 11.12 7.50 1.50 157.40 1.50 158.90 1490
User excl. special arr. (1) 3.77 2.70 0.60 19.40 0.60 20.00 505
User excl. special arr. (m) 6.49 5.40 1.20 21.40 1.20 22.60 869
User excl. special arr. (h) 8.03 6.90 1.50 22.80 1.50 24.30 1076
General practitioner (1) 7.37 5.03 4.15 20.75 4.15 24.90 988
General practitioner (m) 11.12 7.73 6.25 31.25 6.25 37.50 1489
General practitioner (h) 14.42 10.18 8.10 40.50 8.10 48.60 1933
Community pharmacist (1) 13.50 10.97 6.97 40.30 6.97 47.28 1809
Community pharmacist (m) 14.35 1 1.82 7.82 40.30 7.82 48.12 1922
Community pharmacist (h) 15.79 13.29 9.24 40.30 9.24 49.54 2116
National Health Service (I) 20.87 18.76 11.12 44.65 11.12 55.58 2797
National Health Service (m) 25.46 23.15 14.07 46.55 14.07 60.62 3412
National Health Service (h) 30.21 28.14 17.34 53.19 17.34 70.53 4048
CP On y Sample (N=418)
Stakeholder Mean Median Mode Range Min Max Sum
User incl. Special arr. (1) 4.92 4.12 4.29 29.60 1.09 30.69 2057
User incl. Special arr. (m) 6.11 4.95 3.79 39.88 1.69 41.57 2554
User incl. Special arr. (h) 6.81 5.55 3.74 49.09 1.85 50.94 2848
User excl. special arr. (1) 4.76 4.05 4.29 29.60 1.09 30.69 1988
User excl. special arr. (m) 5.77 4.89 3.79 31.30 1.69 32.99 2412
User excl. special arr. (h) 6.39 5.52 3.74 32.69 1.85 34.54 2673
General practitioner (I) 0.00 0.00 0.00 0.00 0.00 0.00 0
General practitioner (m) 0.00 0.00 0.00 0.00 0.00 0.00 0
General practitioner (h) 0.00 0.00 0.00 0.00 0.00 0.00 0
Community pharmacist (I) 0.16 0.16 0.16 0.00 0.16 0.16 67
Community pharmacist (m) 0.45 0.45 0.45 0.00 0.45 0.45 188
Community pharmacist (h) 1.48 1.48 1.48 0.00 1.48 1.48 617
National Health Service (1) 8.90 8.46 8.46 45.65 4.31 49.96 312
National Health Service (m) 13.62 12.95 12.95 68.75 6.70 75.45 557
National Health Service (h) 18.55 17.68 17.68 89.10 9.58 98.68 1095
GP to GP Sample (N=46)
Stakeholder Mean Median Mode Range Min Max Sum
User incl. Special arr. (1) 15.60 9.15 5.70 75.64 3.60 79.24 718
User incl. Special arr. (m) 27.14 18.30 11.40 1 15.84 7.20 123.04 1248
User incl. Special arr. (h) 33.84 22.73 12.75 149.15 9.00 158.15 1557
User excl. special arr. (1) 9.78 8.35 5.70 54.00 3.60 57.60 450
User excl. special arr. (m) 17.51 16.45 11.40 61.60 7.20 68.80 806
User excl. special arr. (h) 21.63 20.40 12.75 66.20 9.00 75.20 995
General practitioner (I) 18.24 16.60 16.60 58.10 8.30 66.40 839
General practitioner (m) 27.48 25.00 25.00 87.50 12.50 100.00 1264
General practitioner (h) 35.61 32.40 32.40 113.40 6.20 129.60 1638
Community pharmacist (1) 27.29 22.61 20.90 85.96 7.56 93.52 1255
Community pharmacist (m) 28.20 23.52 21.82 86.03 8.41 94.44 1297
Community pharmacist (h) 29.72 25.07 23.34 86.13 9.83 95.96 1367
National Health Service (1) 45.54 41.25 35.47 90.03 20.09 110.12 2095
National Health Service (m) 55.68 49.93 42.69 114.78 25.14 139.92 2562
National Health Service (h) 65.34 59.55 49.81 140.72 30.31 171.04 3005
GP to CP Sample (N=5)
Stakeholder Mean Median Mode Range Min Max Sum
User incl. Special arr. (I) 8.73 8.77 7.35 2.65 7.35 10.00 44
User incl. Special arr. (m) 12.60 12.97 10.55 3.10 10.55 13.65 63
User inel. Special arr. (h) 14.76 15.07 12.55 4.25 12.55 16.80 74
User excl. special arr. (1) 8.73 8.77 7.35 2.65 7.35 10.00 44
User excl. special arr. (m) 12.60 12.97 10.55 3.10 10.55 13.65 63
User excl. special arr. (hi 14.76 15.07 12.55 4.25 12.55 16.80 74
General practitioner (1) 6.64 8.30 8.30 4.15 4.15 8.30
•">
JJ
General practitioner (m) 10.00 12.50 12.50 6.25 6.25 12.50 50
General practitioner (h) 12.96 16.20 16.20 8.10 8.10 16.20 65
Community pharmacist (1) 8.36 7.72 7.72 3.76 7.37 11.13 42
Community pharmacist (m) 9.49 8.86 8.86 3.76 8.50 12.26 47
Community pharmacist (h) 11.96 11.36 11.36 3.76 10.95 14.71 60
National Health Service (1) 14.97 15.67 11.87 7.56 11.87 19.43 75
National Health Service (m) 19.49 21.00 15.11 9.66 15.11 24.76 97
National Health Service (h) 24.92 27.16 19.46 11.45 19.46 30.92 125
CP to GP Sample (N=76)
Stakeholder Mean Median Mode Range Min Max Sum
User incl. Special arr. (1) 18.23 13.62 6.95 74.65 4.35 79.00 1386
User incl. Special arr. (m) 27.67 19.10 10.35 124.25 7.55 131.80 2103
User incl. Special arr. (h) 33.18 21.90 15.95 153.09 9.35 162.44 2522
User excl. special arr. (1) 12.65 12.14 6.95 33.80 4.35 38.15 962
User excl. special arr. (m) 17.93 17.09 10.35 36.00 7.55 43.55 1363
User excl. special arr. (h) 20.93 19.72 15.95 36.90 9.35 46.25 1591
General practitioner (1) 11.69 8.30 8.30 29.05 4.15 33.20 888
General practitioner (m) 17.60 12.50 12.50 43.75 6.25 50.00 1338
General practitioner (h) 22.81 16.20 16.20 56.70 8.10 64.80 1733
Community pharmacist (1) 12.20 11.39 11.39 55.80 0.16 56.04 927
Community pharmacist (m) 12.57 11.75 11.75 55.95 0.45 56.40 955
Community pharmacist (h) 13.74 12.87 12.87 56.05 1.48 57.52 1044
National Health Service (1) 23.73 19.53 19.53 60.03 4.15 64.18 1803
National Health Service (m) 29.72 25.00 25.00 62.20 6.25 68.45 2258
National Health Service (h) 35.97 32.40 32.40 68.10 8.10 76.20 2666
CP to CP Sample (N=39)
Stakeholder Mean Median Mode Range Min Max Sum
User incl. Special arr. (1) 12.44 10.13 7.34 37.90 3.98 41.88 485
User incl. Special arr. (m) 15.07 12.99 10.38 39.60 6.18 45.78 588
User incl. Special arr. (h) 16.60 14.39 10.75 40.29 7.44 47.73 647
User excl. special arr. (I) 12.26 10.13 7.34 37.90 3.98 41.88 478
User excl. special arr. (m) 14.69 12.99 10.38 39.60 6.18 45.78 573
User excl. special arr. (h) 16.13 14.39 10.75 40.29 7.44 47.73 629
General practitioner (1) 0.00 0.00 0.00 0.00 0.00 0.00 0
General practitioner (m) 0.00 0.00 0.00 0.00 0.00 0.00 0
General practitioner (h) 0.00 0.00 0.00 0.00 0.00 0.00 0
Community pharmacist (1) 0.61 0.32 0.32 11.23 0.32 11.55 24
Community pharmacist (m) 1.19 0.90 0.90 11.30 0.90 12.20 46
Community pharmacist (h) 3.25 2.96 2.96 1 1.40 2.96 14.35 127
National Health Service (1) 1.62 0.16 0.16 19.53 0.16 19.69 63
National Health Service (m) 2.50 0.45 0.45 23.80 0.45 24.25 98
National Health Service (h) 4.06 1.48 1.48 27.60 1.48 29.08 158
Note: '1' denotes low estimate; 'm' denotes mid estimate; 'h' denotes high estimate
TABLE A5.18: PROPORTIONAL TIME COSTS (MINUTES) ACCRUING TO KEY STAKEHOLDERS
FOR EACH OF THE INITIAL AND FOLLOW-UP CONSULTATION ROUTES
Initial & Follow-Up Consultation Routes




Initial Consultation Routes Only




Follow-Up Consultation Routes Only






First Consultation: P medicine on Rx in GP Appointment (N=176)




First Consultation: P Medicine on Repeat Rx from GP (N=127)




First Consultation: P Medicine Bought OTC at CP (N=882)
Stakeholder




Follow-up Consultation: GP Appointment (N=122)




Follow-up Consultation: CP Consultation (N=44)




TABLE A5.19: PROPORTION TOTAL TIME COST INCURRED BY USERS BY CONSTITUENT
CONSULTATION ELEMENT
First Consultation: P medicine on Rx in GP Appointment (N=176)
Activity % Total Time % Total Time
(Incl. Special Arrangements) (Excl. Special Arrangements)
Waiting time in GP surgery 17 26
Consulting time with GP 15 23
Travel time to GP surgery 13 20
Special arrgmt. time attend GP 21 -
Travel time to CP 11 16
Waiting time at CP 10 15
Special arrgmt. time attend CP 13 -
First Consultation: P Medicine on Repeat Rx from GP (N=127)




Travel time to GP surgery 20 36
Waiting time in GP surgery 4 8
Special arrgmt. time attend GP 24 -
Travel time to CP 19 34
Waiting time at CP 12 22
Special arrgmt. time attend CP 20 -
First Consultation: P Medicine Bought OTC at CP (N=882)




Travel time to CP 55 75
Waiting time at CP 2 3
Special arrgmt. time attend CP 12 -
Waiting time in GP surgery 6 8
Consulting time with GP 5 7
Travel time to GP surgery 5 7
Special arrgmt. time attend GP 15 -
Follow Up Consultation: GP Appointment (N=122)




Waiting time in GP surgery 24 42
Consulting time with GP 11 19
Travel time to GP surgery 10 17
Special arrgmt. time attend GP 37 -
Travel time to CP 5 9
Waiting time at CP 7 12
Special arrgmnt. time attend CP 5 -
Follow Up Consultation: CP Consultation (N=44)




Travel time to CP 63 74
Waiting time at CP 22 26
Special arrgmt. time attend CP 15 -
TABLE A5.20: PROPORTIONAL RESOURCE COSTS (£) ACCRUING TO KEY STAKEHOLDERS
ACROSS VARIED CONSULTATION ROUTES
Initial K Follow-Up Consultation Routes
Stakeholder % Including Spec. Arr. % Excluding Spec. Arr.
Low Mid High Low Mid High
User 46 50 49 40 41 38
General Practitioner 21 23 24 23 27 30
Community Pharmacist 33 27 27 37 32 32
Initial Consultation Routes Only
Stakeholder % Including Spec. Arr. % Excluding Spec. Arr.
Low Mid High Low Mid High
User 49 52 49 46 46 43
General Practitioner 18 20 22 19 23 24
Community Pharmacist 33 28 29 35 31 33
Follow-Up Consultation Routes only
Stakeholder % Including Spec. Arr. % Excluding Spec. Arr.
Low Mid High Low Mid High
User 38 44 45 22 23 23
General Practitioner 29 32 34 36 43 48
Community Pharmacist 33 24 21 42 33 29
First Consultation: P Medicine on Rx in GP Appointment (N=' 76)
Stakeholder % Including Spec. Arr. % Excluding Spec. Arr.
Low Mid High Low Mid High
User 21 27 28 17 18 17
General Practitioner 35 38 41 36 43 47
Community Pharmacist 44 35 32 47 39 36
First Consultation: P Medicine on Repeat Rx from GP (N=127)
Stakeholder % Including Spec. Arr. % Excluding Spec. Arr.
Low Mid High Low Mid High
User 19 26 27 13 18 19
General Practitioner 19 22 24 20 24 27
Community Pharmacist 62 52 48 67 57 54
First Consultation: P Medicine Bought OTC at CP (N=882)
Stakeholder % Including Spec. Arr. % Excluding Spec. Arr.
Low Mid High Low Mid High
User 97 94 83 97 93 82
General Practitioner - - - - - -
Community Pharmacist 3 6 17 13 7 18
Follow-Up Consultation: GP Appointment (N=122)
Stakeholder % Including Spec. Arr. % Excluding Spec. Arr.
Low Mid High Low Mid High
User 35 42 43 16 18 18
General Practitioner 31 33 36 39 47 52
Community Pharmacist 34 25 21 45 35 30
Follow-Up Consultation: CP Consultation (N=44)
Stakeholder % Including Spec. Arr. % Excluding Spec. Arr.
Low Mid High Low Mid High
User 97 94 84 97 94 84
General Practitioner - - - - - -
Community Pharmacist
<■>
J 6 16 ->3 6 16
TABLE A5.21: PROPORTION OF TOTAL RESOURCE COST INCURRED BY USERS BY
CONSTITUENT CONSULTATION ELEMENT
First Consultation: P medicine on Rx in GP Appointment (N=176)




Low Mid High Low Mid High
Waiting time in GP surgery 14 16 16 19 21 21
Consulting time with GP 12 14 14 16 18 18
Travel method to GP 4 4 5 5 5 6
Travel time to GP surgery 10 12 12 14 16 16
Special arrangemt. attend GP 16 15 15 - - -
Travel method to CP 2 3 3 3 3 4
Travel time to CP 9 10 10 12 13 13
Waiting time at CP 8 9 9 11 12 12
Special arrangemt. attend CP 11 10 10 - - -
Prescription fee 14 8 6 19 11 9
First Consultation: P Medicine on Repeat Rx from GP (N=127)




Low Mid High Low Mid High
Travel method to GP 4 5 5 7 7 8
Travel time to GP surgery 14 16 16 22 25 26
Waiting time in GP surgery 3 4 3 5 5 5
Special arrangemt. attend GP 13 14 14 - - -
Travel method to CP 8 7 8 13 12 13
Travel time to CP 13 15 15 20 24 24
Waiting time at CP 9 10 10 13 15 16
Special arrangemt. attend CP 23 22 22 - - -
Prescription fee 13 7 6 20 11 9
First Consultation: P Medicine Bought OTC at 2CP (N=882)




Low Mid High Low Mid High
Travel method to CP 5 7 10 5 7 10
Travel time to CP 12 19 21 13 21 23
Waiting time at CP - 1 1 1 1 1
Special arrangemt. attend CP 2 4 4 - - -
Waiting time at GP 1 2 2 1 2 2
Consulting time with GP 1 2 2 1 2 2
Travel method to GP 1 1 1 1 1 1
Travel time to GP surgery 1 2 2 1 2 2
Special arrangemt. attend GP 3 5 6 - - -
OTC medicine price 73 50 52 78 64 58
Follow Up Consultation: GP Appointment (N=122)




Low Mid High Low Mid High
Waiting time in GP surgery 16 17 17 24 29 30
Consulting time with GP 7 8 8 11 14 17
Travel method to GP 4 3 4 6 6 7
Travel time to GP surgery 7 7 7 10 12 12
Special arrangemt. time GP 29 40 41 - - -
OTC medicine price 1 1 1 2 1 I
Travel method to CP 1 1 1 1 2 2
Travel time to CP 4 4 4 5 7 7
Waiting time at CP 5 5 5 7 9 9
Special arrangemt. attend CP 3 3 3 - - -
Prescription fee 22 12 9 33 21 17
Follow Up Consultation: CP Consultation (N=44)
Activity % Total Time % Total Time
(Inch Special Arrangements) (Excl. Special Arrangements)
Low Mid High Low Mid High
Travel method to CP 3 5 7 4 6 8
Travel time to CP 12 20 22 12 21 23
Waiting time at CP 4 7 8 4 7 8
Special arrangemt. time CP 3 5 5 - - -
OTC medicine price 77 63 57 80 67 60
TABLE A5.22: PROPORTION OF TOTAL RESOURCE COST INCURRED BY GPS BY
CONSTITUENT CONSULTATION ELEMENT
First Consultation: P medicine on Rx in GP Appointment (N=176)
Activity % Total Money
(Incl. NIC of Rx Medicines)
% Total Money
(Excl. NIC of Rx Medicines)
Low Mid High Low Mid High
Consulting time 52 62 68 100 100 100
NIC of medicines 48 38 32 - - -
First Consultation: P Medicine on Repeat Rx from GP (N=127)
Activity % Total Money
(Incl. NIC of Rx Medicines)
% Total Money
(Excl. NIC of Rx Medicines)
Low Mid High Low Mid High
NIC of medicines 71 62 55 - - -
Admin, of repeat prescriptions 1 1 2 3 4 4
Signing repeat prescriptions 28 37 43 97 96 96
First Consultation: P Medicine Bought OTC at CP (N=882)
Activity % Total Money
(Incl. NIC of Rx Medicines)
% Total Money
(Excl. NIC of Rx Medicines)
Low Mid High Low Mid High
No GP costs incurred - - - - - -
Follow Up Consultation: GP Appointment (N=122)
Activity % Total Money
(Incl. NIC of Rx Medicines)
% Total Money
(Excl. NIC of Rx Medicines)
Low Mid High Low Mid High
Consulting time 53 63 69 100 100 100
NIC of medicines 47 37 31 - - -
Follow Up Consultation: CP Consultation (N=44)
Activity % Total Money
(Incl. NIC of Rx Medicines)
% Total Money
(Excl. NIC of Rx Medicines)
Low Mid High Low Mid High
No GP costs incurred - - - - -
Note: NIC=Net Ingredient Cost
TABLE A5.23: PROPORTION OF TOTAL RESOURCE COST INCURRED BY CPS BY
CONSTITUENT CONSULTATION ELEMENT
First Consultation: P medicine on Rx in GP Appointment (N=176)
Activity % Total Money
(Incl. NIC of Rx Medicines)
% Total Money
(Excl. NIC of Rx Medicines)
Low Mid High Low Mid High
Prescription dispensing 6 12 20 23 36 51
Prescription advice 1 1 1 2 3
<■>
J
On-cost allowance 13 12 11 46 37 28
Dispensing fee 8 8 7 30 24 18
NIC of prescription medicines 72 68 61 - - -
First Consultation: P Medicine on Repeat Rx from GP (N=127)
Activity % Total Money
(Incl. NIC of Rx Medicines)
% Total Money
(Excl. NIC of Rx Medicines)
Low Mid High Low Mid High
Repeat prescription dispensing 6 10 18 21 48
Repeat prescription advice - 1 1 2 3 4
On-cost allowance 13 12 11 48 39 30
Dispensing fee 8 8 7 30 25 19
NIC of prescription medicines 73 69 63 - - -
First Consultation: P Medicine Bought Orrc at CP (N=882)
Activity % Total Money
(Incl. NIC of Rx Medicines)
% Total Money
(Excl. NIC of Rx Medicines)
Low Mid High Low Mid High
OTC medicine advice 100 100 100 100 100 100
Follow Up Consultation: GP Appointment (N=122)
Activity % Total Money
(Incl. NIC of Rx Medicines)
% Total Money
(Excl. NIC of Rx Medicines)
Low Mid High Low Mid High
Prescription dispensing 5 9 16 19 31 45
Prescription advice - 1 1 1 J 4
On-cost allowance 13 12 11 50 41 32
Dispensing fee 8 7 7 30 25 19
NIC of prescription medicines 74 70 64 - - -
Follow Up Consultation: CP Consultation (N=44)
Activity % Total Money
(Incl. NIC of Rx Medicines)
% Total Money
(Excl. NIC of Rx Medicines)
Low Mid High Low Mid High
OTC medicine advice 100 100 100 100 100 100
Note: NIC=Net Ingredient Cost
r
TABLE A5.24: MODELLED RESOURCE SAVINGS ACCRUING TO KEY STAKEHOLDERS WHEN
USERS SWITCHED THEIR INITIAL CONSULTATION ROUTE TO THE ALTERNATE ONE
Resource savings: switching from general practitioner to community pharmacy
first consultation routes (N=303)
Stakeholder/





Low Mid High Low Mid High
User -520 18 301 -1.71 0.06 0.99
General practitioner 2271 3422 4438 7.49 11.29 14.64
Community pharmacist 4010 4179 4308 13.23 13.79 14.21
Society 5761 7619 9047 19.01 25.14 29.85
Resource savings: switching from community pharmacy to general practice first
consultation routes (N=882)
Stakeholder/





Low Mid High Low Mid High
User -1303 -2888 -3720 -1.48 -3.27 -4.22
General practitioner -6214 -9371 -12158 -7.04 -10.62 -13.78
Community pharmacist -11797 -12291 -12665 -13.37 -13.94 -14.36
Society -19314 -24550 -28543 -21.90 -27.83 -32.36
